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Abstract 
Chronic obstructive pulmonary disease (COPD), is associated with an increased risk of 
myocardial infarction (MI), and additionally, cardiovascular disease is responsible for up to 1/3 
of deaths in people with COPD. This may be attributable to the fact people with COPD are 
managed differently and have higher mortality after MI compared to people without COPD. 
One reason for the differences in management may be that prognostic risk scores after MI do 
not perform well in those with COPD. Another reason may be that acute exacerbations of 
COPD (AECOPD) are thought to be associated with a transiently increased risk of MI.  
 
The aims of this thesis are to: 1)systematically review the evidence for an increased risk of MI 
associated with COPD and AECOPD, and increased risk of death following MI for those with 
COPD; 2) investigate the potential contribution of differences in management after MI on 
differences in mortality; 3) investigate the performance of prognostic risk scores after MI for 
those with COPD; 4) validate the recording of AECOPD in UK electronic healthcare records 
(EHR); 5) investigate the recording of hospitalisations for AECOPD in UK primary and 
secondary care EHR; and 6) to conduct a self-controlled case series to investigate the risk of MI 
associated with AECOPD.  
 
This work showed an increased risk of MI associated with COPD independent of smoking, and 
evidence for an increased risk of death following hospital discharge for people with compared 
to those without COPD.  
 
This work demonstrated that differences in recognition and management of MI for those with 
COPD may explain some of the higher risk of death for COPD patients following MI. 
Additionally, the GRACE score (commonly used for risk stratification following MI) does not 
perform as well for COPD patients and may explain some of the differences in management.  
 
A validated algorithm was developed for identifying AECOPD both in primary care and 
resulting in hospital admission in electronic health records. 
 
Finally, using a self-controlled case series analysis, data showed that AECOPD is associated 
with increased risk of MI for approximately four weeks following AECOPD onset, and that the 
risk is modified by important patient characteristics. 
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Chapter 1 Introduction 
 
This section defines chronic obstructive pulmonary disease (COPD), acute exacerbations of 
COPD (AECOPD), myocardial infarction (MI) and describes their epidemiology. The use of 
electronic healthcare records (EHR) for research is also introduced. The rationale, aims and 
objectives for the thesis are described. Finally, the chapter concludes with an outline of this 
thesis.   
 
1.1 COPD 
COPD is a heterogeneous collection of conditions characterised by progressive airflow 
limitation which is not fully reversible. COPD is a common disease. Worldwide, the prevalence 
of COPD is estimated to vary between 5-10% (Halbert et al. 2006) and is thought to be 
increasing (Buist et al. 2007) both due to population ageing and increased case finding of 
COPD. The prevalence of diagnosed COPD in the UK is estimated to be 1-2% of the general 
population (Simpson et al. 2010). However, there has been some suggestion that COPD is 
underdiagnosed, the so-called “missing millions” (British Lung Foundation). As the third 
leading cause of death worldwide (Lozano et al. 2012), COPD is of huge public health 
importance. As well as higher mortality (Shavelle et al. 2009), people with COPD have higher 
morbidity than the general population (Divo et al. 2012), and poorer quality of life (Garrido et 
al. 2006).  
 
The most important risk factor for COPD, in the developed world at least, is tobacco smoking 
(Mannino and Buist, 2007). However, genetics and environmental factors appear to play a role 
in influencing which smokers develop COPD, as only around 25% of smokers develop COPD 
(Løkke et al. 2006). As with many diseases associated with smoking, COPD is over-represented 
in those of lower socioeconomic status (SES) (Gershon et al. 2012). In addition, SES may 
contribute to the development of COPD, perhaps through both early life factors and 
occupational exposures. COPD is associated very strongly with age, with around half of those 
with COPD being 70 years or older (Afonso et al. 2011).  
 
COPD is a diagnosis which may be considered in patients over the age of 35 who have a risk 
factor (in the UK, this is normally a history of tobacco smoking), and one or more of cough, 
breathlessness, sputum production, wheeze, or frequent winter bronchitis (NICE 2010). A 
diagnosis of COPD should be based on clinical symptoms and then confirmed by post-
bronchodilator obstructive spirometry. Spirometric obstruction is defined as a ratio of 0.7 of 
FEV1 (forced expiratory volume in one second) to FVC (forced vital capacity), or as FEV1/FVC 
<lower limit of normal. There is no single diagnostic test for COPD, as such, diagnosis is to an 
15 
 
extent a clinical judgement. In many epidemiological studies, COPD has been defined using 
spirometry only, with many studies using pre-bronchodilator spirometry (Buist et al. 2007, Petty 
2000, Tilert et al. 2013). Without information on symptoms or clinical judgement, this may 
result in misclassification of COPD. Recent evidence from NHANES has suggested that using 
pre-bronchodilator spirometry in the general population setting results in over-estimation of the 
prevalence of fixed airflow obstruction by 50% (Tilert et al. 2013). Misclassification of COPD in 
research studies is likely to be minimised if information on symptoms or physician diagnosis 
COPD is available. However, even when such clinical information is available, COPD may still 
be misclassified with, for example, asthma with fixed airflow obstruction in an older person, or 
bronchiectasis.  
 
Irritants, such as tobacco smoke, cause inflammation in the lung, and although inflammation is 
present in the lungs of all smokers, this is exaggerated in people with COPD. Chronic airway 
inflammation in people with COPD results in destruction of the alveoli (emphysema), and 
mucus hypersecretion (chronic bronchitis), which contribute to airway obstruction (Figure 1).    
 
 
 
 
Figure 1. Diagram of A normal lungs and B changes associated with COPD.Image source: 
www.nhlbi.nih.gov/health//dci/Diseases/Copd/Copd_WhatIs; work of the US Federal 
Government and free from copyright restriction. 
 
The mainstay of treatment of COPD includes smoking cessation; inhaled bronchodilators and 
corticosteroids; and pulmonary rehabilitation therapy. The aims of treatment are to improve 
functional status and quality of life, reduce morbidity and mortality, and to prevent 
exacerbations. Smoking cessation improves survival in those with COPD (Anthonisen, Skeans 
et al. 2005, Godtfredsen et al. 2008). However, there is no definitive evidence that 
pharmacological therapy or pulmonary rehabilitation reduces mortality (Mannino and Kiri 
2006).   
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The severity of COPD varies widely between individuals. Traditionally, COPD severity the 
severity of COPD was graded according to FEV1 %predicted only (Table 1). More recently, 
presence of co-morbidities, frequency of exacerbations, degree of dyspnoea, and functional 
status have been recognised to contribute to COPD severity. (GOLD 2016).  
 
 Table 1. GOLD 2010 criteria for grading severity of COPD. 
Grade FEV1 
GOLD 1 Mild FEV1 ≥80% predicted 
GOLD 2 Moderate 50% ≤ FEV1 <80% predicted 
GOLD 3 Severe 30% ≤ FEV1 <50% predicted 
GOLD 4 Very severe FEV1 < 30% predicted 
 
1.2 Acute exacerbations of COPD 
AECOPD are acute worsening of symptoms of cough, breathlessness and sputum volume and 
purulence that goes beyond day-to-day variation, and may require a change in treatment 
(Seemungal et al. 1998).  
 
AECOPD are typically caused by infections, both bacterial and viral (Sethi 2004, Wedzicha 
2004). However, for some exacerbations an infective cause cannot be found. Some health care 
professionals believe that these exacerbations may be attributable to environmental factors, such 
as air pollution (Sunyer et al. 1993). However they are triggered, the stimulus seems to result in 
an increase in airway inflammation and mucus secretion, resulting in the symptoms of 
AECOPD. 
 
AECOPD are important events in the natural history of COPD. AECOPD drive mortality 
(Suissa et al. 2012), FEV1 decline (Donaldson et al. 2002), and reduced quality of life (Miravitlles 
et al. 2004). In addition, as the second most common reason for emergency admission to 
hospital in the UK, they are of great public health importance (Healthcare Commission 2006). 
 
There are numerous reasons for breathlessness and other symptoms of AECOPD in people 
with COPD: cardiovascular diseases, such as heart failure (Hawkins et al. 2009); other lung 
problems, such as pneumonia (MacIntyre and Huang 2008); or psychological issues such as 
anxiety (Maurer et al. 2008). Again, like COPD itself, as there is no single diagnostic test for 
AECOPD, in epidemiological studies, AECOPD may be misclassified with other problems 
such as these.  
 
AECOPD can be graded by severity according to healthcare utilisation, with mild events 
managed by patients themselves, moderate events being treated in primary care (or by use of 
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previously prescribed “rescue packs”), and severe events requiring admission to hospital.  
Typically, COPD patients may experience around two AECOPD per year (including mild 
events) (Donaldson et al. 2002).  In primary care, treatment for moderate AECOPD may 
involve the use of antibiotics and/or oral corticosteroids.  
 
In relation to AECOPD, people with COPD can be characterised as frequent or infrequent 
exacerbators. The frequent exacerbator phenotype is based on moderate and severe AECOPD 
and has been defined as two or more of these events per year (Wedzicha et al. 2013). Infrequent 
exacerbators have fewer than two moderate or severe AECOPD per year. The exacerbator 
phenotypes appear to be stable over the course of several years (Hurst et al. 2010).  
 
Frequent exacerbators have higher levels of inflammation during stable periods, compared to 
infrequent exacerbators (Bhowmik et al. 2000). Additionally, following an AECOPD, levels of 
inflammation take longer to return to baseline levels in frequent exacerbators compared to 
infrequent exacerbators (Perera et al. 2007).   
 
1.3 Myocardial infarction 
Worldwide, cardiovascular disease (CVD) is the leading cause of death (Lozano et al. 2012). 
However, in developed countries such as the UK, the incidence, and mortality due to 
cardiovascular disease is declining (Bhatnagar et al. 2015). One of the largest contributors to 
CVD is myocardial infarction (MI).  
 
A MI occurs when the blood supply to the heart is interrupted resulting in myocardial injury 
and myocardial cell death due to prolonged lack of oxygen supply (Figure 2). Typically, this is a 
result of the blockage of a coronary artery. Most MIs are due to the rupture or erosion of an 
atherosclerotic plaque, which results in activation and aggregation of platelets to form a 
thrombus and local endothelial vasoconstriction, thus blocking blood supply to the 
myocardium. Atherosclerosis itself is hardening of arteries due to the build-up of fatty plaque 
and other material. Atherosclerosis is a complex and dynamic process, and lipid does not just 
passively accumulate in the arteries. Inflammation has been implicated in all stages of the 
atherosclerotic process, and seems to accompany atherogenesis, progression to unstable 
plaques, and thrombosis (Libby et al. 2002).  
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Figure 2. Myocardial infarction. Image source: Blausen Medical Communications, Inc. Image 
licensed under CC BY 3.0, and can be freely copied and distributed. 
 
Major risk factors for MI including age (Lloyd-Jones et al. 2006), sex (Lerner and Kannel 1986), 
smoking (Kannel et al. 1987), hypertension (Castelli 1984), obesity (Hubert et al. 1983), raised 
cholesterol (Ridker et al. 2005), inactivity (Hamilton et al. 2007), low SES (Winkleby et al. 1992), 
and several other diseases such as diabetes mellitus (Kannel and McGee 1979) and chronic 
kidney disease (Muntner et al. 2002). Recently, other diseases which results in increased systemic 
inflammation have also been recognised as risk factors for MI (Wallberg-Jonsson et al. 1997, 
Meune et al. 2009, Ahlehoff et al. 2011, Kristensen et al. 2013).  
 
Diagnosis of MI is made through distinctive changes to the electrocardiogram (ECG) and raised 
blood levels of biomarkers of cardiac necrosis such as troponin fragments (troponin I or T) or 
the MB fraction of creatine kinase, which are components of the contractile architecture of 
cardiac myocytes. Major symptoms of MI include chest pain and breathlessness, but a 
significant proportion of those with acute MI have atypical presentation which may involve 
atypical pain, or even no pain at all (Culic et al. 2002). In addition, many MIs may go 
undetected, so called “silent MIs” (de Torbal et al. 2006). 
 
MIs are classified as either ST-segment elevation MIs (STEMIs) or non-ST-elevation MIs (non-
STEMIs). ST-elevation relates to an increase in the trace between the S and T segments of the 
ECG. ST-elevation indicates that the full thickness of the myocardium has been damaged and 
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generally results from complete and persistent blockage of a coronary artery. Non-STEMIs are 
events in which partial thickness damage to the myocardium occurs and are generally the result 
of partial or transient blockage of a coronary artery.  
 
Recently, the cardiology community has also recognised so called “type 2” MIs which do not 
result from coronary artery plaque rupture. Instead, type 2 MIs may result from a mismatch in 
myocardial supply and demand for oxygen due to, for example, tachyarrhythmia, bleeding, or 
exacerbations of COPD or asthma (Baron et al. 2015).  
 
Treatment of MI depends on whether the event was a STEMI or non-STEMI. Initial treatment 
of STEMI is directed towards restoring blood flow to the myocardium. Until recently, this was 
mostly achieved using pharmacological means, however the predominant method for 
reperfusion is now primary percutaneous coronary intervention (pPCI). This procedure involves 
inflating a balloon in the infarct-related coronary artery to open the artery and restore blood 
flow. Reducing time to reperfusion improves prognosis and hospitals have been targeted to 
initiate reperfusion therapy within 90 minutes of arrival at hospital (O'Gara et al. 2013). 
Pharmacological secondary prevention is used for both STEMIs and non-STEMIs. Current 
guidance suggests that, unless contraindicated, the following drugs are initiated: β-blockers; 
angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB); 
statins; and dual anti-platelet therapy (aspirin and a thienopyridine) (NICE 2013).   
 
Following an MI, patients are often stratified into categories of risk of death, commonly 
expressed as risk of death at 6 months following MI. Several risk scores are available, including 
the TIMI, PURSUIT, and GRACE score. Accurate prediction of risk of death after MI is not 
only important for prognostication, but is also used for decision making about treatment. Those 
at higher risk of death benefit most from early aggressive treatment. This is of most relevance to 
non-STEMI, and current guidelines recommend that those at moderate risk or higher (>3%) 
GRACE score predicted risk of death at 6 months should have angiography, and subsequent 
treatment if necessary, within 72 hours of admission to hospital (NICE 2010, Roffi et al. 2015). 
Previous work has investigated whether other diseases affect the utility of the GRACE score, 
but this has not been investigated in those with COPD (Eagle et al. 2004).  
 
Recent years have seen vast improvements in mortality associated with MI in the general 
population (Yeh et al. 2010). The case fatality rate (risk of death in the 30 days) for MI in the 
UK has fallen from 12.4% in 2003-2004 to 8.1% in 2011-2014 (MINAP 2014). This change is 
thought to be due to introduction of certain technologies such as pPCI and newer secondary 
prevention drugs, and improvement in the quality of care following acute MI such as reduction 
in time to pPCI after STEMI, and targeting early aggressive treatment for those with non-
STEMI and unstable angina. In the UK, it has been estimated that around 50% of the reduction 
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in mortality attributable to MI has been due to primary prevention, and 50% to improved care 
after acute MI (Smolina et al. 2012). For this reason, cardiovascular epidemiologists have been 
interested in both primary prevention of MI and in improving the quality of care following 
acute MI.  
 
1.4 COPD, AECOPD and myocardial infarction 
MI is a common co-morbidity in those with COPD (Müllerova et al. 2013). In addition, 
cardiovascular disease is the cause of death for up to one third of those with COPD (Sin et al. 
2006). Several studies have found that as well as being a risk factor for prevalent MI, COPD 
also seems to be a risk factor for incident MI (Sidney et al. 2005, Schneider et al. 2010, Sode et 
al. 2011, Yin et al. 2014), and this may be independent of smoking status (Feary et al. 2010). 
Cardiovascular disease, and MI in particular, are therefore an important target for reducing the 
mortality associated with COPD.  
 
There are several possible reasons for the increased risk of MI associated with COPD. Firstly, 
irreversible airflow limitation is characteristic of COPD, and it is known that airflow limitation 
is associated with increased risk of MI in the general population (Sin et al. 2005). Several COPD 
medicines have been implicated in increased risk of MI, however findings differ between RCT 
and observational studies (Singh et al. 2008, Wise et al. 2013). Another possible reason for the 
increased risk of MI is the increased systemic inflammation associated with COPD. Increased 
inflammation in those with COPD is thought to “spill over” from the lungs, and influence the 
risk of other diseases (Figure 3). Increased inflammation is known to be a factor in 
atherogenesis (Libby et al. 2002), progression to plaque instability (Lombardo et al. 2004) and is 
associated with increased coaguability (Esmon 2004) in the general population. In COPD 
patients, acute and chronic inflammation is thought to contribute to arterial stiffness (Maclay et 
al. 2009), and to increased platelet activation and an increased prothrombotic and 
hypercoaguable state (Davi et al. 1997, Ashitani et al. 2002, Maclay et al. 2011). One possibility 
which has received particular attention is the role of acute systematic inflammatory response to 
AECOPD and chest infections in those with COPD.  
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Figure 3. The effects of “spill over” of systematic inflammation in those with COPD. Original 
image from Barnes 2010 (Barnes 2010). Licensed under CC BY and can be freely copied and 
distributed. 
 
In the general population, it is known that the period of time following certain infections is 
associated with an increased risk of MI. Of particular relevance, lower respiratory tract 
infections (LRTI) are associated with an almost 5-fold increased risk of MI in the first 3 days 
following onset of infection (Smeeth et al. 2004). This increased risk then gradually falls back 
down to baseline levels.  
 
Two studies have investigated whether AECOPD are associated with increased risk of MI. In a 
study using CPRD data, Dolandson et al. demonstrated a 2 fold increased risk of MI in the 5 
days following AECOPD onset (Donaldson et al. 2010). However, this finding was only 
apparent when AECOPD were defined using prescription of antibiotics and steroids in a 
person with COPD, but not when either prescription of antibiotics or steroids alone were used. 
The validity of using prescription of both antibiotics and steroids to define AECOPD in EHR 
is unclear. Halpin et al. (Halpin et al. 2011), used data from the UPLIFT trial in a post hoc 
analysis and compared the risk of MI in the 30 days following AECOPD to the 30 days before 
AECOPD, and found a 13-fold increased risk of MI in the 30 day period following AECOPD. 
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However, due to a small number of events, uncertainty in this estimate was high, and the 
confidence interval ranged from 1.71-99.7. 
 
Another study (McAllister et al. 2012) demonstrated that one in 12 patients without chest pain 
who were admitted to hospital with a diagnosis of AECOPD met the universal definition of MI 
(rise and fall in serial troponin plus evidence of myocardial ischaemia). There are two 
possibilities for this finding: 1) those patients who met the criteria for MI may have initially 
been misdiagnosed with AECOPD; or 2) those patients who met the criteria for MI had both 
AECOPD and MI. Given that potential for misclassification of MI as AECOPD in those with 
COPD, and the small amount of evidence that AECOPD are associated with MI, it is possible 
both of these situations occurred.  
 
As well as the risk of MI associated with COPD and AECOPD, researchers have also 
investigated the risk of death following MI in COPD patients compared to those without 
COPD. Several investigators have found that people with COPD have a higher risk of death 
after MI compared to those who do not have COPD (Salisbury et al. 2007, Bursi et al. 2010, 
Andell et al. 2014). Others have focussed on differences in treatment after MI, and found that 
those with COPD are significantly less likely to receive certain treatments, such as pPCI after a 
STEMI, or to be discharged on β-blockers (Stefan et al. 2012). Further work has also suggested 
that COPD patients tend to present atypically, with fewer having chest pain than compared to 
people without COPD (Hadi et al. 2010). As much of the fall in MI case fatality has been 
attributed to improvements in management, it is possible that some of the increased risk of 
death following MI for those with COPD can be explained by differences in recognition and 
management of MI.  
 
Taken together with the evidence that many of those hospitalised with AECOPD meet the 
diagnostic criteria for MI, the fact that many of those with COPD present atypically after MI, 
suggests that there could be significant misdiagnosis of MI as AECOPD. This is important for 
epidemiologists as it suggests that for COPD patients, MI and AECOPD may be misclassified. 
This is also important clinically as it suggests that there is potential for delayed, or entirely 
missed, diagnosis of MI in those with COPD.   
 
1.5 Electronic healthcare records 
EHRs are digital collections of patient health related information, and may be used to aid 
clinical management, for audit, or for administrative purposes. Clinical records are used as an 
accessible record of information for individual patients as well as a tool to increase workflow 
efficiency for tasks such as the generation of prescriptions and requesting tests. Administrative 
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EHR records maybe contain clinical information, but are used for non-clinical purposes. One 
common example of administrative EHR are healthcare insurance databases, where information 
is held on claims for consultations, procedures and tests. In the UK, administrative EHR are 
often used to determine remuneration to hospitals for individual episodes of patient care.  
 
EHRs have great potential to be used for research. Their strengths include massive size allowing 
high statistical power and representativeness. In addition, linkages with other datasets allow 
information collected from multiple sources to be used for research. Unlike RCTs and most 
bespoke cohort studies, EHRs allow epidemiology in “real life” to be examined. In this sense, 
the external validity of research conducted using EHRs is high. EHRs also contain detailed 
health care information, which is not only useful when health care itself is being studied, but is 
also useful for the reliable identification of certain diseases, such as COPD. 
 
There are some limitations to the secondary use of EHR, however. The data contained in EHR 
are generally not collected for research. They tend to be clinical, administrative or audit records. 
The major problem that this causes is that sometimes important data can be missing or 
misclassified. In epidemiological studies where data are collected for the purposes of research, 
strict definitions of population, exposures, comparators, and outcomes are created at the outset. 
In general, there may also be opportunities for research staff to clarify issues with participants 
or their treating clinicians. In epidemiological studies using EHR, definitions are developed 
based on data which are already collected and complicated algorithms may be used to create 
disease definitions. A more detailed discussion and examples of these algorithms are presented 
in the next chapter. In addition, further contact with participants, or their treating clinicians, is 
not generally possible. EHR studies are therefore ultimately limited by the accuracy and coding 
behaviour of the clinicians who originally record the data.   
 
At the international level, there are several EHR datasets available which have been used widely 
for research. In the USA, two common sources of EHR data are the Medicare and Medicaid 
datasets, which are administrative claims data from national social insurance programmes for 
the elderly and those with disabilities, and those with low incomes respectively. Another widely 
used North American database in the Saskatchewan health database in Canada, which is another 
administrative database. Although these databases are large, and contained detailed information 
on medicine usage, they do not contain information on lifestyle factors (such as smoking status), 
which make them limited for studying diseases such as COPD and MI due to lack of 
information on important confounders.  
 
There are also several large EHR databases in Europe which can be used for research. The 
Danish National Patient Registry (Schmidt et al. 2015) is a database of all contact with 
secondary care (inpatient, outpatient and A&E attendance) for all patients in Denmark. 
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Although this is an excellent source of information on serious events which might lead to 
hospitalisation (for example, an MI), the database is limited by lack of information on issues 
which are commonly treated in primary care, for example COPD and smoking. The 
construction of a COPD definition using this database would mean defining only patients 
severe enough to be admitted to hospital or referred to secondary care as COPD patients, 
resulting in potential selection bias. The Dutch Integrated Primary Care Information (IPCI) 
database (Erasmus MC) was set up with the purpose of conducting pharmacoepidemiology 
studies, and therefore contains detailed information on primary care diagnoses, medical therapy, 
important lifestyle factors, and events which resulted in hospitalisation.  
 
In the UK, there are several sources of clinical primary care EHR data including: The Health 
Improvement Network (THIN), ResearchOne, QResearch, and the Clinical Practice Research 
Datalink (CPRD). These databases are broadly similar in terms of the data they contain, but do 
differ in terms of size and linkage with other datasets. Data from secondary care in the UK are 
also available separately within each constituent nation. The largest source of secondary care 
data in the UK is the Hospital Episodes Statistics (HES), and is an administrative database 
which contains information on all episodes of admitted patient care, as well as limited 
information on outpatient and A&E attendances.  
 
This thesis uses CPRD data linked with HES (where necessary). The advantages of using CPRD 
are the availability of information on lifestyle factors, such as smoking status, which is important 
when investigating diseases such as COPD and MI; and the availability of linked data between 
primary and secondary care. These databases are described in detail in the next chapter.  
 
1.6 Aims and objectives 
1.6.1 Aims 
The ultimate question that this thesis aims to address is that of the relationship between 
AECOPD and risk of MI. However, in reaching this aim, it will also be necessary to investigate 
both some aspects of the relationship between COPD and MI and consequences of MI; and to 
develop methods to identify, as accurately as possible, AECOPD in EHR. 
 
The thesis has three broad aims: 
1. Improve the understanding of the risk of MI in people with COPD; and differences 
between people with COPD and people without COPD in the presentation, 
management, and outcomes after MI 
2. Improve the identification of AECOPD in EHR 
3. Improve the understanding of the relationship between AECOPD and risk of MI 
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1.6.2 Objectives 
The specific objectives of this thesis are to: 
 
1. Conduct a systematic review and meta-analysis of the risk of MI associated with 
COPD and AECOPD and risk of death in those with COPD following MI. 
Although several studies have investigated the risk of MI associated with COPD and 
AECOPD and risk of death following MI for those with COPD, these studies have not 
been systematically reviewed, assessed or meta-analysed. Previous systematic reviews in 
this area have not focussed on risk of MI associated with COPD, and have instead 
investigated prevalent disease (Chen et al. 2015 , Müllerova et al. 2013).   
2. Investigate the possible contribution of differences in recognition and 
management of MI in those with COPD to differences in mortality in the UK. 
Although many studies have investigated both the risk of death following MI associated 
with COPD (Salisbury et al. 2007, Bursi et al. 2010, Andell et al. 2014), and differences 
in recognition and management between people with and without COPD (Stefan 
2012); this has not been done before in the UK, and no previous studies have 
attempted to directly investigate the potential contribution of differences in recognition 
and treatment to differences in outcomes.  
3. Review the evidence for the effect of COPD on differences in presentation, 
management and outcomes after MI. This review paper synthesises the literature on 
differences in presentation, management and outcomes after MI between people with 
and without COPD. This review extends the discussion on outcomes beyond that of 
all-cause mortality, and proposes mechanisms by which differences in presentation and 
management of MI for those with COPD might increase the risk of death following 
MI. 
4 Investigate the accuracy of prognostic risk scoring after acute coronary 
syndromes for those with COPD, and the impact of the differences in accuracy 
between COPD and non-COPD patients in terms of differences in management 
decisions. Although others have investigated whether prognostic scores after MI are 
accurate for other diseases (Eagle et al. 2004), this has not been done for COPD. In 
addition, no other studies have investigated the impact of different accuracy in terms of 
whether patients would receive different treatment.  
5. Validate the recording of AECOPD in UK EHR. There is currently no validated 
definition of AECOPD in EHR, given the potential for misclassification of AECOPD 
in EHR, this is an important contribution for the future of COPD research in EHR as 
well as a necessary step for completion of Objective 7.  
6. Investigate the recording of hospitalisation for AECOPD in UK primary and 
secondary care EHR. Again, there is no validated definition of hospitalisation for 
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AECOPD in EHR. Recent evidence (Crooks et al. 2012, Baker et al. 2015, Millett et al. 
2016) has demonstrated that definitions of cause-specific hospitalisation based on 
primary care data alone may have low validity. Therefore, work is needed to investigate 
how hospitalisations for AECOPD are recorded in EHR for future COPD research, 
and for the completion of Objective 7.   
7. Conduct a self-controlled case series to investigate the risk of MI associated 
with AECOPD. This study makes use of the validated definitions of AECOPD in 
EHR developed by the studies reported in Chapters 5 and 6. Using these definitions 
means that compared to previous studies into the association between AECOPD and 
MI, many more AECOPD can be identified and included, with greater confidence in 
the validity of the AECOPD definition. This increased number of AECOPD means 
that the current study has higher power. As a result, both the magnitude, and the 
duration of the association between AECOPD and MI can be better quantified. In 
addition, increased power means that this study extends previous findings by using 
stratified analysis to investigate whether the risk of MI associated with AECOPD is 
modified by patient characteristics, such as exacerbator phenotype, and cardiovascular 
medicines. This information will be important, both for informing future studies into 
the pathophysiology behind the association, and in the move towards potential 
interventions to mitigate the increased risk of MI associated with AECOPD.  
 
1.7 Description of thesis  
The following chapter is a description of the data sources used, the remaining parts of this 
thesis are presented as series of research papers before a final overall discussion. The copyright 
for these articles has been retained by the author and they are all licensed under CC BY 4.0 
(proof of retention of copyright is presented in Appendix G). These are presented as pre-print 
versions for ease of reading. For clarity for the reader of the thesis, all references in research 
papers are numbered and are listed at the end of the research paper. References in the 
introduction, description of data sources, preamble and summary of research papers, and the 
overall conclusion use the name date style and are listed at the end of the thesis.  
 
The research papers presented here are the work of the author of this thesis. The author of this 
thesis designed each of the research studies, developed the protocols, obtained necessary 
approvals, obtained the data, managed the data, analysed the data, interpreted the data, wrote 
the first draft of the papers, and wrote the final draft of the papers after comments from the co-
authors. For the systematic review presented in Chapter 3, abstract and full-text screening, and 
risk of bias assessment was carried out both by the primary author and a medical student acting 
as a second reviewer under the supervision of the primary author. For the research paper 
presented in Chapter 7, review of patient material relating to potential AECOPD was carried 
27 
 
out by two respiratory physicians (Dr Jennifer Quint and Dr John Hurst). All codelists used in 
this thesis were developed by the author in collaboration with others in the electronic healthcare 
records group at LSHTM.  
 
Five of the papers have already been published in peer-reviewed journals, the references for 
these are given in the pre-amble for each research paper. One of the papers is currently under 
review. Finally, the last chapter has been prepared for publication, but has not yet been 
submitted.   
 
The relationship of different aspects of the thesis are shown in Figure 4.  
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Figure 4. Diagram representing organisation of this thesis.  
Understanding the 
relationship between 
AECOPD and MI
Aim 7
Understanding MI 
and consequences of 
MI in COPD
Aim 1
Aim 2
Aim 3
Aim 4
Improving 
identification of 
AECOPD in EHR
Aim 5
Aim 6
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Chapter 2 Description of data sources 
 
This chapter introduces and describes the data sources used in this thesis, along with their 
strengths and weaknesses and gives examples for how disease definitions can be constructed 
using the data they hold.  
 
2.1 The Clinical Practice Research Datalink (CPRD) 
The Clinical Practice Research Datalink (CPRD), previously known as VAMP and then GPRD, 
is a large UK database of primary care data which has been used extensively for research.  
CPRD contains data on around 11 million people (5.9 million of these are active patients, which 
is about 6.9% of the population) (Herrett et al. 2015). CPRD contains details of patient 
diagnoses, signs, symptoms, prescriptions, referrals, immunisations and test results. At present, 
CPRD collects data from GP practices throughout the UK which use the Vision system 
(provided by INPS), which has a market share of around 20% of UK GPs. However, efforts are 
ongoing to integrate data from the GPs practices which use the EMIS system into CPRD.  
This section first describes how the Vision system is used in clinical practice, before describing 
how CPRD data it can be used for research.  
 
2.1.1 The Vision system 
During a general practice consultation, in Vision, once a patient’s personal EHR is selected, 
clinical details are entered as consultations. “Consultations” do not necessarily imply direct 
patient contact, and as well as attendances at the practice and telephone calls, they may also 
refer to, for example: administration tasks (such as change of personal details, or transfer out of 
the practice), issue of a repeat prescription, details from a recent discharge from hospital, or 
attendance at an A&E department.  
 
With the exception of immunisation and therapies, clinical details for consultations are mainly 
entered using a structured clinical vocabulary known as “Read terms”. Read terms refer to a 
wide variety of specific clinical concepts, such as diagnoses, signs, and symptoms, as well as life 
events and administrative codes. Read terms are each associated with a Read code. Read codes 
are a hierarchical system of classification and are arranged into several chapters. Chapters 0-9 
relate to concepts such as signs, symptoms, investigations, procedures, and patient occupations. 
Chapters A-Z relate to diagnoses, and are broadly similar to ICD chapters. Within each chapter, 
codes are arranged in a hierarchy, and become more specific further down the hierarchy. For 
example: 
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H…..   Respiratory symptom diseases 
H3…  Obstructive airway diseases 
H33..  Asthma 
H330.11 Allergic asthma 
 
Even further down the hierarchy, however, Read codes may be quite specific, for example, 
“T531000 Accid alighting aircraft – occupant of spacecraft injured”, or vague, for example, 
“R2yz.11 [D]God only knows” 
 
As the Read term dictionary contains many synonyms, clinicians generally have a wide choice of 
Read terms to use. For example, “G30..00 Acute myocardial infarction”, “G30..15 MI – acute 
myocardial infarction”, “G30..14 Heart attack”, and “G30.11 Attack - heart” all refer to the 
same clinical concept.  
 
Read terms can both be entered directly into the patient’s medical history, or into a structured 
data area, for example, when entering results, such as blood pressure. When Read terms are 
entered, the Vision system associates these to the corresponding Read code. The Vision system, 
to an extent, can be customised. One example of this is that Read terms may “auto-populate” 
with preferred terms, for example if a GP types “MI” in the Read term box, Vision may auto-
populate this with the Read term “MI – acute myocardial infarction”.  
 
Once a Read code is entered for a consultation, the GP has the opportunity to enter 
“comments” for each Read code. These are free-text information which may be used to add 
more details. For example, the free-text associated with the Read term “H06z011 Chest 
infection” may be: “productive cough 5/7, green sputum, sob, feels unwell, chest quiet lower R 
zone, for amox and r/v”.  
 
Dates are associated with each Read code. Firstly, the system date is the date of the 
consultation. Secondly, the event date is auto-populated as the system date, but may be changed 
by the clinician to record historical events, such as an admission to hospital a few weeks 
previously.  
 
In the Vision system terminology “Therapy” relates to prescriptions. The system uses the 
Gemscript dictionary, with Gemscript codes as unique identifiers. These dictionaries may be 
modified to include a “Practice formulary” depending on local prescribing practices. Each 
Gemscript item will have a product name, and may also additionally have a drug substance 
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name, route of administration, strength, formulation, and BNF code. The Therapy module 
within Vision may be modified to auto-populate the dose, duration, and patient advice for 
certain items, but these may be changed by the clinician. Prescriptions can be printed directly 
from the Therapy module once these details are entered. For the purposes of the Vision system, 
immunisation records are separate from other therapies, but as these records are not used in this 
thesis, they are not described further.  
 
Referrals to secondary care are also generated in Vision and are associated with a Read code. 
Referrals may be specified further in structured data areas by speciality, urgency and as inpatient 
or outpatient referrals, but this information is not necessarily always recorded.  
 
Test results are associated with a Read code, and may be automatically uploaded from pathology 
departments. Alternatively, these may also be entered directly by primary care clinicians. Other 
measurements and lifestyle factors (such as blood pressure or smoking status) are also 
associated with a Read code and entered directly by primary care clinicians. These might be 
triggered automatically, for example, if the Read term “O/E – blood pressure reading” is 
entered, this opens a structured data area to enter the details.   
 
2.1.2 Using CPRD for research 
Data from practices which have consented to take part in CPRD are regularly uploaded to the 
CPRD servers. Data are then processed and go through quality checks before being 
pseudonomised and made available for research.  
 
There are two quality assurance processes that CPRD carry out before data are released to 
researchers. Firstly, individual patients are deemed to be “acceptable” for research if their data 
passes quality standards. Reasons for being deemed “unacceptable” include, for example, not 
having a registration date, not having a date of birth, or having a transfer out date before the 
current registration date. Patients who are unacceptable are not recommended to be used for 
research. Secondly, CPRD also generate an “up-to-standard” (UTS) date for each included 
practice. Practices are deemed to be UTS if they have no meaningful gaps in data recording and 
if their rate of deaths is close to the expected level. Data from each practice can be used for 
research after the UTS date.  
 
After the necessary study approvals have been obtained, data can be downloaded from the 
CPRD system. This is done in two stages. In the first stage, the population is defined. This can 
be done on the basis of patient records containing certain Read codes or product codes. At this 
stage patients can also be excluded on the basis of Read codes or product codes, or on the basis 
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of age or sex. The define stage results in a list of unique patient identifiers (patids) who meet the 
initially entered inclusion criteria. The second stage involves extracting all of the records for the 
list of patients created in the first stage. The rationale for obtaining all the of the available EHR 
data for each patient, not just that during the study period is that this data may be required to 
create co-variates, for example, history of MI prior to the study period, or for inclusion and 
exclusion criteria.  
 
In CPRD, data are organised into several different types of file. These are: patient, practice, 
consultation, clinical, test, additional, therapy, staff, and immunisation. Information from staff 
and immunisation files are not used in this thesis. The relationship between the types of files 
used in this thesis is displayed in Figure 5. 
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Figure 5. Data structure in CPRD. Adapted from Herrett et al. 2015 (Herrett et al. 2015). 
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To identify clinical events which are to be used as exposure, outcome or co-variate definitions, 
codelists of Read codes which might identify the clinical concept in question must be created. 
These can then be used to search patient’s entire EHR to identify these events. If the codelist or 
strategy has not been validated however, this does require some judgment as to the possible 
meaning of the codes. For this thesis Read codes were developed by searching the dictionary for 
possible synonyms of the target concept. In addition, as Read codes are hierarchical, all codes in 
the “level” above that in question were screened. After this process was conducted, codes were 
checked against any similar ones available from colleagues or published online. An example of 
this process is shown in Figure 6. All codelists used in this thesis have been reproduced in the 
relevant appendix.  
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Figure 6. Example strategy for identifying possible acute MI in CPRD. 
 
Information on prescriptions issued to patients are also automatically entered into the patient’s 
EHR as these are generated. Generally, information is also available on daily dose and the 
quantity prescribed.  
 
Not all data are contained within Read or product codes in CPRD however. Information from 
numerical test results, for example, are stored directly in the “Test File”. An example of an 
algorithm to identify spirometry results is shown in Figure 7. One added complication is that, 
for some tests, there are likely to be many results over the course of the patient’s observation 
period. Researchers may choose to use test results at or close to a baseline period, or may wish 
to “time update” these variables. In addition, strategies may have to be developed for dealing 
with unlikely results (for example FEV1 of 67L, or height of 5m 8cm), and possibly 
contradictory results which occur on the same day or in a short space of time (for example, 
BMI of 21.3 and 31.2 on the same day).   
Step 1
•Search Read term dictionary using synonyms for target condition, e.g. "myocardial infarction", 
"heart attack", "MI"
•Example results: "Acute myocardial infarction", "Acute non-ST segment elevation myocardial 
infarction", "Anterior myocardial infarction NOS"
Step 2
•Search Read code dictionary manually using Read code headings identified in step 1, e.g. G3* 
•Example: G30..16 "Thrombosis - coronary"
Step 3
•Remove results which are not relevant
•Example: "FH: Myocardial Infarction", "Old myocardial infarction", "ECG: no myocardial infarction"
Step 4
•Check results against other's codelists for missing codes
•Example : "Attack - heart"
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Figure 7. Algorithm for identifying spirometry results (FEV1/FVC and FEV1%predicted) 
within EHR.  
 
Completeness of many pieces of lifestyle data was improved following the introduction of the 
financial incentives as part of the Quality and Outcomes Framework (QOF), which was 
introduced in 2004. One aspect of QOF incentivises GPs to record key pieces of information, 
such as smoking status.  
 
There is, therefore, no general way of defining individual concepts in EHR and researchers 
should consider re-assessing previously used algorithms for each individual study they conduct.  
 
Although information about contact with secondary care which has been sent to the GP should 
be recorded in the patient’s primary care EHR, this is not always complete and may not be 
recorded in such a way as to be useful for researchers (as free-text, for example). One major 
advantage of using CPRD data is that it can be linked to other databases which provide this 
information.  
 
Once exposures, co-variates and outcomes have been identified, individual follow up time for 
patients can be identified. In CPRD studies, apart from the usual considerations of cohort 
studies, patients are generally followed up from the date the practice’s data became up to 
standard, and are censored at practice last collection date or patient transfer out of practice. An 
example of this is shown in Figure 8.  
Step 1
• Identify all records for spirometry results (FEV1,
FEV1%predicted, FVC & directly entered FEV1/FVC)
Step 2
• Convert raw FEV1 to %predicted
• Calculate FEV1/FVC
Step 3
• Remove implausible results (e.g. FEV1=67L), or widely 
differing results on the same day
• Find the closest results to the index date
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Figure 8. Examples of follow-up time in a hypothetical CPRD study investigating the risk of MI associated with COPD.  Patients are followed up from index 
COPD diagnosis (COPD), or practice up to standard date (UTS) and censored at date of MI (MI), death, transfer out of practice (TO) or practice last collection 
date (LCD).
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MI 
LCD 
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2.2 Hospital Episodes Statistics (HES) 
Hospital episodes statistics (HES) are administrative data detailing all episodes of admitted 
patient care (overnight admissions, not including A&E only attendance) in the NHS in England. 
Details on all episodes of admitted patient care in England have been collected since the 
1989/1990 financial year, and are currently collected monthly. HES is an administrative 
database. The primary purpose of HES data on admitted patient care is to provide information 
on reason for admission and any co-morbidities, which is used along with age, length of stay, 
and any procedures carried out to determine hospital remuneration for each episode of care.  
 
Data relating to spells of admitted patient care are organised as “finished consultant episodes” 
(FCEs). These relate to a period of care under a single consultant. New FCEs in a single 
hospitalisation often refer to transfer of patients to a different team, for example, from an acute 
admissions unit to a more specialised ward.  
 
Each FCE is accompanied by up to twenty diagnoses coded using ICD-10, these may relate to 
either reasons for the current hospitalisation or may be co-morbidities. Like Read codes, ICD-
10 codes are also organised as a hierarchy. However, there are fewer synonyms and their use is 
more strictly controlled in HES.  
 
Certain conditions (such as COPD) are associated with higher remuneration per admitted 
episode (Department of Health 2012), whether or not the hospitalisation was related to the co-
morbidity, and so hospitals have a financial incentive to code several co-morbidites. Diagnoses 
in each FCE are ordered, and generally the diagnosis in the first position is taken to be the 
primary diagnosis or reason for admission.  
 
More recent additions to the available HES datasets include A&E and outpatient attendances. 
Although these add more information in terms of patient contact with secondary care which 
does not result in hospitalisation, the granularity of the information they contain is much lower 
than that for episodes of admitted patient care. Data on outpatient attendances only contain 
information on the speciality of the consultant caring for the patient. HES data on A&E 
attendance is slightly more detailed, however there are only 56 possible diagnoses. For 
respiratory problems, these are either classified as “Respiratory conditions - bronchial asthma” 
or “Respiratory conditions - other non-asthma” (HSCIC 2016).  
 
HES data have been made available for secondary purposes through the Health & Social Care 
Information Centre (HSCIC). These data are regularly used for service planning and local and 
national commissioning bodies, as well as for academic and commercial research. 
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Pseudonomised HES data from 1997 onwards have been linked to a sub-set of CPRD data by 
HSCIC. Patients registered at CPRD practices in England are eligible to be linked. Currently 
around 75% of those eligible are registered at practices which have consented to linkage, and 
this represents almost 60% of those in CPRD (Herrett et al. 2015). Linked HES-CPRD data are 
generally made available in bi-annual builds, rather than monthly updates. This has implications 
for study design as study end dates may need to be shortened to make sure all included patients 
have coverage both in HES and CPRD if linked data are used.  
 
As described in subsequent chapters, for this thesis linked HES-CPRD data are used to identify 
both AECOPD and MI for COPD patients who are included in CPRD. As a diagnosis of MI 
would result in admission to hospital, the addition for HES outpatient and A&E data would not 
be useful. Although COPD patients are likely to attend A&E for treatment of AECOPD, there 
is not sufficient detail to confidently identify AECOPD. HES outpatient data too, lacks the 
detail to identify recent AECOPD. Therefore, for this thesis, only HES data on spells of 
admitted patient care are used.  
 
2.3 Myocardial Ischaemia National Audit Project (MINAP) 
The Myocardial Ischaemia National Audit Project (MINAP) is a national clinical audit of care 
after admission to hospital for acute coronary syndromes (ACS), which includes unstable angina 
(UA) as well as MI. The purpose of MINAP is to audit the quality of care and outcomes for 
patients admitted to hospital for ACS, and MINAP aims to collect detailed data from admission 
to discharge. The primary purpose of MINAP data is to compare the performance of individual 
hospitals (in terms of process and outcome) against national averages. MINAP started collecting 
data in 1998.  
 
The exact variables collected by MINAP have changed over time with changing clinical 
guidelines. Broadly however, data are collected on: date and time of admission, cardiovascular 
drugs used at admission, final diagnosis, timing and use of reperfusion, drugs used in hospital, 
use of angiography in hospital, and use of drugs for secondary prevention on discharge. 
MINAP also has details on important comorbidities, such as heart failure, chronic kidney 
disease and obstructive airway disease, cardiovascular drugs used at admission, and some other 
patient characteristics such as age, smoking status, heart rate, systolic blood pressure, and serum 
creatinine on admission. Data are entered onto a bespoke platform by nurses or clinical coders.  
 
Several variables indicate death in hospital in MINAP and may differ, however reliable data on 
vital status at 7, 30, and 180 days post-admission are available through linkage to office of 
national statistics (ONS) mortality data.  
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MINAP has data available for research from 2003, however the completeness of data for non-
STEMIs and UA before 2004 is variable. With over 1,250,000 records, MINAP is the largest 
database of care and outcomes for people admitted to hospital for ACS in the world.  
 
The strengths of the MINAP database are its size, generalisability to the UK population, and the 
detailed level of coding of care received while in hospital.   
 
One limitation of MINAP is that patients must be alive when they arrive at hospital before they 
are entered into the MINAP database. As up to 20% of those who die shortly following their 
MI die before they reach hospital (Law et al. 2002), this means that many of those with the most 
severe MIs are likely not to be represented in MINAP.  
 
2.4 Validity of definitions used in this thesis 
Validity of measures in epidemiological studies are generally expressed in similar terms to 
diagnostic accuracy studies. That is in terms of specificity, sensitivity, positive predictive value 
(PPV), and negative predictive value (NPV).  
 
Specificity relates to the ability of a definition to identify those who do not have a condition, 
and is the proportion of those who do not have the target condition who are correctly identified 
as such. Similarly, sensitivity relates to the ability to identify those who do have a condition, and 
is the proportion of those who have the condition who are correctly identified.  
 
PPV is the proportion of those who are classified as having a condition by a definition who do 
actually have that condition. NPV is the proportion of those classified as not having a condition 
who do not indeed have it.  
 
For acute events, such as AECOPD, the most meaningful statistics are PPV, and sensitivity. 
This is because, generally, for most days of follow up, the vast majority of people will not have 
the acute condition in question. Under any definition for an acute condition, the NPV and 
specificity would be very high. 
 
2.4.1 Identification of COPD in EHR 
Strategies to identify patients with COPD within CPRD have been previously validated against 
a reference standard of respiratory physician review of patient notes and questionnaire material 
(Quint et al. 2014). Using a combination of a specific set of COPD codes, a smoking history, 
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and in patients aged over 35, COPD can be found with a PPV of 86.5% (95% CI, 77.5–92.3%). 
Adding use of COPD medicines increases the PPV to 89.4% (95% CI, 80.7–94.5%), but results 
in a significantly lower number of cases identified. The sensitivity and specificity of these 
approaches is not clear. In this thesis, both definitions are used. For the two validation studies 
(Chapters 7 and 8), the definition including COPD medicines is used. To maximise power, the 
less strict definition was used for the self-controlled case series presented in Chapter 9. 
 
When linked HES data are used in this thesis, COPD is first defined in CPRD, and linked 
records for these patients are obtained, rather than constructing a definition of COPD in HES.  
 
In MINAP, there is no variable which identifies COPD. Instead, there is a variable for 
obstructive airway disease, however this may also relate to asthma. In order to identify people 
with COPD in MINAP, an algorithm was constructed and assessed using a sub-set of the data 
which was linked to CPRD. This is described in Chapter 4.  
 
2.4.2 Identification of AECOPD in EHR 
Due to the numerous ways that GPs may record AECOPD in EHR, the identification of 
AECOPD is not clear. Previous studies have used combinations of prescriptions of oral 
corticosteroids and antibiotics in people with COPD to identify AECOPD (Donaldson et al. 
2010). The validity of this approach is not clear, and may result in misclassification with other 
infections. It was therefore decided to validate the recording of AECOPD in EHR. This is the 
subject of investigation in the research papers presented in Chapters 7 and 8.  
 
2.4.3 Identification of MI in EHR 
The recording of MI in EHR has previously been validated in linked CPRD-HES-MINAP data, 
using MINAP data as a reference standard (Herrett et al. 2013). This study indicated that using 
either primary care or secondary care data alone underestimated the number of MIs, and that 
the PPV of both primary care identified (92.2% (95% CI 91.6%-92.8%)) and secondary care 
identified (91.5% (95% CI, 90.8%-92.1%)) MI was high. For the study presented in Chapter 9, 
both linked primary care and secondary care data are used to identify MIs.  
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Chapter 3: Systematic review and meta-analysis of the risk of 
MI and risk of death after MI for people with COPD (Research 
Paper I) 
 
3.1 Preamble   
This chapter reports a systematic review of evidence for three important areas in the 
relationship between COPD and MI related to this thesis: 1) the risk of MI associated with 
COPD; 2) the risk of death following MI in people with and without COPD; and 3) the risk of 
MI associated with AECOPD. The purpose of this review was to synthesise and appraise the 
current evidence for these areas so as to inform the rest of the thesis.  
 
Although others have conducted systematic reviews of the association between COPD and MI 
(Chen et al. 2015, Müllerova et al. 2013), they have not distinguished prevalent MI from 
incident MI, and therefore did not assess risk. Crucially, neither have others focussed on 
whether the association is independent from smoking. This is the first systematic review to 
assess the relationship between AECOPD and MI; and also the first to assess the relationship 
between COPD and death following acute MI.  
 
This paper was originally published in BMJ Open, and is available here: 
Rothnie KJ, Yan R, Smeeth L, Quint JK. ‘The risk of myocardial infarction (MI) and death 
following MI in people with chronic obstructive pulmonary disease: A systematic review and 
meta-analysis’. BMJ Open. 2015 5(9). 
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3.2 Research paper 
 
The risk of myocardial infarction (MI) and death following MI in people with chronic 
obstructive pulmonary disease: A systematic review and meta-analysis 
 
Authors Kieran J Rothnie, Ruoling Yan, Liam Smeeth, Jennifer K Quint 
 
Abstract 
Objectives Cardiovascular disease is an important co-morbidity in COPD patients. We aimed 
to systematically review the evidence for: i) risk of MI in people with COPD; ii) risk of MI 
associated with AECOPD; iii) risk of death after MI in people with COPD.  
Design Systematic review and meta-analysis. 
Methods MEDLINE, EMBASE and SCI were searched up to January 2015. Two reviewers 
screened abstracts and full text records, extracted data and assessed studies for risk of bias. We 
used the generic inverse variance method to pool effect estimates where possible. Evidence was 
synthesised in a narrative review where meta-analysis was not possible. 
Results Searches yielded 8362 records, and 24 observational studies were included. Meta-
analysis showed increased risk of MI associated with COPD (HR 1.72, 95% CI 1.22-2.42) for 
cohort analyses, but not in case-control studies OR 1.18 (0.80-1.76).  Both included studies that 
investigated the risk of MI associated with AECOPD found an increased risk of MI after 
AECOPD (IRR 2.27, 1.10-4.70, and IRR 13.04, 1.71-99.7). Meta-analysis showed weak evidence 
for increased risk of death for COPD patients in-hospital after MI (OR 1.13, 0.97-1.31). 
However meta-analysis showed an increased risk of death after MI for COPD patients during 
follow-up (HR 1.26, 1.13-1.40).      
Conclusions There is good evidence that COPD is associated with increased risk of MI, 
however it is unclear to what extent this association is due to smoking status. There is some 
evidence that the risk of MI is higher during AECOPD than stable periods. There is poor 
evidence that COPD is associated with increased in-hospital mortality after an MI, and good 
evidence that longer term mortality is higher for COPD patients after an MI.  
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Strengths and limitations of the study 
 This systematic review investigated three important areas relating to the relationship 
between COPD and cardiovascular disease: 1) the risk of MI associated with COPD; 2) 
the risk of MI associated with acute exacerbations of COPD; and 3) the risk of death 
following MI in COPD patients compared to non-COPD patients. 
 
 Strengths of this review were the wide search strategy, broad inclusion criteria, and 
rigorous risk of bias assessment of included studies. 
 
 We found strong evidence for an increased risk of MI in people with COPD and an 
increased risk of longer term death after MI for COPD patients, however it is unclear 
how much of this increased risk may be due to smoking status. 
 
 We found poorer evidence for an increased risk of MI during periods of acute 
exacerbation of COPD compared to stable periods, and for an increased risk of death 
in-hospital after MI for COPD patients. We make recommendations on how future 
studies can improve our understanding of these relationships. 
 
 Due to statistical and clinical heterogeneity, meta-analysis could only be conducted for 
some of the research questions. 
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Introduction 
Cardiovascular disease is a common co-morbidity and cause of death in people with chronic 
obstructive pulmonary disease (COPD), with up to one third dying of cardiovascular disease1.  
Reducing the cardiovascular disease in this population is an important strategy for reducing the 
burden of COPD.  
 
Several studies have shown that people with COPD have a higher risk of myocardial infarction 
(MI) than people without COPD2-4. One of the reasons for the increased risk of MI in patients 
with COPD is the shared major risk factor of smoking. In addition, several other cardiovascular 
risk factors including hypertension, diabetes, inactivity, poor diet, and older age are also 
prevalent in COPD patients5-7.   In addition, several studies have found an association between 
reduced FEV1 and cardiovascular mortality in the general population8. However, COPD itself is 
also thought to be an independent risk factor for MI with increased risk of MI possibly being 
mediated through increased systemic inflammation, or reduced FEV1, in people with COPD.  
  
Acute exacerbations of COPD are events in the natural history of COPD which are 
characterised by an increase in COPD symptoms such as breathlessness, cough, sputum 
volume, and sputum purulence. It has recently been suggested that acute exacerbations of 
COPD (AECOPD) represent a period of increased risk of MI for people with COPD9. A sub-
type of COPD patients appears to have more frequent exacerbations than others.  Frequent 
exacerbators have been defined as individuals who have two or more treated exacerbations per 
year. Frequent exacerbators may be at higher risk of MI compared to infrequent exacerbators, 
even during stable periods.  
 
Several investigators have found that patients with COPD have worse mortality in-hospital and 
following discharge after an MI compared to non-COPD patients10-12. However, the finding 
that COPD patients have greater in-hospital and short term mortality has not been found by all 
investigators13-15.  
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We aimed to systematically review the literature reporting on: i) The risk of MI in people with 
COPD; ii) The risk of MI associated AECOPD, either during AECOPD or that associated with 
the frequent exacerbator phenotype; and iii) the risk of death after MI in people with COPD. 
These questions represent the most salient aspects of current research into the relationship 
between COPD and cardiovascular disease and no systematic reviews have been published on 
these topics to date.  
 
Methods 
Literature search 
MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, BIOSIS & 
Science Citation Index were searched up to January 2015. A search strategy was devised which 
would pick up articles relevant to all three research questions. All strategies were based on the 
MEDLINE search strategy, which is presented in the supplementary material. In brief, the 
literature was searched for terms which relate to COPD and terms with relate to MI, and these 
searches were combined using the AND Boolean logic operator. MeSH terms were combined 
with natural language searching using truncation where appropriate.  
 
Inclusion and exclusion criteria 
Inclusion and exclusion criteria were applied for each of the three research questions as follows. 
Studies were included if they met the population, exposure, comparator and outcome criteria. 
These are presented below for each research question. Studies were included from database 
start date and were not restricted by language.  
 
i) Risk of MI in people with COPD 
The population of interest was the general population. The exposure of interest was diagnosis 
of COPD. The un-exposed group were people without a diagnosis of COPD. The outcome of 
interest was acute MI. 
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ii) Risk of MI associated with AECOPD 
The population of interest was people with a diagnosis of COPD. The exposures of interest 
were either: 1) discrete episodes of AECOPD or periods within 8 weeks of an AECOPD; or 2) 
frequent exacerbator phenotype. The comparators of interest were either: 1) periods of stable 
COPD; or 2) infrequent exacerbator phenotype. Studies were included if they reported a relative 
risk of MI, or if this could be calculated.  
 
iii) Risk of death after MI in people with COPD 
The population of interest was those presenting to a hospital with an MI. Studies were included 
if they compared those with a diagnosis of COPD to those without a diagnosis of COPD. 
Outcomes of interest were death in hospital and at any reported time points post-discharge. 
Studies investigating risk of death for COPD patients after an interventional procedure 
following an MI (such as percutaneous coronary intervention or coronary artery bypass graft) 
were specifically excluded under the population criterion.   
 
Selection of included studies 
Titles and abstracts, where available, were initially screened for potential inclusion by one 
reviewer. Full text versions of potentially included studies were then obtained and were 
screened by two reviewers. Authors were contacted if the information provided in articles was 
not sufficient to assess whether inclusion criteria were satisfied.   
 
Risk of bias assessment 
All included studies, except for those only reported as conference abstracts, were assessed for 
risk of bias. The risk of bias tool was informed by the Newcastle-Ottawa scale16, however did 
not use of a summary score as this is not advisable17 18. Risk of bias was assessed across the key 
domains of: selection of participants, comparability of groups and measurement of outcomes. 
Several items were included under each domain, and were adapted for different study types. 
Where reports of studies included more than one analysis (for example, a case control as well as 
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a cohort analysis) the risk of bias for these analyses were conducted separately. Risk of bias 
assessment was completed by one reviewer and checked by another.  
 
Evidence synthesis 
Characteristics and findings of studies were tabulated and compared. Data on severity of COPD 
was extracted as GOLD stage or FEV1 %predicted, where available. Information was also 
extracted on smoking status and previous cardiovascular disease. Estimates of effect were 
extracted or calculated and are presented as odds ratios (OR), risk ratios (RR), incidence rate 
ratios (IRR), or hazard ratios (HR).   
 
Where included studies were reasonably statistically and clinically similar, we pooled results 
using random effects meta-analysis. We used the generic inverse variance method to pool 
maximally adjusted effect estimates.  Analysis was conducted in Review Manager 5.3.  Where 
studies were too statistically (I2 over 75%) or clinically heterogeneous, meta-analysis was not 
conducted, but study summary results were graphed on forest plots without pooling the results. 
Studies which were not adjusted at all were not included in forest plots. For the question on risk 
of MI associated with COPD, studies were stratified by adjustment for smoking status (yes or 
no) and study design (cohort or case-control). For the question on risk of death following MI in 
COPD compared to non-COPD patients, studies were stratified by outcome time-point (in-
hospital mortality or follow-up mortality). For follow-up mortality, studies were further 
stratified by analysis method (cumulative incidence or time-to-event).  
 
Results 
Identified studies 
Literature searches yielded 8362 records. After title and abstract screening, 49 records were 
selected for full text assessment, which resulted in the inclusion of 24 studies. The inclusion and 
exclusion process is summarised in Figure 1.  Of the 24 included studies, 9 investigated the risk 
of MI in COPD patients compared to non-COPD patients; 2 investigated the risk of MI 
associated with AECOPD, no studies were found which investigated the risk of MI associated 
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with the frequent exacerbator phenotype; and 12 investigated outcomes after MI for COPD 
patients compared to non-COPD patients. Summary characteristics of included studies are 
presented in Tables 1, 2 and 3. 
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Figure 1. Study selection  
24 studies included: 
Risk of MI and COPD: 9 
Risk of MI and AECOPD: 2 
Risk of death after MI: 12 
 
25 full text articles excluded: 
Incorrect outcome: 18 
Incorrect population: 3 
Incorrect exposure: 2 
Review article: 2 
Incorrect comparator: 1 
 
 
 
49 full text articles assessed for eligibility 
6586 records excluded 6635 records screened 
6635 records after duplicates removed 
8362 records identified through 
database screening 
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Table 1. Detailed Characteristics of included studies – risk of MI associated with COPD 
Study Design and setting  Population Characteristics of 
COPD patients  
MI definition Maximally 
adjusted estimate 
(95% CI) 
Factors adjusted for 
Curkendall 
2006a and 
2006b  
Cohort in the 
Saskatchewan Health 
databases 1998-2001.  
11 493 COPD patients ≥ 
40 years, identified by 
physician claim or 
hospital discharge COPD 
code and at least two 
prescriptions for COPD 
medicines within 6 
months of the index 
COPD code. 
 
22 986 age and sex 
matched non-COPD 
patients 
Age 
NR 
 
Sex 
NR 
 
COPD severity 
NR 
 
Current smokers 
16% 
 
History of CVD 
Previous MI - 2.3% 
Previous angina – 6.6% 
Any MI during follow 
up: any inpatient or 
outpatient diagnosis of MI 
 
Hospitalisation due to 
MI: primary hospital 
discharge diagnosis of MI 
 
Fatal MI: underlying 
cause of death which 
initiated the sequence of 
events that lead to death 
recorded as MI 
Any MI during 
follow up (period 
prevalence): OR 
1.61 (1.43-1.81) 
 
Hospitalisation 
due to MI: IRR 
1.49 (0.71-3.13) 
 
Fatal MI: IRR 1.51 
(1.14-2.01) 
 
 
Period prevalence of MI: Age, 
sex, history of cardiovascular 
disease, diabetes, hypertension, 
hypercholesterolaemia 
 
Hospitalisation for MI: 
adjusted for history of 
cardiovascular events, diabetes, 
hypertension, and 
hypercholesterolemia using 
Poisson regression, age and sex 
by matching.   
 
Fatal MI: age and sex by 
matching only.   
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Feary 2010 Cohort in The Health 
Improvement 
Network, 2005-2007 
29 870 COPD patients 
>35 years identified by 
COPD diagnostic code. 
 
1 174 240 non-COPD 
patients 
Age 
35-44 – 1.8% 
45-54 – 7.0% 
55-64 – 20.5% 
65-74 – 31.7% 
≥75 – 39.0% 
 
Sex 
48.1% male 
 
COPD severity 
FEV1 % predicted 
50-80% - 37.5% 
30-49% - 19.1% 
<30% - 5.3% 
 
Current smokers 
65.3% 
 
History of CVD 
Prior CVD – 28.0% 
 
Diagnostic code for MI in 
primary care record 
35-44 years: 
HR 10.34 (3.28-
32.6) 
 
45-54 years: 
HR 1.22 (0.55-2.74) 
 
55-64 years: 
HR 1.55 (1.07-2.26) 
 
65-74 years: 
HR 1.78 (1.37-2.31) 
 
≥75 years: 
1.34 (1.03-1.73) 
Age, sex and smoking status 
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Huiart 2005  Cohort in the 
Saskatchewan Health 
databases 1990-1999 
5 648 COPD patients ≥ 
50 years, identified by 
prescription of three or 
more bronchodilators 
within the period of one 
year. 
 
Rates of MI compared to 
those of general 
Saskatchewan population 
Age 
NR 
 
Sex 
NR 
 
COPD severity 
NR 
 
Current smokers 
NR 
 
History of CVD 
NR 
 
Characteristics were not 
split by COPD status. 
 
Primary hospital discharge 
diagnosis of MI 
Standardised IRR:  
1.30 (1.15-1.44) 
Age and sex by standardisation 
Mapel 2005 Cohort in the 
Veterans 
Administration 
COPD patients identified 
by discharge codes 
(1991-1999) and/or 
Age 
Median 60 (IQR, 49-62) 
 
Sex 
Specific ICD-9-CM code 
for MI during 1999 that 
was not present in 1998 
COPD patients 
identified using 
discharge codes 
Age and sex by matching 
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Medical System, 1991-
1999 
outpatient codes (1997-
1999) 
 
Age and sex matched 
controls without COPD 
95.7% male 
 
COPD severity 
NR 
 
Current smokers 
NR 
 
History of CVD 
Cardiovascular disease – 
71.2% 
 
IRR: 1.28 (1.18-
1.38) 
 
COPD patients 
identified using 
outpatient codes 
IRR: 5.31 (4.54-
6.21) 
Rodriguez 
2010  
Cohort and case-
control study in the 
General Practice 
Research Database, 
1996-2001 
1532 patients with a first 
COPD diagnosis in 1996, 
and no history of 
cardiovascular disease 
 
13 500 age and sex 
matched non-COPD 
patients, with no history 
of cardiovascular disease 
Age 
NR 
 
Sex 
NR 
 
COPD severity 
NR 
 
Current smokers 
Diagnostic code for MI in 
primary care record 
Cohort analysis: 
IRR 1.18 (0.81-1.71) 
 
Case-control 
analysis: OR 0.93 
(0.62-1.39) 
 
Cohort analysis: 
Age and  sex 
 
Case control analysis: 
Age, sex, smoking and  number 
of primary care physician visits 
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NR 
 
History of CVD 
NR 
 
 
Schneider 
2010  
Cohort and nested 
case-control study in 
the General Practice 
Research Database, 
1995-2005 
35 772 patients with a 
first COPD diagnosis 
between 1995-2005  
 
35 772 non-COPD 
patients matched on age, 
sex and calendar time 
and general practice 
Age 
40-49 – 6.8% 
50-59 – 19.9% 
60-69 – 33.8% 
>70 – 39.6% 
  
Sex 
51.3% male 
 
COPD severity 
NR 
 
Current smokers 
43.3% 
 
History of CVD 
Diagnostic code for MI 
along with death or 
hospitalisation within 30 
days of the diagnosis; 
and/or start of new 
treatment with ACE 
antagonist, β-blocker, 
statin, vitamin K 
antagonist,  platelet 
aggregation inhibitor or 
aspirin within 90 days of 
the diagnosis in primary 
care record 
Cohort analysis: 
IRR 1.56 (1.43-1.75) 
 
Case control 
analysis: 
Any COPD : 
OR 1.40 (1.13-1.73) 
 
Mild COPD: 
OR 1.79 (1.12-2.86) 
 
Moderate COPD: 
OR 1.30 (1.04-1.62) 
 
Severe COPD: 
OR 3.00 (1.53-5.86) 
Cohort analysis: matched on 
age, sex, calendar time and 
general practice 
 
Case-control analysis: Smoking 
status, BMI, hypertension, 
hyperlipidaemia, diabetes and 
NSAID use 
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Prior MI/CHD – 18.3% 
Prior CHF – 8.4% 
 
Sidney 2005  Cohort in health 
insurance database. 
North Carolina, 1996-
1999 
COPD defined as: 
hospitalisation or 
outpatient diagnosis of 
COPD, two or more 
prescriptions for COPD 
medicines, aged over 40 
years. 
 
Non-COPD patients 
matched on age, sex and 
length of care plan 
membership. 
Age 
40-59 – 35% 
60-79 – 55% 
>80 – 10% 
 
Sex 
55.4% male 
 
COPD severity 
NR 
 
Current smokers 
NR 
 
History of CVD 
Prior MI – 1.8% 
Prior angina – 1.0% 
Prior CHF – 7.2% 
 
ICD code for acute MI Overall: 
IRR 1.89 (1.71-2.09) 
 
Men: 
IRR 1.77 (1.56-2.01) 
 
Women: 
IRR 2.09 (1.78-2.46) 
 
40-64 years: 
IRR 2.43 (1.98-2.98) 
 
≥65 years: 
IRR 1.73 (1.54-1.94) 
Age, sex and baseline 
cardiovascular risk profile. 
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Sode 2011  Cohort study within 
the National Danish 
patient registry, 1980-
2006 
Entire Danish 
population. COPD 
identified through 
hospital admission codes 
or COPD as cause of 
death 
Age 
<30 – 7% 
30-59 – 54%  
60-79 –35 % 
>80  - 3% 
 
Sex 
55% male 
 
COPD severity 
NR 
 
Current smokers 
NR 
 
History of CVD 
NR 
 
Discharge diagnosis of MI 
or cause of death from 
Danish Causes of Death 
Registry listed as MI 
HR 1.26 (1.25-1.27) Age, sex, Danish ancestry, 
geographical residency (rurality), 
and level of education 
Yin 2014 Cohort of all residents 
of Sweden aged over 
18, July 2005- 
December 2008.  
51 348 COPD patients 
identified by diagnostic 
codes from patient 
Those with no previous 
MI or stroke 
Age 
Mean 71.1 
Diagnostic code for MI, or 
primary cause of death 
listed as MI 
No previous MI or 
stroke: 
 
Age, sex, socioeconomic status, 
use of cardiovascular and 
respiratory medicines.  
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records. 6 743 342 non-
COPD patients.  
 
Sex 
44.3% male 
 
COPD severity 
NR 
 
Current smokers 
NR 
 
History of CVD 
No previous MI 
 
Those with previous 
MI 
Age 
Mean 69.2 
 
Sex 
58.4% male 
 
COPD severity 
HR 1.47 (1.41-
1.55)* 
 
Previous MI: 
 
HR 1.33 (1.23-
1.43)* 
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NR 
 
Current smokers 
NR 
 
History of CVD 
All had previous MI 
 
 
*Data from personal communication (Magnus Back. Email communication. 18/08/2014). 
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Table 2. Characteristics of included studies – risk of MI associated with AECOPD 
Study Design and 
setting 
Population Characteristics AECOPD definition MI definition Risk periods Risk estimate 
(95% CI) 
Donaldson 
2010  
Self controlled 
case series in 
The Health 
Improvement 
Network, 
2003-2005 
426 patients with 
COPD and MI 
during study period. 
COPD defined 
using Quality and 
Outcomes 
Framework codes.  
Age Median 74 years (IQR, 67-80) 
 
Sex 61% male 
 
Current smokers NR 
 
COPD severity  
Median FEV1 % predicted: 55.9% 
(IQR, 43-73) 
 
History of CVD  
NR 
Three definitions used: 
 
1) Prescription of oral 
steroids 
2) Prescription of pre-
specified antibiotic 
3) Prescription of pre-
specified antibiotic 
and prescription of 
oral steroid 
Diagnostic code for 
MI in primary care 
record 
1-5days, 6-10 
days, 11-15 
days, 16-49 
days, and 1-
49 days. 
Antibiotics and 
steroids 
definition: 
 
1-5 days: 
IRR 2.27 (1.10-
4.70) 
 
6-10 days: 
IRR 1.74 (0.80-
4.0) 
 
11-15 days: 
IRR 0.90 (0.30-
2.90) 
 
16-49 days: 
IRR 0.83 (0.50-
1.40) 
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 1-49 days: 
IRR 1.11(0.70-
1.70) 
 
Halpin 
2011  
Secondary 
analysis of 
patients in 
UPLIFT RCT 
3 512 COPD 
patients who 
survived at least 
their first 
AECOPD. COPD 
defined as age ≥40 
years, smoking 
history ≥10 pack-
years, FEV1 ≤70% 
predicted, and 
FEV1/FVC≤70%. 
Age Mean 64 (SD, 8) 
 
Sex 74% male 
 
COPD severity  
GOLD stage II 43% 
GOLD stage III 46% 
GOLD stage IV 9% 
 
Mean FEV1 % predicted 38% (SD, 
12) 
 
Current smokers 29% 
 
History of CVD  
NR 
Increase in or new 
onset of more than one 
of: cough, sputum, 
sputum purulence, 
wheezing or dyspnoea; 
lasting 3 or more days 
and requiring treatment 
with an antibiotic or 
oral steroid. Data on 
timing of AECOPD 
collected at study visits 
MI ascertained during 
RCT follow-up and 
recorded as a serious 
adverse event 
30 days after 
AECOPD, 
compared to 
30 days 
before 
AECOPD 
IRR 13.04 (1.71-
99.7) 
63 
 
Table 3. Characteristics of included studies – risk of death after MI   
Study Design and setting Population COPD patient 
characteristics  
Maximally adjusted 
estimate for mortality  
(95% CI) 
Factors adjusted for 
Andell 2014 Cohort study within 
the Swedish 
SWEDEHEART 
registry between 
2005-2010. 
Consecutive patients admitted to 
Swedish coronary care units. COPD 
diagnosis ascertained through linkage 
to the Swedish National Patient 
Registry.  
Age  
Mean 75 years (SD, 9) 
 
Sex  
54% male 
 
COPD severity  
NR 
 
Current smokers  
32.9% 
 
History of CVD  
Prior MI 13.7% 
Prior HF 20.2% 
 
Mortality at one year: 
HR 1.14 (1.07-1.21) 
Age, sex, smoking, comorbidity 
(previous MI, previous stroke, 
heart failure, renal failure, 
hypertension, diabetes, peripheral 
artery disease, cancer and previous 
bleeding), in hospital treatment and 
discharge medications (heparin, 
fondaparinux, dalteparin, 
enoxaparin, glycoprotein IIb/IIa 
inhibitors, angioplasty, coronary 
stenting, β-blockers, aspirin, 
clopidogrel, prasugrel, calcium 
channel blockers, digoxin, diuretics, 
statins, nitrates and warfarin).  
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Behar 1992 Cohort study in 
Israel between 1981-
1983 
2276 consecutive patients surviving an 
MI after admission to 13 coronary care 
units. Patients with a history of chronic 
bronchitis or chronic airways 
obstruction and clinical and/or 
radiographic findings compatible with 
COPD during hospitalisation for MI 
were included.  
Age  
Mean 66.8 years (SD, 9.7) 
 
Sex  
79.3% male 
 
COPD severity  
NR 
 
Current smokers  
43.3% 
 
History of CVD  
Prior MI – 28.8% 
Prior angina – 55.4% 
Unadjusted:* 
In –hospital RR 1.39 
(1.16-1.67) 
 
1 year RR 1.34 (1.16-
1.55) 
 
5 years RR 1.28 (1.18-
1.40) 
 
  
 
Bursi 2010 Cohort study of the 
population in the 
Rochester 
Epidemiology 
project involving 
residents in Olmsted 
Local residents in Olmsted County. MI 
ascertained from medical records 
compatible with ICD criteria. 
Information on COPD was also 
obtained from ICD codes.   
Age  
Mean 73 years (SD, 11) 
 
Sex  
59% male 
 
COPD severity  
HR 1.30 (1.10 to 1.54), 
mean follow up 4.7 
years.  
Age, sex, smoking, hypertension, 
MI type (STEMI/non-STEMI), 
creatine kinase level, 
killip class, reperfusion treatment in 
hospital, use of drugs on discharge 
(β-blockers, ACEi, diuretics) 
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County, Minnesota 
from 1979 to 2007  
NR 
 
Current smokers  
35% 
 
History of CVD  
Those with prior CVD 
excluded 
Dziewierz 
2010 
Cohort study within 
Krakow Registry of 
ACS in February 
2005-March 2005 
and December 
2005-January 2006 
1414 patients with MI admitted to 
hospital in Krakow, Poland. Those 
with a previous history of COPD and 
current treatment with a steroid or 
bronchodilator were classified as 
COPD patients.   
Age  
Mean 71.8 years (SD, 11) 
 
Sex  
62% male 
 
COPD severity  
NR 
Current smokers  
40.7% 
History of CVD 
MI 34.6% 
Angina 80.2% 
HF 30.9% 
HR 2.15 (1.30-3.55) Age, sex, BMI, diabetes, 
hypertension, hyperlipidaemia, 
prior 
angina, prior MI, prior heart failure, 
left 
ventricular ejection fraction, prior 
PCI, prior CABG, 
prior stroke or transient ischaemic 
attack, smoking status, 
peripheral arterial disease, chronic 
renal insufficiency, parameters on 
admission (chest pain, 
cardiogenic shock, heart rate, 
systolic blood 
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pressure, diastolic blood pressure), 
time from chest pain 
onset to admission and type of MI 
(STEMI or NSTEMI) 
Enriquez 
2013 
Cross sectional 
study of National 
Cardiovascular Data 
Registry in the USA 
between January 
2008 and December 
2010 
158 890  patients admitted to one of 
445 sites with an MI. COPD patients 
had a history of COPD or were using 
long term inhaled or oral β-agonists, 
inhaled  anti-inflammatory agents, 
leukotriene receptor antagonists or 
inhaled steroids.   
Age  
STEMI – median 66 years 
nSTEMI – median 70 
years 
 
Sex  
STEMI – 60.4% male 
nSTEMI – 57.5% male 
 
COPD severity  
NR 
 
Current smokers  
STEMI – 57.0% 
nSTEMI – 41.9% 
 
History of CVD  
STEMI 
In-hospital mortality 
 
STEMI OR 1.05 (0.95-
1.17) 
 
Non-STEMI OR 1.21 
(1.11-1.33) 
 
Age, serum creatinine, systolic 
blood pressure, troponin elevation, 
heart failure or cardiogenic shock 
at presentation,  ST-segment 
changes, heart rate and prior 
peripheral arterial disease.  
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Prior MI – 29.7% 
Prior CHF – 15.3% 
 
nSTEMI 
Prior MI – 39.% 
Prior CHF – 33.3% 
Hadi 2010 Cross sectional 
study of patients 
hospitalised with 
ACS in May 2006 
and January 2007 to 
June 2007 in six 
Middle Eastern 
countries 
8169 consecutive patients in the Gulf 
RACE registry presenting with ACS at 
65 centres across six countries. COPD 
patients were identified from 1) 
medical records or 2) use of COPD 
medicines. 
Age 
Median 64 (IQR, 56-71) 
 
Sex 
NR 
 
COPD severity 
NR 
 
Current smokers 
38.7% 
 
History of CVD 
Prior MI - 34.8% 
Prior angina – 54.4% 
 
In hospital mortality: 
OR 0.40 (0.20-1.24) 
Age, sex, cardiogenic shock, use of 
thrombolysis, use of aspirin, use of 
β-blocker, use of ACEi 
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Hawkins 
2009 
Cohort study of 
patients with acute 
MI enrolled in 
VALIANT trial 
Patients with MI complicated by 
LVSD and HF. COPD was identified 
by a questionnaire completed by trial 
site investigators.  
Age 
Mean 68.1 (SD, 9.9) 
 
Sex 
71.1% male 
 
COPD severity 
NR 
 
Current smokers 
42.0% 
 
History of CVD 
Prior MI – 39.9% 
Prior angina – 46.1% 
Prior HF – 27.3% 
HR 1.14 (1.02-1.28)  
 
 
Age, heart rate, systolic and 
diastolic blood pressure, weight, 
baseline creatinine, smoking status, 
diabetes, dyslipidaemia, 
hypertension, killip classification, 
anterior MI, new lower bundle 
branch block, thrombolytic 
therapy, primary PCI, coronary 
artery bypass graft, history of heart 
failure, atrial fibrillation, previous 
MI, angina, previous stroke, 
peripheral arterial disease, renal 
insufficiency, alcohol abuse, 
country of enrolment, beta blocker 
use, randomised treatment 
 
 
 
 
Kjoller 
2004 
Cohort study of 
consecutive patients 
Danish hospitals between May 1990 
and July 1992 as part of TRACE study. 
COPD was identified using either 1) 
Age 
Median 70.5 (5-95 
percentiles, 50.7-83.5) 
Cohort entry to 30 
days: 
HR 0.89 (0.68-1.11) 
Age, sex,  BMI, hypertension, 
diabetes, smoking status, previous 
angina, wall motion index, angina, 
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recruited 1-6 days 
after an MI  
medical records or 2) patient report in 
addition to use of COPD medicines 
 
Sex 
68.2% men 
 
COPD severity 
NR 
 
Current smokers 
60.0% 
 
History of CVD 
Previous MI – 25.1% 
Previous angina – 43.9 
Previous CHF – 28.2% 
 
 
Cohort entry to 7 
years: 
HR 1.15 (1.04-1.28) 
history of CHF, new CHF, atrial 
fibrillation, bundle branch block, 
wall motion index, use of 
thrombolytic therapy 
Quint 2011 
(abstract) 
Cohort study of 
patients admitted 
after a first MI using 
data from the UK 
CALIBER database 
8 065 patients admitted to UK 
hospitals with a first MI between Jan 
2003-Dec 2008. COPD was identified 
using primary care records.  
 
Age 
NR 
 
Sex 
NR 
 
COPD severity 
Mortality up to 7 
years: 
HR 1.37 (1.23-1.52) 
Age and sex 
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NR 
 
Current smokers 
NR 
 
History of CVD 
NR 
 
Raposeiras 
2012 
(abstract) 
Cross sectional and 
cohort study of 
patients with ACS 
4 497 consecutive patients admitted to 
Spanish hospitals for ACS. The 
ascertainment method for COPD was 
unclear.  
Age 
NR 
 
Sex 
NR 
 
COPD severity 
NR 
 
Current smokers 
NR 
 
History of CVD 
NR 
In-hospital death  
OR 1.04 (1.03-1.04) 
 
Follow up mortality  
HR 1.69 (1.41-2.03), 
median follow up 3.1 
years 
GRACE score 
β-blocker therapy 
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Rha 2009 
(abstract) 
Case control study 
in Korea AMI 
registry from 2005 
to 2007 
AMI patients in KAMIR Age 
Mean 71.7 (SD 10.0) 
 
Sex 
NR 
 
COPD severity 
NR 
 
Current smokers 
NR 
 
History of CVD 
NR 
 
Mortality at 8 months 
OR 2.69, 95% CI could 
not be calculated from 
reported information.  
Unadjusted  
Salisbury 
2007 
19 centre 
prospective study of 
patients presenting 
with MI in a cohort 
study  
MI patients in PREMIER study 
restricted to patients discharged alive 
after MI. Patients were considered to 
have COPD if they had a documented 
history of obstructive pulmonary 
disease (COPD or asthma) or had 
Age 
Mean 64.5 (SD, 12.4) 
 
Sex 
61.8% male 
 
COPD severity 
Mortality up to 1 year 
HR 2.00 (1.44-2.79)  
Age, gender, race, avoidance of 
health care due to cost, smoking, 
diabetes, hypertension, CHF, 
ejection fraction, previous CVD, 
MI diagnosis type, new onset HF 
after MI, diseased vessels on 
angiogram, enrolling site, 
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therapy specific for obstructive 
pulmonary disease.  
NR 
 
Current smokers 
37.6% 
 
History of CVD 
Previous MI – 29.7% 
Previous HF – 24.3% 
 
percentage of MI quality of care 
indicators of the centre, treatment 
type  
Stefan 2012 Cross sectional 
study with follow up 
of patients 
hospitalised with 
AMI at greater 
Worcester, 
Massachusetts 
between 1997-2007 
Patients hospitalised with AMI in 
greater Worcester, Massachusetts 
medical centres. COPD patients were 
identified by previous mention of 
clinical or radiographic evidence for 
COPD in their medical record. 
Age 
Mean 74 years 
 
Sex 
52.4% male 
 
COPD severity 
NR 
 
Current smokers 
27.3% 
 
History of CVD 
In hospital: OR 1.25 
(0.97-1.34) 
 
30 day mortality: OR 
1.31 (1.10-1.58) 
Age, sex, year of hospitalisation, 
history of CVD, history of renal 
failure, type of MI (STEMI/non-
STEMI), length of stay, smoking 
status used in secondary analysis  
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Prior angina – 22.3% 
 
Prior HF – 38.6% 
 
 
*Calculated from reported data.
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All of the included studies which investigated risk of MI in people with COPD used data from 
either routine clinical or administrative databases. COPD was defined using diagnostic codes, 
these varied between COPD diagnosis in primary care, outpatient departments, hospital 
admission or discharge codes and cause of death codes. Three studies also required that COPD 
patients had been prescribed COPD medicines. One of the studies, Rodriguez 201019, included 
only patients with a recent diagnosis of COPD and followed up for up to 5 years after this to 
identify MI. Only one study3 reported a summary of COPD severity, and only two reported 
prevalence of current smokers. Four studies reported a cohort analysis only.  Two studies4 19 
reported a cohort analysis as well as a case control analysis. One study reported the results of a 
cohort analysis and an analysis of period prevalence. One study20 compared rates of MI in 
patients with COPD to standardised populations rates of MI.  
 
Two studies9 21 were identified which investigated the risk of MI associated with AECOPD. 
Both studies defined risk periods after the onset of AECOPD and used within person designs 
to compare the risk to a baseline period.   
 
Nine studies reported mortality for COPD patients after an MI compared to non-COPD 
patients. Five studies11 12 14 15 22 reported a comparison of in-hospital mortality after an MI 
between COPD patients and non-COPD patients. Eight studies10 12 13 23-27 used a time to event 
analysis to investigate death after discharge from a hospital admission for MI.   
 
Risk of bias assessment 
The proportion of studies (or analyses, where appropriate) which were assessed as either lower, 
unclear, or higher risk of bias for each of the research questions is presented in Figure 2. 
Detailed results from the risk of bias assessment for individual studies are presented in the 
appendix.
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Figure 2. Summary of risk of bias for risk assessments for: A 
studies investigating risk of MI associated with COPD; B studies investigating risk of MI associated with AECOPD; and C studies investigating risk of death 
following MI in people with COPD. AECOPD, acute exacerbation of COPD; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction.
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Risk of MI in people with COPD 
Of 9 included studies, 8 found a higher risk of MI in COPD patients compared to non-COPD 
patients. Six studies estimated the ratio of incidence rates of MI in COPD patients compared to 
non-COPD patients. Five studies4 19 20 28 29 estimated this for all MIs, this ranged from IRR 1.18 
(95% CI, 0.81-1.71) to 5.31 (4.54-6.21). One study2 30 estimated the IRR for hospitalisation due 
to MI (IRR 1.49, 95% CI 0.71-3.13) and fatal MIs (1.51, 1.14-2.01). Two studies31 32 estimated 
the ratio of hazard of MI in COPD patients compared to non-COPD patients one study 
estimated this to be HR 1.26, 95% CI 1.25-1.27, the other study estimated this to be HR 1.47 
(1.41-1.55) for those with no previous MI, and HR 1.33 (1.23-1.43) for those with a previous 
MI. One study2 30 estimated the ratio of odds of period prevalence over five years of acute MI in 
COPD patients compared to non-COPD patients (OR 1.61, 95% CI 1.43-1.81). Only one3 of 
the included cohort studies comparing risk of MI in people with COPD and people without 
COPD adjusted for smoking status. This study reported results stratified by age groups. Meta-
analysis of these results showed an increased risk of MI for people with COPD (HR 1.72, 95% 
CI 1.22-2.42) (Figure 3).  Two of the included case-control studies adjusted for smoking status. 
Meta-analysis of these results did not show an increased risk of MI for people with COPD (OR 
1.18, 95% CI 0.80-1.76) (Figure4). Meta-analysis was not conducted for the studies which did 
not adjust for smoking as heterogeneity was too high (I2=93%). These results are graphically 
summarised in Figure 5.  
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Figure 3. Forest plot showing risk of MI associated with COPD in cohort studies which 
adjusted for smoking status. CIs may vary slightly from those quoted in tables due to 
transformation during meta-analysis. COPD, chronic obstructive pulmonary disease; MI, 
myocardial infarction. 
 
 
Figure 4. Forest plot showing risk of MI associated with COPD in case-control studies which 
are adjusted for smoking status. CIs may vary slightly from those quoted in tables due to 
transformation during meta-analysis. COPD, chronic obstructive pulmonary disease; MI, 
myocardial infarction. 
 
 
Figure 5. Forest plot showing risk of MI associated with COPD in cohort studies which did 
not adjust for smoking status. CIs may vary slightly from those quoted in tables due to 
transformation during meta-analysis. COPD, chronic obstructive pulmonary disease; MI, 
myocardial infarction. 
 
Some studies investigated whether the effect of COPD on the risk of MI was different in terms 
of age and severity of airflow obstruction. Feary 20103 found that the effect of COPD on risk 
of MI was higher in the 35-44 year age group (HR 10.34, 95% CI 3.28-32.6) compared to older 
age groups (45-54 years HR 1.22 (95% CI, 0.55-2.74), 55-64 years HR 1.55 (95% CI, 1.07-2.26), 
65-74 years HR 1.78 (95% CI, 1.37-2.31), ≥75 years HR 1.34 (95% CI, 1.03-1.73)). Sidney 
200529 reported similar findings, the effect of COPD on risk of MI was higher in those who 
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were aged 40-64 years (HR 2.43, 95% CI 1.98-2.98) compared to those who were aged over 64 
years (HR 1.73, 95% CI 1.54-1.94).  Schneider 20104 investigated the risk of MI by sub-group of 
COPD severity. They found that the effect of COPD on the risk of MI was greater in those 
with severe COPD (OR 3.00, 95% CI 1.53-5.86) compared to those with moderate (OR 1.30, 
95% CI 1.04-1.62) or mild COPD (OR 1.79, 95% CI 1.12-2.86).  
 
Risk of MI associated with AECOPD 
Donaldson 20109 conducted a self controlled case series using data from The Health 
Improvement Network (THIN). They used prescription of antibiotics and steroids in COPD 
patient to identify AECOPD and report an increased risk of MI in the 1-5 days following the 
onset of AECOPD (IRR 2.27, 95% CI 1.10-4.70). No difference in the risk of MI was found 
for the period 6-49 days, or at any time point when the alternative definitions of AECOPD of 
prescription of steroids alone or antibiotics alone were used. Halpin 201121 reported a secondary 
analysis of the UPLIFT trial, which was an RCT comparing inhaled tiotropium and placebo in 
COPD patients with a primary outcome of reduction in FEV1 decline. Time to first AECOPD 
was a secondary outcome. AECOPD were identified using a symptom based definition and 
were reported to trial staff at regular study visits. Data on MI were collected as serious adverse 
events. This study found that compared to the 30 days prior to AECOPD risk of MI in the 30 
days following AECOPD was increased (IRR 13.04; 95% CI 1.71-99.7).These results are 
graphically summarised in Figure 6. Due to different exposure time periods, the results for 
within person studies investigating the risk of MI associated with AECOPD were not pooled in 
meta-analysis.  
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Figure 6. Forest plot showing risk of MI associated with acute exacerbations of COPD. CIs 
may vary slightly from those quoted in tables due to transformation during meta-analysis. 
COPD, chronic obstructive pulmonary disease; MI, myocardial infarction. 
 
Risk of death after MI in people with COPD 
Of the studies investigating differences in in-hospital mortality after an MI, two12 22 found an 
increased risk of mortality for COPD patients (RR 1.39, 95% CI 1.16-1.67 (unadjusted); and OR 
1.04, 95% CI 1.03-1.04). Two studies14 15 did not find evidence for increased in-hospital 
mortality for COPD patients (OR 0.40, 95% CI 0.20-1.24; OR 1.25, 95% CI 0.97-1.34). One 
study11 reported results split by type of MI and did not find an increased in-hospital mortality 
for COPD patients after a STEMI (OR 1.05, 95% CI 0.95-1.17), but did after a non-STEMI 
(OR 1.21, 95% CI 1.11-1.33). Meta-analysis of adjusted results showed weak evidence for an 
increased risk of in-hospital death for COPD patients (OR 1.13, 95% CI 0.97-1.31) (Figure 7).  
 
 
Figure 7. Forest plot showing risk of in-hospital death following MI for patients with COPD 
compared to patients without COPD. CIs may vary slightly from those quoted in tables due to 
transformation during meta-analysis. COPD, chronic obstructive pulmonary disease; MI, 
myocardial infarction.  
 
One study14 reported mortality at 30-days for COPD patients compared to non-COPD patients. 
This study found increased mortality for COPD patients (OR 1.31, 1.10-1.58). Another study33 
reported mortality at 8 months, and in an unadjusted analysis, found increased mortality for 
COPD patients compared to non-COPD patients (OR 2.69, 95% CI was not reported and 
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could not be calculated).  One study22 also found, on unadjusted analysis, that mortality was 
greater for COPD patients at 1 (RR 1.34, 95% CI 1.16-1.55) and 5 years (RR 1.28, 95% CI 1.18-
1.40) after MI. 
 
Eight studies10 12 13 23-27 reported results of survival analysis of mortality during follow up after an 
MI. All of the studies reported higher mortality for COPD patients compared to non-COPD 
patients during follow up after discharge following an MI. Hazard ratios ranged from 1.15 (95% 
CI, 1.04-1.28) to 2.15 (95% CI, 1.30-3.55). However, one of these studies13 found no evidence 
of a difference in mortality when restricting the time period to the first 30 days following 
discharge (HR 0.89, 95% CI 0.68-1.11). Meta-analysis of studies which reported adjusted results 
showed an increased risk of death after discharge following MI for COPD patients compared to 
non-COPD patients (HR 1.26, 1.13-1.40) (Figure 8). Four of the studies included under this 
question were excluded from meta-analysis for methodological12 33 or clinical heterogeneity25 27.     
 
 
Figure 8. Forest plot showing risk of death after discharge following MI for patients with 
COPD compared to patients without COPD. Cis may vary slightly from those quoted in tables 
due to transformation during meta-analysis. COPD, chronic obstructive pulmonary disease; MI, 
myocardial infarction. 
 
Discussion 
Main findings 
Most studies which investigated the risk of MI in people with COPD found that those with 
COPD have higher risk of MI than people who do not have COPD, however it is unclear how 
much of this increased risk is due to smoking status. The included cohort study which adjusted 
for smoking status showed an increased risk of MI in people with COPD, but this was not 
apparent in pooled analysis of the case-control studies which adjusted for smoking status. Both 
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of the included studies which investigated the risk of MI associated with AECOPD found an 
increased risk of MI in the weeks following AECOPD. Most studies which investigated 
mortality after an MI for COPD patients compared to non-COPD patients found that mortality 
after discharge was greater for those with COPD, and an increased risk of death was found on 
pooled analysis. However, findings on in-hospital mortality after an MI were mixed, and there 
was only weak evidence for increased risk of death in-hospital for COPD patients on pooled 
analysis.  
 
Limitations of included studies and future work 
One common limitation among the included studies, particularly those which investigated the 
risk of MI associated with COPD was missing information on smoking status. As smoking is 
very strongly associated with both COPD and risk of MI, it is likely to be a major confounder in 
all studies investigating this association. All of the studies in this review which investigated this 
association used either clinical or administrative routine data sources. Routine data is a 
potentially rich source of information on huge numbers of patients. However, data on smoking 
is not routinely recorded in all administrative databases. Indeed, all of those studies which did 
not have data for smoking in this question used administrative databases. Future studies on the 
association between COPD and cardiovascular disease should use data sources which contain 
reliable information on smoking status.  
 
Further studies should be carried out to confirm findings that AECOPD are periods of 
increased risk of MI for people with COPD. These studies should ensure they use validated 
exposure measures and are adequately powered. Possible reasons for an increased risk of MI 
during AECOPD include both increased inflammation and the potential cardiovascular effects 
of the drugs used to treat AECOPD. If indeed the finding of increased risk during AECOPD is 
confirmed, future studies should attempt to disentangle the reasons for increased risk of MI. In 
addition, studies should investigate factors which might modify this relationship, such as drugs 
used for treatment of COPD and cardiovascular prevention. Another potential bias in studies 
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which investigate the relationship between AECOPD and MI which could explain some of the 
increased risk of MI after AECOPD is differential misclassification of episodes of angina as 
AECOPD.   
 
No studies were found which investigated the risk of MI associated with the frequent 
exacerbator phenotype. The frequent exacerbator phenotype may prove to be a useful 
characteristic for stratifying cardiovascular risk among COPD patients. Future cohort studies of 
cardiovascular disease in people with COPD should, where possible, phenotype participants 
and investigate the relationship between exacerbator phenotype and risk of MI. Few included 
studies assessed the influence of severity of COPD on risk of MI, further research should 
investigate this relationship as well as the influence of severity of COPD on risk of death 
following MI. 
 
A further limitation of several of the included studies into death following MI was availability of 
information on cause of death. Collection of information on cause of death in future studies 
would allow investigators to draw more confidence conclusions about the reasons for increased 
risk of death following MI for people with COPD.  
 
Strengths and limitations of this review 
This review benefitted from using a comprehensive search strategy which covered several 
bibliographic databases. As the relationship between AECOPD and MI has not been 
extensively studied, the inclusion criteria for this research question were kept purposively broad. 
This allowed all information pertaining to this relationship to be included in the evidence 
synthesis. One potential limitation of systematic reviews is publication bias. The potential for 
publication bias was highest for the review of outcomes after MI. In order to reduce the risk of 
this bias, we only included studies which specifically investigated the risk of COPD on MI 
rather than several different potential prognostic factors, as studies which investigated several 
factors which did not find an association between COPD and MI may not have reported this in 
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the abstract, or even in the text.  Due to clinical and statistical heterogeneity, meta-analysis 
could only be conducted for some of the research questions. Where meta-analysis was 
conducted, statistical heterogeneity was in general high, and this may limit the generalisability of 
pooled estimates.  
 
Conclusions 
There is good evidence of an increased risk of MI in people with COPD, however it is unclear 
to what extent this association is due to smoking status. 
 
There is some evidence that among people with COPD, AECOPD represent periods of 
increased risk of MI. However, further larger studies using validated exposure methods are 
needed to support this finding.  
 
There is weak evidence that in-hospital mortality is higher for people with COPD after an MI. 
There is good evidence that post-discharge mortality after an MI is higher for people with 
COPD.  
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3.3 Summary  
 
 People with COPD are at higher risk of MI than those who do not have COPD 
 This increased risk of MI cannot be completely explained by smoking or other 
confounders 
 There is some suggestion that AECOPD represent periods of increased risk of MI for 
those with COPD, however studies have been limited by lack of validated AECOPD 
definitions and low power 
 There is weak evidence that COPD patients have higher in-hospital mortality after MI 
compared to those who do not have COPD 
 There is good evidence that COPD patients have higher risk of death following 
discharge from hospital after MI compare to those who do not have COPD 
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Chapter 4: Closing the mortality gap after a myocardial 
infarction in people with and without Chronic Obstructive 
Pulmonary Disease (Research paper II) 
 
4.1 Preamble 
Following the systematic review (Research Paper I), it was clear that there was evidence for an 
increased risk of death following MI for those with COPD. Previous work has also suggested 
that COPD patients receive different treatment compared to people without COPD (Stefan et 
al. 2012), and that COPD patients would benefit from increased prescription of β-blockers 
following MI (Quint et al. 2013).  
 
As previously mentioned, 50% of the decrease in mortality due to MI has been attributed to 
improved care after acute MI (Smolina et al. 2012). This study therefore aimed to investigate the 
risk of death following MI in those with COPD compared to those without COPD, and to 
investigate whether any differences in mortality could be explained by differences in recognition 
and management between people with and without COPD.  
 
 
This paper was published in Heart, and is available here:  
 
Rothnie KJ, Smeeth L, Herrett E, Pearce N, Hemingway H, Wedzicha J, Timmis A, Quint JK. 
‘Closing the mortality gap after a myocardial infarction in people with and without Chronic 
Obstructive Pulmonary Disease’. Heart. 2015 101:1103-1110.  
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4.2 Research paper 
Closing the mortality gap after a myocardial infarction in people with and 
without COPD 
Authors Kieran J Rothnie1, Liam Smeeth1,5, Emily Herrett1, Neil Pearce1, Harry Hemingway2,5, 
Jadwiga Wedzicha3, Adam Timmis4,5, Jennifer K Quint1  
 
Abstract 
Objective Patients with chronic obstructive pulmonary disease (COPD) have increased 
mortality following myocardial infarction (MI) compared with patients without COPD. We 
investigated the extent to which differences in recognition and management after MI could 
explain the mortality difference. 
Methods 300 161 patients with a first MI between 2003 and 2013 were identified in the UK 
Myocardial Ischaemia National Audit Project database. Logistic regression was used to compare 
mortality in hospital and at 180 days postdischarge between patients with and without COPD. 
Variables relating to inhospital factors (delay in diagnosis, use of reperfusion and time to 
reperfusion/use of angiography) and use of secondary prevention were sequentially added to 
models. 
Results Mortality was higher for patients with COPD both inhospital (4.6% vs 3.2%) and at 
180 days (12.8% vs 7.7%). After adjusting for inhospital factors, the effect of COPD on 
inhospital mortality after MI was reduced for both ST-elevation myocardial infarctions 
(STEMIs) and non-STEMIs (STEMIs OR 1.24 (95% CI 1.10 to 1.41) to 1.13 (95% CI 0.99 to 
1.29); non-STEMIs OR 1.34 (95% CI 1.24 to 1.45) to 1.16 (95% CI 1.07 to 1.26)). Adjusting for 
inhospital factors reduced the effect of COPD on mortality after non-STEMI at 180 days (OR 
1.56 (95% CI 1.47 to 1.65) to 1.37 (95% CI 1.31 to 1.44)). Adjusting for use of secondary 
prevention also reduced the effect of COPD on mortality at 180 days for STEMIs and non-
STEMIs (STEMIs OR 1.45 (95% CI 1.31 to 1.61) to 1.25 (95% CI 1.11 to 1.41); non-STEMIs 
OR 1.37 (95% CI 1.31 to 1.44) to 1.26 (95% CI 1.17 to 1.35). 
Conclusions Delayed diagnosis, timing and use of reperfusion of a STEMI, use of angiography 
after a non-STEMI and use of secondary prevention medicines are all potential explanations for 
the mortality gap after MI in people with COPD.
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Key Messages 
What is already known about the subject? 
People with chronic obstructive pulmonary disease (COPD) have both a higher risk for 
myocardial infarction (MI) and poorer long-term outcomes following MI. Previous 
studies have also shown that patients with COPD are less likely to receive β blockers on 
discharge after an MI and are less likely to receive PCI after an ST-elevation myocardial 
infarction (STEMI). Findings for differences in inhospital mortality have been mixed, 
with some studies finding higher mortality for patients with COPD and some studies 
finding no difference. The heterogeneity in findings may be due to differences in 
treatment practices. The extent to which differences in treatment can explain 
differences in mortality at the population level, the ‘mortality gap’, is unclear. 
What does this study add? 
This study aimed to determine whether differences in inhospital treatment and 
discharge between patients with and without COPD could explain all or some of the 
difference in mortality for both inhospital and at 180 days postdischarge at the 
population level. We found that delayed diagnosis of MI, decreased use of reperfusion 
and increased time to reperfusion after a STEMI, decreased use of angiography after a 
non-STEMI and decreased use of secondary prevention medicines might all explain 
some of the mortality gap for people with COPD after an MI. 
How might this impact on clinical practice? 
We have found that differences in potentially modifiable inhospital processes may 
explain some of the mortality gap between patients with and without COPD after an 
MI. Clinicians need to be aware that it may be easier to miss MIs in people with COPD 
and may need to be aware of more unusual presentations of MI in people with COPD. 
In addition, our results suggest that patients with COPD may benefit from more 
aggressive treatment after an MI. 
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Introduction 
People with chronic obstructive pulmonary disease (COPD) are at higher risk of cardiovascular 
disease,[1, 2], and are known to have poorer medium and longer term outcomes after 
myocardial infarction (MI) compared to people without COPD, however findings for in-
hospital mortality have been mixed,[3, 4, 5, 6]. The heterogeneity in findings on in-hospital 
mortality may be due to differences in treatment practices. COPD is currently the third leading 
cause of death worldwide,[7]. As up to a third of deaths in people with COPD are due to 
cardiovascular disease,[8], reducing deaths after MI in this population is important. In addition, 
there is a lack of evidence for the effectiveness of treatments in those with co-morbidities.  
 
Recent years have seen improvements in outcomes for patients after MI,[9]. However, several 
recent studies have continued to report poorer mortality for COPD patients after an MI. 
Although the reasons for increased mortality after MI in patients with COPD are likely to 
include biological factors related to COPD, differences in recognition and management between 
patients with and without COPD may play a role. Recent work has demonstrated that patients 
with COPD are less likely to receive reperfusion treatment or β-blockers after an MI,[10], and 
that not prescribing β-blockers to patients with COPD impacts on mortality,[11].  
 
Little is known about potential differences in prescribing of other secondary prevention 
medicines, inhospital treatment, or on the effects that any differences in these potentially 
modifiable factors may have on mortality.  
 
We used Myocardial Ischaemia National Audit Project (MINAP), a national register of hospital 
care for acute coronary syndromes (ACS), to investigate the extent to which differences in 
recognition and management of an MI might account for the mortality gap in patients with 
COPD at the population level.  
 
Methods 
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Data source 
The MINAP database is a registry of all admissions for MI and other ACS to hospitals in the 
UK. The dataset includes information on patient demographics, comorbidities, drugs on 
admission, initial diagnosis, final diagnosis, inhospital drug treatment, timing of reperfusion 
therapies, inhospital outcome and drugs given on discharge.,[12].  
 
We included all patients with a first diagnosis of ST-elevation myocardial infarction (STEMI) 
from January 2003 to June 2013 or non-ST-elevation myocardial infarction (non-STEMI) from 
January 2004 to December 2012. Records were excluded if they did not have a patient unique 
identifier, if patients had missing values for presence of obstructive airway disease or smoking 
history or if Office of National Statistics (ONS) mortality data were missing. 
 
Exposure identification 
The obstructive airway disease variable in MINAP does not differentiate between COPD and 
asthma. In order to identify patients with COPD for this analysis, a strategy was developed and 
tested in a subset of the data linked with data from the Clinical Practice Research Datalink 
(CPRD). CPRD is a large UK clinical database of primary care medical records which includes 
over 5.5 million active patients (8% of the population). [13]. Around half of the CPRD records 
have been linked to the MINAP database through the CALIBER linkage scheme. [14] Patients 
with COPD can be identified in CPRD through the use of validated diagnostic codes. Using 
this subset of linked data, we developed strategy for identifying COPD patients in MINAP 
using CPRD-identified COPD as a reference standard. In this subset of data, patients with 
COPD were identified using a combination of MINAP-recorded obstructive airway disease and 
a smoking history (ex or current smoker). This strategy resulted in adequate identification of 
patients with COPD in MINAP, with agreement of 90.9%. 
 
Outcome definitions 
Recognition and management 
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Delay in diagnosis of MI, reperfusion after a STEMI, use of angiography in hospital after a non-
STEMI and discharge on secondary prevention drugs were investigated. Two definitions of 
delay in diagnosis were investigated for patients with a final diagnosis of STEMI: (1) delay in 
diagnosis of definite STEMI (defined as those who did not have an initial diagnosis of definite 
STEMI) and (2) delay in diagnosis of ACS (defined as those whose initial diagnosis was not 
STEMI, probable MI or ACS). For those patients with a final diagnosis of non-STEMI, one 
definition for delay in diagnosis was investigated: delay in diagnosis of ACS (defined as those 
whose initial diagnosis was not STEMI, probable MI or ACS). 
 
Mortality outcomes 
The UK ONS collects data on all recorded deaths in England and Wales. MINAP is linked with 
ONS mortality data, which provides data on vital status at 180 days postdischarge. Mortality at 
180 days postdischarge was assessed for those who survived until discharge. 
 
Statistical analysis 
Demographic and clinical characteristics were tabulated for patients with COPD and non-
COPD patients. All analyses were stratified by type of MI (STEMI or non-STEMI). The models 
were adjusted for smoking status, age, sex and calendar year, comorbidities including prior 
angina, cerebrovascular disease, chronic kidney failure, diabetes, congestive heart failure, 
hypertension, hyperlipidaemia, peripheral vascular disease, previous percutaneous coronary 
intervention (PCI) and previous coronary artery bypass graft and cardiovascular drugs (ACE 
inhibitor or angiotensin receptor blocker, β blocker, statin and thienopyridine) use on 
admission. Following the suggested practice for missing data in MINAP,[15] missing values for 
comorbidities and drugs on admission were recoded to ‘no’. Other variables were not recoded 
and analyses were conducted on the basis of complete case analysis. Data were analysed using 
Stata V.13.0. 
 
Analysis was conducted in three parts: 
i) Describing the problem: differences in mortality after MI between patients with 
COPD and non-COPD patients 
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We compared crude proportions of patients with COPD dying inhospital and at 180 days 
postdischarge to patients without COPD. We then used logistic regression to adjust the 
comparisons of mortality for possible confounders for age, sex, smoking status, calendar year, 
comorbidities and drugs used on arrival. 
 
ii) Possible inhospital explanations: differences in recognition and management after an 
MI between patients with COPD and non-COPD patients 
For STEMIs, we investigated differences in delay in STEMI diagnosis, use of primary PCI 
(pPCI), use of thrombolysis, time to reperfusion from hospital admission and use of secondary 
prevention drugs on discharge. We investigated the impact of delay in diagnosis on time to 
reperfusion, and we assessed whether COPD modified this relationship. For non-STEMIs, we 
investigated delay in diagnosis of MI, use of angiography in hospital and use of secondary 
prevention drugs on discharge. 
 
iii) Accounting for differences in mortality after MI between patients with COPD and 
non-COPD patients in terms of hospital processes 
In order to investigate to what extent differences in diagnosis and treatment of patients with 
COPD after an MI might account for differences in mortality, variables relating to inhospital 
processes investigated in (2) were sequentially added to mortality models created in (1) with 
reference to a directed acyclic graph (See supplementary material). Attributable risk of death due 
to COPD following MI was calculated before and after adjustment for inhospital processes 
using the formula (OR-1)/OR×100. 
 
We conducted sensitivity analyses to investigate the potential impact of misclassification of 
asthma with COPD, and to investigate the impact of suboptimal management on risk of death 
among people with COPD (supplementary material).  
 
Results 
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Characteristics of participants 
Of the 300 146 patients with first MI identified over the period, 34 027 (11.3%) had COPD. 
The inclusion and exclusion of records in the MINAP database are detailed in Figure 1. The 
characteristics of the patients included in the study are detailed in Table 1. Mortality was higher 
for COPD patients both in-hospital (4.6% vs 3.2%) and at 180 days (12.8% vs 7.7%). 
98 
 
Table 1. Characteristics of patients in the study. 
Characteristic COPD n (%) Non-COPD n (%) 
Sex 
Male  
Female 
 
21 053 (61.9) 
12 908 (37.9) 
 
178 611 (67.1) 
86 504 (32.5) 
Missing 80 (0.2) 956 (0.36) 
Age 
<60 
60-70 
71-80 
>80 
 
7627 (22.6) 
8830 (26.0) 
10 622 (31.3) 
6786 (20.0) 
 
90 557 (34.1) 
62 947 (23.7) 
61549 (23.2) 
50 126 (18.9) 
Missing 
 
0 0 
Smoking status 
Current 
Ex 
Never 
Missing 
 
 
14 666 (43.2) 
19 244 (56.8) 
0  
0 
 
90 026 (34.0) 
87 612 (33.0) 
87 541 (33.0) 
0 
Previous Angina 
Yes 
No 
Missing 
 
 
7 426 (21.8) 
25 936 (76.2) 
679 (2.0) 
 
41 417 (15.6) 
223 089 (83.9) 
1 565 (0.6) 
Previous PCI 
Yes 
No 
Missing 
 
 
908 (2.7) 
32 082 (94.3) 
1 051 (3.1) 
 
6 622 (2.5) 
255 449 (96.0) 
3 916 (1.5) 
Previous CABG 
Yes 
No 
Missing 
 
 
786 (2.3) 
32 227 (94.7) 
1 028 (3.0) 
 
5 704 (2.1) 
256 574 (96.4) 
3 793 (1.4) 
Diabetes 
Yes – diet controlled 
Yes – oral  
Yes – insulin  
Yes – insulin and oral 
No 
Missing 
 
 
1 193 (3.5) 
2 902 (8.5) 
1 241 (3.7) 
176 (0.5) 
28 030 (82.3) 
499 (1.5) 
 
8 322 (3.1) 
21 418 (8.1) 
8 986 (3.4) 
1 178 (0.4) 
223 040 (83.8) 
3 127 (1.2) 
Treated for hypertension 
Yes 
No 
Missing 
 
 
15 304 (45.0) 
18 151 (53.3) 
586 (1.7) 
 
117 886 (44.3) 
146 459 (55.1) 
1 726 (0.7) 
Treated for 
hyperlipidaemia 
Yes 
No 
Missing 
 
 
 
9 091 (26.7) 
23 399 (68.7) 
1 551 (4.6) 
 
 
73 641 (27.7) 
185 043 (69.6) 
7 387 (2.8) 
Peripheral vascular 
disease 
Yes 
 
 
1 962 (5.8) 
 
 
9 061 (3.4) 
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No 
Missing 
 
30 872 (90.7) 
1 207 (3.6) 
 
253 720 (95.4) 
3 290 (1.2) 
Previous cerebrovascular 
disease 
Yes 
No 
Missing 
 
 
 
2 823 (8.3) 
30 354 (89.2) 
864 (2.5) 
 
 
16 829 (6.3) 
247 418 (93.0) 
1 824 (0.7) 
Heart failure 
Yes 
No 
Missing 
 
 
2 037 (6.0) 
31 080 (91.3) 
924 (2.71) 
 
7 426 (2.8) 
256 677 (96.5) 
1 968 (0.7) 
Renal failure 
Yes 
No 
Missing 
 
 
1 681 (4.9) 
31 452 (92.4) 
908 (2.7) 
 
8 428 (3.2) 
255 732 (96.1) 
1 911 (0.7) 
Beta blocker on arrival 
Yes 
No 
Missing 
 
 
 
3 016 (8.9) 
23 544 (69.1) 
7 481 (22.0) 
 
44 585 (16.8) 
162 876 (61.2) 
58 610 (22.0) 
ACEi/ARB on arrival 
Yes 
No 
Missing 
 
 
8 228 (24.2) 
18 331 (53.9) 
7 482 (22.0) 
 
57 288 (21.53) 
150 036 (56.4) 
58 747 (22.1) 
Statin on arrival 
Yes 
No 
Missing 
 
 
9 446 (27.8) 
17 409 (51.1) 
7 186 (21.1) 
 
 
65 062 (24.5) 
144 498 (54.3) 
56 511 (21.2) 
 
Thienopyridine on 
arrival 
Yes 
No 
Missing 
 
 
2 948 (8.7) 
22 729 (66.8) 
8 364 (24.6) 
 
 
23 240 (8.7) 
176 548 (66.4) 
66 283 (24.9) 
 
Death in hospital 
 
1 561 (4.6) 8 574 (3.2) 
Death at 180 days 
(survivors to discharge) 
 
4 166 (12.8) 19 693 (7.7) 
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Figure 1. Study selection. 
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ST-elevation myocardial infarctions 
i) Describing the problem: differences in mortality after MI between patients with COPD and non-COPD 
patients 
After adjusting for age, sex, smoking status, calendar year, comorbidities and drugs on arrival, 
mortality in patients with COPD was higher than non-COPD patients in hospital (OR 1.24, 
95% CI 1.10 to 1.41), and 180 days after discharge (OR 1.45, 95% CI 1.33 to 1.59).  
 
ii) Possible inhospital explanations: differences in recognition and management after an MI between patients with 
COPD and non-COPD patients 
Differences in diagnosis and inhospital recognition management are presented in Table 2. 
Patients with COPD who had a STEMI were more likely to have an initial diagnosis other than 
definite STEMI (OR 1.24, 95% CI 1.19 to 1.30) or ACS (OR 1.52, 95% CI 1.42 to 1.62). After a 
STEMI, patients with COPD were less likely to have pPCI (OR 0.87, 95% CI 0.83 to 0.92). 
There was no evidence that patients with COPD were less likely to receive thrombolysis (OR 
0.96, 95% CI 0.91 to 1.10). 
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Table 2. Differences in recognition and treatment of STEMIs between patients with COPD and non-COPD patients 
In-hospital treatment and 
diagnosis 
COPD  
N (%) 
Non-COPD  
N (%) 
Unadjusted OR 
(95% CI) 
Minimally adjusted  
OR (95% CI)* 
Adjusted OR (95% 
CI)** 
Initial diagnosis other than 
definite STEMI (for final 
diagnosis is STEMI) 
 
 3 080 (23.9) 24 752 (19.9) 1.26 (1.21-1.32) 1.28 (1.23-1.34) 1.24 (1.19-1.30) 
Initial diagnosis other than 
ACS 
 
1 186 (9.2) 7 398 (6.0) 1.59 (1.50-1.71) 1.68 (1.64-1.73) 1.52 (1.42-1.62) 
Primary PCI  
 
4108 (31.8) 44177 (35.6) 0.84 (0.81-1.87) 0.69 (0.67-0.71) 0.87 (0.83-0.92) 
Thrombolysis  
 
5449 (42.6) 52414 (42.7) 0.99 (0.96-1.03) 1.00 (0.96-1.03) 0.96 (0.91-1.10) 
Time to reperfusion  COPD  
Minutes (median 
IQR) 
Non-COPD 
Minutes(median 
IQR) 
Unadjusted 
exponentiated 
regression 
coefficient (95% CI) 
Minimally adjusted 
exponentiated 
regression 
coefficient (95% 
CI)* 
Adjusted 
exponentiated 
regression 
coefficient (95% 
CI)** 
Time to reperfusion from 
admission (overall) 
 
37.1 (21.8-67.7) 35.0 (21.8-63.4) 1.07 (1.04-1.09) 1.05 (1.03-1.07) 1.04 (1.02-1.07) 
Time to reperfusion from 
admission (initial diagnosis 
other than STEMI) 
 
152.9 (74.3-705.6) 109.2 (50.2-260.0) 1.44 (1.24-1.67) 1.35 (1.16-1.58) 1.47 (1.15-1.88) 
Time to reperfusion from 
admission (initial diagnosis 
STEMI) 
35.0 (21.8-63.4) 35.0 (21.8-61.2) 1.04 (95% CI, 1.01-
1.06) 
1.03 (1.01-1.05) 1.03 (1.00-1.05) 
Discharge treatment COPD n (%) Non-COPD n (%) Unadjusted OR 
(95% CI) 
Minimally adjusted 
OR* (95% CI) 
Adjusted OR (95% 
CI)** 
Discharge on β-blockers 5776 (44.7) 94784 (76.4) 0.25 (0.24-0.26) 0.25 (0.24-0.26) 0.26 (0.25-0.27) 
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Discharge on ACE inhibitor 
or angiotensin receptor 
blocker 
 
9579 (74.2) 96508 (77.8) 0.83 (0.79-0.86) 0.87 (0.83-0.91) 0.89 (0.85-0.93) 
Discharge on aspirin 
 
10344 (80.1) 102925 (82.9) 0.83 (0.79-0.87) 0.87 (0.83-0.92) 0.90 (0.85-0.94) 
Discharge on statin 
 
10373 (80.4) 102785 (82.8) 0.85 (0.81-0.89) 0.88 (0.84-0.93) 0.91 (0.86-0.95) 
Discharge on thienopyridine 7799 (60.4) 77543 (62.5) 0.91 (0.88-0.95) 0.96 (0.92-1.01) 0.98 (0.94-1.03) 
*Adjusted for age, sex smoking status and calendar year 
**Adjusted for age, sex, smoking status, calendar year, drugs on admission and co-morbidities 
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In adjusted results, differences in time to reperfusion have been expressed in terms of 
exponentiated linear regression coefficients which, in this case, represent ratios of geometric 
means. The relationship between COPD and time to reperfusion was found to be different 
depending on whether diagnosis of MI was delayed (p value for interaction <0.001). The 
median time to reperfusion was 43.7 min longer for patients with COPD compared with non-
COPD patients among those who had a delay in diagnosis (median time to reperfusion 152.9 
min (IQR, 74.3–705.6 min) for patients with COPD, and 109.2 min (IQR, 50.2–260.0 min) for 
non-COPD patients). This difference remained on adjusted analysis and corresponded to 47% 
(95% CI 15% to 88%) longer time to reperfusion for patients with COPD with delayed 
diagnosis of MI, compared with non-COPD patients with delayed diagnosis of MI. There was 
no difference in time to reperfusion between patients with COPD and non-COPD patients 
among those without a delay in diagnosis (see details in online supplementary appendix). 
Patients with COPD were less likely to receive any of the secondary prevention drugs, apart 
from thienopyridines, on discharge compared with non-COPD patients, β blockers significantly 
more so than other drugs (OR 0.26 (95% CI 0.25 to 0.27)). 
 
iii) Accounting for differences in mortality after MI between patients with COPD and non-COPD patients in 
terms of hospital processes 
When compared with the result found in i), inhospital mortality was reduced after adjusting 
separately for both diagnostic delay (OR 1.20 (95% CI 1.06 to 1.36)) and time to reperfusion 
and use of pPCI (OR 1.11 (95% CI 0.94 to 1.311; Table 3). After adjusting for all inhospital 
factors, the OR for mortality was 1.13 (95% CI 0.99 to 1.29). For mortality at 180 days, the OR 
was 1.45 (95% CI 1.33 to 1.59) after adjusting for age, sex, smoking, calendar year, drugs used 
on admission and comorbidities, and was 1.45 (95% CI 1.31 to 1.61) after additionally adjusting 
for diagnostic delay, use of pPCI and time to reperfusion. Adjusting for use of secondary 
prevention drugs on discharge substantially reduced ORs for 180 day mortality compared with 
models only adjusting for inhospital factors (OR 1.25 (95% CI 1.11 to 1.41)).
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Table 3. Mortality after STEMI 
 
 
 
 
 
 
All 
ORs 
compare patients with COPD with non-COPD patients 
 
 Adjusted for age, 
sex, smoking status 
and year 
 
 
 
Model 1 
Adjusted for model 
1 variables and  co-
morbidities and 
drugs on arrival 
 
 
Model 2 
Adjusted for model 
1 and 2 variables 
and diagnostic delay 
 
 
 
Model 3 
Adjusted for model 
1 and 2 variables 
and use of 
reperfusion and 
time to reperfusion 
 
Model 4 
Adjusted for model 
1, 2, 3 and 4 
 
 
 
 
Model 5 
Adjusted for model 
1, 2, 3 and 4 
variables and 
secondary 
prevention 
 
Model 6 
 OR (95% CI)      
In- hospital 
mortality 
1.27 (1.16-1.39) 1.24 (1.10-1.41) 1.20 (1.06-1.36) 1.11 (0.94-1.31)  1.13 (0.99-1.29) - 
180 day 
mortality 
1.43 (1.29-1.58) 1.45 (1.33-1.59) 1.43 (1.32-1.54) 1.46 (1.32-1.62) 1.45 (1.31-1.61) 1.25 (1.11-1.41) 
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After adjusting for inhospital processes, the estimated attributable risk of inhospital death 
following a STEMI due to COPD in patients with COPD decreased from 19.4% (95% CI 9.1% 
to 29.1%) to 11.5% (95% CI −1.0% to 22.4%). After adjusting for inhospital processes, the 
estimated attributable risk for death at 180 days due to COPD in patients with COPD following 
a STEMI decreased from 31.0% (95% CI 24.8% to 37.1%) to 20.0% (95% CI 9.9% to 29.1%). 
 
Non-ST-elevation myocardial infarctions 
i) Describing the problem: differences in mortality after MI between patients with COPD and non-COPD 
patients 
After adjusting for age, sex, smoking status, calendar year, comorbidities and drugs on arrival, 
mortality in patients with COPD was higher than non-COPD patients in hospital (OR 1.34 
(95% CI 1.24 to 1.45)) and 180 days after discharge (OR 1.56 (95% CI 1.47 to 1.65)). 
 
ii) Possible inhospital mechanisms: differences in diagnosis and management after an MI between patients with 
COPD and non-COPD patients 
Results from the comparison of treatment and diagnosis after a non-STEMI are presented in 
Table 4. Patients with COPD were more likely to have an initial diagnosis other than ACS after 
a non-STEMI (OR 1.46 (95% CI 1.41 to 1.50)). After a non-STEMI, patients with COPD were 
less likely to receive angiography in hospital (OR 0.69 (95% CI 0.66 to 0.71)). Patients with 
COPD were less likely to receive any of the secondary prevention drugs on discharge, apart 
from thienopyridines, compared with non-COPD patients, β blockers significantly more so than 
other secondary prevention drugs (OR 0.25 (95% CI 0.24 to 0.25)). 
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Table 4. Differences in recognition and inhospital treatment of non-STEMIs between patients with COPD and non-COPD patients 
In-hospital treatment 
and diagnosis 
COPD  
N (%) 
Non-COPD  
N (%) 
Unadjusted OR (95% 
CI) 
Minimally adjusted 
OR* (95% CI) 
Adjusted OR (95% 
CI)** 
Initial diagnosis 
other than MI 
 
9 551 (45.2) 50 365 (35.5) 1.50 (1.46-1.54) 1.68 (1.64-1.73) 1.46 (1.41-1.50) 
Angiography in 
hospital 
 
8 629 (40.9) 74 304 (52.2) 0.77 (0.76-0.79) 0.63 (0.61-0.65) 0.69 (0.66-0.71) 
Discharge treatment COPD n (%) Non-COPD n (%) Unadjusted OR (95% 
CI) 
Minimally adjusted 
OR* (95% CI) 
Adjusted OR (95% 
CI)** 
Discharge on beta 
blockers 
 
6 632 (31.4) 925059 (64.9) 0.25 (0.24-0.26) 0.24 (0.23-0.25) 0.25 (0.24-0.25) 
Discharge on ACE 
inhibitor or 
angiotensin receptor 
blocker 
 
12 762 (60.4) 89368 (63.0) 0.90 (0.87-0.92) 0.91 (0.88-0.94) 0.94 (0.91-0.97) 
Discharge on aspirin 
 
15 234 (72.1) 106 652 (75.1) 0.86 (0.83-0.88) 0.88 (0.85-0.91) 0.91(0.88-0.94) 
Discharge on statin 
 
15 141 (71.7) 104 804 (73.8) 0.90 (0.87-0.93) 0.90 (0.87-0.93) 0.93 (0.90-0.96) 
Discharge on 
thienopyridine 
11 277 (53.4) 78 233 (55.1) 0.93 (0.90-0.96) 0.95 (0.91-0.98) 0.97 (0.94-1.01) 
*Adjusted for age, sex smoking status and calendar year 
**Adjusted for age, sex, smoking status, calendar year, drugs on admission and co-morbidities. 
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iii) Accounting for differences in mortality after MI between patients with COPD and non-COPD patients in 
terms of hospital processes 
When compared with results found in (1), inhospital mortality was reduced after adjusting 
separately for both delay in diagnosis (OR 1.29 (95% CI 1.19 to 1.39)) and use of angiography 
(OR 1.18 (95% CI 1.09 to 1.29); Table 5). After adjusting for both delay in diagnosis and use of 
angiography the OR for inhospital mortality was 1.16 (95% CI 1.07 to 1.26). Inhospital factors 
also appeared to explain some of the mortality difference after a non-STEMI at 180 days. For 
mortality at 180 days, the OR was reduced from 1.56 (95% CI 1.47 to 1.65) to 1.37 (95% CI 
1.31 to 1.44). Use of secondary prevention also seemed to explain some of the gap in mortality 
at 180 days. Compared with the model which only adjusted for inhospital processes, the OR for 
mortality at 180 days was reduced from 1.37 (95% CI 1.31 to 1.44) to 1.26 (95% CI 1.17 to 
1.35). 
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Table 5. Mortality after non-STEMI. 
 Adjusted for age, 
sex, smoking status 
and year 
 
 
 
Model 1 
Adjusted for model 
1 variables and  co-
morbidities and 
drugs on arrival 
 
  
Model 2 
Adjusted for model 
1 and 2 variables 
and diagnostic delay 
 
 
 
Model 3 
Adjusted for model 
1 and 2 variables 
and use of 
angiography in 
hospital 
 
Model 4 
Adjusted for model 
1, 2, 3 and 4 
variables 
 
 
 
Model 5 
Adjusted for model 
1, 2, 3 and 4 
variables and 
secondary 
prevention 
 
Model 6 
 OR (95% CI)      
In-hospital 
mortality 
1.40 (1.30-1.52) 1.34 (1.24-1.45) 1.29 (1.19-1.39) 1.18 (1.09-1.29) 1.16 (1.07-1.26) - 
180 day 
mortality 
1.63 (1.56-1.70) 1.56 (1.47-1.65) 1.45 (1.38-1.52) 1.43 (1.34-1.50) 1.37 (1.31-1.44) 1.26 (1.17-1.35) 
 
All ORs compare patients with COPD with non-COPD patients 
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After adjusting for inhospital processes, the estimated attributable risk for inhospital death 
following a non-STEMI due to COPD in patients with COPD decreased from 25.4% (95% CI 
19.4% to 31.0%) to 13.8% (95% CI 6.5% to 21.6%). After adjusting for inhospital processes, 
the estimated attributable risk for death at 180-days due to COPD in patients with COPD 
following a non-STEMI decreased from 35.9% (95% CI 32.0% to 39.4%) to 20.6% (95% CI 
14.5% to 25.9%). 
 
Discussion 
Summary of main findings 
For STEMIs, some of the in inhospital mortality difference between patients with COPD and 
non-COPD patients may be attributable to delays in diagnosis and use of and increased time to 
reperfusion. Some of the increased mortality for STEMIs at longer time periods up to 6 months 
may be attributable to decreased use of secondary prevention medicines, especially β blockers, 
but not inhospital processes. For non-STEMIs, some of the difference in inhospital mortality 
may be attributable to delays in diagnosis and decreased use of angiography shortly after MI. 
Some of the increased mortality for non-STEMIs at longer time periods up to 6 months may be 
attributable to decreased use of secondary prevention medicines, and to inhospital delays in 
diagnosis and decreased use of angiography in hospital. 
 
Interpretation and comparison with other studies 
Several studies have shown both the increased risk for death following MI for people with 
COPD and differences in management. These studies specifically showed reduced use of 
secondary prevention and pPCI after a STEMI in patients with COPD,[5, 10, 16, 17, 18], these 
findings have been replicated here. This study has also shown that these differences in 
treatment are possible explanations for some of the mortality gap at the population level for 
both STEMIs and non-STEMIs. In particular, we were able to make use of the detailed timing 
variables available in MINAP to investigate differences in time to reperfusion after a STEMI. 
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F or STEMIs, we found that diagnosis of MI is more likely to be delayed for patients with 
COPD compared with non-COPD patients, and that time to reperfusion is longer after a 
STEMI. We also showed that the effect of delay in diagnosis of MI on the time to reperfusion 
was greater in patients with COPD compared with non-COPD patients. Patients with COPD 
were more likely to have a delay in diagnosis and the effect of this delay in diagnosis in time to 
reperfusion was more severe for them than non-COPD patients. The reason for the delay in 
diagnosis of MI in patients with COPD may be because symptoms of MI in patients with 
COPD may be incorrectly attributed to their COPD rather than an MI. 
 
We found that after a non-STEMI, patients with COPD were less likely to receive angiography 
in hospital than non-COPD patients, and this explained some of the excess inhospital and 180-
day mortality. Use of angiography is driven by risk scoring, and patients at moderate and higher 
risk of death within 6 months should be offered angiography within 96 h of admission to 
hospital after a non-STEMI. [19]. It is unclear why, as a population, that although patients with 
COPD are at a higher risk of mortality they are less likely to receive angiography in hospital. 
 
After both STEMIs and non-STEMIs, patients with COPD were less likely to be prescribed 
secondary prevention medicines than non-COPD patients. This may only have been to a 
clinically relevant degree for β blockers. It is known that patients with COPD are less likely to 
be prescribed β blockers after an MI, and that prescribing them improves survival. [11] This 
study has demonstrated that the increased mortality associated with not prescribing secondary 
prevention medicines could explain some of the mortality gap up to 6 months at the population 
level. 
 
We found that recognition of MI in patients with COPD was impaired compared with non-
COPD patients. However, all patients included in this analysis were eventually diagnosed with 
MI. This suggests that patients with COPD may be at higher risk of having a completely missed 
MI. Indeed, recent work has suggested that as many as 1 in 12 patients admitted to hospital with 
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an exacerbation of COPD meet the criteria for MI, and that this represents underdiagnosis of 
MI in patients with COPD. [20] However, as troponin may also be increased during stable 
periods of COPD,[21] there is also a potential for overdiagnosis of MI in people with COPD. 
Any future intervention which aims to increase recognition of MI in people with COPD should 
also investigate the potential effects of overdiagnosis. 
 
Strengths and limitations 
The major strengths of this study were its size, representativeness and level of detail on in-
hospital management and outcomes. The study included over 300,000 people and used data 
collected from all hospitals in the UK which admit patients for ACS. As secondary prevention 
treatment is known to be different for COPD patients compared to non-COPD patients, only 
using first MIs allowed us to assess the effect of COPD on mortality after an MI without bias 
due to differences in previous treatment. Another strength of this study was our ability to 
separate factors which could explain increased in-hospital mortality from increased mortality 
following discharge. If COPD patients were more likely to die in-hospital, as we found, the 
reasons that they did not receive certain treatments may have been because they were more 
likely to die before they received these treatments compared to non-COPD patients. In order to 
avoid this bias, for mortality at 180 days, we only analysed data for those who had survived until 
at least discharge. This also allowed the potential contribution of secondary prevention to the 
mortality gap to be investigated.   
 
One of the limitations of this study is potential misclassification of COPD status. The strategy 
used to identify may have misclassified asthmatic smokers as COPD patients, and may have 
misclassified COPD patients as non-COPD patients. However, the prevalence of COPD in our 
study is similar to that of previous work in similar settings,[5, 10, 16, 22]. The presence of 
asthmatics in our COPD group and COPD patients in the non-COPD group is likely to have 
biased our findings towards the null. However, this would not change our findings. In addition, 
the sensitivity analysis which compared mortality for asthmatic patients compared to non-
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asthmatic patients found that mortality was not increased in the asthmatic group (supplementary 
material). One of the limitations of using an audit database such as MINAP is the lack of 
available data which would not have been collected at hospital admission. Ideally, information 
on COPD severity and cause of death would have been collected. In addition, ideally 
information on socioeconomic status would have been available as this is a potential 
confounder for the relationship between COPD and mortality after MI. Future studies should 
investigate the relationship between COPD severity and explanations for the mortality gap in 
COPD patients after MI and cause of death in COPD patients following MI.    
 
Conclusions  
Patients with COPD appear to receive poorer treatment after an MI compared with non-COPD 
patients. These differences in recognition and treatment of MI seem to explain some of the 
mortality gap between patients with COPD and non-COPD patients both inhospital and at 6 
months postdischarge. Delayed diagnosis, timing and use of reperfusion of a STEMI, use of 
angiography after a non-STEMI and use of secondary prevention medicines are all potential 
explanations for the mortality gap after MI in people with COPD. 
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4.3 Summary 
 
 People with COPD are more likely to experience a delay in diagnosis of MI than those 
who do not have COPD, less likely to have reperfusion after a STEMI or angiography 
in hospital after a non-STEMI, and are less likely to be discharged on secondary 
prevention medicines, notably β-blockers 
 COPD patients are more likely than those without COPD to die in hospital and at 180 
days following MI 
 The effect of COPD on risk of death following MI is higher for non-STEMIs than it is 
for STEMIs 
 Some of the increased risk of death following MI for those with COPD can be 
explained by the differences in recognition and management of MI, highlighting the 
importance of cardiovascular medicine and other therapies in reducing cardiovascular 
risk for those with COPD 
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Chapter 5 Chronic obstructive pulmonary disease and acute 
myocardial infarction: effects on presentation, management, 
and outcomes (Research paper III) 
 
5.1 Preamble  
The research paper presented in this chapter is a review article which I was commissioned to 
write following the publication of research papers I and II. The aim of this article was to outline 
the current evidence for differences in presentation, management, and outcomes following MI 
between people with and without COPD. Although there is some repetition of earlier findings 
on mortality, this article extends the discussion on outcomes to include other outcomes such as 
stroke, re-current MI, and the development of heart failure. The paper concludes with a 
conceptual model combining the findings on differences in presentation, management and 
outcomes after MI for those with COPD, and how these might relate to each other.  
 
This article was originally published in European Heart Journal: Quality of Care and Clinical Outcomes, 
and is available here:  
 
Rothnie KJ & Quint JK. ‘Chronic obstructive pulmonary disease and acute myocardial 
infarction: effects on presentation, management, and outcomes.’ European Heart Journal: Quality of 
Care and Clinical Outcomes. 2016, 2(2): 81-90. 
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5.2 Research paper 
COPD and myocardial infarction: effects on presentation, management and 
outcomes 
Authors: Kieran J Rothnie & Jennifer K Quint 
 
Abstract 
Cardiovascular disease is a common cause of death in patients with chronic obstructive 
pulmonary disease (COPD) and is a key target for improving outcomes. However, there are 
concerns that patients with COPD may not have enjoyed the same mortality reductions from 
acute myocardial infarction (AMI) in recent decades as the general population. This has raised 
questions about differences in presentation, management and outcomes in COPD patients 
compared to non-COPD patients. The evidence points to an increased risk of death after AMI 
in patients with COPD, but it is unclear to what extent this is attributable to COPD itself or to 
modifiable factors including under-treatment with guideline-recommended interventions and 
drugs. We review the evidence for differences between COPD and non-COPD patients in 
terms of the presentation of AMI, its treatment, and outcomes both in hospital and in the 
longer term. 
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Background 
Myocardial infarction (MI) is a very common reason for admission to hospital and is associated 
with substantial morbidity and mortality. Recent decades have seen a large decrease in the 
incidence of and mortality from acute MI1. Much of the decrease in the incidence of MI has 
been attributable to a decrease in ST-elevation MI (STEMI). Rates of non-ST-elevation MI 
(non-STEMI) may not have decreased and may well be increasing2. People who have a non-
STEMI rather than STEMI tend to be older and are more likely to have co-morbidities. The 
reasons for the increasing prevalence of non-STEMI may include increased prevalence of risk 
factors, or better clinical awareness. It has been recognised that comorbidity is a major risk 
factor for death following an MI, and that multimorbidity due to population ageing has created 
a more complex population of those with acute MI3. As well as prevention of MI, much of the 
decrease in MI mortality has been attributed to improved care after MI4. Although drives to 
improve acute care and secondary prevention of MI have drastically decreased mortality after 
MI, it is not clear if this has been optimised for all patient groups. Some groups have received a 
lot of attention, for example, in people with diabetes, thresholds are lower for treating risk 
factors for MI (for example, blood pressure) and it is recognised that presentation may be 
different, for example, without chest pain. One common co-morbid condition which has 
previously been understudied, but is now coming under increasing attention is chronic 
obstructive pulmonary disease (COPD). 
 
Chronic obstructive pulmonary disease (COPD) is a common and progressive lung disease 
characterised by airflow limitation which is not fully reversible. The prevalence of diagnosed 
COPD varies between countries. In Europe the average prevalence of diagnosed COPD is 
around 1.5% of the adult population, however the true prevalence may be as high as 10% as 
many remain undiagnosed5. In the developed world, the biggest risk factor for COPD is 
tobacco smoking 6. COPD is also associated with increasing age, indoor and outdoor pollution, 
poor nutrition and low socioeconomic status6.  
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COPD is associated with an increased risk of many other diseases, which are thought to be due, 
in part, to “spill over” of inflammation in the lung to the systemic circulation7 (Figure 1). 
Cardiovascular disease is perhaps the most common and important co-morbidity in those with 
COPD. People with COPD are at higher risk of MI than those who do not have COPD, 
independent of smoking status8, 9. As well as increased inflammation, it is thought that this 
increased risk may be due to increased endothelial dysfunction and increased arterial stiffness in 
those with COPD10. This increased burden of MI attributable to COPD seems to be borne by 
younger COPD patients9. Most people with COPD do not die from respiratory diseases11, and 
one of the most common reasons for death in those with COPD is cardiovascular disease, with 
up to 30% of people with COPD dying from cardiovascular disease12. Due to both shared risk 
factors and the increased risk of MI for those with COPD, COPD is very common in those 
with acute MI. The prevalence of COPD in those with acute MI varies between countries, and 
has been estimated to be 10-17%13-16.  
 
This article aims to review the literature on the effect of COPD on presentation, management 
and outcomes after acute MI and how these may be interrelated.  
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Figure 1. Diagram representing how inflammation in chronic obstructive pulmonary disease 
may ‘spill over’ into the systemic circulation and increase the risk of several diseases including 
cardiovascular disease. Original image from Barnes.7 
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Presentation of acute myocardial infarction 
Several studies have investigated differences in presentation between those with COPD and 
those without COPD. The prevalence of previously diagnosed COPD among all people 
presenting to hospital with an MI has been estimated to be between 10-17%13-16. Particularly, as 
COPD is a risk factor for MI, however, the true prevalence including those with undiagnosed 
COPD may be significantly higher. In terms of presenting symptoms, several studies have 
reported that COPD patients with MI are less likely to present with typical chest pain, and are 
more likely than non-COPD patients to present with breathlessness13-15, atypical chest pain13, 
and palpitations13. In terms of type of MI, two studies have found that COPD patients are more 
likely to present with a non-STEMI than a STEMI compared to non-COPD patients16, 17. 
Intriguingly, several studies have found that COPD patients had lower levels of peak cardiac 
enzymes after an MI and this was true for both troponin18 and creatine kinase19. In addition, 
Bursi et al19 found that COPD patients had a higher average heart rate than non-COPD patients 
and were more likely to have a delay (>12 hours) in presentation to hospital after MI. 
 
Differences in recognition and management of MI between COPD and non-COPD 
patients 
One possible consequence of differences in presentation after an MI between COPD and non-
COPD patients is delay in recognition of MI. For people with COPD, even with presentation of 
typical MI symptoms, these symptoms may be erroneously attributed to their COPD. This is of 
particular importance for those with STEMI, as early identification of MI should reduce time to 
reperfusion and therefore would be expected to improve outcomes. In an analysis of over 
300,000 first MIs in the UK Rothnie et al.16 found that after a STEMI, COPD patients were 
more likely to have an initial incorrect diagnosis (i.e. not MI) and had a longer median time to 
reperfusion. This was 153 min (IQR, 74-706 min) for those with COPD and 109 min (IQR, 50-
260 min) for those without COPD, and was only apparent in COPD patients with a delay in 
diagnosis of MI compared to non-COPD patients with a delay in diagnosis of MI. This 
difference also remained on analysis adjusted for age, sex and comorbidities.  
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Recent studies conducted in Sweden and the UK have shown that COPD patients are less likely 
to receive primary percutaneous intervention or other reperfusion strategies after a STEMI14, 16. 
Older studies in the USA also showed that those with COPD were less likely to receive primary 
percutaneous coronary intervention (pPCI) after a STEMI 15, 19, however a more recent study 
has found no difference in the proportion of COPD and non-COPD patients receiving pPCI 
after STEMI in the USA, suggesting they have started to recognise previous discrepancies in 
recognition and management and are changing clinical practice18.  
 
After a non-STEMI, current guidelines20, 21 suggest that patients who are at moderate (3%) or 
higher predicted risk of death within 6 months receive angiography in-hospital within 72 hours 
of the event. Angiography, and then subsequent PCI if indicated improves outcomes after non-
STEMI and it is known that those who are at higher risk have more to gain from this 
intervention22, 23. Several studies14-16, 18, 19 have shown that those with COPD are less likely to 
receive angiography in hospital after a non-STEMI compared to non-COPD patients, despite 
being at higher risk of death. One explanation for this difference could be that COPD patients 
are older and more likely to be deemed sicker or frailer than non-COPD patients, and as a result 
are not thought to be appropriate for more aggressive intervention. However, one study16 
conducted a sensitivity analysis excluding those who were deemed inappropriate for 
angiography for example, due to advanced cancer or dementia, and this did not change the 
findings that those with COPD appear to be under treated compared to non-COPD patients 
with similar patient characteristics.  
 
After a MI, current guidelines20, 21 suggest that unless these are contraindicated, patients should 
be prescribed a β-blocker, an ACE inhibitor or angiotensin receptor blocker, a statin, and dual 
antiplatelet therapy (aspirin indefinitely and P2Y12 receptor antagonist for one year following the 
event). For some time it was thought that β-blockers were contraindicated in those with COPD 
as it was thought that they might cause bronchospasm. However, many studies have since 
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demonstrated that cardioselective β-blockers are not associated with either change in FEV1 or 
an increase in exacerbations of COPD 24. Despite this, β-blockers continue to be underused in 
those with COPD with several studies demonstrating they are much less likely to be prescribed 
following MI than in non-COPD patients14-16, 19. Smaller differences are apparent for other 
secondary prevention medicines although discrepancies do exist. Some studies have reported 
that COPD patients are slightly less likely to receive aspirin, statins and ACE 
inhibitors/angiotensin receptor blockers14-19, however no studies reported significant differences 
in the prescription of P2Y12 receptor antagonist. Findings from studies which have investigated 
differences in treatment between COPD and non-COPD patients after an MI are summarised 
in Table 1. An interesting observation is that differences in management between COPD and 
non-COPD patients are not apparent in all settings and appear to have changed over time. As 
previously mentioned, differences between rates of pPCI after a STEMI between COPD and 
non-COPD patients appears to have narrowed over time in the USA18. There is also evidence 
that prescription of β-blockers to those with COPD after MI by physicians in the USA has also 
improved markedly over time15, however it is not apparent that this increase has also occurred 
in European countries 14, 16. These differences between countries suggest two things: that 
differences in treatment between COPD and non-COPD patients do represent undertreatment, 
and that change is possible.  
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Table 1. Summary of studies which investigated differences in treatment after MI between COPD and non-COPD patients 
Study Design and setting Population Differences in management 
Andell 201414 Cohort study within the Swedish 
SWEDEHEART registry 
between 2005-2010. 
 
Consecutive patients admitted to 
Swedish coronary care units. 
COPD diagnosis ascertained 
through linkage to the Swedish 
National Patient Registry.  
In-hospital management: 
 
Percutaneous coronary intervention 
COPD: 37.7 % 
Non-COPD:  55.7%  
p<0.001 
 
Coronary angiography: 
COPD: 72.5% 
Non-COPD: 55.4% 
P<0.001 
 
Discharge medicines: 
ACE inhibitors 
COPD: 50.6% 
Non-COPD: 55.5% 
p<0.001 
 
Angiotensin receptor blockers 
COPD: 12.6% 
Non-COPD: 11.1% 
p=0.001 
 
Aspirin 
COPD: 85.5%  
Non-COPD: 90.1% 
p<0.001 
 
β-blockers  
COPD: 77.7% 
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Non-COPD: 86.1% 
p<0.001 
 
Statin 
COPD: 68.4% 
Non-COPD: 79.2%  
p<0.001 
 
P2Y12 inhibitor 
COPD: 62.5% 
Non-COPD: 72.2% 
P<0.001 
 
Bursi 2010 Cohort study in Olmsted County, 
Minnesota from 1979-2007  
3438 local residents in Olmsted 
County. ICD-10 codes used to 
ascertain COPD.   
In-hospital management: 
 
Reperfusion 
COPD: 41% 
Non-COPD: 52% 
p<0.01 
 
Angiography-in hospital 
COPD: 51% 
Non-COPD: 59%  
p<0.01 
 
Discharge medicines: 
ACE inhibitor 
COPD: 37%  
Non-COPD: 29% 
p<0.01 
 
β-blocker  
128 
 
COPD: 47% 
Non-COPD: 61% 
p<0.01 
 
Diuretic 
COPD: 34% 
Non-COPD: 23% 
p<0.01 
Statin 
COPD: 29% 
Non-COPD: 30% 
P=0.61 
 
Enriquez 2013 Cross sectional study of National 
Cardiovascular Data Registry in 
the USA between January 2008- 
December 2010 
158,890 patients with an acute 
MI. COPD was ascertained from 
history of COPD or were using 
long term inhaled or oral β-
agonists, inhaled  anti-
inflammatory agents, leukotriene 
receptor antagonists or inhaled 
steroids.   
STEMIs 
 
In-hospital management 
 
Primary percutaneous coronary intervention 
COPD: 83.1% 
Non-COPD: 85.4% 
p<0.001 
 
Overall reperfusion  
COPD:92.8% 
Non-COPD: 94.3% 
p<0.001 
 
Discharge medicines: 
 
Aspirin 
COPD: 97.8% 
Non-COPD: 98.7% 
P<0.001 
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β-blocker  
COPD: 89.4% 
Non-COPD: 93.1% 
P<0.001 
 
ACE inhibitor or angiotensin receptor blocker 
COPD: 78.0% 
Non-COPD: 78.4% 
p= “not statistically significant” 
 
Statin  
COPD: 92.9% 
Non-COPD: 94.7% 
p<0.001 
 
P2Y12 inhibitor 
COPD: 79.6% 
Non-COPD: 86.6% 
P<0.001 
 
nSTEMIs 
 
In-hospital management 
 
Cardiac catheterisation 
COPD: 69.9% 
Non-COPD:81.2% 
p<0.001 
 
Percutaneous coronary intervention within 48 hours  
COPD: 37.2% 
Non-COPD 48.9% 
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p<0.001 
 
 
Discharge medicines: 
 
Aspirin 
COPD: 95.9% 
Non-COPD: 97.3 
p<0.001 
 
β-blocker  
COPD: 85.5% 
Non-COPD: 90.5% 
p<0.001 
 
ACE inhibitor or angiotensin receptor blocker 
COPD: 69.6% 
Non-COPD: 69.6% 
p= “not statistically significant” 
 
Statin  
COPD: 85.9% 
Non-COPD: 89.5% 
p<0.001 
 
P2Y12 inhibitor 
COPD: 65.5% 
Non-COPD: 71.6% 
p<0.001 
 
Rothnie 2015 
 
 
All UK patients admitted to 
hospital in the MINAP registry 
between 2003-2013 
300161 patients with a first MI  STEMI 
In-hospital management  
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 Primary PCI 
OR 0.87 (95% CI, 0.83-0.92)* 
 
Discharge medicines 
Aspirin  
OR 0.90 (95% CI, 0.85-0.94)* 
 
β-blocker  
OR 0.26 (95% CI, 0.25-0.27)* 
 
ACE inhibitor or angiotensin receptor blocker 
OR 0.89 (95% CI, 0.85-0.93)* 
 
Statin  
OR 0.91 (95% CI, 0.86-0.95)* 
 
P2Y12 inhibitor 
OR 0.98 (95% CI, 0.94-1.03)* 
 
Non-STEMI 
In-hospital management  
 
Angiography in-hospital  
OR 0.69 (95% CI,0.66-0.71)* 
 
 
 
Discharge medicines 
 
Aspirin  
OR 0.91 (95% CI, 0.88-0.94)* 
 
β-blocker  
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OR 0.25 (95% CI, 0.24-0.25)* 
 
ACE inhibitor or angiotensin receptor blocker 
OR 0.94 (95% CI, 0.91-0.97)* 
 
Statin  
OR 0.93 (95% CI, 0.90-0.96)* 
 
P2Y12 inhibitor 
OR 0.97 (95% CI, 0.94-1.01)* 
 
* All ORs compared COPD to non-COPD patients and are adjusted for 
age, sex, smoking status and co-morbidities 
 
Salisbury 2007 Cohort study in 19 centres in the 
USA between 2003-2004 
2481 MI patients in PREMIER 
study restricted to patients 
discharged alive after MI 
In-hospital management 
 
Cardiac catheterisation 
COPD: 45.7% 
Non-COPD: 41.2% 
p=0.094 
 
Percutaneous coronary intervention 
COPD: 50.9% 
Non-COPD: 62.9% 
p<0.001 
 
Discharge medicines 
 
Aspirin 
COPD: 87.8% 
Non-COPD: 94.5% 
p<0.001 
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β-blocker  
COPD: 86.2% 
Non-COPD: 92.6% 
p<0.001 
 
 
Stefan 2012 Cohort study up of patients 
hospitalised with acute MI at 
greater Worcester, Massachusetts 
between 1997-2007 
6,290 Patients hospitalised with 
acute MI in greater Worcester, 
Massachusetts medical centres 
In-hospital management 
Cardiac catheterisation  
OR 0.56 (95% CI, 0.48-0.65)** 
 
Percutaneous coronary intervention 
OR 0.64 (95% CI, 0.54-0.77)** 
 
Discharge medicines 
 
β-blocker  
OR 0.44 (95% CI, 0.35-0.50)** 
 
Anticoagulant  
OR 0.81 (95% CI, 0.69-0.95)** 
 
Statin 
OR 0.70 (95% CI,0.60-0.82)** 
 
Calcium channel blocker 
OR 1.31 (95% CI, 1.13-1.52)** 
** ORs compare COPD to non-COPD patients and are adjusted for age, 
sex, year, cardiovascular disease history, renal failure, length of stay and 
type of MI (STEMI or non-STEMI) 
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Outcomes after MI in people with COPD 
All-cause mortality 
Several studies in different settings have demonstrated an increased risk of death after MI for 
those with COPD compared to non-COPD patients. However, there have been mixed findings 
concerning an increased risk of in-hospital death for those with COPD, with some finding an 
increased risk14, 15, 18, 19, 25-28, and others finding no difference13, 29. A recently conducted 
systematic review and meta-analysis8  which appraised this evidence concluded that after 
pooling maximally adjusted estimates from several studies, there is weak evidence for a 
difference in in-hospital mortality for those with COPD (OR 1.13, 95% CI 0.97-1.31) and 
strong evidence for an increased risk of death during follow-up (HR 1.26, 1.13-1.40, Figure 2). 
However, heterogeneity of effects for these meta-analyses was moderately high. It is known that 
differences in treatment for MI between COPD and non-COPD patients varies between 
countries. If some of the increased risk of death associated with COPD is due to this difference 
in treatment, this may explain some of the heterogeneity in findings.    
 
 
Figure 2. Long term risk of death following MI comparing COPD to non-COPD patients. 
Original image from Rothnie et al. 20158.  
 
Interestingly, the effect of COPD on risk of death following MI is modified by some patient 
characteristics. A recent study in the UK demonstrated that after adjusting for potential 
confounders the effect of COPD on the risk of death after MI was higher after a non-STEMI 
than a STEMI for both in-hospital (OR 1.40 (95% CI, 1.30-1.52) compared to OR 1.27 (95% 
CI, 1.16-1.39)) and 6-month mortality (OR 1.63 (95% CI, 1.56-1.70) compared to OR 1.43 
(95% CI, 1.29-1.58)). A study in the USA also demonstrated an increased effect of COPD on 
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risk of death after a non-STEMI (OR 1.21, 95% CI 1.11-1.33) compared to that for STEMIs 
(OR 1.05, 95% CI 0.95-1.17)18. In addition, it appears that the effect of COPD on risk of MI is 
greater for younger compared to older patients (Figure 3). This suggests that the “excess” risk 
of death, and therefore potentially avoidable deaths, for COPD patients attributable to COPD 
are clustered in younger patients. This effect was also demonstrated in a study by Dziewierz et 
al27 who only found an increase in the risk of death in those under the age of 75 after MI for 
those with COPD compared to non-COPD patients.   
 
 
Figure 3. Effect of COPD on risk of death 6 months after MI split by age group. Adapted 
from data presented in Rothnie et al. 201516. 
 
As previous studies have demonstrated that there may be a significant degree of delay in 
diagnosis of MI for those with COPD. It would seem likely that there are a proportion of 
COPD patients who have an MI and this is missed entirely. The prevalence and impact of this 
potential problem is currently unclear. In addition, all of the studies which have investigated the 
risk of death for COPD patients compared to non-COPD patients after MI have done so in 
patients admitted to hospital. As many of those who have an MI do not survive until admission 
to hospital, the impact of COPD on risk of death after MI may be underestimated.  
 
Other outcomes 
As well as death following MI, other outcomes are important and have been investigated in 
those with COPD.  
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In terms of in hospital adverse events, Stefan et al15 found that after adjusting for possible 
confounders, people with COPD were more likely to experience acute heart failure (OR 1.59, 
95% CI 1.37-1.83), but not atrial fibrillation, cardiogenic shock or stroke. In unadjusted analysis, 
Hadi et al13 also found an increased risk of acute heart failure in people with COPD, but not 
cardiogenic shock, re-infarction or stroke in hospital. In another unadjusted analysis, Enriquez 
et al18 found an increased risk of acute heart failure, cardiogenic shock, re-infarction, stroke and 
major bleeding for in hospital COPD patients following an MI.  
In terms of adverse events following discharge from hospital, two studies have investigated the 
risk of heart failure for COPD patients after MI. Andell 2014 et al14 found that COPD patients 
were at higher risk of new-onset heart failure during the year following MI (HR 1.35, 95% CI 
1.24-1.47). In a study including those with both MI and heart failure or left ventricular systolic 
dysfunction,  COPD patients were more likely to have a hospitalisation for heart failure in the 
three years following MI (HR 1.19, 95% CI 1.05-1.34)30. Hawkins 2009 also found that COPD 
patients had a higher risk of sudden death compared to non-COPD patients (HR 1.26, 95% CI 
1.03-1.53). However, this study was conducted in a population who all had heart failure or left 
ventricular systolic dysfunction and had been selected for a randomised controlled trial of 
treatment for heart failure and therefore may not be representative of the general population.  
 
After a MI, COPD patients do not appear to be at higher risk of re-current MI14, 30, stroke30, 
angina17, or major bleeds14 compared to non-COPD patients.  
 
Are differences in recognition and management related to differences in outcomes? 
As it is known that people with COPD have poorer outcomes compared to people without 
COPD, that they are less likely to have their MI recognised, and that they are less likely to 
receive guideline recommended treatment and investigation, one important question is whether 
these differences in management explain some of the differences in outcomes.  
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It is known that people with atypical presentations of MI have poorer outcomes compared to 
individuals with typical presentations, and that this might be related to differences in 
treatment31, 32. People who present atypically are less likely to receive any reperfusion therapy 
after a STEMI, or angiography and percutaneous coronary intervention after a non-STEMI, and 
are less likely to receive β-blockers, statins or antiplatelet therapy on discharge from hospital32. 
It has been known for some time that older individuals, women, and people with diabetes or 
heart failure are more likely to have atypical presentations of MI. However, it has not been 
widely recognised that those with COPD may present with atypical symptoms of MI.  
 
A recent study16 aimed to investigate whether differences in recognition and management of MI 
could explain some of the difference in mortality after MI for those with COPD. The findings 
showed that both recognition and management explained some of the difference in mortality 
after MI between COPD and non-COPD patients. Particularly, delay in diagnosis, timing and 
use of reperfusion after a STEMI, use of angiography after a non-STEMI and use of secondary 
prevention medicines were all potential explanations for the difference in mortality between 
COPD and non-COPD patients after an MI. Similarly, Andell et al14 found that adjusting for 
differences in in-hospital and discharge treatment reduced the HR comparing mortality in 
COPD patients to non-COPD patients from an HR of 1.32 (95% CI, 1.24-1.40) to an HR of 
1.14 (95% CI, 1.07-1.21). However, adding treatment into the regression models in a study by 
Salisbury et al17 made no difference to the effect of COPD on mortality. These findings suggest 
that much of the difference in mortality between COPD and non-COPD patients after MI may 
be mediated by differences in recognition and treatment of MI rather than differences in 
treatment confounding the effect of COPD on risk of death. Differences in treatment between 
countries may be a possible reason for heterogeneity in effects of COPD on risk of death after 
MI. This is an important finding as, although some of the increased risk of death is likely to be 
due to COPD itself, if a proportion is due to differences in treatment, then this could 
potentially be modified.  
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One of the largest differences in management after MI between COPD and non-COPD 
patients in prescription of β-blockers as secondary prevention. As well as being safe for COPD 
patients recent work has demonstrated their effectiveness for secondary prevention after MI. 
Quint et al33 conduced a propensity score matched cohort study among those with COPD after 
MI comparing those prescribed β-blockers and those not prescribed β-blockers after MI. Those 
started on a β-blocker during hospital admission for MI had significantly better survival than 
those not prescribed β-blockers (HR 0.50, 95% CI 0.36-0.69). Similarly, in a population of 
people with heart failure, Hawkins et al 200930 found that COPD patients prescribed a β-
blocker following an MI had better survival than those not prescribed a β-blocker (HR 0.74, 
95% CI 0.68-0.80). COPD did not appear to modify the effect of β-blockers on mortality. The 
reluctance to prescribe β-blockers to COPD patients may drive much of the increased risk of 
heart failure and death in the months and years following an MI in those with COPD.  
 
A schematic diagram of the possible mechanisms underlying the relationship between COPD 
and risk of death after MI is presented in Figure 4.  
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Figure 4. Schematic diagram of the possible mechanisms underlying the relationship between COPD and risk of death after MI 
COPD MI 
Smoking and other 
shared risk factors 
Death 
after MI 
Inflammation, 
thrombosis, arterial 
stiffening & endothelial 
dysfunction 
Atypical presentation & 
misdiagnosis 
Missed MI 
Delayed reperfusion 
after STEMI 
Underuse of secondary 
prevention 
Misunderstanding of 
benefits and risks of 
secondary prevention 
for COPD patients 
Heart failure 
140 
 
Areas for future research 
Are MIs completely missed with those with COPD? 
Evidence has shown that there is sometimes delayed recognition of acute MI in people with 
COPD. One likely explanation for this is that the symptoms of their MI, such as breathlessness, 
may be misattributed to their COPD. In addition, atypical presentation may also contribute to 
the delay in diagnosis. It is therefore possible that the diagnosis of many MIs in those with 
COPD are not only delayed, but may also be missed completely. Indeed, it is known that 
around 8% of patients admitted to hospital with an acute exacerbation of COPD meet the 
Universal Definition for Myocardial Infarction (raised troponin with ECG changes and/or 
chest pain)34. As it is known that exacerbations of COPD are a period of higher risk of MI for 
COPD patients, it is unclear how many of these are MIs triggered by an exacerbation and how 
many are MIs initially misdiagnosed as exacerbations. In another study, among those 
hospitalised for an acute exacerbation of COPD, it was found that around 2/3 of all COPD 
patients with evidence of a previous MI as assessed by the cardiac infarction injury score had a 
recorded diagnosis of MI, and that this was even higher among women with COPD35. Missed 
diagnosis of MI has been a long established finding in those with diabetes, and is associated 
with increased mortality in this group31. Further research should investigate the prevalence of 
missed diagnosis of MI and the impact of this potential problem.  
 
What other aspects of COPD are related to mortality after MI? 
Although several studies have investigated mortality after MI for those with COPD, none have 
investigated which aspects of COPD itself may modify this relationship.  
COPD severity defined by degree of airflow obstruction appears to be a risk factor for MI36. It 
is unclear however, if degree of airflow obstruction is also a risk factor for death after MI in 
those with COPD. Much of the research on risk of death after MI in those with COPD has 
been conducted using national MI registries, and as such do not have data on lung function.  
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After an MI, one of the most effective things a current smoker can do to reduce their risk of 
death and further MI is to quit smoking37. As many COPD patients are current smokers and 
can be very heavily dependent on nicotine, quit rates may be lower in those with COPD and 
recidivism may be higher in those COPD patients who do quit. Recent work has suggested that 
smokers are not frequently prescribed recommended smoking cessation pharmacotherapy38 and 
that in contrast to those with stable coronary artery disease, pharmacotherapy may not be 
effective for smoking cessation after acute MI39. However, COPD patients may well represent a 
group in whom this therapy could be targeted towards.  
 
COPD exacerbations are an acute worsening of symptoms of cough, breathlessness and sputum 
volume and/or purulence beyond normal day-to-day variation and which may require a change 
in treatment. Acute exacerbations of COPD are associated with increased systematic 
inflammation and are important drivers of morbidity and mortality in those with COPD40. 
Some COPD patients appear to be particularly susceptible to exacerbations, and these patients 
have been termed frequent exacerbators. Periods of exacerbation have been found to be 
associated with increased risk of MI for those with COPD8, 41, 42. Further research is needed to 
investigate what effect, if any, the frequent exacerbator phenotype has on outcomes after MI.   
 
Predicting risk of death after MI in people with COPD and differences in treatment 
The risk management paradox refers to the observation that although those who are at highest 
predicted risk of death after MI are most likely to benefit from early aggressive intervention, 
especially after a non-STEMI, they are the least likely to receive it43. As those with COPD 
certainly seem to be at higher risk of death after MI, and less likely to receive early aggressive 
intervention, such as cardiac catheterisation within 72 hours after a non-STEMI, this may apply 
to those with COPD. There may be several reasons for this paradox in those with COPD. The 
first is that current systems which score patients based on risk of death after MI do not perform 
well in those with COPD compared to non-COPD patients. Early findings from a study of the 
performance of the GRACE score in those with COPD compared to those who do not have 
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COPD suggests that it does not perform as well at predicting risk of death after acute coronary 
syndromes in COPD patients44. However, evidence also suggests that even when COPD 
patients have the same GRACE score predicted risk of death as non-COPD patients, they are 
less likely to receive guidelines recommended investigation and treatment, suggesting there may 
be other forces at play44. The second is perhaps therapeutic nihilism towards treating 
comorbidities in those with COPD. It may be that COPD patients are seen as older, frailer 
patients in whom secondary prevention is not worthwhile. However, as previously discussed, 
many COPD patients do in fact die from cardiovascular disease. In addition, much of the excess 
deaths after MI in those with COPD are among younger patients and even in studies which 
adjusted for age and comorbidities, differences in treatment did seem to be associated with 
poorer mortality for those with COPD. Both performance of risk scores after MI and clinical 
decision making around the selection of patients for invasive treatment and secondary 
prevention drugs is needed.  
 
Conclusions 
It is clear that COPD patients have poorer long term mortality after MI compared to non-
COPD patients. The effect of COPD on risk of death after MI is higher for younger people and 
for those with a non-STEMI. They do not appear to be at higher risk of recurrent MI, however 
they do seem more likely than non-COPD patients to develop heart failure. COPD patients also 
seem to be at higher risk of in-hospital death after MI in some settings, however this may 
depend on quality of care for COPD patients after MI. Some of the difference in in-hospital 
and longer term mortality appears to be due to differences in recognition and management of 
MI in those with COPD.  
 
Those with COPD present differently after acute MI than non-COPD patients. They are more 
likely to present with breathlessness and atypical chest pain. This may contribute to a delay in 
recognition of MI in those with COPD, and may also mean that many MIs in those with COPD 
are missed entirely.  
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In terms of in-hospital care, COPD patients are less likely to receive reperfusion after a STEMI, 
and prompt angiography after a non-STEMI. COPD patients are also less likely to receive 
secondary prevention drugs after an MI, in particular β-blockers. β-blockers are safe and 
effective for secondary prevention after MI in those with COPD and should not be withheld 
from this group. 
 
Further research is needed to investigate the extent and impact of missed diagnosis of MI in 
those with COPD. In addition, identifying those with undiagnosed COPD after an MI is vital 
for reducing mortality in this group. Researchers should also focus on investigating how risk 
scores function in those with COPD and how they are used to guide treatment in this group.  
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5.3 Summary  
 
 People with COPD are more likely to present atypically following MI than those who 
do not have COPD 
 Several studies indicate that age is an important effect modifier for the effect of COPD 
on risk of death following MI  
 Differences in recognition and management of MI have been found in a range of 
settings, as well as the UK 
 COPD patients are at higher risk of death and development of heart failure following 
MI, but do not appear to be at higher risk of other vascular outcomes, compared to 
those who do not have COPD 
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Chapter 6 Predicting mortality after acute coronary syndromes 
in people with chronic obstructive pulmonary disease 
(Research paper IV) 
 
6.1 Preamble  
Findings from the previous chapters have indicated that COPD patients have higher mortality 
following MI than those who do not have COPD, and that this may be explained, in part, by 
differences in treatment.  
 
This research paper uses data from the MINAP dataset. In addition to data from MI, data from 
admissions for unstable angina are also included. Unstable angina is a less severe form of acute 
coronary syndrome (ACS). Unstable angina is similar to non-STEMI, however relates to partial 
or transient occlusion of a coronary artery which is not severe enough to cause necrosis (or at 
least not severe enough such that any increase in serum troponin is detectable). Unstable angina 
episodes are included here as they are necessary to fit the GRACE score prognostic models.  
 
In the UK, NICE recommend the use of the GRACE score to guide treatment following non-
STEMI and unstable angina (NICE 2010). Those with a predicted risk of death at 6 months of 
over 3% should be considered for angiography in hospital, and subsequent treatment if 
necessary. The findings from Chapter 3 indicated that although they are at higher risk of death, 
those with COPD are less likely to have angiography in hospital, even after adjustment for age, 
sex, smoking status and co-morbidites. This finding could be explained if the GRACE score 
does not provide as accurate risk stratification in COPD patients as it does in those who do not 
have COPD. Although the accuracy of the GRACE score has been investigated in other 
diseases, this has not been done in COPD (Eagle et al. 2004).  
 
In presenting the results of this analysis, I felt it was important to represent differences in 
potential models in a clinically meaningful way. Therefore, as well as expressing results in terms 
of statistical concepts of calibration (Hosmer-Lemeshow statistic) and discrimination (C-
statistic), more clinically meaningful measures, such as the relative risk of death for COPD 
patients compared to those without COPD with the same predicted risk of death. Also, the 
percentage of COPD patients who could be considered for different treatment under a more 
accurate scoring system are presented. Calibration refers to the ability of a model to accurately 
predict the probability of an event, higher p-values for the Hosmer-Lemeshow static indicate 
better calibration. Discrimination refers to whether patients who do have an event have higher 
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predicted probabilities, higher C-statistics indicate better discrimination. A recent addition to 
diagnostic statistics for prognostic models is the net-reclassification index (NRI) (Kerr et al. 
2014), and this relates to the ability of a new addition to a prognostic model to classify those 
with the event upwards (that is increase their predicted probability of the event), while 
classifying those who do not have the event downwards (that is decrease their predicted 
probability of the event). A positive NRI indicates better classification.   
 
This paper was originally published in Heart and is available at:  
Rothnie KJ, Smeeth L, Pearce N, Herrett E, Hemingway H, Wedzicha J, Timmis A, Quint JK. 
‘Predicting mortality after acute coronary syndromes in people with chronic obstructive 
pulmonary disease.’ Heart. 2016, [epub ahead of print]. 
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6.2 Research paper 
Predicting mortality after acute coronary syndromes in people with chronic obstructive 
pulmonary disease 
Authors Kieran J Rothnie, Liam Smeeth, Neil Pearce, Emily Herrett, Adam Timmis, Harry 
Hemingway, Jadwiga Wedzicha, Jennifer K Quint  
 
Abstract  
Objective 
To assess the accuracy of Global Registry of Acute Coronary Events (GRACE) scores in 
predicting mortality at 6 months for people with COPD and to investigate how it might be 
improved.  
Methods  
Data were obtained on 481,849 patients with acute coronary syndrome (ACS) admitted to UK 
hospitals between January 2003-June 2013 from the myocardial ischaemia national audit project 
(MINAP) database. We compared risk of death between chronic obstructive pulmonary disease 
(COPD) and non-COPD patients at 6 months, adjusting for predicted risk of death. We then 
assessed whether several modifications improved the accuracy of the GRACE score for people 
with COPD.  
Results 
The risk of death after adjusting for GRACE score predicted risk of death was higher for 
COPD patients than for other patients (RR 1.29, 95% CI 1.28-1.33). Adding smoking into the 
GRACE score model did not improve accuracy for COPD patients. Either adding COPD into 
the model (RR 1.00, 0.94-1.02) or multiplying the GRACE score by 1.3 resulted in better 
performance (RR 0.99, 0.96-1.01).  
Conclusion 
GRACE scores underestimate risk of death for people with COPD. A more accurate prediction 
of risk of death can be obtained by adding COPD into the GRACE score equation, or by 
multiplying the GRACE score predicted risk of death by 1.3 for people with COPD. This 
means that one third of COPD patients currently classified as low risk should be classified as 
moderate risk, and could be considered for more aggressive early treatment after non-ST-
elevation myocardial infarction or unstable angina.
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What is already known about this subject? 
Despite being at higher risk of death following admission for acute coronary syndromes, those 
with chronic obstructive pulmonary disease (COPD) are less likely to receive investigation and 
treatment than non-COPD patients and this difference may explain some of the difference in 
mortality. It is recommended that those at moderate (3-6%) or high (>6%) Global Registry of 
Acute Coronary Events (GRACE) score predicted risk of death at 6 months after admission to 
hospital for non-ST-segment elevation myocardial infarction or unstable angina receive earlier 
aggressive investigation and treatment. 
 
What does this study add? 
This nationwide multicentre study involving 481,849 hospital admissions demonstrates that 
GRACE scores underestimate risk of death after acute coronary syndromes for those with 
COPD. This study also found that multiplying the predicted risk of death for those with COPD 
by 1.3 provides a better approximation for their risk of death.  
 
How might this impact on clinical practice? 
Using a more accurate estimate of risk of death for those with COPD after admission for acute 
coronary syndromes one third of COPD patients previously categorised as low risk would be 
reclassified as moderate risk, and therefore would be eligible for earlier, more aggressive 
investigation and treatment.  
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Introduction  
Accurate prediction of risk of death after acute coronary syndromes (ACS) is important not 
only for prognostication, but also for decision making about treatment, as individuals at higher 
risk of death after ACS benefit most from early aggressive treatment[1, 2].  Early and accurate 
assessment of future risk allows clinicians to identify patients who might benefit most from 
therapies and to avoid unnecessary treatment for those who are less likely to benefit.  
 
GRACE (Global Registry of Acute Coronary Events) scores are used internationally to predict 
the probability of death at six-months after admission to hospital for ACS. They have been 
developed and validated in several different settings[3, 4, 5, 6, 7]. The predicted risk of death 
can be used to stratify patients into low (<3%), moderate (3-6%) and high (>6%) risk of death 
at 6 months post-ACS. Current guidelines recommend that those classified as moderate-high 
risk of death using the GRACE score should receive more aggressive early therapy after non-ST 
elevation myocardial infarction (non-STEMI) or unstable angina[8, 9].  
 
People with chronic obstructive pulmonary disease (COPD) have a higher risk of MI than 
people without COPD, and cardiovascular disease is an important cause of death in people with 
COPD. In addition, COPD is very common in people with MI, with prevalences ranging from 
10-17%[10, 11]. Several studies have also found an increased risk of death after MI in people 
with COPD compared to people without COPD[10, 12, 13]. Previous work [14] has shown 
that, after adjusting for confounders, even though people with COPD have a higher mortality at 
6-months post discharge than non-COPD patients, they are less likely to receive angiography 
in-hospital after a non-STEMI, or to receive secondary prevention drugs after any MI. One of 
the reasons for this may be that GRACE scores may not predict risk of death in COPD patients 
as well as they do in non-COPD patients.  
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Using data from the UK Myocardial Ischaemia National Audit Project (MINAP) registry, we 
investigated whether GRACE scores performed as well in people with COPD as they do in 
people without COPD, and how they might be improved for people with COPD.  
 
Methods 
Data source 
MINAP is a UK registry of all admissions for ACS to hospitals in England and Wales. The 
following variables were collected which are needed for the equation for 6-month mortality 
(post-admission): age, heart rate, systolic blood pressure, creatinine, heart failure, cardiac arrest 
at admission, ST-segment deviation and elevated cardiac enzymes[15]. Vital status is available 
through linkage with the Office of National Statistics (ONS) mortality data.  
 
We included all patients with a diagnosis of ST-elevation myocardial infarction (STEMI) from 
January 2003 to June 2013, or non-STEMI or unstable angina from January 2004 to December 
2012. Diagnosis of STEMI, non-STEMI and unstable angina were based on physician diagnosis 
and records of electrocardiogram and cardiac biomarker findings. Records were excluded if they 
did not have a patient unique identifier; if patients had missing values for presence of 
obstructive airway disease or smoking history; or if ONS mortality data were missing.  
 
We identified COPD in MINAP using a strategy previously validated in MINAP data linked 
with primary care[14].  Briefly, we used the obstructive airway disease indicator and a smoking 
history (ex or current smoker) to identify COPD, and this identified COPD with a 
misclassification rate of less than 10%.  
 
Statistical methods 
GRACE scores 
GRACE scores and predicted risks of death at 6 months were constructed using published 
nomograms for the Fox model[16]. Values available from nomograms were used to construct 
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algorithms to score patients and to convert these to predicted risk death. As Killip class is not 
recorded in MINAP, we used a previously validated[17] method to score patients based on 
Killip class of heart failure by using in-hospital prescription of diuretics as a proxy.  
 
We estimated the observed and GRACE score predicted risks of death at six months and 
compared these between people with and without COPD.  We estimated the Mantel-Haenszel 
risk ratio averaged over the GRACE score deciles to estimate the average relative risk for death 
at six months post-admission for COPD patients with the same GRACE score as non-COPD 
patients. If GRACE scores work equally well in COPD patients and non-COPD patients, then 
the risk ratio would be 1. A risk ratio of less than 1 would suggest that GRACE scores 
overestimate the risks of death in COPD patients after admission; a risk ratio of more than 1 
would suggest that GRACE scores underestimate the risks of death in COPD patients. We also 
compared the risk of death for people with diabetes to people who do not have diabetes, 
adjusted for GRACE score predicted risk of death.  
 
We then investigated the observed risk of death between COPD and non-COPD patients 
within GRACE score predicted levels of risk (0-3% low, 3-6% moderate, and >6% high). 
 
We explored the extent of and possible reasons for missingness of GRACE score variables and 
performed a multiple imputation analysis (details in supplementary material).  
 
Model modifications 
We investigated several strategies for improving GRACE scores for people with COPD. We 
prespecified three potential modifications to the GRACE models which might improve their 
accuracy for COPD patients: 1) Adding COPD into the models as a risk factor; 2) Adding 
smoking history into the models as a risk factor; and 3) multiplying the predicted risk of death 
for COPD patients by the RR for risk of death for COPD patients compared to non-COPD 
patients after adjusting for GRACE score predicted risk of death.   
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For the approaches which involved adding new variables to the models (smoking and COPD), 
we had to re-specify the GRACE models. We did this by building logistic regression models 
which included all of the GRACE variables (with or without smoking or COPD) with death at 
6 months as the outcome and used these to predict risk of death. As an internal validation 
procedure, we also bootstrapped the logistic regression models with 100 reps each, and 
compared the parameter estimates with those from the main analysis.  
 
In order to assess which models performed best, we calculated the Mantel-Haenszel risk ratios 
to compare the risk of death at 6 months between COPD and non-COPD patients adjusting for 
predicted risk of death for the model in question. We also calculated C-statistics and Hosmer-
Lemeshow goodness of fit tests. Strategies involving multiplication of risk for COPD patients 
using the existing GRACE model were compared to the existing GRACE model. In order to 
make a fair comparison, models which involved adding other variables (smoking or COPD) 
were compared to our models which included all of the GRACE variables. In order to assess 
how well each model stratified risk, we also plotted the proportion of all deaths by deciles of 
predicted risk of death at 6 months for the normal GRACE model and for modifications. We 
calculated how many people would be re-classified in terms of risk level (low, moderate or high) 
for each modification, we also performed this analysis stratified by type of ACS. Finally, we also 
calculated the continuous net reclassification improvement (NRI) statistic[18] for adding COPD 
to the GRACE score model.  
 
Ethics 
This study was approved by LSHTM Observational Ethics Committee (6468) and the MINAP 
academic group (13-MNP-07).  
 
Results 
Patient characteristics  
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In total, 481,489 patients with ACS were included, of whom 58,739 (12.2%) had COPD (Figure 
1). Patient characteristics of COPD and non-COPD patients are shown in Table 1. In terms of 
mortality, COPD patients were more likely to have died by 6 months post-admission compared 
to non-COPD patients (17.7% compared to 11.6%). COPD patients, on average also had 
higher GRACE score predicted risk of death than non-COPD patients (14.0% (SD, 12.7) 
compared to 11.7% (SD, 12.3)).  
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Figure 1. Flow of participants through the study. ACS, acute coronary syndromes; COPD, 
chronic obstructive pulmonary disease; MINAP, Myocardial Ischaemia National Audit Project; 
non-STEMI, non-ST-elevation myocardial infarction; OAD, obstructive airway disease; ONS, 
Office of National Statistics. 
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Table 1 Characteristics of patients included in the analysis  
Characteristic Non-COPD  COPD  
Age group (n=481,489)   
<55 79,603 (18.8%) 6,575 (11.2%) 
55-64 92,446 (21.8%) 10,858 (18.5%) 
65-74 101,654 (24.0%) 17,402 (29.6%) 
75-84 100,660 (23.8%) 18,011 (30.7%) 
≥85 48,747 (11.5%) 5,893 (10.0%) 
Sex (n=481,489)   
Male 285,502 (67.5%) 37,135 (63.2%) 
Female 137,608 (32.5%) 21,604 (36.8%) 
Diagnosis (n=481,489)   
STEMI 137,724 (32.6%) 14,984 (25.5%) 
Non-STEMI 183,447 (43.4%) 29,198 (49.7%) 
Unstable angina 101,393 (24.1%) 3,136 (24.8%) 
Previous MI (n=478,530) 79,733 (18.9%) 14,485 (25.1%) 
Previous angina (n=477,494)  107,991 (25.7%) 19,962 (34.7%) 
Previously treated hyperlipidemia 
(n=467,096) 135,236 (32.9%) 18,573 (33.2%) 
Previously treated hypertension 
(n=477,515) 201,174 (47.9%) 28,256 (49.0%) 
Peripheral vascular disease (n=473,652) 17,216 (4.1%) 4,182 (7.4%) 
Cerebrovascular disease (n=476,863) 31,563 (7.5%) 5,858 (10.3%) 
Chronic renal failure (n=476,351) 17,368 (4.1%) 3,697 (6.5%) 
Chronic heart failure (n=476,324) 18,216 (4.3%) 4,955 (8.7%) 
Previous percutaneous coronary 
intervention (n=472,614) 29077 (7.0%) 4,256 (7.5%) 
Previous coronary artery bypass graft 
(n=473,891) 22,567 (5.4%) 3,320 (5.8%) 
Smoking history (n=481,849)   
Never smoker 142,254 (33.6%) 0 (0%) 
Ex-smoker 151,560 (35.8%) 35,103 (59.8%) 
Current smoker 129,296 (30.6%) 23,636 (40.2%) 
Raised cardiac markers* (n=481,849) 365,730 (91.8%) 51,206 (92.2%) 
ST segment deviation* (n=413,253) 221,205 (60.7%) 27,165 (55.3%) 
Use of diuretic in hospital* (n=481,849) 93,116 (22.0%) 19,069 (32.5%) 
Mean heart rate* (n=433,721) 80.2 ±21.9 87.2 ±23.7 
Mean systolic blood pressure* 
(n=432,854) 139.9 ±28.6 138.2 ±29 
Mean serum creatinine* (n=287,893) 101 ±56.6 103.4 ±58.3 
 
* Mean ±SD 
COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; STEMI, ST-
segment elevation myocardial infarction; non-STEMI, non-ST-segment elevation myocardial 
infarction.
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GRACE score performance 
The Mantel-Haenszel pooled risk ratio comparing risks of death for COPD patients to non-
COPD patients after adjusting for GRACE score predicted risk of death was 1.30 (95% CI, 
1.27-1.33). Observed and predicted mortality for COPD and non-COPD patients, split by 
deciles of GRACE score predicted risk of death, is presented in Table 2. These results stratified 
by year of admission are presented in the supplementary material (Table S1). People with 
diabetes also had a higher risk of death than those without diabetes with the same GRACE 
score predicted risk of death; however, this was lower than for people with COPD (RR 1.14, 
95% CI, 1.12-1.16).  
 
Table 2 Predicted and observed mortality using normal GRACE model 
GRACE 
predicted 
risk decile 
Average 
predicted 
mortality (%) 
Observed mortality - 
non-COPD (%) 
Observed 
mortality – COPD 
(%) 
1 1.3 0.6 0.8 
2 2.5 1.3 2.4 
3 4.0 2.4 4.6 
4 5.0 3.2 6.4 
5 6.5 4.5 7.4 
6 8.9 7.1 12.2 
7 12.4 10.7 17.1 
8 17.2 16.7 21.9 
9 26.6 27.2 32.1 
10 48.4 44.0 47.9 
 
Model modifications 
Findings from model modifications are displayed in Table 3. Compared to the MINAP derived 
GRACE score model using the original variables, the model including COPD as a risk factor 
resulted in better predictions for COPD patients. Including smoking history as a risk factor in 
the model did not result in better predictions for COPD patients. Bootstrapped results did not 
differ from the main analysis. Multiplying the GRACE score predicted risk of death by the RR 
for risk of death for COPD patients adjusted for GRACE score predicted risk of death (1.3) 
resulted in a very close approximation to adding COPD into the model as a risk factor. C-
statistics were improved for the model which multiplied the risk of death for COPD patients by 
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1.3 and the model which included COPD as a risk factor. Adding smoking to the GRACE score 
model did not significantly change the C-statistic. Hosmer-Lemeshow statistics showed that all 
models tested had adequate calibration.  
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Table 3 – Predictive ability of modifications to the GRACE score in COPD patients 
Method for obtaining 
predicted risk of 
death 
M-H pooled RR 
(95% CI) for 
death at 6 
months adjusted 
for predicted risk 
of death 
C-statistic Hosmer-Lemshow p-
value 
Normal GRACE 
score  (comparator 
for 1) 
1.29 (1.28-1.33) 0.8166 >0.999 
1. Normal GRACE 
score – multiply risk of 
death by 1.3 for COPD 
patients 
0.99 (0.96-1.01)  0.8181 
(p<0.001)* 
>0.999 
MINAP derived 
GRACE score 
(comparator for 2-3) 
1.23 (1.20-1.26) 0.8322 >0.999 
2. MINAP derived 
GRACE score + 
smoking 
1.20 (1.17-1.23) 0.8323 
(p=0.274)* 
>0.999 
3. MINAP derived 
GRACE score + 
COPD 
1.00 (0.94-1.02)  0.8333 
(p<0.001)* 
>0.999 
*p-values compare the C-statistics for the modified models compared to either the 
normal GRACE score or the MINAP derived GRACE score.   
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The proportions of all deaths in COPD patients in deciles of predicted risk for the normal 
GRACE model, the GRACE model multiplied by 1.3, and the MINAP derived model including 
COPD are displayed in Figure 2. The plot shows a steeper increase in the proportion of deaths 
in each decile for the GRACE model multiplied by 1.3, and the MINAP derived model 
including COPD compared to the normal GRACE model, indicating better stratification for 
these two modifications. Observed mortality within GRACE score predicted risk groups for the 
normal GRACE model and for the modifications for COPD and non-COPD patients in 
presented in Table 4.  
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Figure 2. Proportion of deaths occurring in COPD patients in each decile of predicted risk for the Normal GRACE model, the GRACE model multiplied by 1.3 
for COPD patients, and the MINAP derived model including COPD. GRACE=Global Registry of Acute Coronary Events; COPD= chronic obstructive 
pulmonary disease. 
167 
 
Table 4 – Observed mortality at 6 months for COPD and non-COPD patients stratified by 
different versions of the GRACE score predicted risk of death 
Normal GRACE score 
GRACE score predicted 
risk level 
Observed mortality - non-
COPD (%) Observed mortality – COPD (%) 
Low (<3%) 1.0 1.9 
Med (3-6%) 3.1 5.8 
High (>6%) 18.4 23.3 
Normal GRACE score x 1.3 for COPD patients 
GRACE score predicted 
risk level 
Observed mortality - non-
COPD (%) Observed mortality – COPD (%) 
Low (<3%) 1.0 1.3 
Med (3-6%) 3.1 3.8 
High (>6%) 18.4 21.4 
MINAP derived GRACE score 
GRACE score predicted 
risk level 
Non Observed mortality - 
non-COPD (%) Observed mortality – COPD (%) 
Low (<3%) 1.1 1.1 
Med (3-6%) 3.4 6.0 
High (>6%) 20.6 25.2 
MINAP derived GRACE score & COPD 
GRACE score predicted 
risk level 
Observed mortality - non-
COPD (%) Observed mortality – COPD (%) 
Low (<3%) 1.1 1.4 
Med (3-6%) 3.7 4 
High (>6%) 21.0 23.3 
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The findings for re-classification of risk levels after different model modifications are displayed 
in Table 5. Compared to the normal GRACE score model, when patients with COPD were 
stratified into risk groups based on the multiplying the GRACE score predicted risk of death by 
1.3, 33.9% of those classified as low risk (<3%) were reclassified as moderate risk (3-6%), and 
64.3% of those who were classified as moderate risk were reclassified as high risk (>6%). When 
stratified by type of ACS, the results were similar to the main analysis, with the exception of 
change in risk group after a STEMI in the MINAP derived model including COPD 
(Supplementary material, Tables S2-S4). The NRI for adding COPD to the GRACE score 
model was 0.133 (p<0.001) indicating an improvement in classification of subjects when COPD 
is added to the model. 
 
The findings from the multiple imputation analysis were similar to those form the main analysis, 
and are presented in the supplementary material (Table S5). 
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Table 5 Changes in level of risk for COPD patients after modifications 
 
 
 
Discussion 
We found that GRACE scores for predicting risk of death at 6 months after ACS do not 
perform as well for people with COPD compared to those who do not have COPD. On 
average, COPD patients had a 30% higher risk of death than non-COPD patients with the same 
GRACE score. In order to improve GRACE scores for COPD patients, one option would be 
to re-specify the GRACE model including COPD as a risk factor. Alternatively, multiplying 
GRACE score predicted risk of death by 1.3 for COPD patients provides a very close 
approximation.  
 
We found that, conditional on GRACE score predicted risk of death, COPD patients had a 
higher risk of death than non-COPD patients, indicating that these scores underestimate the 
risks of death in those with COPD. One might argue that this might be true for any co-
morbidity; however, when we also estimated the relative risk of death comparing those with 
diabetes to those without diabetes adjusted for GRACE score predicted risk of death, although 
 Multiplying risk by 1.3 
GRACE score 
predicted 
risk of death Low risk (<3%) Moderate risk (3-6%) High risk (≥6%) 
Low risk 
(<3%) 4,107 (66.1%) 2,108 (33.9%) 0 
Moderate 
risk (3-6%) 0 2,000 (35.7%) 3,609 (64.3%) 
High risk 
(>6%) 0 0 20,799 (100.0%) 
 Adding COPD into MINAP derived GRACE model 
GRACE score 
predicted 
risk of death Low risk (<3%) Moderate risk (3-6%) High risk (≥6%) 
Low risk 
(<3%) 4,635 (71.5%) 1,582 (25.5%) 184 (3.0%) 
Moderate 
risk (3-6%) 681 (12.2%) 2,792 (50.0%) 2,117 (37.9%) 
High risk 
(>6%) 15 (0.1%) 994 (4.8%) 19,527 (95.1%) 
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we found an increased risk, this was much lower than for COPD. Although the relative risk of 
death for COPD might seem modest, this may have a large impact on patient treatment. 
Indeed, our results suggest that a large portion of COPD patients would have been reclassified 
upwards in terms of level of risk if either of our suggested modifications (multiplying the risk 
for COPD patients by 1.3 and adding COPD to the model) to the GRACE score had been 
used. Although we found that GRACE score predicted risk was closer to observed risk in those 
with COPD, the explanation for this is likely to be that for patients with the same predicted risk 
of death, COPD patients have always been at higher risk and observed mortality for all patients 
has fallen since GRACE scores were created such that they now by chance align well for those 
with COPD. This is consistent with our findings when we tabulated predicted and observed risk 
stratified by admission year. Although the GRACE score is the most accurate and widely used 
score for predicting risk of death after admission for ACS, others are in use. Clinicians should 
be aware that scores which use similar parameters are likely to underestimate risk of death for 
COPD patients to a similar degree. 
 
Our findings are an important contribution to discussion around the risk-treatment paradox.  
The paradox is that although those who are at highest risk of death after ACS are most likely to 
benefit from early aggressive therapy, they are the least likely to receive it[19]. This may go some 
way in explaining why COPD patients receive less in-hospital treatment after MI, such as in-
hospital angiography after non-STEMI. Using risk scores and recommendations based on these 
to guide treatment decisions is one way to resolve this paradox. However, these risk scores must 
be able to predict risk of death well, they must be able to do this around levels of risk important 
for decision making, and they must do this for those at high risk of death.  
 
A strength of our study is that it is large and representative of the national population, including 
all hospital admissions for ACS in England and Wales. A well as our complete case analysis, we 
also explored reasons for missing data and conducted a multiple imputation analysis. This 
further analysis did not change our conclusions. We calculated the proportion of COPD 
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patients who would have changed risk category as a result of the increase in predicted risk of 
death. This allowed us to demonstrate that although the relative risk of death adjusting for 
GRACE score predicted risk of death may seem modest, at the critical region of 0-6% predicted 
risk of death, this could have resulted in a change in management for a substantial proportion of 
COPD patients. One limitation of our study was that we used the NICE amended mini-
GRACE score[17] rather than the model including Killip class. We used prescription of 
diuretics in hospital as a surrogate for acute heart failure. However, it is highly unlikely that the 
differences between COPD and non-COPD patients could be explained by this. In addition, 
recent work[17] has shown that this GRACE score is a very good approximation to the full 
GRACE score, and the amended mini-GRACE score is being used in practice as it is now 
available on the GRACE 2.0 calculator[20].  
 
There are several possible reasons why GRACE score predicted risk of death is not as accurate 
for COPD patients. Our previous work showed that the relative risk of death after MI for 
COPD patients is greater after non-STEMIs than STEMIs[14], and non-STEMIs will be scored 
lower than STEMIs, all other things being equal. In addition, the effect of COPD on risk of 
death after MI was greater for younger COPD patients, and younger people will be scored 
lower on average.  In the development of the GRACE score, although several clinical 
characteristics, including diabetes, hypertension and hyperlipidemia were tested for inclusion as 
risk factors, COPD was not[21]. Although some of the increased risk of death may be due to 
differences in treatment, others have concluded that the GRACE score maintains its predictive 
ability even in groups with different treatment[22]. In addition, among a wide range of in-
hospital treatments tested, none entered the GRACE score model as predictors of death[21]. 
Previous work has investigated the performance of the GRACE score in other high risk groups 
such as people with diabetes and people with chronic renal failure[23]. However, this work only 
assessed the C-statistic in these groups, and did not involve assessing the GRACE score in 
those with COPD. Our findings have important clinical implications for the care of COPD 
patients after admission to hospital for ACS. Multiplying the GRACE score predicted risk of 
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death by 1.3 for COPD patients would mean that 34% of people with COPD would move 
from being classified as low risk to moderate risk (<3% to 3-6%). These changes have 
important implications as recommendations for treatment after non-STEMI and unstable 
angina are based on classification as moderate or high predicted risk of death. This is 
particularly relevant as it is known that COPD patients are more likely to present with a non-
STEMI than non-COPD patients and that the effect of COPD on risk of death after MI is 
highest in non-STEMIs, and after adjusting for patient characteristics, they are less likely to 
receive early invasive treatment after a non-STEMI compared to non-COPD patients[14, 24].   
 
Conclusions 
GRACE score predicted risk of death after ACS does not predict risk of death for people with 
COPD as well as they do for those who do not have COPD, and underestimates risk of death 
for this group. When future versions of the GRACE score model are created, those developing 
the scores may want to include COPD as a risk factor for death. Clinicians should multiply 
GRACE score predicted risk of death by 1.3 to obtain a more accurate prediction. Using this 
rule would mean that one third of COPD patients previously considered to be low risk, should 
be considered moderate risk and would be considered for more aggressive early treatment under 
current guidelines for non-STEMI and unstable angina. 
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6.3 Summary 
 
 The GRACE score does not perform as well in COPD patients as it does in those who 
do not have COPD, and underestimates risk of death at 6 months following MI for 
those with COPD. This may be because age is an effect modifier for the risk of death 
following MI for people with COPD 
 Prediction of risk of death can be made more accurate for people with COPD by 
multiplying the predicted risk of death by 1.3, and this may result in a change in 
management for a significant proportion of COPD patients 
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Chapter 7: Validation of the recording of acute exacerbations of 
COPD in UK primary care electronic healthcare records 
(Research paper V) 
 
7.1 Preamble  
Currently, there is no validated definition of AECOPD in UK EHR. There are many ways in 
which a GP might code a diagnosis of AECOPD, for example, this may be done using a code 
for AECOPD, a code for LRTI, a code for a symptom of AECOPD (such as cough) or may 
simply just be recorded as a prescription for an antibiotic.   
 
The research paper presented in this chapter aims to validate the recording for AECOPD in 
UK primary care EHR, and uses data from the CPRD as well as information from 
questionnaires which were sent to GPs. The validity of 15 pre-specified algorithms is assessed 
against a reference standard of respiratory physician review of questionnaire material.  
 
In terms of this thesis, the primary motivation for validating the recording of AECOPD is to 
provide a definition of AECOPD to be used in the investigation of the relationship between 
AECOPD and MI. The previous study (Donaldson et al. 2010) of the relationship between 
AECOPD and MI using UK EHR data used three definitions of AECOPD: 1) prescription of 
oral corticosteroids, 2) prescription of antibiotics, and 3) prescription of oral corticosteroids and 
antibiotics on the same day. A major concern with using prescription of antibiotics as a 
definition of AECOPD as the exposure in the later study relating this to MI is misclassification 
of other infections with AECOPD. This is important as other infections, for example urinary 
tract infections, are known to be associated with risk of MI (Smeeth  et al. 2004). These 
definitions, as well as others are assessed here.  
 
This paper was originally published in PLoS ONE, and is available at: 
Rothnie, KJ, Müllerová, H, Hurst, JR, Smeeth, L, Davis, K, Thomas, SL and Quint, JK. 
‘Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic 
Healthcare Records.’ 2016. PLoS ONE. (11)3:e0151357. 
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7.2 Research paper 
Validation of the recording of acute exacerbations of COPD in UK primary care 
electronic healthcare records 
Authors: Kieran J Rothnie, Hana Müllerová, John R Hurst, Liam Smeeth, Kourtney Davis, Sara 
L Thomas, Jennifer K Quint 
Abstract 
Background  
Acute Exacerbations of COPD (AECOPD) identified from electronic healthcare records 
(EHR) are important for research, public health and to inform healthcare utilisation and service 
provision. However, there is no standardised method of identifying AECOPD in UK EHR. We 
aimed to validate the recording of AECOPD in UK EHR. 
Methods 
We randomly selected 1385 patients with COPD from the Clinical Practice Research Datalink. 
We selected dates of possible AECOPD based on 15 different algorithms between January 2004 
and August 2013. Questionnaires were sent to GPs asking for confirmation of their patients' 
AECOPD on the dates identified and for any additional relevant information. Responses were 
reviewed independently by two respiratory physicians. Positive predictive value (PPV) and 
sensitivity were calculated.  
Results 
The response rate was 71.3%. AECOPD diagnostic codes, lower respiratory tract infection 
(LRTI) codes, and prescriptions of antibiotics and oral corticosteroids (OCS) together for 5-14 
days had a high PPV (>75%) for identifying AECOPD. Symptom-based algorithms and 
prescription of antibiotics or OCS alone had lower PPVs (60-75%). A combined strategy of 
antibiotic and OCS prescriptions for 5-14 days, or LRTI or AECOPD code resulted in a PPV 
of 85.5% (95% CI, 82.7-88.3%) and a sensitivity of 62.9% (55.4-70.4%).  
Conclusion 
Using a combination of diagnostic and therapy codes, the validity of AECOPD identified from 
EHR can be high. These strategies are useful for understanding health-care utilisation for 
AECOPD, informing service provision and for researchers. These results highlight the need for 
common coding strategies to be adopted in primary care to allow easy and accurate 
identification of events.   
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a common, progressive disease characterised 
by airflow obstruction which is not fully reversible.  As the third leading cause of death 
worldwide[1], COPD represents a substantial public health problem. Acute exacerbations of 
COPD (AECOPD) are important drivers of mortality[2, 3] and reduced quality of life[4] in 
COPD patients and as the second most common reason for emergency hospital admission[5], 
they are also of great public health importance. Several studies[6-8] of AECOPD have been 
conducted in UK electronic healthcare records (EHR) which are becoming an increasingly 
important resource for evidence from real life research.  
 
Data from primary care are used by organisations such as Public Health England (PHE) to 
compare data on AECOPD incidence and management across localities and by clinical 
commissioning groups to inform delivery of care and design of services. In addition, the 
recording of AECOPDs is important for clinicians as GPs need an easy and reliable way of 
accessing information on the timing and severity of previous AECOPD to tailor management 
programmes for their patients.  
 
The investigation of AECOPD using EHR has so far been limited by the use of non-validated 
strategies to identify AECOPD events based on clinical experience. Previous studies used 
different combinations of drug therapy (for example, oral steroids and/or antibiotics)[7] and/or 
medical diagnosis codes. However, the validity of these approaches is not clear. Antibiotics may 
not be given if AECOPD are thought to be viral and, therefore, use of prescription of 
antibiotics alone may lead to misclassification of other diseases for AECOPD, particularly as up 
to 50% of AECOPD are known to be associated with a virus[9]. In addition, these prescriptions 
may be rescue packs intended for future use and may not represent individual acute events.   
 
This study aimed to investigate a comprehensive set of pre-specified algorithms for the 
identification of AECOPD within UK primary care electronic healthcare records.   
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Methods 
Data source 
We used the Clinical Practice Research Datalink (CPRD), a large electronic database of UK 
general practice data that has been widely used for research. The Clinical Research Practice 
Datalink (CPRD)[10] is a large electronic database of primary care medical records. CPRD 
contains anonymised records for over 13 million patients, of which 4.4 million are currently 
registered with a practice that is contributing data to the CPRD, representing about 7% of the 
UK population. Data held include information on consultations, diagnoses, tests, referrals to 
secondary care and prescriptions from primary care as well as some lifestyle data. Around 60% 
of the patients included in the CPRD have been linked to hospital episode statistics data (HES).  
 
Codelist and algorithm development 
Codelists (Read codes and product codes) were developed prior to the beginning of the study. 
Read codes are a hierarchical coding system of clinical terms used in the UK general practice 
which are entered into the GP software system and uploaded to the CPRD. Prescriptions for 
drugs are recorded in the CPRD as unique product codes. The codes used to construct 
AECOPD algorithms are available in the supplementary appendix.   
 
Strategies to ascertain AECOPD, translated into coding algorithms, were developed prior to the 
beginning of the study. These were based on both previous definitions that have been used in 
published papers, as well as definitions deemed to show high face validity. Face validity was 
determined after discussion between respiratory, primary care physicians with experience of UK 
primary care, and epidemiologists with experience in the design and analysis of studies using 
large UK primary care EHR databases.  We used the August 2013 CPRD build and Read code 
dictionary. The fifteen algorithms are described in Table 1.  
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Table 1. Description of the algorithms tested 
Algorithm Notes 
1. Oral corticosteroid (OCS) prescription  For 5-14 days 
2. Antibiotic prescription  For 5-14 days 
3. Oral corticosteroid and antibiotic prescription  For 5-14 days, both on the same day 
4. Exacerbation Symptom definition  Codes suggesting increase in two or more 
of: breathlessness, cough, or sputum 
volume and/or purulence 
5. Exacerbation Symptom definition and oral 
corticosteroid prescription 
Symptom definition the same as 4. 
Medical codes must have been on the 
same day as prescription. Duration of 
prescription was not limited.  
6. Exacerbation Symptom definition and 
antibiotic prescription 
Symptom definition the same as 4. 
Medical codes must have been on the 
same day as prescription. Duration of 
prescription was not limited. 
7. Exacerbation Symptom definition and oral 
corticosteroid & antibiotic prescription 
Symptom definition the same as 4. 
Medical codes must have been on the 
same day as prescription. Duration of 
prescription was not limited. 
8. Lower respiratory tract infection (LRTI) code  Specifically excluding codes for 
pneumonia 
9. LRTI code and oral corticosteroid 
prescription 
Medical codes must have been on the 
same day as prescription. Duration of 
prescription was not limited. 
10. LRTI code and antibiotic prescription Medical codes must have been on the 
same day as prescription. Duration of 
prescription was not limited. 
11. LRTI code and oral corticosteroid & 
antibiotic prescription 
Medical codes must have been on the 
same day as prescription. Duration of 
prescription was not limited. 
12. AECOPD code  
13. AECOPD code and oral corticosteroid 
prescription 
Medical codes must have been on the 
same day as prescription. Duration of 
prescription was not limited. 
14. AECOPD code and antibiotic prescription Medical codes must have been on the 
same day as prescription. Duration of 
prescription was not limited. 
15. AECOPD code and oral corticosteroid & 
antibiotic prescription 
Medical codes must have been on the 
same day as prescription. Duration of 
prescription was not limited. 
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As prescription of rescue packs and acute codes used at annual reviews may be identified by our 
algorithms, we developed further codelists to identify consultations during which rescue packs 
were prescribed or annual reviews occurred.   
 
Study population  
COPD patients were identified in the CPRD using a previously validated strategy[11]. For this 
analysis, we specifically defined COPD patients as having a record for a specific COPD Read 
code, history of current or past smoking, at least two prescriptions for COPD medicines (one 
within 4 weeks of the initial COPD Read code) and of age over 35 years at the time of the initial 
COPD Read code. Inclusion was further restricted to those patients whose GP practice last 
collection date was four months or less from the end of the study (August 2013) and were alive 
and registered at the GP practice at the time of the last CPRD data collection.  
 
Patients were followed up from January 2004, date of COPD diagnosis or date of registration 
with an eligible practice, whichever was later and were followed up until August 2013, date of 
death, last collection date, or date of transfer out of an eligible GP practice, whichever was 
earlier. The fifteen pre-specified AECOPD algorithms were used to ascertain any potential 
AECOPD event which occurred during this time period. 
 
For the validation purposes, potential AECOPD events identified via algorithms were further 
selected using stratified random sampling. This procedure was designed such that it would 1) 
select events randomly within algorithms, 2) maximise the amount of information available per 
questionnaire, and 3) select potential events from rarer algorithms preferentially over events 
from algorithms which had potential events which were more common. Briefly, 1600 patients 
were selected such that each algorithm was represented by potential AECOPD events in at least 
100 patients. Up to 10 potential AECOPD events (up to 5 from a single algorithm) were then 
randomly selected from each patient’s individual pool of AECOPD events. This procedure 
ensured that several dates could be enquired about for each patient; that none of the definitions 
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had no, or very few, potential AECOPD events in the final sample; and that the number of 
dates enquired about for each patient was not so high as to make response by the GP unlikely.  
 
Questionnaires 
We sent a short questionnaire to GPs asking them to confirm whether their patients had 
AECOPD on the dates identified. GPs were allowed to respond with “Yes”, “No” or 
“Uncertain”. We also asked about any dates in the last 12 months on which the patient had an 
AECOPD, not already listed on the dates specified. Finally, we asked GPs to send copies of any 
relevant material, such as extracts from patient notes or hospital discharge letters. All material 
was anonymised by the CPRD before being returned to investigators. We sent two reminders to 
GP practices who did not initially respond.   
 
Outcome assessment 
The reference standard for diagnosis of AECOPD was an independent review of all material 
from the GP (questionnaire and other relevant material) by two respiratory physicians. Each 
respiratory physician independently reviewed all available information before discussing 
disagreements. We calculated Cohen’s Kappa to assess inter-rater agreement. Information from 
CPRD on dates which the GP specified that their patient had an AECOPD, but which were not 
listed on the questionnaire, were also reviewed by a respiratory physician. These events were 
included in the analysis if they were judged to be an AECOPD. For potential AECOPD events 
which the GP responded with “uncertain”, we obtained and reviewed anonymised medical 
notes and information from the CPRD GP “free-text” field records corresponding to the 
appropriate date.  
 
Sample size 
Assuming a conservative minimum of a 50% response rate and only 100 potential events 
identified per algorithm (50 AECOPD events per algorithm) in the final analytical sample, we 
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calculated that the confidence intervals around example PPVs would be: 50% (95% CI, 35.5-
64.5%); 70% (95% CI, 55.4-82.1%); 90% (95% CI, 78.2-96.7%).  
 
Analysis 
The main outcome was positive predictive value (PPV). True positives were defined as events 
which were identified by the algorithm, sampled from the AECOPD pool and confirmed by the 
reference standard.  False positives were defined as events which were identified by the 
algorithm, sampled from the AECOPD pool and not confirmed by the reference standard. PPV 
was calculated as: True positives / (True Positives + False Positives).  
 
To estimate the sensitivity, we used a combination of algorithm and GP identified dates of 
AECOPD events in the last 12 months.  True positives were defined as events (1) which were 
identified by the algorithm, sampled from the AECOPD pool and confirmed by the reference 
standard or (2) which were listed as additional events by the GP, which were also identified by 
algorithm but had not been sampled. False negatives were defined as events which were (1) 
listed by the GP as additional dates, but which were not identified by the algorithm or (2) as 
event dates which were identified and confirmed by the reference standard for other 
algorithm(s) only (i.e. confirmed events which were not in the AECOPD pool for that 
algorithm, whether sampled or not). For the analysis of sensitivity, events which occurred 
within two weeks of another event were considered part of the same episode. Sensitivity was 
calculated as: True Positives / (True Positives + False Negatives). 
 
We used bootstrapping to obtain cluster-robust confidence intervals for PPV and sensitivity. 
We excluded events which were still “uncertain” after respiratory physician review. Events 
which occurred on the same day as annual reviews or rescue pack prescriptions were not 
included in the main analysis.  
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We repeated the analysis of PPV and sensitivity restricted to those patients for whom GPs sent 
additional information (patient notes and discharge summaries). In this group of patients, 
respiratory physicians who were assessing questionnaires would have been able to see 
information from several sources in order to reach a decision on whether they thought the 
patient had an AECOPD on the dates in question. We also repeated the analysis of PPV 
stratified by characteristics identified from the CPRD: age group, sex, smoking status, GOLD 
2006 grade of airflow limitation[12], Medical Research Council (MRC) dyspnoea score[13], 
socioeconomic status[14], WHO Body Mass Index (BMI) category, previous record of asthma 
diagnosis, previous records of gastro-oesophageal reflux disease (GORD) diagnosis, and 
previous record of diagnosis for cardiovascular disease (either of myocardial infarction, angina 
or heart failure).  
 
Finally, we assessed the PPV and sensitivity for several combinations of algorithms to identify 
AECOPD. Our strategy was to achieve an adequate sensitivity while maintaining a high PPV. 
Initially we combined algorithms which had the highest PPV (those with PPV>80%). We then 
added algorithms which had PPV>75% in order to improve sensitivity. We also calculated PPV 
and sensitivity using all of the algorithms.  
 
Ethics 
Ethical approval was obtained from the London School of Hygiene and Tropical Medicine 
(LSHTM) Observational Research Ethics Committee (approval number 6481) and the Clinical 
Practice Research Datalink (CPRD) Independent Scientific Advisory Committee (ISAC) 
(approval number 13_116). Patient records and questionnaires were de-identified and 
anonymised by CPRD staff before being sent to the investigators.  
 
Results 
Patient characteristics 
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We selected 1600 patients for the study, of whom 215 had GP practices which had left the 
CPRD and were therefore excluded from the sampling frame (Figure 1). Our final study 
consisted of questionnaires related to the remaining 1385 patients. Of these 988 (71%) were 
returned by their GPs, representing 8258 potential AECOPD events. Characteristics of patients 
included in the study are detailed in table 2. Mean age in our final sample of COPD patients was 
62.4 years (SD, 10.6), 49% were male, 38% had severe or very severe airflow limitation (GOLD 
2006 grades 3 or 4), 53% reported moderate/severe dyspnoea (MRC score of 3 or more), and 
55% were current smokers. Restricting the sample to those dates which did not occur on annual 
review dates or dates of rescue pack prescriptions reduced the sample to 7136 events in 955 
patients. Characteristics of patients whose GPs responded to the questionnaire were similar to 
those who did not, with the exception of socioeconomic status (supplementary table 1). Patients 
whose GPs did not respond were on average more deprived than those whose GP responded. 
Details of the event flow through the study stratified by algorithm are presented in table 3. 
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Figure 1 – Patient flow through the study 
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Table 2 Characteristics of the 988 patients included in the analysis 
Characteristic n % (N=988) 
Age group   
≤55 212 21.5 
55 to 64 359 36.3 
65 to 74 301 30.5 
≥ 75 116 11.7 
Sex   
Male 481 48.7 
Female 507 51.3 
MRC breathlessness scale 
(N=950) 
  
≥3 449 47.3 
< 3 501 52.7 
BMI   
< 19 39 4.0 
19 – 25 353 35.7 
≥25 596 60.3 
Record of cardiovascular disease   
No 731 74.0 
Yes 257 26.0 
Record of asthma   
No 482 48.8 
Yes 506 51.2 
Record of GORD   
No 729 73.8 
Yes 259 26.2 
GOLD 2006 grade (N=592)   
1 76 12.8 
2 285 48.1 
3 185 31.3 
4 46 7.8 
Smoking status  
Ex-smoker 447 45.2 
Current smoker 541 54.8 
Index of multiple deprivation quintile (N=985)  
1 (least deprived) 152 15.4 
2 213 21.6 
3 188 19.1 
4 216 21.9 
5 (most deprived) 216 21.9 
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Table 3. Flow of events through the study 
Algorithm 
N events 
identified in the 
CPRD 
N events 
sampled 
N events from 
returned 
questionnaires 
N events adjudicated 
for uncertain response 
N events uncertain after 
respiratory physician review (% of 
those returned questionnaires) 
All 261981 11697 8253 914 227 (2.8) 
1.OCS prescription for 5-14 days 33898 1956 1285 120 32 (2.5) 
2.Antibiotic prescription for 5-14 days 225761 9622 6283 809 208 (3.3) 
3.OCS and antibiotic prescription  for 
5-14 days 
22990 1374 919 72 22 (2.4) 
4. Symptom definition 1745 462 341 11 2 (0.6) 
5. Symptom definition and OCS 
prescription 
553 232 156 6 1 (0.6) 
6. Symptom definition and antibiotic 
prescription 
165 132 108 5 0 (0) 
7. Symptom definition and OCS & 
antibiotic prescription 
142 112 90 3 0 (0) 
8. LRTI code 60099 2753 1809 214 36 (2.0) 
9. LRTI code and OCS prescription 53460 2488 1617 200 34 (2.1) 
10. LRTI code and antibiotic 
prescription 
9354 600 411 25 2 (0.5) 
11. LRTI code and OCS & antibiotic 
prescription 
8770 569 388 25 2 (0.5) 
12. AECOPD code 20905 1371 966 21 0 (0) 
13. AECOPD code and OCS 
prescription 
15020 992 698 14 0 (0) 
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14. AECOPD code and antibiotic 
prescription 
8571 674 466 11 0 (0) 
15. AECOPD code and OCS & 
antibiotic prescription 
7440 601 418 10 0 (0) 
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PPV and sensitivity  
Inter-rater agreement in outcome assessment was high. The respiratory physicians reviewing the 
questionnaires agreed for 92.5% of the potential AECOPD dates before discussion, and this 
resulted in a Cohen’s Kappa of 0.844. All disagreements were resolved by discussion between 
the two respiratory physicians and none were referred to a third physician. The PPVs and 
sensitivity of each algorithm are presented in table 4. The algorithms with the higher PPVs 
(>80%) were those that used (1) an LRTI code along with either prescription of an antibiotic or 
a steroid or antibiotic and a steroid, and (2) AECOPD code either with or without prescription 
of antibiotics; and (3) the symptom definition with either prescription of OCS or antibiotics. 
The LRTI code alone (79.6%, 76.9-82.3%) and prescription of both antibiotics and OCS for 5-
14 days (79.3%, 75.8-82.9%) had slightly lower PPVs. The symptom definition alone, 
prescription for 5-14 days of antibiotics and prescription of 5-14 days of OCS had poorer PPVs 
(60-73%).  
 
193 
 
Table 4. PPV and sensitivity for the algorithms 
Algorithm 
N events 
identified 
in the 
CPRD 
N events 
confirmed by 
reference 
standard 
PPV (95% CI) 
N events identified 
in the CPRD in last 
year 
N extra events identified 
by other algorithms or 
GPs in last year 
Sensitivity (95% CI) 
1.OCS prescription 1152 841 
73.0  
(69.5 - 76.5) 
164 379 
30.2 
(25.8 - 34.6) 
2.Antibiotic 
prescription 
5840 3559 
60.9  
(59.0 - 62.9) 
386 157 
71.1  
(66.8 - 75.4) 
3.OCS and 
antibiotic 
prescription 
823 653 
79.3  
(75.8 - 82.9) 
133 410 
24.5  
(20.4 - 28.6) 
4. Symptom 
definition 
142 92 
64.8  
(56.2 - 73.3) 
14 529 
2.6  
(1.1 -  4.0) 
5. Symptom 
definition and OCS 
prescription 
88 79 
89.8  
(82.9 - 96.7) 
12 531 
2.2  
(0.9 -  3.6) 
6. Symptom 
definition and 
antibiotic 
prescription 
57 53 
93.0  
(85.6 - 100.0) 
10 533 
1.8  
(0.6 -  3.1) 
7. Symptom 
definition and OCS 
& antibiotic 
prescription 
48 47 
97.9  
(94.5 – 100.0) 
9 534 
1.7  
(0.5 -  2.9) 
8. LRTI code 1745 1389 
79.6  
(76.9 - 82.3) 
125 418 
23.0  
(19.2 - 26.8) 
9. LRTI code and 
OCS prescription 
1558 1268 
81.4  
(78.7 - 84.1) 
108 435 
19.9  
(16.3 - 23.5) 
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10. LRTI code and 
antibiotic 
prescription 
393 347 
88.3  
(84.4 - 92.2) 
65 478 
12.0  
(9.3 - 14.7) 
11. LRTI code and 
OCS & antibiotic 
prescription 
371 327 
88.1  
(84.1 - 92.1) 
62 481 
11.4  
(8.8 - 14.0) 
12. AECOPD code 885 850 
96.0  
(94.5 - 97.6) 
136 407 
25.1  
(20.9 - 29.2) 
13. AECOPD code 
and OCS 
prescription 
638 618 
96.9  
(95.4 - 98.3) 
99 444 
18.2  
(14.6 - 21.8) 
14. AECOPD code 
and antibiotic 
prescription 
423 408 
96.5  
(94.5 - 98.4) 
95 448 
17.5  
(13.8 - 21.2) 
15. AECOPD code 
and OCS & 
antibiotic 
prescription 
377 365 
96.8  
(95.0 - 98.6) 
87 456 
16.0  
(12.6 - 19.5) 
Antibiotics = selected antibiotics with clinical application in management of AECOPD 
OCS = oral corticosteroids specific to AECOPD management
195 
 
Sensitivity was low (<30%) for all algorithms except for prescription of an antibiotics course for 
5-14 days (71.1%, 66.8-75.4%). More restrictive definitions had poorer sensitivity than those 
without any restriction.  Sensitivity was particularly low for all of the algorithms which used 
respiratory symptoms.  
 
Restricting the analysis to those patients for whom GPs sent supporting information resulted in 
slight increases in PPV for some algorithms (Table 5). This restriction also reduced the 
sensitivity for the use of OCS for 5-14 days to 22.7% (95% CI, 16.1-29.2%) from 30.2% (95% 
CI, 25.8-34.6%); the use of antibiotics for 5-14 days to 63.4% (95% CI, 55.4-71.4%) from 
71.1% (95% CI, 66.8-75.4%); and the use of both antibiotics and OCS for 5-14 days to 18.6% 
(95% CI, 12.4-24.7%) from 24.5% (95% CI, 20.4-28.6%).  
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Table 5. PPV and sensitivity of the algorithms to identify AECOPD including only patients for whom additional information was available from their 
GP questionnaire  
 
Algorithm (inclusive 
definitions) 
N events 
identified in the 
CPRD 
N events 
confirmed by 
reference 
standard 
PPV (95% CI) 
N events 
identified in 
the CPRD in 
last year 
N extra events 
identified by GPs in 
last year 
Sensitivity (95% CI) 
1.OCS prescription 367 265 
72.2  
(66.5 - 77.9) 
44 150 
22.7  
(16.1 - 29.2) 
2.Antibiotic prescription 2245 1376 
61.3  
(58.3 - 64.3) 
123 71 
63.4  
(55.4 - 71.4) 
3.OCS and antibiotic 
prescription 
251 200 
79.7  
(73.5 - 85.8) 
36 158 
18.6  
(12.4 - 24.7) 
4. Symptoms definition 83 53 
63.9  
(52.7 - 75.0) 
4 190 
2.1  
(0.1 -  4.0) 
5. Symptoms definition 
and OCS 
Prescription 
50 47 
94.0  
(88.0 - 100.0) 
4 190 
2.1  
(0.1 -  4.0) 
6. Symptoms definition 
and antibiotic prescription 
36 34 
94.4  
(86.8 – 100.0) 
3 191 
1.6  
(0.1 - 3.2) 
7. Symptoms definition 
and OCS & antibiotic 
prescription 
31 31 
100.0  
(88.8 - 100.0) 
3 191 
1.6  
(0.1 - 3.2) 
8. LRTI code 
 
693 574 
82.8  
(78.8 - 86.9) 
48 146 
24.7  
(18.8 - 30.7) 
9. LRTI code and OCS 
prescription 
621 525 
84.5  
(80.6 - 88.5) 
40 154 
20.6  
(15.2 - 26.0) 
10. LRTI code and 
antibiotic prescription 
142 132 
93.0  
(88.3 - 97.6) 
24 170 
12.4  
(7.8 - 16.9) 
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11. LRTI code and OCS & 
antibiotic prescription 
129 119 
92.2  
(87.1 - 97.4) 
21 173 
10.8  
(6.7 - 15.0) 
12. AECOPD code 350 344 
98.3  
(96.9 - 99.6) 
52 142 
26.8  
(19.7 - 33.9) 
13. AECOPD code and 
OCS prescription 
236 234 
99.2  
(98.1 - 100.0) 
36 158 
18.6  
(12.4 - 24.7) 
14. AECOPD code and 
antibiotic prescription 
155 152 
98.1  
(96.0 - 100.0) 
33 161 
17.0  
(10.8 - 23.2) 
15. AECOPD code and 
OCS & antibiotic 
prescription 
140 138 
98.6  
(96.8 - 100.0) 
30 164 
15.5  
(9.7 - 21.2) 
 
Antibiotics = selected antibiotics with clinical application in management of AECOPD 
OCS = oral corticosteroids specific to AECOPD management 
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The analysis of PPV and sensitivity analyses were repeated for all event date including these 
dates occurring on annual COPD review and those with prescription for suspected rescue packs 
of OCS (supplementary material, Table S2). The PPVs stratified by patient demographic and 
disease severity characteristics are presented in the supplementary material (Supplementary 
Table S3). Briefly, PPVs for the OCS course for 5-14 days appeared to differ by some of the 
characteristics. PPV for the OCS course for 5-14 days was higher for patients with no or mild 
dyspnoea, without CVD co-morbidity, and for women. 
 
The PPV and sensitivity for the composite strategies are presented in Table 6.  Combining 
algorithms with PPV > 80% (5, 6, 8 or 12) resulted in a PPV of 88.1% (95% CI, 85.3-90.8) and 
a sensitivity of 51.6 (95% CI, 44.1-59.0). Using algorithms with a PPV >75% (3, 5, 6, 8 or 12) 
resulted a in very high PPV of 85.5% (95%CI, 82.7-88.3%) with a sensitivity of 62.9% (95%CI, 
55.4-70.4%). Use of all pre-defined algorithms to identify AECOPD reduced the PPV to 63.8% 
(95%CI, 61.0-66.6%), but achieved a sensitivity of 88.1% (95%CI, 82.9-93.4%).  
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Table 6. PPV and sensitivity of composite strategies to identify AECOPD including only 
patients for whom additional information was available from their GP questionnaire 
 
Strategy PPV (95% CI) Sensitivity (95% CI) 
Algorithms with PPV > 80% 
 
Algorithms 5, 6, 8 or 12 
 
Symptom definition with 
prescription of antibiotic or 
OCS; or LRTI; or AECOPD 
code 
 
88.1 (85.3-90.8) 51.6 (44.1-59.0) 
Algorithms with PPV > 75% 
 
Algorithms 3, 5, 6, 8 or 12  
 
Prescription of antibiotics 
and OCS for 5-14 days; or 
Symptom definition with 
prescription of antibiotic or 
OCS; or LRTI code; or 
AECOPD code  
 
85.5 (82.7-88.3) 62.9 (55.4-70.4) 
All algorithms 
 
63.8 (61.0-66.6) 88.1 (82.9-93.4) 
 
 
 
200 
 
Discussion 
This is the first study to describe the recording of AECOPD by general practitioners in UK 
EHRs. Although the definitions used in future studies may depend on the individual needs and 
potential objectives, particularly with respect to the need for maximising either PPV or 
sensitivity, our recommendation for identifying AECOPD events in EHR is to use a composite 
of several of the definitions with higher PPV. To maximise sensitivity over PPV for identifying 
AECOPD in UK EHR, investigators would need to use prescription of antibiotics, as the PPV 
was low for this algorithm, this strategy is likely to misclassify many other infections as 
AECOPD. One recommended approach would be to use the following strategy that resulted in 
PPV of 86% and sensitivity of 63%:  a combination of: (1) a medical diagnosis of LRTI or 
AECOPD, or (2) a prescription of COPD-specific antibiotic combined with OCS for 5-14 days, 
or (3) a record of two or more respiratory symptoms of AECOPD along with a prescription of 
COPD-specific antibiotics and/or OCS on the same day. These combined strategies should be 
used only after removing any AECOPD events occurring on the same date as codes suggestive 
of a visit for annual COPD review or provision of rescue packs for COPD-specific antibiotics 
or OCS. We do not recommend using definitions based on respiratory symptoms without 
COPD-specific antibiotics or OCS, or COPD-specific antibiotics or OCS without medical 
diagnosis of LRTI, AECOPD or respiratory symptoms due to mediocre PPVs. This has 
important implications as previous studies of AECOPD outcomes have used prescription of 
either antibiotics and or oral steroids to define AECOPD, and our findings suggest that this 
strategy may lead to a high level of misclassification of AECOPD events. Compared to previous 
studies, which have attempted to identify AECOPD in EHRs, we used a very specific list of 
antibiotics and OCS pertaining to management of AECOPD.  
 
Having a validated definition of a COPD outcome, representing a substantial source of burden 
to patients and health-care providers, such as AECOPD is important. It provides a robust 
method for deriving statistics on AECOPD which can inform health-care service planning and 
evaluation of programs over time. In addition, as well as being a resource for “real life” 
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observational studies, electronic healthcare records have the potential to be used in pragmatic 
clinical trials. This requires standardised and accurate definitions of exacerbations, and our 
research provides that.  
 
Our findings illustrate that there are multiple strategies adopted by health care workers when 
recording AECOPD events in the UK EHR. Only about one half of the AECOPD events were 
recorded using a medical diagnosis code either for LRTI , AECOPD or respiratory symptoms, 
whilst the remaining events were recorded only as  prescriptions of COPD-specific antibiotics 
and/or OCS. Even using all pre-defined algorithms, about 12% of AECOPD events failed to 
be captured (false negatives). We explored medical codes at these dates and did not find any 
leads allowing derivation of further algorithms. The most frequent events recorded on the 
AECOPD dates not captured by any algorithm included: “reviewed patient”, “home visit” or 
single symptoms. This heterogeneity makes ascertainment of AECOPD events challenging. We 
recommend that AECOPD events are recorded consistently by care providers, preferably using 
medical diagnosis codes stating AECOPD, and that these codes are recorded only at the time of 
acute events and not to record a historical number of prior episodes. This should be achieved 
through better education of prescribers, but also by improving health-care information systems 
to enable health care workers an easy and consistent way to record severity of AECOPD into 
EHRs, including patient reported AECOPD as milder events and retrieving hospital discharges 
for AECOPD. Moreover, AECOPD events which are treated by community COPD teams 
should be reported to GPs via linked health-care information systems to provide an integrated 
record of critical events. Ideally, GPs should be able to access AECOPD history of their 
patients with a “one-click” menu given its prognostic value, allowing for individually targeted 
treatment strategies for COPD patients at high risk of future events. One of the strengths of 
this study is the robust reference standard used to identify episodes of AECOPD though 
respiratory physicians independent adjudication of supplementary information from GPs as well 
as the anonymized “free-text” notes section from the CPRD.  
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Although we obtained information on AECOPD from GPs, there were still limitations to the 
available data. To maximize the rigor of the study, we used respiratory physician review of all 
available information as the reference standard, and we have presented a sensitivity analysis of 
only those events for which additional information was available. Although we had a reasonable 
response rate, GPs whose patients were more deprived were less likely to respond to our 
questionnaire and the extent to which the coding practices differ in association with patient 
deprivation level could not be determined. In addition, because we needed patients to be alive at 
the time of the study, our results may not be generalisable to those with the most severe COPD. 
Another limitation is that by using EHR to identify AECOPD, we will miss events which are 
self-managed by COPD patients, and therefore this study does not capture the full range of 
severity. Our results should therefore be interpreted as the accuracy of AECOPD events 
recorded by primary care clinicians. Our stratified analysis of PPV presented in the 
supplementary material showed that the algorithms based on symptom definitions and 
prescription of OCS alone for 5-14 days had different PPV depending on patient characteristics. 
These differences could potentially cause bias, however we do not recommend that prescription 
of OCS for 5-14 days alone is used to identify AECOPD, and the symptom-based definitions 
only contribute to a small number of the AECOPD events. In addition, the PPVs for 
definitions included in our recommended strategy (based on LRTI codes, AECOPD codes and 
prescription of both antibiotics and OCS) did not vary significantly depending on patient 
characteristics.  Our recommended strategy for identifying AECOPD achieved a high PPV, 
however the sensitivity was lower, suggesting that although this strategy is valid it will tend to 
underestimate the number of events. One option for investigators wishing to assess the burden 
of AECOPD is to conduct an analysis using both a strategy with high PPV and one with high 
sensitivity in order to estimate a minimum and maximum number of events per patient. Our 
study was conducted in the UK, and this may limit generalisability of the results to EHR 
databases which collect data from other countries. Although we used definitions of AECOPD 
used in previous studies to develop our algorithms, it may be difficult to relate our findings to 
the validity of some previously used definitions. This is for two reasons, firstly, in order to 
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achieve high validity, we used a narrow list of antibiotics in our algorithms. This is likely to have 
increased the PPV of our algorithms, and studies which used a broader list of antibiotics may 
have lower PPV for AECOPD identification. Secondly, poor reporting of previously used 
definitions of AECOPD mean that it is difficult to relate these to our current findings. One 
further limitation of the analysis presented here is that these results do not include hospital 
events, however this is the focus of a current study. This limitation should not affect the PPV, 
however this does mean that our estimates of sensitivity relate to events which are 
treated/recorded in primary care only and not the total number of AECOPD events.  
 
We have validated strategies to identify AECOPD within electronic healthcare records, however 
our strategies may underestimate the total number of true AECOPD events. Our results should 
be used for future research studies and by public health bodies when identifying AECOPD in 
the UK. We found that some previously used definitions have low PPV. Our results also 
highlight the lack of standardisation of the recording of AECOPD in EHRs, and efforts should 
be made to standardise the recording of AECOPD within EHRs.  
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7.3 Summary 
 
 AECOPD can be identified in UK primary care EHR with high validity 
 The PPV for an algorithm which combines codes for LRTI, AECOPD, antibiotics and 
oral corticosteroids prescribed on the same day, and symptoms of AECOPD along 
with either prescription of antibiotics or steroids results in a PPV of over 85% and a 
sensitivity of almost 63% 
 Studies which use prescription of antibiotics or steroids alone are not likely to identify 
AECOPD with high validity 
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Chapter 8: Recording of hospitalisations for acute 
exacerbations of COPD in UK primary and secondary care 
electronic healthcare records (Research paper VI) 
 
8.1 Preamble  
The research paper presented in the previous chapter concluded with recommendations on how 
AECOPD might be identified in EHR in a valid way. Later in this thesis, in the study 
investigating the association between AECOPD and risk of MI, it will be necessary to 
differentiate between moderate AECOPD (GP treated) and severe AECOPD (those resulting 
in hospitalisation). As hospitalisation for AECOPD is also an important outcome in COPD 
studies, other researchers would benefit from recommendations on how hospitalisation for 
AECOPD might be identified in EHR.  
 
The study presented here, therefore, aims to investigate the recording of hospitalisation of 
AECOPD in UK primary and secondary care EHR, and uses linked data from CPRD and HES. 
First, a definition of hospitalisation for AECOPD in HES is validated, and then this definition 
is used as a reference standard to assess the validity of primary care data only definitions of 
hospitalisation for AECOPD.  
 
As information about hospitalisations should be entered into the primary care EHR by GPs, 
theoretically, the primary care EHR used on its own, could be a complete source of information 
for both GP treated and hospitalised AECOPD. This would be advantageous for two reasons. 
Firstly, as not all of the primary care records are linked to secondary care records, using primary 
care EHR alone would mean that studies have higher power. Secondly, although monthly 
CPRD datasets are released, linked HES data is only available in less frequently released builds. 
As well as a further reduction in power for studies, this is also problematic for studies which 
require near real time reporting, such as RCTs run within EHR.  
 
 However, there are numerous ways in which GPs might enter information on a hospitalisation 
for AECOPD. Recent studies have suggested that although information on hospitalisations for 
specific reasons are recorded in primary care EHR, they are not recorded in such a way as to be 
identifiable by researchers (Crooks et al. 2012, Baker et al. 2015, Millett et al. 2016). 
Additionally, as there may be a lag in the recording of hospitalisations by GPs (due to the time it 
takes for discharge letters to reach GPs), information on specific timing of hospitalisation may 
not be accurate. Accuracy of timing of the event will be of great importance to the study 
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presented in this thesis which investigates the relationship between AECOPD and risk of MI 
(Chapter 9).  
 
The research paper presented here has been prepared for publication and is currently under 
peer-review. The title and current authorship are presented at the beginning of the paper. 
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8.2 Research paper 
Recording of hospitalisations for acute exacerbations of COPD in UK electronic 
healthcare records 
Authors: Kieran J Rothnie, Hana Müllerová, Sara L Thomas, Joht Chandan, Liam Smeeth, John 
R Hurst, Kourtney Davis , Jennifer K Quint 
Abstract 
Background 
Accurate identification of hospitalisations for acute exacerbations of COPD (AECOPD) within 
electronic healthcare records (EHR) is important for research, public health and to inform 
healthcare utilisation and service provision. We therefore aimed to develop a strategy to identify 
hospitalisations for AECOPD in secondary care data, and to investigate the validity of strategies 
to identify hospitalisations for AECOPD in primary care data.  
Methods 
We identified patients with COPD in the Clinical Practice Research Datalink (CPRD) with 
linked Hospital Episodes Statistics (HES) data. We used discharge summaries for recent 
hospitalisations for AECOPD in a sub-sample of these patients to develop a strategy to identify 
the recording of hospitalisations for AECOPD in HES. We then used the HES strategy as a 
reference standard to investigate the PPV and sensitivity of strategies for identifying AECOPD 
using general practice CPRD data. We tested two strategies: 1) codes for hospitalisation for 
AECOPD; and 2) a code for AECOPD other than hospitalisation on the same day as a code 
for hospitalisation due to un-specified reason. We also investigated how many hospitalisations 
for AECOPD were recorded with either an AECOPD code or a hospitalisation code.  
Results 
In total 27,182 patients with COPD were included in the study. Our strategy to identify 
hospitalisations for AECOPD in HES had a sensitivity of 87.5%.When compared with HES,  
using a code suggesting hospitalisation for AECOPD in CPRD resulted in a PPV of 50.2% 
(95% CI, 48.5-51.8%) and a sensitivity of 4.1% (95% CI, 3.9-4.3%). Using a code for AECOPD 
on the same day as a code for hospitalisation due to un-specified reason resulted in a PPV of 
43.3% (95% CI, 42.3-44.2%) and a sensitivity of 5.4% (95% CI, 5.1-5.7%). Many 
hospitalisations were recorded with an AECOPD code or a hospitalisation for un-specified 
reason code only, however using this strategy to identify hospitalisations for AECOPD in 
CPRD resulted in a very low PPV.  
Conclusions 
Hospital admission for COPD can be identified with high sensitivity in the HES database. The 
PPV and sensitivity of strategies to identify hospitalisations for AECOPD in primary care data 
alone are very poor. Primary care data alone should not be used to identify hospitalisations for 
AECOPD. Instead, researchers should use data which are linked to data from secondary care.  
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Introduction  
Chronic obstructive pulmonary disease (COPD) is a common, progressive lung disease 
characterised by airflow obstruction which is not fully reversible. In the UK over 1 million 
people have been diagnosed with COPD, with an estimated further 2 million undiagnosed[1, 2]. 
People with COPD often have periods of acute worsening of symptoms beyond normal day to 
day variation which may require a change in the patient’s treatment; these episodes are known as 
acute exacerbations (AECOPD). On average, people with COPD experience around two 
AECOPD every year[3] (including mild events) and AECOPD are important drivers of 
morbidity and mortality[4-6].  Most episodes of AECOPD are managed in primary care or by 
the patient, however more severe events and or events in patients with more severe disease or 
significant comorbidities may require admission to hospital. Hospitalisations for AECOPD are 
serious events with around 8%[7] of those admitted dying in hospital and 23% dying within one 
year. As well as being important for individuals, as the second most common reason for 
emergency admission to hospital in the UK[8], they are also of great public health importance. 
Consequently, hospitalisations for AECOPD are a key outcome in clinical trials and 
observational studies in people with COPD.  
 
Healthcare in the UK is mainly provided by the NHS, a public healthcare system. Primary 
healthcare in the NHS is provided by general practitioners (GPs) and over 98% of the UK 
population are registered with an NHS GP. In the UK, both data from primary care and data 
related to admissions to hospitals are readily available and are routinely used for research and 
for health service planning. With potentially very large sample sizes and representative and 
detailed real life data, electronic healthcare records provide an excellent resource in which to 
conduct epidemiological studies, including disease epidemiology and comparative safety and 
effectiveness assessments of interventions. As well as observational studies, an exciting new area 
in electronic healthcare records research is their use for recruitment and follow up of patients in 
pragmatic clinical trials[9], and these will require valid definitions of important outcomes.  In 
addition to research, electronic healthcare records can also be used in areas such as national 
audits of care and by commissioning groups to plan local services.  
 
However, as routine electronic medical or health-care records data are not collected for the 
purpose of research or audit, one potential limitation of these data is the accuracy and 
completeness of coded diagnoses. The Clinical Practice Research Datalink (CPRD) is a large 
database of data from UK primary care. It has been used extensively for research. Many studies 
have investigated the validity of CPRD diagnoses for use in research, and in general, these have 
been found to be high[10]. For specific conditions, the validity of research using CPRD data 
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will depend on both the validity of the algorithm that researchers use to identify the condition 
and the propensity for the condition to be missed, mis-recorded, or misdiagnosed by GPs. 
 
Our study had two aims: 1) to investigate sensitivity of recording of hospital admissions for 
AECOPD in UK secondary care electronic health records (HES); and 2) to use linked primary 
and secondary care data (CPRD-HES) to assess the positive predictive value and sensitivity of 
strategies to identify hospitalisations for AECOPD using primary care data. 
 
Methods 
Data sources 
The Clinical Practice Research Datalink (CPRD) is a very large clinical electronic healthcare 
record database of primary healthcare records in the UK. It contains information on areas such 
as diagnoses, prescriptions and test results, and some lifestyle data such as smoking status and 
BMI. Currently, there are data for over 11 million patients in CPRD, with 4.4 million of these 
active patients (representing around 6.9% of the UK population)[11]. Much of the clinical data 
recorded in CPRD is in the form of Read codes. Read codes are a clinical classification system 
used to record diagnoses, symptoms, test results, lifestyle factors such as smoking, and other 
details of consultations. Some information about patient contacts with secondary care, such as 
referrals, emergency room visits and hospital admissions may be also captured in CPRD. 
However as this requires someone in the GP practice to manually enter such encounters, their 
recording may be incomplete. 
 
Hospital Episodes Statistics (HES) is an administrative database containing information on all 
episodes of admitted patient care in England requiring overnight stay in hospital these inpatient 
data used for this study specifically exclude those only seen in A&E. Records for admission to 
hospital in HES are split up into “finished consultant episodes”, these each represent an episode 
of care under a single consultant. Each admission to hospital may be made up of several 
finished consultant episodes. Finished consultant episode records contain information on up to 
20 diagnoses recorded during that episode and are recorded using ICD-10 codes. As well as 
recording the reason for hospitalisation, diagnoses recorded in HES may relate to coexistent 
comorbidities. In addition, there is a financial incentive for hospitals to accurately record 
comorbidities during each hospitalisation. The diagnostic code in the first position in the first 
finished consultant episode is commonly taken to be the reason for hospitalisation. Around 
60% of the CPRD population are linked to HES [11].  
 
Study population 
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The total study population consisted of patients in CPRD who had a validated diagnosis of 
COPD and who were eligible for linkage to HES. Briefly, COPD patients were aged 35 years or 
older, current or ex-smokers, had a validated diagnostic code suggesting COPD and at least two 
prescriptions for a COPD medicine, one within four weeks of COPD diagnosis[12]. Patients 
were followed up from 1 January 2004, their date of COPD diagnosis, 35th birthday, or CPRD 
practice “up to standard” date whichever was latest; to 31 March 2014, date of death, transfer 
out of practice or practice last collection date, whichever was earliest.  
 
Recording of hospitalisations for AECOPD in HES 
A summary of the analytical approaches for each of the aims is presented in Figure 1. For the 
first aim, we used hospital discharge summaries to identify how hospitalisations for AECOPD 
are recorded in HES. Hospital discharge summaries were available for a sub-set of patients 
(n=40) who were also included in two previous validation studies (one validating the recording 
of COPD and one validating the recording of AECOPD in CPRD[12, 13]. As part of these 
studies, GPs were contacted and asked to send material related to their patient’s COPD, 
including hospital discharge - summaries, to investigators. We used these summaries as a 
reference standard to estimate the sensitivity of the possible HES strategies to identify 
hospitalisations for AECOPD. Firstly, ICD codes which could be used to record 
hospitalisations for AECOPD in HES were pre-specified: “J44.0” and “J44.1”as specific 
AECOPD codes, the code for lower respiratory tract infection “J22” and the code for COPD 
“J44.9”. Next, we visualised the diagnostic position of each of the ICD codes used which might 
potentially be used to record hospitalisations for AECOPD. Then, we used these codes to 
create strategies which might relate to hospitalisations for AECOPD based on combinations of 
these codes being in the first position or any position in of finished consultant episodes (Table 
1). We then estimated the sensitivity of each of these strategies in identifying hospitalisations for 
AECOPD using hospital discharge summaries as the reference standard. Finally, we then 
calculated the total number of events each of these strategies would identify if they were used in 
the sample. 
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AIM 1 – How are hospitalisations for AECOPD recorded in secondary care (HES)? 
 
AIM 2 – How are hospitalisations for AECOPD recorded in primary care (CPRD)? 
 
Figure 1. Summary of the methods for each of the aims of the study 
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Table 1. Possible strategies for identifying hospitalisations for AECOPD using primary care 
data alone 
Definition Example 
Diagnostic code or codes suggesting 
hospitalisation for AECOPD 
“Admit COPD emergency” 
Diagnostic code(s) suggesting AECOPD (using 
our previously validated algorithm) and non-
specific code(s) suggesting admission to hospital 
on the same day 
“Acute lower respiratory tract infection” and 
“Admission to hospital” on the same day 
 
 
Recording of hospitalisations for AECOPD in CPRD 
For the second aim, we identified strategies which might be used to identify hospitalisations for 
AECOPD in stand-alone primary care records. Broadly there were two strategies: 1) Presence 
of a code which suggested hospitalisation for AECOPD; and 2) presence of a code or codes on 
the same day which suggested that the patient both had an AECOPD and had been admitted to 
hospital. In order to identify records for AECOPD in CPRD we used our previously validated 
algorithm[13]. We did not include codes suggesting pneumonia in either of these strategies, as 
although AECOPD may be (incorrectly) coded using these codes, they are unlikely to be used 
in a strategy to identify hospitalisations for AECOPD for research purposes. Further, we 
searched the Read code dictionary for codes which suggested hospitalisation for AECOPD or 
for hospitalisation without a specified reason. These strategies are summarised in Table 2.  We 
also removed dates which were coded as COPD “annual review” dates as we have previously 
demonstrated that AECOPD codes are used at these times despite these not being acute 
episodes of AECOPD[13]. Details of the Read codes used are available in the supplementary 
material. 
216 
 
Table 2. Strategies for identifying admissions to hospital for AECOPD in HES – not sure if 
need this one 
HES definition of AECOPD hospitalisation 
1. Specific AECOPD code or COPD code in any position in any FCE during spell 
2. Specific AECOPD code in any position or COPD code in first position in any FCE during 
spell 
3. Specific AECOPD code in any position in any FCE during spell 
4. Specific AECOPD code in any position in or LRTI code or COPD code in first position 
in any FCE during spell 
5. Specific AECOPD code or LRTI code in any position or COPD code in first position in 
any FCE during spell 
6. Specific AECOPD code in first position in first FCE during spell 
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In order to test the validity of different strategies to identify hospitalisations for AECOPD in 
primary care data, we calculated the positive predictive value (PPV) and sensitivity of the 
strategies listed in Table 2 using HES recorded hospitalisation for AECOPD as the reference 
standard. For the estimation of PPV, we looked backwards in the HES record for 30 days 
following a potential AECOPD hospitalisation in CPRD; and for sensitivity, we looked forward 
in the CPRD patient record 30 days after the HES recorded admission to hospital to allow for 
any delays in recording in the GP surgery. As an additional analysis, we increased this window 
to 60 days. We repeated these analyses stratified by different pre-defined definitions of HES 
recorded hospitalisation for AECOPD (definitions 1, 3, and 5 in Table 2).  
 
We conducted an additional analysis to investigate other ways in which hospitalisations for 
AECOPD may be coded which would not have been picked up by either of the strategies that 
we developed. To accomplish this goal, we investigated the PPV and sensitivity of just using 
either a code or codes which suggested the patient had an AECOPD or had been to hospital in 
identifying hospitalisations for AECOPD (for example “admission to hospital” alone; or “lower 
respiratory tract infection” alone); i.e. when there was information that the COPD patient had 
either a) been to hospital for an unspecified reason; or b) had an AECOPD but no code to 
suggest that the patient had been to hospital. As admission to hospital may also be recorded by 
GPs using “consultation types” and “referral” types rather than separate Read codes, we also 
extended the CPRD definition of a AECOPD code on the same day as a hospitalisation code to 
include these consultation types and referral types, and then assessed this extended definition 
against our main HES definition of hospitalisation for AECOPD. In addition, we also explored 
a random sample of 100 Read codes present on days in which there was a record for a 
hospitalisation for AECOPD in HES and were not associated with codes for AECOPD or 
hospitalisations.  Statistical analysis was conducted in Stata 14.1 MP and R 3.2.3.  
 
Ethics 
Ethics approval was obtained from the London School of Hygiene and Tropical Medicine 
(LSHTM) Observational Research Ethics Committee (approval number 6481) and the Clinical 
Practice Research Datalink (CPRD) Independent Scientific Advisory Committee (ISAC) 
(approval number 13_116A). Patient records and questionnaire responses were de-identified 
and anonymised by CPRD staff before being sent to the investigators. The ISAC protocol is 
available on request.  
 
Results 
In total 27,182 COPD patients with linked HES-CPRD data were included in the initial cohort 
after fulfilling inclusion criteria. A flow diagram of patient flow into the study is presented in 
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Figure 2. The characteristics of patients included in the study are summarised in Table 3. 
Additional questionnaire data were available for 637 patients, of whom 40 had linkable HES 
data and discharge letters for an admission to hospital for AECOPD. In the total cohort, the 
mean age was 65.5 years (SD: 11.1), 46.5% were females, and 59.7% current smokers. 54.4% 
had moderate-severe dyspnoea (MRC>=3) and 36.4% had GOLD grade of airflow limitation 3 
or higher.
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Figure 2. Flow of patients through the study.
Patients included in the main 
analysis 
N=27,182 
 
Patients eligible 
N=27,182 
Excluded: 
Not linked with HES 
 
N= 18,843 
Patients with diagnosis of COPD in 
CPRD with at least two prescriptions 
of a COPD medicine (one within 4 
weeks of COPD index date) 
N=46,025 
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Table 3 – Characteristics of patients included in the study 
Characteristic Overall 
Those with hospital  
discharge information 
 N  % (N=27,182) N % (N=40) 
Age group   
≤55 5003 (18.4) 7 (17.5) 
55 to 64 7746 (28.5) 16 (40.0) 
65 to 74 8537 (31.4) 12 (30.0) 
≥ 75 5896 (21.7) 5 (12.5) 
Sex   
Male 14556 (53.6) 18 (45.0) 
MRC breathlessness scale (N=21,151)   
<3 9645 (45.6) 21 (46.2) 
≥3 11506 (54.4) 18 (46.2) 
BMI (N=26,447)   
< 19 1441 (5.5) 1 (2.5) 
19 – 25 9568 (36.2) 18 (45.0) 
≥25 15438 (58.4) 21 (52.5) 
GOLD 2006 grade (N=14,055)   
1 2829 (20.1) 4 (16.7) 
2 6116 (43.5) 6 (25.0) 
3 4075 (29.0) 10 (41.7) 
4 1035 (7.4) 4 (16.7) 
Smoking status   
Ex-smoker 10963 (40.3) 19 (47.5) 
Current smoker 16219 (59.7) 21 (52.5) 
Index of multiple deprivation quintile 
(N=25,852) 
 
 
1 (least deprived) 3632 (14.1) 8 (20.0) 
2 5259 (20.3) 7 (17.5) 
3 4989 (19.3) 7 (17.5) 
4 5794 (22.4) 6 (15.0) 
5 (most deprived) 6178 (23.9) 12 (30.0) 
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Recording of hospitalisations for AECOPD in HES 
Graphs demonstrating the diagnostic positions of ICD codes in HES for AECOPD, LRTI and 
COPD in finished consultant episodes (FCE) for hospitalised COPD patients are shown in 
Figure 3. These graphs demonstrate that codes for AECOPD and LRTI tend to be used in the 
first position. The code for COPD, although it is commonly used in the first position, is also 
often used in subsequent positions.   
 
 
 
Figure 3. Diagnostic positions of ICD codes for acute exacerbations of COPD, lower 
respiratory tract infections, and COPD in hospital episodes statistics records for hospitalisations 
for COPD patients. 
 
The findings for the investigation of the validity of the strategies used to identify 
hospitalisations for AECOPD are presented in Table 4. For the assessment of sensitivity, 40 
discharge letters were available. The lowest estimated sensitivity was definition 6, using only a 
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specific AECOPD code in the first position in the first finished consultant episode for a 
hospitalisation (sensitivity 65.0%, 95% CI 45.8-78.6%). The highest estimated sensitivity was 
definition 5, using either a specific AECOPD code or an LRTI code in any position or a COPD 
code in first position in any FCE during a hospitalisation (sensitivity 87.5%, 95% CI 72.4-
94.9%). 
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Table 4. Validity of HES definitions of AECOPD hospitalisation 
 Discharge summary analysis Full HES sample analysis 
HES definition of AECOPD 
hospitalisation 
Number of discharge 
summary confirmed 
AECOPD hospitalisations 
identified using strategy 
(N=40 events from discharge 
letters) 
Sensitivity (95% CI) (% of discharge 
summary confirmed AECOPD 
hospitalisations picked up) 
Number of potential AECOPD 
hospitalisation events in total 
sample identified using  
strategy (full HES sample for 
all COPD patients included in 
the study) *  
Specific AECOPD code or LRTI code in 
any position or COPD code in 1st position 
in any FCE during spell 
35/40 87.5% (72.4-94.9%) 40,174 
Specific AECOPD code or COPD code in 
any position in any FCE during spell 
34/40 85.0% (69.6-93.3%) 74,590 
Specific AECOPD code in any position in 
or LRTI code or COPD code in 1st position 
in any FCE during spell 
34/40 85.0% (69.6-93.3%) 37,966 
Specific AECOPD code in any position or 
COPD code in 1st position in any FCE 
during spell 
31/40 77.5% (61.3-88.2%) 35,793 
Specific AECOPD code in any position in 
any FCE during spell 
31/40 77.5% (61.3-88.2%) 33,933 
Specific AECOPD code in first position in 
first FCE during spell 
26/40 65.0% (48.5-78.6%) 21,387 
* These potential events will represent both true and false positives; FCE, finished consultant episode. 
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Recording of hospitalisations for AECOPD in primary care records 
Using the most sensitive definition of AECOPD hospitalisation identified in HES as the 
reference standard, the PPV for the specific AECOPD hospitalisation code in CPRD was 
50.2% (95% CI, 48.5-51.8%) and the sensitivity was 4.1% (95% CI, 3.9-4.3%) (Table 5). Using 
AECOPD identified using the previously validated algorithm on the same day as a Read code 
suggesting hospitalisation for un-specified reason in the primary care record resulted in a PPV 
of 43.3% (95% CI, 42.3-44.2%) and a sensitivity of 5.4% (95% CI, 5.1-5.7%). The use of 
different HES definitions of hospitalisation for AECOPD did not result in markedly different 
results (Table 5). The results of the additional analysis repeated using only the day of the HES 
recorded event, and using a 60 day window rather than a 30 day window following the HES 
recorded event are presented in the supplementary material. With the exception of an increase 
in the sensitivity of use of AECOPD code alone or non-specific hospitalisation code alone as 
the window was increased, these results did not differ significantly from the analysis using a 30 
day window.  
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Table 5. PPV and sensitivity of CPRD strategies to identify hospitalisations for AECOPD 
using different HES definitions as reference standard allowing 30 days after HES record of 
hospitalisation for AECOPD 
HES AECOPD 
definition 
CPRD strategy PPV (95% CI) Sensitivity (95% 
CI) 
AECOPD 
hospitalisation or 
LRTI code in any 
position or COPD in 
first position in any 
FCE 
AECOPD 
hospitalisation code 
50.2% (48.5-51.8%) 4.1% (3.9-4.3%) 
AECOPD identified 
using validated 
algorithm & 
hospitalisation code 
43.3% (42.3-44.2%) 5.4% (5.1-5.7%) 
Either specific 
AECOPD code in 
any position or 
COPD code in 1st 
position 
AECOPD 
hospitalisation code 
49.0% (47.3-50.6%) 4.6% (4.5-4.9%) 
AECOPD identified 
using validated 
algorithm & 
hospitalisation code 
38.5% (37.6-39.4%) 5.5% (5.2-5.9%) 
Either specific 
AECOPD code in 
first position in any 
finished consultant 
episode 
AECOPD 
hospitalisation code 
45.9% (44.2-47.6%) 4.7% (4.4-4.9%) 
AECOPD identified 
using validated 
algorithm & 
hospitalisation code 
37.2% (36.3-38.1%) 5.7% (5.4-6.0%) 
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When the definition using AECOPD codes on the same day as hospitalisation codes was 
extended to use consultation or referral types indicating hospitalisation, this reduced the PPV to 
14.6% (95% CI, 14.2-14.9%), and increased the sensitivity to 6.0% (95% CI, 5.7-6.3%). In the 
additional analysis to investigate the use of either a code or codes suggesting AECOPD or 
hospitalisation for any reason, the use of the AECOPD algorithm alone resulted in a PPV of 
1.8% (95% CI, 1.7-1.8%) and a sensitivity of 34.2% (95% CI, 33.7-34.6%). The use of a code 
suggesting hospitalisation alone resulted in a PPV of 14.5% (95% CI, 14.3-14.6%) and a 
sensitivity of 53.5% (95% CI, 53.0-54.0%). These results repeated using different HES 
definitions for hospitalisation due to AECOPD are presented in the supplementary material.   
 
When assessing a random sample of 100 Read codes on the day of admission on which patients 
had a HES hospitalisation for AECOPD (after excluding codes which  either suggested 
AECOPD according to our algorithm, or hospitalisation for any reason), we found many of 
these related to non-specific Read Terms suggesting patient contact such as “Had a chat to 
patient”, “Patient reviewed”, and “Seen in out of hours centre” (N=41); several related to 
recording of either heart rate or blood pressure (N=16); some related to contact with secondary 
care (but not necessarily suggesting admission to hospital), such as “seen by respiratory 
physician” or “letter from specialist” (N=10); few related to symptoms of an AECOPD such as 
“Cough” (N=5); the remaining  (N=28) were not specific for AECOPD.  
 
Discussion  
We developed a valid strategy to identify hospitalisations for AECOPD using HES linked 
CPRD data. Using this definition as a reference standard, we found that using information from 
primary care data alone resulted in low PPV and sensitivity for identifying hospitalisations for 
AECOPD.  
 
When we assessed the validity of the recording of hospitalisations for AECOPD in HES, we 
found that the most sensitive strategy was the use of a specific AECOPD or LRTI ICD-10 
code in any position in any finished consultant episode; or the COPD ICD-10 code in first 
position only in any finished consultant episode in a hospitalisation (sensitivity 87.5%). The use 
of the COPD ICD-10 code in any position results in a very large number of events and this 
likely represents it being used to record COPD as a co-morbidity not as a reason for 
hospitalisation. Although the exact definition used in future studies may differ depending on the 
needs of the study, this definition is likely to represent the “optimal” way to identify 
hospitalisations for AECOPD in HES. Restricting the definition to the specific AECOPD 
codes in the first position only in the first finished consultant episode reduced the sensitivity to 
around 65%. The failure to recognise the remaining patients is likely to represent COPD 
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patients receiving a non-specific ICD-10 code such as “shortness of breath” on an assessment 
ward before being moved to a specialist ward.  
 
For the analysis of the accuracy of using primary care data only to identify hospitalised 
AECOPD, using the most sensitive HES definition of AECOPD as the reference standard, the 
maximum PPV achievable was 50.2% and the maximum sensitivity achievable was only 5.4%. 
The use of such strategies to identify hospitalisations for AECOPD would mean that the vast 
majority of “true” events would not be picked up, and that of those events which were picked 
up, only half would be “true” events. The findings from our additional analysis suggest that GPs 
are recording the majority of AECOPD hospitalisations simply by using generic hospitalisation 
codes and/or AECOPD codes alone. The use of consultation and referral type data increased 
the sensitivity very slightly, however resulted in a large decrease in PPV. Although use of non-
specific hospitalisation codes or AECOPD codes alone had a higher sensitivity, particularly 
when the window was extended to 60 days, the PPV were very low and it is unclear if these 
relate to the index HES recorded event or further moderate AECOPD or hospitalisations. For 
the other CPRD definitions of AECOPD hospitalisation, increasing the window beyond 60 
days may have improved performance, but it would become difficult to differentiate multiple 
hospitalisations from each other. The findings from the examination of Read codes on days on 
which AECOPD hospitalisations occurred but were not identified by any of the CPRD 
strategies suggest that on the day of hospitalisation, many AECOPD hospitalisations are also 
recorded using even less specific codes than a generic hospitalisation code.  This is of clinical 
concern given the impact of prognosis for patients admitted to hospital with first, and 
subsequent exacerbations of COPD[14]. 
 
Our finding that validity of primary care recorded hospitalisations for AECOPD is low is 
certainly striking, but perhaps not surprising. Previous work in cause-specific hospitalisation in 
other disease areas have produced similar results. Recent studies investigating the validity and 
completeness of UK primary care recording of admission to hospital for acute myocardial 
infarction[15], poisonings, fractures and burns[16], and gastrointestinal bleeding[17] have all 
found that strategies to identify these events in primary care tend to have low-moderate 
sensitivity, and varying levels of PPV. In addition, a recent study showed that using HES-linked 
CPRD data, rather than CPRD data alone, resulted in a doubling of incidence of community 
acquired pneumonia and that this could be attributable to patients presenting directly to hospital 
without first consulting their GP[18]. These findings are consistent with our results. A recent 
study did find a high PPV for codes suggesting hospital admission for community acquired 
pneumonia in the general population, but this was only after restricting to those with a recent 
non-specific respiratory infection code, and this study did not assess sensitivity[19]. 
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Interestingly, another study in UK primary care records found an increasing trend towards 
coding episodes of influenza-like-illness (ILI) using non-specific codes rather than definite ILI 
codes, and a tendency not to use definite ILI codes in populations in whom there was more 
likely to be diagnostic uncertainty[20]. These findings are reflected in our results. The reasons 
that the PPV and sensitivity of the recording in primary care of hospitalisations for AECOPD is 
particularly low are likely to be: the use of non-specific codes, diagnostic uncertainty, and the 
use of apparently acute codes to record historical events. Our findings from this analysis are in 
stark contrast to our validation of the recording of AECOPD treated in general practice, where 
we found high PPV and adequate sensitivity[13].  
 
Electronic healthcare records are becoming increasingly used both for research and for audit 
and service planning. Due to its universal public healthcare system the UK is an attractive 
setting to use electronic healthcare records to study diseases and medical interventions. 
Although GPs should be informed when their patients are admitted to hospital, this may not be 
recorded in such a way that is useful for researchers. Just as details such as comorbidities, prior 
medicine use and sociodemographic details might be missing from secondary care records, 
detailed information about hospital admissions may be missing from primary care records. The 
present study underlines previous findings that hospital admission diagnoses and procedures are 
not consistently recorded in primary care. Although this may reduce sample sizes, and result in a 
lag in available linked data, it seems that, for some conditions, use of primary care data alone 
may not result in valid definitions when used to study events which may result in admission to 
hospital. Although the validity of definitions will likely differ between different conditions, 
researchers should be cautious about using primary care data alone to define cause-specific 
hospitalisations.    
 
The major strength of this study is the size and representativeness of the sample. We used data 
for over 27,182 COPD patients. Our assessment of the validity of the HES definitions of 
AECOPD hospitalisation was only based on 40 patients, however, which may have affected the 
precision of the sensitivity estimates for the HES definitions. We also made use of a validated 
strategy to identify patients with COPD in the CPRD. Although there is some uncertainty in the 
best definition of hospitalisation for AECOPD in HES to use as the reference standard, we 
used hospital discharge summaries to validate how these were recorded in HES. In addition, we 
repeated our main analysis using several different HES definitions of hospitalisation for 
AECOPD and these did not change our conclusions. One weakness of the study is that the 
HES strategy did not identify all of the hospitalisations for AECOPD, however in the main 
analysis, we used a strategy with a sensitivity of 87.5%, and this is unlikely to have impacted on 
the conclusions of the study. In addition, although we were able to assess the sensitivity of the 
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strategies to identify hospitalisations for AECOPD in HES, we were unable to assess their PPV. 
The impact of this limitation is likely to be small, however.  Imperfect PPV of the definition of 
hospitalisations for AECOPD in HES would have the effect of underestimating the sensitivity 
of CPRD algorithms. Using a range of hypothetical PPVs, we can estimate the potential effect 
of lower PPV of the HES definitions by multiplying the estimated sensitivity of the CPRD 
definitions by the inverse of the PPV (1/hypothetical PPV). For example, if the PPV of our 
main HES definition were only 80%, the sensitivity of the CPRD definition using AECOPD 
hospitalisation codes would only rise from 4.1% to 5.1%; and the algorithm using an AECOPD 
code and a hospitalisation code on the same day would rise to 6.8%. Even in the unlikely 
situation that the PPV of our main HES algorithm was as low as 60%, the respective 
sensitivities would only increase to 6.8% for an AECOPD hospitalisation code and 9.0% for an 
AECOPD code and hospitalisation code on the same day. We also assessed the CPRD 
definitions of hospitalisation for AECOPD using several definitions of AECOPD 
hospitalisations in HES, and the findings did not change when we used definitions with varying 
sensitivities.  
 
Conclusions 
In the UK, primary care electronic health records data should not be used alone to identify 
hospitalisations for exacerbations of COPD. In order to accurately identify hospitalisations for 
AECOPD, and to correctly classify AECOPD either as those treated in primary care or 
resulting in hospitalisation, researchers should use linked primary care data linked with 
secondary care data on hospitalisations.  
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8.3 Summary 
 
 Hospitalisations for AECOPD can be identified in HES with a high sensitivity, 
however the PPV is unclear 
 Primary care data alone (that is not linked to secondary care EHR) cannot be used to 
reliably identify hospitalisation for AECOPD due to both low PPV and sensitivity 
 Researchers should use linked primary and secondary care EHR to identify AECOPD 
which result in hospitalisation 
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Chapter 9: Risk of myocardial infarction associated with acute 
exacerbations of COPD: A self-controlled case series (Research 
paper VII) 
 
9.1 Preamble  
The research paper presented in this chapter aims to answer the ultimate aim of this thesis by 
investigating the relationship between AECOPD and the risk of MI.   
 
The findings of the previously presented research papers have provided important information 
for the rationale for and design of this study. Firstly, findings from the systematic review 
highlighted the higher risk of MI in people with COPD, and that this higher risk of MI could 
not entirely be explained by smoking. Findings from the two studies in the MINAP database 
along with the review paper indicated the higher risk of death following MI for people with 
COPD, the delay in diagnosis of MI in people with COPD (which is consistent with co-
occurrence or misclassification with another condition, such as AECOPD), the higher risk of 
and impact from non-STEMI in people with COPD, the importance of age (which is a major 
driver of the GRACE score) as an effect modifier for the increased risk of MI and impact of MI 
on risk of death in people with COPD, and the importance of cardiovascular medicines, and 
other therapies for modifying cardiovascular risk in people  with COPD. The previous analysis 
has also provided validated definitions of AECOPD and hospitalisation for AECOPD.  
 
The definitions of AECOPD and hospitalisation for AECOPD which were validated in 
previous chapters will be used in this study. The results of the AECOPD validation study can 
also be used to re-examine the results of Donaldson et al. (Donaldson et al. 2010), who also 
investigated the relationship between AECOPD and MI. Donaldson et al. used three definitions 
of AECOPD (1 prescription of antibiotics alone; 2 prescription of oral corticosteroids alone; 
and 3 prescription of antibiotics and oral corticosteroids) in a self-controlled case series analysis 
which investigated the risk of MI in the days and weeks following AECOPD. The results of this 
analysis are presented below next to an estimated PPV obtained from the AECOPD validation 
study in this thesis: 
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Estimated PPV* 
Antibiotics:    IRR 1.14 (95% CI, 0.7-1.8)   ~60% 
Oral steroids:    IRR 1.55 (95% CI, 0.9-2.8)   ~70% 
Antibiotics and oral steroids:  IRR 2.27 (95% CI, 1.1-4.7)   ~80% 
* Based on Rothnie et al. 2016 
 
Although not all of the definitions of AECOPD were associated with an increased risk of MI, 
there was an association when a definition with the highest validity was used, and the effect size 
increased with increasing PPV. This suggests that the analysis which did find an association 
between AECOPD and risk of MI was the most robust in terms of validity of the exposure 
definition. 
 
The study presented here aims to use a larger sample and a validated AECOPD definition to 
confirm the association between AECOPD and MI, quantify the magnitude and duration of the 
increased risk, and to stratify the analysis by important characteristics. Stratified analysis is 
important as this will inform future studies into possible interventions to mitigate the risk of MI 
associated with AECOPD.  
 
The study design used in this research paper is the self-controlled case series. The self-
controlled case series is a within person design which can be used to investigate the effect of a 
transient exposure on an outcome (Whitaker et al. 2006). The self-controlled case series is based 
on the cohort model, in the sense that exposures are fixed and outcomes are random. The key 
feature of the self-controlled case series is that the comparisons are made within person: 
exposed periods are compared to individual’s own baseline periods. A diagram representing the 
study design is displayed in Figure 9. The advantage of this design is that fixed between-person 
confounding, due to factors such as genetics, socioeconomic status or long term medicine use, 
are completely and implicitly controlled for. The design does not implicitly control for the effect 
of within-person time varying confounders, however. Confounding may arise in this situation if 
change in confounder levels temporally associates closely with the exposure, or if the probability 
of experiencing the exposure and the confounder increases or decreases over time. In order to 
deal with this source of confounding, age-bands are often constructed and statistically 
controlled for (Figure 10). The age bands not only control for the effects of age, but also 
control for the effects of time varying confounders. The age bands, however, must be 
sufficiently small such that important confounders will not vary significantly within bands.  
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Figure 9. Diagram representing the self-controlled case series design 
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Figure 10. Diagram representing the use of age bands to control for time varying confounders in the self-controlled case series 
Age bands 
Event 
Baseline time 
Exposed time 
Time varying smoking status 
Time varying medicine use 
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The self-controlled case series method was originally designed to be used to investigate adverse 
effects of vaccines (Farrington 1995). Since then, it has been used extensively in 
pharmacoepidemiology (Tata et al. 2005, Gribbin et al. 2011, Douglas et al. 2013, Brauer et al. 
2015), and more recently in investigating the effects of infections, viral reactivation, and other 
inflammatory events on the risk of vascular outcomes (Smeeth et al. 2004, Minassian et al. 2010, 
Langan et al. 2014). 
 
There were two main reasons for selecting the self-controlled case series as the method for 
investigating the relationship between AECOPD and MI for this thesis. Firstly, there are many 
potential sources of confounding in the relationship between AECOPD and MI, such as 
socioeconomic status, genetics and co-morbidities, which are likely to be difficult to describe in 
EHR, which would be controlled for implicitly using the self-controlled case series. Secondly, 
the transient nature of the exposure lends itself to this study design, and would allow duration 
of the increased risk to be studied. An alternative study design might have been a cohort study, 
however this would have introduced confounding. Another within-person design which would 
have also have eliminated between-person confounding and would have been computationally 
simpler is a case-crossover design (Maclure 1991). However this would have relied on the 
assumption that the probability distribution of experiencing the exposure is exchangeable 
within-persons in successive time periods (Vines and Farrington 2001), which is not likely to be 
the case with AECOPD.  
 
There are some limitations to the self-controlled case series study design. Firstly, due to the way 
individuals are sampled, it is not possible to produce absolute measures of effect. Secondly, 
although the method implicitly accounts for fixed confounders, time varying confounders are 
not implicitly controlled for, but their effect can be minimised by using age bands. Finally, the 
method relies on several assumptions (Whitaker et al. 2006).  
 
The assumptions of the self-controlled case series are:  
1. The probability of experiencing future exposures (AECOPD) is not influenced 
by occurrence of the outcome event (MI).  
It is unlikely that this assumption will be violated, and no studies have suggested that MI would 
modify the natural history of AECOPD.  
 
2. Outcomes (MI) are independent (that is, occurrence of the outcome does not 
influence the probability of experience subsequent outcome events (MIs)). 
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Since having an MI increases the risk of future MIs (Smolina et al. 2012), this assumption may 
be violated if recurrent events are included. To overcome this problem, this analysis will only 
look at first events.  
 
3. The outcome event (MI) does not lead to observation censoring (notably due to 
death).  
As MIs increase the risk of death, this assumption could be violated in this analysis. The analysis 
presented in chapter 4 indicated that during this time period in the UK, the mortality after MI is 
around 4.6% in-hospital, and 12.8% at 180 days after MI for those with COPD. Sensitivity 
analyses will be used in order to assess the potential impact of violation of this assumption.  
 
The research paper presented in this chapter has been prepared for publication, however has 
not yet been submitted for peer review. The reason for this is that I would like to extend the 
analysis to also investigate pneumonias as exposures in addition to AECOPD, and also to 
investigate potential effect modification by COPD medicines. I am currently arranging the 
necessary approvals to do this. The working title and current authorship is presented at the 
beginning of the research paper.  
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9.2 Research paper 
Risk of myocardial infarction associated with acute exacerbations of COPD: A self-
controlled case series 
Authors: Kieran J Rothnie, Hana Müllerová, Liam Smeeth, Neil Pearce, Ian Douglas, Jennifer 
K Quint 
Abstract 
Background 
People with COPD are at higher risk of MI compared to people without COPD, and this 
increased risk is independent of smoking status. Cardiovascular disease is also a common cause 
of death for those with COPD. Previous studies have suggested that acute exacerbations of 
COPD (AECOPD) may be temporally associated with increased MI risk. Using a large dataset, 
we precisely quantified the size and duration of the increased MI risk associated with 
AECOPD, and investigated factors which may modify that risk.  
Methods 
We used linked data from the Clinical Practice Research Datalink and Hospital Episodes 
statistics to conduct a self-controlled case series on COPD patients with at least one AECOPD 
and a first MI between January 2004-March 2015. We used conditional Poisson regression to 
compare the rate of MI in the 91 days following AECOPD to patient’s own stable periods, 
adjusting for age (in 2 year bands) and season. We then stratified the analysis by patient 
characteristics.  
Results 
We included 2,745 COPD patients in the analysis. The 91 days following AECOPD were 
associated with increased risk of MI for people with COPD (IRR 1.65, 95% CI 1.50-1.81). This 
peaked in the first 3 days following AECOPD onset (IRR 2.80, 2.26-3.49), and returned to 
baseline within 4 weeks of AECOPD. Risk of MI associated with AECOPD was higher for 
hospitalised events compared to GP treated events (GP treated days 1-3 IRR 1.96, 1.52-2.52; 
hospital treated IRR 8.00, 5.81-11.01; p-value for interaction <0.001). Risk of MI associated 
with AECOPD was higher for infrequent exacerbators (Days 1-3 IRR 4.28, 2.94-6.24; p-value 
for interaction p=0.009), those with more severe airflow limitation (Days 1-3 IRR 4.67, 3.11-
7.01; p-value for interaction=0.007), and for non-STEMIs compared to STEMIs (Days 1-3 IRR 
3.15, 2.30-4.33; p-value for interaction<0.001).The risk of MI associated with AECOPD was 
not modified by age, sex, use of cardiovascular medicines at baseline or previous cardiovascular 
disease.   
Conclusions 
People with COPD are at higher risk of MI in the weeks following an AECOPD compared to 
stable periods. In the first 3 days following AECOPD onset, the increased risk of MI peaks at 
around a doubling of risk for primary care treated AECOPD, and an eight-fold increased risk 
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for severe AECOPD. The relative effect of AECOPD on risk of MI is higher for infrequent 
exacerbators, for those with more severe airflow limitation, and following a non-STEMI.  
242 
 
Introduction 
Chronic obstructive pulmonary disease (COPD) is a common progressive lung disease 
characterised by airflow obstruction which is not fully reversible. People with COPD are at 
increased risk of MI compared to the general population[1]. This increased risk cannot be 
completely explained by smoking[2] and has been attributed to increased systemic 
inflammation[3]. Not only is the incidence of MI greater in people with COPD compared to the 
general population, up to one third of COPD patients die from cardiovascular disease[4]. 
Therefore, targeting cardiovascular disease in people with COPD is an important step in 
reducing their mortality and understanding the reasons for increased risk of MI in people with 
COPD is important for reducing cardiovascular morbidity.  
 
Acute exacerbations of COPD (AECOPD) have been defined as increases in a patient’s 
breathlessness, cough, or sputum volume and/or purulence which is beyond normal day-to-day 
variation and may require a change in treatment[5] . AECOPD normally last several days and 
most are thought to be triggered by infection (bacterial or viral)[6,7] and are associated with 
increased systemic inflammation[8,9]. People with COPD can be classified as either frequent or 
infrequent exacerbators, based on the number of exacerbations they have in a given one year 
period. The frequent exacerbator phenotype has previously been well characterised, and has 
been defined as individuals who have two or more treated exacerbations per year[10]. This 
phenotype appears to be stable over time[11], and is associated with faster FEV1 decline[12], 
poorer quality of life[5], and higher levels of systematic inflammation, even during stable 
periods[10].  
 
Previous work has shown that lower respiratory tract infections (LRTI) are associated with 
increased risk of MI in the general population[13]. In addition, it has been suggested that there 
might be an increased risk of MI following periods of AECOPD compared to stable 
periods[14,15] . Also, frequent exacerbators seem to have a higher risk of MI than infrequent 
exacerbators[14]. Recent improvements in the methods to identify AECOPD in electronic 
health records (EHR) means that more AECOPD can now be identified than ever before, and 
with greater sensitivity and precision [16]. 
 
Further studies into the relationship between AECOPD and MI which have both a validated 
exposure definition and sufficient power are therefore required. We used a self-controlled case 
series to investigate the effect of AECOPD on risk of MI. In addition, we investigated potential 
effect modification by: severity of AECOPD; exacerbator phenotype; GOLD stage of airflow 
limitation; previous non-MI cardiovascular disease; use of cardiovascular medicines, age, and 
sex.  
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Methods 
Data Sources 
We used data from the Clinical Practice Research Datalink (CPRD) linked with Hospital 
Episodes Statistics (HES) data. The CPRD is a very large data base of primary care data. It 
contains details on more than 11 million patients in the UK, with over 4 million of these active 
patients (around 7% of the UK population)[17]. Data includes details on symptoms, diagnoses, 
tests, prescriptions, details on patient demographics and health behaviours, and referrals to 
secondary care. Details in CPRD are mainly recorded using a system of Read codes, which is a 
hierarchical classification system. HES is an administrative database containing details of all 
episodes of admitted patient care in England and Wales. Data are structured into episodes of 
care by single consultants “finished consultant episodes”, such that each hospitalisation may be 
made up from several finished consultant episodes. Data are recorded using ICD-10 codes. 
Each finished consultant episode may be associated with up to 20 ICD-10 codes, with the first 
code generally representing the reason for hospitalisation. The remaining codes may represent 
other acute problems, or co-morbidities. Data for around 60% of CPRD patients are linked to 
HES. CPRD-HES data were also linked to office of national statistics (ONS) data to determine 
exact date of death.  
 
Study design 
The self-controlled case series is a within-person design developed to account for confounding 
between individuals by comparing the incidence rate of an outcome following an exposure 
within the same individual using only those who have the outcome[18]. We used this design to 
estimate the incidence of MI following periods of AECOPD compared to stable periods. As 
well as being able to estimate the transient effect of an exposure, the major advantage of this 
design is that since inference is made within-person, it implicitly controls for the effects of fixed 
confounders such as sex, socioeconomic status and genetic factors. The effects of transient 
confounders can be controlled by adjusting for age-bands.  
Following a previous study[13] we made an a priori decision to include the 91 days following the 
onset of AECOPD as the exposure period. Additionally, we segmented the 91 day exposure 
period into periods of 1-3, 4-7, 8-14, 15-28, and 29-91 days. As is common practice for this 
design, and to reduce misclassification of AECOPD with MI, we created a 14 window of pre-
exposure time including the first day of the AECOPD.  A diagram representing the study design 
is shown in Figure 1.  
Patients were followed up between 1 January 2004, date of COPD diagnosis, 35th birthdate, or 
CPRD practice “up to standard” date whichever was later; and 31 March 2015, date of death, 
transfer out of practice or practice last collection date, whichever was earlier. 
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Figure 1. Diagram representing the study design. In this hypothetical example the patient has two AECOPD during follow up and a first MI within 91 days of the 
start of the second AECOPD.   
Start of 
observation 
End of 
observation 
Start of 
AECOPD 
Time 
- Baseline period 
- Pre-exposure time (14 days pre-exposure) 
MI 
- Exposed period 
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Population, exposure, co-variates, and outcomes 
The population included were COPD patients who had at least one AECOPD and a first MI 
during the study period. COPD patients were identified using a previously validated 
algorithm[19], and had a diagnostic Read code for COPD, a smoking history (ex or current 
smoker), and were aged over 35. Patients were also excluded if their CPRD records could not 
be linked to HES or ONS.  
 
AECOPD (exposures) were defined using a previously validated algorithm [16]. Briefly, 
AECOPD were defined in CPRD as one of: 1) an AECOPD code; 2) an LRTI code; 3) 
prescription of both antibiotics or oral steroids from a pre-defined list for 5-14 days; or 4) 
symptoms of AECOPD (two of cough, sputum, or breathlessness) and either prescription of 
antibiotics or oral steroids on the same day. Hospitalisations for AECOPD were defined using 
linked HES data, we have also previously validated the recording of AECOPD in HES [Chapter 
8]. Briefly, hospitalisation for AECOPD was defined as 1) an ICD-10 code for AECOPD or 
LRTI in any position in a hospitalisation record in a patient with a diagnosis of COPD in their 
CPRD record; or 2) an ICD-10 code for COPD in the first diagnostic position in any finished 
consultant episode in a hospitalisation record in a patient with a diagnosis of COPD in their 
CPRD record.  We characterised AECOPD severity according to health care utilisation, with 
those requiring treatment from the general practitioner (GP) as moderate events, and those 
requiring hospitalisation as severe events. AECOPD which occurred within two weeks of the 
onset of a previous AECOPD were taken to be a continuing event.  
 
Apart from age, sex and type of MI, all potential effect modifiers were defined at baseline using 
CPRD data. Cardiovascular drug (β-blocker, aspirin, and statins) use was defined as at least one 
prescription during the pre-baseline year. Previous cardiovascular disease (stroke, heart failure, 
and angina) was defined as any code suggesting one of these conditions at any time prior to 
follow up. GOLD status was defined using pre-baseline spirometry results. Patients were 
phenotyped as frequent or infrequent exacerbators depending on the number of exacerbations 
in the pre-baseline year. When assessing for effect modification, age was stratified into three 
groups: <61, 61-83, and ≥83.    
 
MI events (outcomes) were defined using both primary care (CPRD) and hospital data (HES). 
Read codes were used to define MI in CPRD. In HES, MI was defined as an ICD-10 code for 
MI in the first position of a finished consultant episode. The date of MI was taken as the date of 
the start of the finished consultant episode, rather than the date of admission to hospital. ICD-
10 codes I21.0, I21.1, I21.2, I21.3, and I21.4 were used to identify MI in HES.  
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Statistical analysis 
We used conditional Poisson regression to estimate the incidence rate ratio (IRR) of first MI in 
the 91 days following AECOPD compared to stable periods.  
 
To account for time-varying confounders, we adjusted for age, initially in five year bands, and 
then in two year bands. In addition, as weather may be associated with both AECOPD [20] and 
MI[21], and because season varies within the age bands, we adjusted for the effects of season 
(split into October-March and April-September).  
 
One of the assumptions of the self-controlled case series analysis is that the outcomes do not 
alter the probability of future exposure or result in censoring of the observation time. As MI is 
associated with death, which would decrease the probability of further AECOPD and result in 
censoring, we conducted a sensitivity analysis to assess the potential impact of breaking this 
assumption. To do this, we repeated the main analysis in those whose follow up was not 
censored first for at least 6 months following MI, and also in those whose follow up was not 
censored for at least 12 months following MI.  
 
As occurrence of both MI and at least one AECOPD during the study period were necessary 
criteria for entry into the study, those who had a fatal MI before their first recorded AECOPD 
would not enter into the study. This might result in a spuriously low rate of MI in the stable 
period between study entry and first AECOPD, which would bias the effect of AECOPD on 
MI towards the null. To assess the impact of this potential bias, we carried out another 
sensitivity analysis excluding the first period of baseline time between study entry and first 
AECOPD.  
 
Analysis was conducted using Stata 14.1MP.  
 
Ethical approval 
Ethical approval was obtained from the LSHTM Observational Research Ethics Committee, 
CPRD’s Independent Scientific Advisory Committee and the GSK protocol review forum. The 
protocol is available on request.   
 
Results 
We identified 2,475 individuals with COPD who had a first MI and at least one AECOPD 
during the study period (Figure 2). The characteristics are summarised in Table 1. Briefly, the 
median age was 73.3 years (IQR, 66.0-80.3). Around half of the patients had an AECOPD 
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requiring hospitalisation during the study and about 60% were frequent exacerbators. Of the 
index MIs for which patients were included, almost two-thirds were non-STEMIs. 
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Figure 2.  Patient flow in the study. 
COPD patients in CPRD with linked 
data 
N= 100,487 
Excluded – no HES or ONS linkage 
N= 69,413 
COPD patients with at least one 
AECOPD and one MI during study 
period 
N= 3,886 
N=  
Excluded - COPD patients who 
don’t have an AECOPD or MI 
during follow up 
N= 96,601 
COPD patients with at least 1 
AECOPD and 1 MI and no previous 
MI, and no previous MI and at 
least one year of pre-baseline time 
N=2,475 
Excluded COPD patients who have 
previous MI or don’t have at least 
a year of pre-baseline time 
N= 1,409 
COPD patients in CPRD 
N= 169,900 
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Table 1. Characteristics of 2,745 eligible COPD patients with myocardial infarction and acute 
exacerbation of COPD during the study period  
Characteristic  
Age at index myocardial infarction, median (IQR) 73.3 years (66.0-80.3) 
Average observation time, median (IQR) 8.2 years (6.0-10.3) 
Male sex, n (%) 1,631 (59.4%) 
Number with at least one severe event (requiring 
hospitalisation), n (%) 
1,400 (51.0%) 
Frequent exacerbators, n (%) 1,629 (59.3%) 
Non-MI cardiovascular disease  
Total, n (%) 716 (26.1%) 
Angina, n (%) 493 (18.0%) 
Heart failure, n (%) 211 (7.7%) 
Stroke, n (%) 153 (5.6%) 
Prescribed cardiovascular drug during follow up  
Total, n (%) 1,336 (48.7%) 
Statin, n (%) 804 (29.3%) 
Aspirin, n (%) 791 (28.8%) 
Beta-blocker, n (%) 671 (24.4%) 
GOLD stage of airflow limitation (N=1476)  
Stages I-II, n (%) 945 (64.0%) 
Stages III-IV, n (%) 531 (36.0%) 
Type of MI (N=1872)  
STEMI, n (%) 667 (35.6%) 
Non-STEMI, n (%) 1,205 (64.4%) 
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Results for the main analysis including all AECOPD events, and by severity of AECOPD are 
presented in Table 2.  Compared to stable periods, the 91 days following the onset of 
AECOPD were associated with a 65% increased risk of MI (IRR 1.65, 95% CI 1.50-1.81). 
During the first 3 days following AECOPD, the rate of MI was almost three times as high as 
stable periods, the risk gradually fell back to baseline level after 28 days. The effect of 
AECOPD on risk of MI was modified by severity of AECOPD (p-value for interaction 
<0.001), with the risk of MI over 2.5 times  that of stable periods in the 91 days following a 
severe AECOPD, compared to 1.4 times that of stable periods for moderate events. The first 
three days following a severe AECOPD were associated with an 8 fold increase in risk of MI, 
compared to a doubling of risk for moderate events. The risk of MI gradually decreased to 
baseline levels following a severe AECOPD. However, there was a noticeable second peak in 
risk of MI following moderate AECOPD at 8-14 days following onset before decrease to 
almost baseline levels at 29-91 days.  
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Table 2. Incidence rate ratios of first myocardial infarction in risk periods after an acute exacerbation of COPD (AECOPD) relative to stable periods and stratified 
by AECOPD severity 
  AECOPD severity 
 All AECOPD  
(moderate and severe events) 
Moderate AECOPD (not resulting in 
hospitalisation) 
Severe AECOPD (resulting in 
hospitalisation) 
Risk period N outcome 
events 
(MI) 
IRR (95% CI) 
N  outcome events 
(MI) 
IRR (95% CI) 
N  outcome events 
(MI) 
IRR (95% CI) 
Total risk 
period (91days) 
883 1.65 (1.50-1.81) 619 1.44 (1.33-1.57) 264 2.58 (2.26-2.95) 
1-3 days 90 2.80 (2.26-3.49) 51 1.96 (1.52-2.52) 39 8.00 (5.81-11.01) 
4-7 days 97 2.38 (1.93-2.93) 49 1.53 (1.19-1.97) 48 7.78 (5.82-10.59) 
8-14 days 159 2.36 (1.99-2.80) 112 1.98 (1.67-2.36) 47 4.78 (3.57-6.40) 
15-28 days 213 1.91 (1.64-2.21) 143 1.64 (1.41-1.91) 70 4.00 (3.14-5.09) 
29-91 days 324 1.17 (1.04-1.33) 264 1.15 (1.02-1.29) 60 1.01 (0.78-1.31) 
   p for interaction <0.001 
 
AECOPD – acute exacerbation of COPD; MI – myocardial infarction; IRR – incidence rate ratio. 
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The effect of AECOPD on risk of MI was higher for infrequent exacerbators compared to 
frequent exacerbators (p-value for interaction=0.0085), with infrequent exacerbators having a 
78% higher rate of MI in the 91 days following onset of AECOPD compared to their stable 
periods; and frequent exacerbators having a 57% higher rate of MI compared to their stable 
periods (Table 3).  
 
Table 3: Incidence rate ratios of first myocardial infarction in risk periods after an acute 
exacerbation of COPD (AECOPD) relative to stable periods stratified by exacerbator 
phenotype 
p for interaction =0.009 
AECOPD – acute exacerbation of COPD; MI – myocardial infarction; IRR – incidence rate 
ratio. 
 Exacerbator phenotype 
 Frequent exacerbators (≥2 
AECOPD per year) 
Infrequent exacerbators (<2 
events per year) 
Risk period N  outcome 
events (MI) 
IRR (95% CI) 
N  outcome 
events (MI) 
IRR (95% CI) 
Total risk period (91 
days) 
635 1.57 (1.40-1.76) 248 1.78 (1.53-2.07) 
1-3 days 61 2.32 (1.78-3.03) 29 4.28 (2.94-6.24) 
4-7 days 70 2.11 (1.64-2.71) 27 3.08 (2.09-4.54) 
8-14 days 112 2.05 (1.67-2.52) 47 3.20 (2.37-4.33) 
15-28 days 158 1.79 (1.50-2.14) 55 2.11 (1.59-2.79) 
29-91 days 234 1.18 (1.02-1.38) 90 1.10 (0.87-1.37) 
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The effect of AECOPD on risk of MI was also higher for those with more severe airflow 
limitation (GOLD stage 1-2 IRR 1.69, 95% CI 1.45-1.98; GOLD stage 3-4 IRR 1.98, 95% CI 
1.61-2.05; p-value for interaction=0.007) (Table 4). 
 
Table 4: Incidence rate ratios of first myocardial infarction in risk periods after an acute 
exacerbation of COPD (AECOPD) relative to stable periods stratified by GOLD stage of 
airflow limitation 
p for interaction=0.007 
 
When we stratified the analysis by the type of MI which occurred, we found that the effect of 
AECOPD on risk of MI in the 91 days following AECOPD was higher for non-STEMIs (IRR 
1.80, 95% CI 1.56-2.06) than for STEMIs (IRR 1.39, 95% CI 1.16-1.68), p-value for 
interaction<0.001 (Table 5).  
 Degree of airflow limitation 
 GOLD stage 1-2 GOLD stage 3-4 
Risk period N  outcome 
events (MI) 
IRR (95% CI) 
N  outcome 
events (MI) 
IRR (95% CI) 
Total risk period (91 
days) 
305 1.69 (1.45-1.98) 192 1.98 (1.61-2.05) 
1-3 days 23 2.22 (1.45-3.39) 28 4.67 (3.11-7.01) 
4-7 days 43 3.25 (2.36-4.48) 24 3.17 (2.05-4.89) 
8-14 days 56 2.54 (1.91-3.39) 35 2.83 (1.95-4.09) 
15-28 days 78 2.10 (1.64-2.69) 49 2.42 (1.75-3.34) 
29-91 days 105 1.11 (0.90-1.38) 56 1.16 (0.86-1.57) 
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Table 5: Incidence rate ratios of first myocardial infarction in risk periods after a acute 
exacerbation of COPD (AECOPD) relative to stable periods stratified by MI phenotype 
(STEMI or non-STEMI)  
p for interaction<0.001 
 
There was no modification of effect of AECOPD on risk of MI by either previous 
cardiovascular disease or use of cardiovascular drugs in the baseline period (Tables 6 and 7), or 
by age or sex.  
 
Following MI, 517 COPD patients were censored within 6 months, and 832 were censored 
within 12 months. In the sensitivity analysis on individuals whose observation time was not 
censored significantly following MI, results were similar to, but slightly smaller in magnitude 
than the main analysis (supplementary material). In the sensitivity analysis which excluded the 
period of stable time prior to the initial AECOPD in each patients’ observation period, the 91 
day period following AECOPD was associated with a slightly higher risk of MI compared to the 
main analysis (supplementary material).  
 
 
 
 Type  of MI 
 STEMI Non-STEMI 
Risk period N  outcome 
events (MI) 
IRR (95% CI) 
N  outcome 
events (MI) 
IRR (95% CI) 
Total risk period (91 
days) 
195 1.39 (1.16-1.68) 407 1.80 (1.56-2.06) 
1-3 days 24 2.87 (1.89-4.39) 43 3.15 (2.30-4.33) 
4-7 days 15 1.42 (0.84-2.39) 51 2.96 (2.20-3.97) 
8-14 days 37 2.09 (1.47-2.96) 70 2.46 (1.90-3.18) 
15-28 days 41 1.39 (0.99-1.94) 111 2.36 (1.91-2.91) 
29-91 days 78 1.08 (0.84-1.39) 132 1.14 (0.94-1.39) 
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Table 6: Incidence rate ratios of first myocardial infarction in risk periods after a acute exacerbation of COPD (AECOPD) relative to stable periods and 
interactions with cardiovascular drugs 
  Cardiovascular drug 
 All time periods (same 
as table 1 column 1) 
Statin Aspirin Beta-blocker 
Risk 
period 
N  
outcome 
events 
(MI) 
IRR (95% 
CI) 
N  outcome 
events (MI) 
IRR (95% CI) 
N  outcome 
events (MI) 
IRR (95% CI) 
N  outcome 
events (MI) 
IRR (95% CI) 
Total risk 
period (91 
days) 
883 1.65 (1.50-
1.81) 
261 1.60 (1.35-
1.89) 
250 1.72 (1.45-
2.04) 
204 1.64 (1.36-
1.98) 
1-3 days 90 2.80 (2.26-
3.49) 
27 2.77 (1.86-
4.12) 
29 3.40 (2.32-
5.00) 
26 3.62 (2.41-
5.44) 
4-7 days 97 2.38 (1.93-
2.93) 
27 2.19 (1.47-
3.26) 
24 2.22 (1.49-
3.38) 
26 2.85 (1.90-
4.29) 
8-14 days 159 2.36 (1.99-
2.80) 
55 2.70 (2.02-
3.62) 
49 2.75 (2.02-
3.73) 
36 2.39 (1.68-
3.40) 
15-28 days 213 1.91 (1.64-
2.21) 
57 1.68 (1.26-
2.24) 
59 1.97 (1.49-
2.62) 
43 1.70 (1.23-
2.36) 
29-91 days 324 1.17 (1.04-
1.33) 
95 1.13 (0.89-
1.42) 
89 1.17 (0.92-
1.48) 
73 1.11 (0.86-
1.44) 
 
 
p-value for interaction statin = 0.671 
p-value for interaction aspirin = 0.454 
p-value for interaction β-blocker = 0.579 
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Table 3: Incidence rate ratios of first myocardial infarction in risk periods after an acute exacerbation of COPD (AECOPD) relative to stable periods 
stratified by previous non-MI cardiovascular disease 
 Previous non-MI cardiovascular disease 
 Any None Heart failure No heart failure Angina No angina Stroke No stroke 
Risk 
period 
N  
outco
me 
events 
(MI) 
IRR 
(95% 
CI) 
N  
outco
me 
events 
(MI) 
IRR 
(95% 
CI) 
N  
outco
me 
events 
(MI) 
IRR 
(95% 
CI) 
N  
outco
me 
events 
(MI) 
IRR 
(95% 
CI) 
N  
outco
me 
events 
(MI) 
IRR 
(95% 
CI) 
N  
outco
me 
events 
(MI) 
IRR 
(95% 
CI) 
N  
outco
me 
events 
(MI) 
IRR 
(95% 
CI) 
N  
outco
me 
events 
(MI) 
IRR 
(95% 
CI) 
Total risk 
period (91 
days) 
207 1.18 
(1.02-
1.36) 
676 1.36 
(1.23-
1.49) 
56 1.22 
(0.92-
1.61) 
827 1.31 
(1.20-
1.42) 
149 1.13 
(0.96-
1.34) 
734 1.35 
(1.23-
1.48) 
42 1.39 
(0.99-
1.96) 
841 1.29 
(1.19-
1.40) 
1-3 days 21 1.98 
(1.37-
2.86) 
69 2.14 
(1.67-
2.74) 
8 2.18 
(1.13-
4.18) 
82 2.08 
(1.68-
2.59) 
11 2.34 
(1.86-
2.92) 
79 1.38 
(0.85-
2.26) 
9 4.39 
(1.31-
8.34) 
81 1.97 
(1.58-
2.44) 
4-7 days 22 1.40 
(0.95-
2.06) 
75 1.85 
(1.46-
2.34) 
5 1.36 
(0.66-
2.79) 
92 1.74 
(1.41-
2.14) 
17 1.78 
(1.42-
2.24) 
80 1.46 
(0.95-
2.23) 
4 0.94 
(0.30-
3.00) 
93 1.75 
(1.42-
2.14) 
8-14 days 32 1.71 
(1.29-
2.27) 
127 1.81 
(1.50-
2.19) 
9 2.04 
(1.26-
3.31) 
150 1.75 
(1.48-
2.07) 
24 1.77 
(1.48-
2.12) 
135 1.80 
(1.32-
2.44) 
6 1.88 
(0.97-
3.67) 
153 1.78 
(1.51-
2.09) 
15-28 days 52 1.34 
(1.05-
1.72) 
161 1.56 
(1.32-
1.83) 
14 1.11 
(0.67-
1.83) 
199 1.53 
(1.33-
1.76) 
38 1.56 
(1.34-
1.82) 
175 1.26 
(0.95-
1.69) 
11 1.94 
(1.14-
3.30) 
202 1.46 
(1.27-
1.68) 
29-91 days 80 0.86 
(0.70-
1.06) 
244 1.02 
(0.89-
1.16) 
20 0.94 
(0.64-
1.37) 
304 0.97 
(0.87-
1.09) 
59 1.01 
(0.89-
1.15) 
265 0.85 
(0.67-
1.07) 
12 0.49 
(0.43-
1.37) 
312 0.98 
(0.87-
1.10) 
Any CVD p for interaction= 0.671 
Angina p for interaction = 0.162 
HF p for interaction = 0.793 
Stroke p for interaction =  0.679
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Discussion 
We have demonstrated that the weeks following AECOPD represent an increased risk of MI 
for those with COPD. In the days following AECOPD the risk of MI is almost three times as 
high as baseline, and falls down to the baseline level after around four weeks. The increased risk 
is higher for those AECOPD which result in hospitalisation. We also found that the relative 
increased risk of MI following AECOPD is higher for infrequent exacerbators, those with 
greater airflow limitation, and is higher following a non-STEMI than STEMI.  
 
Our finding that AECOPD is associated with a transient increased risk of MI confirms previous 
work which has suggested that AECOPD are associated with MI[14,15] and myocardial 
injury[22]. In an analysis of 426 COPD patients and using prescription of antibiotics and oral 
steroids as a definition of AECOPD, Donaldson et al. also found an increased risk of MI 
associated with AECOPD, but this was limited to the first 5 days following AECOPD onset. 
Our large study size and validated exposure measures meant that we could estimate a more 
precise effect size and length of increased risk. Broadly, our results are comparable with those 
from Smeeth et al.[13], who investigated the relationship between lower respiratory tract 
infection (LRTI) and risk of MI in 20,921 people from the general population. Smeeth et al. 
found a five-fold increased risk of MI in the 3 days following LRTI, which declined towards 
baseline over time, but lasted over 4 weeks. The higher risk of MI following LRTI in the general 
population compared to AECOPD may be due to a smaller relative difference in inflammation 
between AECOPD/LRTI and stable periods for those with COPD. Alternatively, those with 
COPD may attend their GP with milder LRTI (in terms of inflammatory burden) than would 
those from the general population. Compared to previous work, this study was able to provide 
much more precise information on the magnitude and duration of increased risk of MI 
associated with AECOPD, investigate the effect of severe AECOPD compared to moderate 
events.  In addition this study had the necessary power to stratify the analysis to identify 
important effect modifiers which should inform future work on the pathophysiology of 
increased risk of MI associated with AECOPD and potential interventions to mitigate this risk.  
 
We found an eight-fold increased risk of MI in the first 3 days following hospitalised AECOPD, 
compared to a two-fold increased risk for moderate events, suggesting a dose-response 
relationship to severity of AECOPD. Additionally, our results suggest that risk of MI increases 
again at around 8-14 days after falling for the first 7 days following moderate but not severe 
AECOPD. This could be a chance finding, however the timing may correspond to secondary 
bacterial infection in those with a viral exacerbation[23].  
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Previous studies have suggested that frequent exacerbators have higher risk of MI[14]. Our 
study found that the effect of AECOPD in risk of MI was lower for infrequent exacerbators. 
Crucially, our study compared relative risk of MI during AECOPD to participant’s own stable 
periods, not risk of MI between people. One explanation could be that frequent exacerbators 
have a higher risk of MI during stable periods (due to perhaps increased baseline inflammation), 
and thus there is less of a relative difference between stable and exacerbation periods for them. 
Indeed, as most of this sample of COPD patients with a first MI and at least one AECOPD 
were frequent exacerbators, this suggests that overall, frequent exacerbators do have a higher 
risk of MI than infrequent exacerbators.  
 
Previous studies have found that increased airflow limitation is associated with increased risk of 
MI [24]. This is reflected in our finding that COPD patients with worse airflow limitation are 
more susceptible to the effects of AECOPD on risk of MI than those with lesser limitation. 
Although there may be other differences between these patients, this finding points to the 
possibility that acutely worsening airflow limitation during AECOPD may be involved in the 
increased risk of MI associated with AECOPD. This finding lends support to the idea that 
AECOPD may be a risk factor for type-2 MI; which are a result of mismatch of myocardial 
supply and demand of oxygen, but not due to plaque rupture[25].  
 
We have previously demonstrated that after adjusting for age, sex, smoking status, and co-
morbidities, people with COPD and acute MI are more likely to have a non-STEMI than a 
STEMI, compared to people without COPD with acute MI [26]. Our finding that the effect of 
AECOPD on MI is higher for non-STEMIs may go some way in explaining these excess non-
STEMIs in those with COPD.  
 
We did not find that aspirin, beta-blockers, or statins modified the effect of AECOPD on risk 
of first MI. This is not evidence that these medicines do not prevent MI associated with 
AECOPD, but suggests that the particular risk of MI associated with AECOPD may not be 
mitigated by use of these medicine. However, this finding might be explained by the definition 
of medicine use.We defined medicine use at baseline rather than as a time-varying effect 
modifier as prescription of these drugs are very much more likely after acute MI. Since we only 
included first MIs in the analysis, this period would be associated with an apparent rate of MI of 
zero, and as such would have resulted in bias had we used a time-varying definition of 
cardiovascular medicines. This approach, however, may have resulted in underestimation of any 
effect modification by these medicines. We also did not find evidence that previous non-MI 
cardiovascular disease modified the risk of MI associated with AECOPD.  
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Our study has several implications, firstly, our findings suggest that AECOPD may explain 
some of the increased cardiovascular risk in those with COPD, particularly the increased risk of 
non-STEMI. AECOPD are known to drive mortality in those with COPD, and our findings are 
another reason that clinicians should focus on preventing AECOPD. However, the recently 
reported SUMMIT trial[27], which investigated the effects of vilanterol and fluticasone furoate 
did not find a reduction in cardiovascular events despite a reduction in AECOPD. However, 
most of the SUMMIT population had previous coronary artery disease. It is difficult to 
disentangle the effects of treatment of AECOPD on MI from the effects of AECOPD itself. In 
order to investigate this, future studies should collect detailed information on the use of 
medicines during AECOPD. Further analyses should also investigate the relationship between 
AECOPD and risk of stroke, and the effect of pneumonia in people with COPD on risk of MI. 
Finally, clinicians should be aware that COPD patients are at higher risk of MI in the weeks 
following an AECOPD.  
 
Our study had several strengths. Firstly, the within person nature of the study design meant that 
there was no confounding between individuals included in the study, such as the effects of sex, 
genetics, long term medicine use and socioeconomic status. In addition, compared to previous 
studies, we used a validated definition of AECOPD in EHR which allowed us to accurately 
identify AECOPD and we used linked secondary care HES data to categorise them as moderate 
(GP treated) or severe (hospital treated). In addition, we obtained data on MI events from both 
primary and linked HES data which allowed us to identify more MI[28]. Previous work has 
shown that data from both primary and secondary care are necessary to identify adequate 
numbers of MI. Another strength of our study was the size, compared to previous work in 
similar populations, our study was significantly larger. This increased power allowed us to 
confirm previous findings in a larger sample, and to give a more precise estimate of both the 
size and duration of the effect.  
 
Our study also has some weaknesses. Although our study is without between-person 
confounding, there is still potential for within-person confounding by factors which vary over 
time. In order to deal with time-varying confounders, we split time up into two year age bands 
and adjusted for these. In addition, we specifically adjusted for the effects of season. However, 
our study could still be susceptible to time-varying confounders if these correlated very closely 
in time with AECOPD, such as the use of treatments for AECOPD. Additionally, our study 
may have been susceptible to misclassification of AECOPD and MI. We have previously 
demonstrated that people with COPD have delayed diagnosis of MI[26], if these events are 
originally diagnosed as AECOPD, this may result in a spurious association between AECOPD 
and MI. However, to reduce the impact of this bias we excluded the first day of AECOPD 
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from the analysis, and used a validated algorithm for identifying AECOPD[16]. Such a bias is 
very unlikely to explain a substantial proportion of the effect however, as the effect of 
AECOPD in the risk of MI lasted for several weeks. Finally, due to the case-only nature of the 
study design, it was not possible to examine absolute measures of effect.  
 
Conclusions 
Compared to stable periods, people with COPD are at higher risk of MI in the weeks following 
AECOPD. In the first 3 days following AECOPD onset, the increased risk of MI peaks at 
around a doubling of risk for primary care treated AECOPD, and an eight-fold increased risk 
for severe AECOPD. The relative effect of AECOPD on risk of MI is higher for infrequent 
exacerbators, and for those with more severe airflow limitation.  
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9.3 Summary  
 
 AECOPD represent a period of increased risk of MI for those with COPD 
 The increased risk of MI peaks during the first three days following AECOPD onset 
and falls back to baseline levels after four weeks 
 The effect of AECOPD on risk of MI is higher for: AECOPD which result in 
hospitalisation, infrequent exacerbators, those with more severe airflow limitation, and 
for non-STEMIs compared to STEMIs 
 The increased risk of MI associated with AECOPD does not appear to explain the 
effect modification of the risk of MI associated with COPD by age 
 Cardiovascular medicines (at least those used at baseline) do not appear to modify the 
effect of AECOPD on the risk of MI 
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Chapter 10 Overall Discussion 
 
This chapter provides an overall summary of the findings for each of the aims of this thesis, 
highlights some of the important strengths and limitations of each of the studies and provides 
recommendations, both for practice and future research.  
 
10.1 Aim 1: Understanding MI and outcomes after MI in those with COPD: 
10.1.1 Systematic review of the risk of MI associated with COPD and AECOPD and 
risk of death after MI for those with COPD (Research paper I) 
The systematic review and meta-analysis presented in Chapter 3 aimed to investigate 1) the risk 
of MI associated with COPD; 2) the risk of MI associated with AECOPD; and 3) the risk of 
death following MI in COPD patients compared to people without COPD.  
 
The findings from the first aim, investigating the risk of MI associated with COPD, 
demonstrated that people with COPD have a higher risk of MI compared to those who do not 
have COPD, and this was evident even after adjusting for smoking status. Compared to 
previous systematic reviews on similar areas (Chen et al. 2015, Müllerova et al. 2013), the 
systematic review presented here focussed on incident MI, rather than both incident and 
prevalent MI. Thus, inferences could be drawn about risk of MI associated with COPD. One 
limitation of this study was that only one study (Feary et al. 2010) reported risk of MI associated 
with COPD after adjusting for smoking status, and there is the possibility of residual 
confounding by smoking. Results from those studies which did not adjust for smoking status 
could not be pooled due to high levels of statistical heterogeneity.  
 
For the second aim of the systematic review, investigating the risk of MI associated with 
AECOPD, only two studies (Donaldson et al. 2010, Halpin et al. 2011) were found which 
investigated the risk of MI associated with AECOPD. Both of these studies used within person 
designs to investigate the risk of MI during AECOPD compared to participant’s own stable 
periods. Although both studies demonstrated a higher risk of MI associated with AECOPD, 
conclusions were limited as both studies included a small number of participants, and 
uncertainly about the validity of exposure definitions (Donaldson et al. 2010). Due to 
heterogeneity in study designs, a meta-analysis of these results was not possible.  
 
For the third aim of the systematic review, investigating the risk of death following MI for those 
with COPD, following meta-analysis, there was weak evidence that those with COPD have 
higher in-hospital mortality following MI compared to non-COPD patients. There was strong 
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evidence that those with COPD had higher levels of mortality in longer term following MI. 
However, both of these associations were modest in size. Although an increased risk of death 
following MI for those with COPD was demonstrated, the cause was uncertain. The increased 
risk could have been due to factors relating to the MI, for example COPD patients having more 
severe events; factors relating to COPD or associated characteristics, such as death from COPD 
or lung cancer; or factors relating to the differences in care after MI which others have 
demonstrated (Stefan et al. 2012). 
 
10.1.2 Closing the mortality gap after a myocardial infarction in people with and 
without Chronic Obstructive Pulmonary Disease (Research paper II) 
Following the findings of aim 3 of the systematic review, the study presented in chapter 4 aimed 
to 1) investigate the risk of death following MI for COPD patients compared to people without 
COPD; 2) to investigate any differences in recognition and management following MI between 
people with and without COPD; and 3) to investigate the extent that any difference may be 
explained by differences in recognition and management of MI at the population level.  
 
The findings demonstrated that both in-hospital and 180-day mortality were higher for COPD 
patients compared to people without COPD. The effect of COPD on risk of death remained 
after adjustment for age, sex, smoking status and other co-morbidites, and was higher for non-
STEMIs than STEMIs.  
 
For both STEMIs and non-STEMIS, people with COPD had a delay in diagnosis of MI. For 
those with a delay in diagnosis following a STEMI, people with COPD had a longer time to 
reperfusion. COPD patients were less likely to have angiography in hospital following a non-
STEMI or reperfusion following a STEMI. COPD patients were less likely to be prescribed 
secondary prevention medicines at discharge following an MI, notably for β-blockers.  
 
Delay in diagnosis, and timing and use of reperfusion after a STEMI explained some of the in-
hospital mortality difference between people with and without COPD. A larger proportion of 
the difference in 180-day mortality was explained by the use of secondary prevention drugs at 
discharge.  
 
Delay in diagnosis and use of angiography after a non-STEMI explained some of the mortality 
difference between people with and without COPD.  For 180-day mortality, delay in diagnosis, 
use of angiography in-hospital, and use of secondary prevention medicines at discharge all 
explained some of the difference in mortality between people with and without COPD. .  
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The strengths of this study were the large size and the representative nature of the data. In 
addition, information on patient care during admission was available, which is not true of other 
hospital based EHR datasets, such as HES. The findings presented on the effects of treatment 
are however observational, and may be susceptible to residual confounding.  
 
10.1.3 Chronic obstructive pulmonary disease and acute myocardial infarction: 
effects on presentation, management, and outcomes (Research paper III) 
The research paper presented in Chapter 5 aimed to review the evidence for differences in 
presentation, management and outcomes between people with and without COPD following 
MI.  
 
There is good evidence that COPD patients have atypical presentation of MI, and on average 
have lower peak levels of troponin after acute MI compared to people without COPD.  
  
Several studies found that the increased risk of death following MI associated with COPD was 
higher for younger people than older people with COPD. Other studies have found an 
increased risk of incident heart failure following MI for COPD patients compared to people 
without COPD. This is one possible mechanism behind the increased risk of death for those 
with COPD. No studies found evidence of an increased risk of re-current MI, stroke, or angina 
for those with COPD compared to non-COPD patients.  
 
10.1.4 Predicting mortality after acute coronary syndromes in people with chronic 
obstructive pulmonary disease (Research paper IV) 
The study presented in chapter 6 aimed to: 1) investigate whether the GRACE score performs 
as well at predicting the risk of death at 6 months following admission to hospital for ACS in 
people with COPD compared to those without; and 2) to investigate if the GRACE score could 
be amended to perform better for those with COPD.  
 
For aim 1, it was found that the GRACE score does not perform as well in COPD patients as it 
does in people without COPD, and tends to underestimate risk of death for those with COPD. 
COPD patients with the same GRACE score as people without COPD had a 30% higher risk 
of dying at 6 months following admission for ACS.  
 
For aim 2, both re-specifying the GRACE score model including a variable for COPD and 
multiplying the risk of death following ACS by 1.3 resulted in better performance of the 
GRACE score for those with COPD.  
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The strengths of this study, again, like the previous study using this data, were the large size and 
representativeness. In addition, the results of the study are presented in a way which can be 
easily implemented.  
 
The limitations of this study were that a measure of severity of acute heart failure was not 
available in the MINAP dataset, and a proxy for this had to be used. In addition, although 
internal validation was conducted, findings were not validated externally.  
 
10.1.5 Recommendations for practice 
Clinicians should be aware that people with COPD are at higher risk of MI, and this risk is 
independent of smoking status.  
 
Clinicians should also be aware that people with COPD are more likely to have an atypical 
presentation of MI, and that this may lead to a delay in diagnosis of MI. Delay in diagnosis of 
MI, reduced use of reperfusion and angiography in-hospital, and secondary prevention drugs 
(particularly) beta-blockers seem to contribute to the increased risk of death following MI for 
those with COPD. Efforts should be made to ensure that COPD patients receive guideline 
recommended investigation and treatment, where appropriate.  
  
When calculating the predicted risk of death at 6 months following MI using the GRACE score, 
clinicians should multiply the risk of death by 1.3 for COPD patients to ensure that risk of 
death for COPD patients is not underestimated. As this predicted risk of death is used to 
determine eligibility for more early aggressive treatment following non-STEMI or UA (NICE 
2010), accurate risk stratification is important to ensure that COPD patients receive guideline 
recommended treatment. Current guidelines recommend that after a non-STEMI or UA those 
with a moderate or higher risk of death at 6 months (higher than 3%) should receive more early 
aggressive treatment. Multiplying that risk of death by 1.3 for those with COPD would result in 
one third of those previously categorised as low risk being re-categorised as moderate risk, and 
therefore should be considered for more aggressive treatment.  
 
10.1.6 Recommendations for research 
It is currently unclear why COPD patients have an increased risk of MI compared to people 
without COPD, and further work is needed to investigate this. Researchers should also 
investigate which COPD patients are at particular risk of MI, and if this risk can be modified. 
The relationship between AECOPD and MI should be investigated further, using validated 
exposure measures, and this is the subject of a subsequent chapter of this thesis.  
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As well as delay in diagnosis of MI for people with COPD, it is possible that MIs might be 
completely missed for some of these patients, and this should be investigated. As the MINAP 
data used for the studies presented here is now three years old, some practices may have 
improved since then, and differences in management between people with and without COPD 
should be re-visited in the future. Future studies may also wish to relate differences in 
management to outcomes other than death, such as development of heart failure.  
 
Although differences in the performance of the GRACE score may explain some of the 
difference in treatment after MI for people with and without, there may be other reasons. 
10.2 Aim 2: Improving the definitions of AECOPD in EHR 
10.2.1 Validation of the recording of acute exacerbations of COPD in UK primary care 
electronic healthcare records (Research paper V) 
The aim of the study presented in chapter 7 was to validate the recording of AECOPD in UK 
primary care EHR. For this study, 15 different EHR algorithms were tested against a reference 
standard of respiratory physician review of questionnaires, additional material sent by GPs, and 
free-text information.  
 
The findings indicated that only those algorithms which used code for LRTI, AECOPD, 
prescription of antibiotics and steroids for 5-14 days, and a symptom definition of AECOPD 
when combined with prescription of either antibiotics or steroids had an acceptable PPV 
(>75%). When these algorithms were combined, this resulted in an AECOPD definition which 
had a PPV of 85.5%, and a sensitivity of 62.9%.  
 
The strengths of this study were the size of the sample, and the detailed information which was 
obtained from GP records, including free-text information, which was used by respiratory 
physicians when reviewing events. However, as there is no single diagnostic test for AECOPD, 
the results of the reference standard (respiratory physician review) are still, to an extent, a 
judgment. In addition, the sensitivity of the definition was relatively lower.  
 
10.2.2 Recording of hospitalisations for acute exacerbations of COPD in UK primary 
and secondary care electronic healthcare records (Research paper VI) 
The aim of the study presented in chapter 8 was to investigate how hospitalisations for 
AECOPD were recorded in primary and secondary care EHR, and to determine whether a valid 
definition of AECOPD hospitalisation in primary care EHR could be constructed.  
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Using discharge summaries, a definition of recording of hospitalisation for AECOPD in HES 
was validated. Using a combination of a specific ICD-10 code for AECOPD or LRTI in any 
diagnostic position, or an ICD-10 code for COPD in the first position, resulted in a definition 
with a sensitivity of 87.5%. This HES definition was then used as a reference standard for 
testing the validity of primary care EHR definitions of hospitalisation for AECOPD.  
 
Two primary care EHR definitions were tested against the HES reference standard: 1) 
AECOPD hospitalisation code; and 2) AECOPD identified by the previously validated 
algorithm on the same day as a code suggesting hospitalisation. Both of these definitions had 
very modest PPVs (<55%), and had even lower sensitivities (<6%). Delay in recording of 
hospitalisation by GPs could not account for the low apparent validity. Many of the AECOPD 
hospitalisations appeared to be recorded using either an AECOPD code, or a code suggesting 
hospitalisation, but not both. Further, there was evidence that many hospitalisations for 
AECOPD were recorded using even less specific codes.  
 
One of the major strengths of this study was the size, we included information from linked data 
for over 27,182 patients with COPD. The study was limited however by the lack of information 
on PPV for the HES definition of AECOPD hospitalisation. However, when several different 
possible definitions of HES were used as a reference standard in sensitivity analysis, this did not 
change the findings.  
 
10.2.3 Recommendations for practice 
In future, studies should use the validated definition of AECOPD in UK primary care EHR 
presented here. These will not only be useful for observational studies, but may also be used for 
RCTs run within the EHR. Researchers should not attempt to identify AECOPD using 
prescription of either antibiotics or oral steroids alone, or a symptom definition of AECOPD 
alone, as these definitions are associated with a low PPV. These definitions will also be useful 
for identifying AECOPD for service planning and for national and local audits. To identify 
hospitalisations for AECOPD, researchers should use linked primary and secondary care data, 
as definitions based on primary care data alone are not likely to be valid.  
 
Although accurate coding of AECOPD and hospitalisations for AECOPD in EHR is important 
for secondary users of data, it is also important for clinical care. Given the importance of 
AECOPD for decisions on patient management, GPs should have easy access to information 
on the number of recent AECOPD that patients have had. Primary care clinicians should 
therefore consider coding AECOPD in a more precise way.  
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10.2.4 Recommendations for research 
There is room for improvement in GP recording of AECOPD. Possible solutions to this are 
the use of training or incentives for GPs to improve the way they code diagnoses, or a reduction 
in the number of Read codes available. Other researchers may wish to investigate whether these 
solutions are effective.  
 
In the future, researchers may wish to investigate the PPV of HES definitions of AECOPD. In 
particular, attention should be paid to investigating the misclassification between AECOPD and 
admissions to hospital for pneumonia for those with COPD.  
 
Validity of primary care definitions of cause-specific hospitalisation for other diseases may also 
be poor, and further research should be conducted on the validity of primary and secondary 
care recording of hospitalisation for other diseases.  
 
10.3 Aim 3: Improve the understanding of the relationship between AECOPD 
and risk of MI  
10.3.1 Risk of myocardial infarction associated with acute exacerbations of COPD: A 
self-controlled case series (Research paper VII) 
The ultimate aim of this thesis, and the aim of the study presented in Chapter 9 was to 
investigate the risk of MI associated with AECOPD. This study extended the findings of 
previous studies (Donaldson et al. 2010, Halpin et al. 2011) by providing a more precise 
estimate of the size and duration of the effect of AECOPD on MI. In addition, increased power 
meant that this study was able to investigate effect modification of the effect of AECOPD on 
the risk of MI. The use of linked data also meant that effect modification by severity of 
AECOPD on the risk of MI could be investigated.  
 
The self-controlled case series findings indicated that AECOPD are temporally associated with 
risk of MI. The risk of MI increases immediately after onset of AECOPD, and peaks at a 
relative risk of around 2.8 for the first 3 days following onset of AECOPD before declining to 
almost baseline levels after around four weeks. The effect of AECOPD was higher (around an 8 
fold increase in risk of MI in the first 3 days following AECOPD onset) for those events which 
resulted in hospitalisation, demonstrating a dose response relationship between severity of 
AECOPD and risk of MI.  
 
Both exacerbator phenotype and GOLD stage of airflow limitation modified the effect of 
AECOPD on risk of MI, with the effect of AECOPD on risk of MI being higher for infrequent 
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exacerbators and those with more severe airflow limitation. In addition, the effect of AECOPD 
on risk of MI was higher for non-STEMIs than STEMIs.  
 
One of the major strengths of this study was the within-person nature of the comparisons, 
which meant that fixed confounders were implicitly controlled for. In addition, validated 
definitions of both AECOPD and MI were used.  
 
The study also had a relatively large size, which meant power was available to precisely estimate 
the magnitude and duration of the increased risk of MI following AECOPD. Increased power 
also meant that stratified analysis could be carried out to investigate potential effect 
modification, which may inform future studies into the pathophysiology around the increased 
risk of MI and into interventions to mitigate this risk.  
 
Although confounding from fixed factors was eliminated by the study design, there may still 
have been confounding from time-varying confounders. Although this was minimilised by 
adjusting for age bands, confounders which vary very closely in time with AECOPD, such as 
medicines, may still have been an issue.  
 
Misclassification of AECOPD and MI may have biased the results of this study. A particular 
concern is that an MI may have been originally coded as an AECOPD before being coded as an 
MI, this would induce a spurious association between AECOPD and MI. Although validated 
definitions of AECOPD and MI were used, this may still have been a problem for this study. 
This is unlikely to have explained the whole association, however. In addition, when the 
exposure time following AECOPD was segmented, the risk of MI was higher for several weeks 
following onset of AECOPD, and this pattern is unlikely to have occurred if the association 
were entirely spurious. The algorithm used to identify AECOPD had a relatively lower 
sensitivity (63%) which would have meant that up to around one third of time which should 
have been “exposed time” is likely to have been classified as baseline time. This is not likely to 
be an explanation for the findings of the self-controlled case series, however, as this 
misclassification would probably have resulted in bias towards, rather than away from, the null.  
 
10.3.3 Recommendations for practice  
There is a large burden of CVD in those with COPD, and preventing MI associated with 
AECOPD by preventing AECOPD may be a good way to reduce CVD in those with COPD. 
As the MIs associated with AECOPD in this study did not seem to be “harvested”, that is the 
period of higher risk was not followed by a period of lower risk, preventing MI associated with 
AECOPD may be a good strategy for lowering MI overall in those with COPD. Clinicians 
should be aware that the weeks following AECOPD (or apparent AECOPD) are a period of 
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higher risk of MI for people with COPD. This is especially true for AECOPD which result in 
hospitalisation.  
 
10.3.4 Recommendations for research   
The mechanism behind the increased risk of MI associated with AECOPD is currently unclear, 
and the findings from this study are compatible both with increased risk due to increased 
systemic inflammation or increasing airflow limitation during AECOPD. Future studies should 
investigate these possibilities.  
 
Age was not found to be an effect modifier for the effect of AECOPD on the risk of MI. The 
effect of COPD on risk of MI appears to be higher for younger patients (Feary et al. 2010), and 
as found in previous chapters, the impact of age on mortality (and prediction of mortality) is 
higher for younger patients. The effect of AECOPD on risk of MI does not appear to explain 
this, and researchers should investigate other reasons for this effect.   
 
Although this study did not find that cardiovascular medicines modified the risk of MI 
associated with COPD, this study defined use of these medicines at baseline in order to prevent 
bias. The investigation of potential effect modification by these medicines would perhaps be 
better investigated using time-varying effect modifiers in a cohort study. Future studies should 
also be conducted to investigate any potential effect modification by COPD medicines in a 
similar way.  
 
COPD patients are at high risk of developing pneumonia (Crim et al 2009), and as these events 
are likely to represent a higher inflammatory burden than AECOPD, they may be associated 
with an even higher risk of MI. Future studies should investigate this potential relationship, and 
any factors which might modify the risk of MI associated with pneumonia.  
 
Recent work on AECOPD has focussed on different distinct “clusters” of AECOPD defined 
by different inflammatory patterns or causes (Bafadhel et al. 2011), future researchers may wish 
to investigate whether the risk of MI associated with AECOPD is modified by type of 
AECOPD.  
 
10.4 Overall conclusions 
There is a large burden of cardiovascular disease in those with COPD. People with COPD are 
at higher risk of cardiovascular disease than people without COPD, and cardiovascular disease 
is a common cause of death for people with COPD. People with COPD are at higher risk of 
MI than people without COPD.  
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People with COPD are also at higher risk of death following MI than people who do not have 
COPD. This increased risk of death may be partly explained by differences in recognition and 
management between people with and without COPD. Current risk scores which stratify risk of 
death following MI do not perform as well in people with COPD compared to those without 
COPD, and tend to underestimate risk of death for people with COPD. More accurate 
prediction of risk of death for people with COPD may result in more people with COPD being 
considered for more aggressive treatment.  
 
AECOPD and hospitalisations for AECOPD can be identified accurately in EHR, however 
primary care EHR data should not be used alone to identify hospitalisations for AECOPD.  
 
The weeks following AECOPD represent a period of increased risk of MI for people with 
COPD. This risk peak in the first three days following AECOPD onset and persists for at least 
four weeks before returning to almost baseline levels. The effect of AECOPD on the risk of MI 
is higher for AECOPD which result in hospitalisation, for infrequent exacerbators, those with 
more severe airflow limitation, and following non-STEMI.  
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Appendices 
Appendix A – Additional material for Chapter 3 – Research paper I 
 
MEDLINE search strategy 
1. Lung Diseases, Obstructive/ 
2. exp Pulmonary Disease, Chronic Obstructive/ 
3. (chronic$ adj3 bronchiti$).tw. 
4. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).tw. 
5. COPD.tw. 
6. COAD.tw. 
7. COBD.tw. 
8. AECB.tw. 
9. emphysema$.tw. 
10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 
11. exp Myocardial Infarction/ 
12. MI.tw. 
13. acs.tw. 
14. exp Acute Coronary Syndrome/ 
15. (myocardial adj3 infarction$).tw. 
16. (heart adj3 attack$).tw. 
17. (acute adj3 coronary adj3 syndrome$).tw. 
18. (coronary adj3 infarc$).tw. 
19. (myocardial adj3 thrombos$).tw. 
20. (coronary adj3 thrombos$).tw. 
21. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 
22. 10 and 21 
 
 
Quality assessment detailed study (or analysis) level results.  
Risk of MI associated with COPD 
Comparability between the exposed and unexposed groups was a major problem, with none of 
the reports being completely classed as low risk of bias for this item. The main reason for 
studies being high risk of bias for this item was that they did not adjust for smoking status as 
this was not available in several of the administrative healthcare databases which were used in 
these studies. The case control analyses reported in Rodriguez 2010(Rodriguez, Wallander et al. 
2010) and Schneider 2010(Schneider, Bothner et al. 2010), however, were assessed as lower risk 
of bias for comparability between groups. Another common problem was lack of 
representativeness of the exposure group. In 3/8 studies representativeness was assessed as 
higher risk of bias. Some of these studies only included those with a recent diagnosis of COPD 
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and followed up for a short period after. Others only classified patients with COPD if they 
attended secondary care for their COPD and so are likely only to have included patients with 
more severe COPD.  
 
Risk of MI associated with AECOPD 
In general the two studies included under this research question were assessed as lower risk of 
bias for most items. Donaldson 2010(Donaldson, Hurst et al. 2010) was unclear risk of bias for 
selection and representativeness of exposed and un-exposed groups as the method used to 
identify AECOPD has not been validated. Halpin 2011(Halpin, Decramer et al. 2011) was 
assessed as higher risk of bias for selection of unexposed time as this compared only to 30 days 
prior to the AECOPD, not the entire stable period. This study was also considered to be at 
higher risk of bias under the “other bias” item as it appeared to be very underpowered (in total 
only 14 MIs were included, 1 during the 30 day pre-exacerbation period, and 13 in the 30 day 
post-exacerbation period) resulting in a very wide confidence interval (IRR 95% CI 1.71-99.1).   
 
Risk of death after MI associated with COPD 
Comparability between groups was again a problem for several of the studies included under 
this research question. Only 4/10 full text studies were assessed as lower risk of bias for 
comparability between groups. Again, the major problem was that several of the studies did not 
adjust for smoking status. Some studies were assessed as unclear risk of bias under some of the 
items of the selection domain as the definition of COPD used was unclear. 
285 
 
Figures S1-S3. Detailed study level risk of bias assessment. 
Research Question 
  1 2 3 4 5 6 7 7 9 
Risk of MI in COPD           
Curkendall 2006          
Feary 2010          
Huiart 2005          
Mapel 2005          
Rodriguez 2010 cohort         
Rodriguez 2010 case control         
Schneider 2010 cohort         
Schneider 2010  case control         
Sidney 2005          
Sode 2011          
Yin 2014          
 
Figure S1. Detailed study level risk of bias assessment for the studies reporting risk of MI associated with COPD. 
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MI and AECOPD 
 
 
 
1 2 3 4 5 6 7 7 9 
Donaldson 2010          
Halpin 2011          
 
Figure S2. Detailed study level risk of bias assessment for the studies reporting risk of MI associated with AECOPD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
287 
 
 
  1 2 3 4 5 6 7 7 9 
Outcomes after MI           
Andell 2014          
Bursi 2010          
Dziewierz 2010          
Enriquez 2013          
Hadi 2010          
Hawkins 2009          
Kjoller 2004          
Salisbury 2007          
Stefan 2012          
 
Figure S3. Detailed study level risk of bias assessment for the studies reporting risk of death following MI.  
 
 
 
 
Key for figures S1-3 
Selection  
Representativeness of exposed/cases 1 
Selection of non-exposed/controls 2 
Ascertainment of exposure/cases 3 
Outcome of interest not present at start of study 4 
Comparibility  
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Comparability of groups on basis of desgin/analysis 5 
Outcome  
Assessment of outcome 6 
Follow up long enough for outcomes to occur 7 
Adequacy of follow up 8 
Other 9 
 
lower risk of bias unclear risk of bias higher risk of bias 
 
. 
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Appendix B – Additional material for Chapter 4 – Research paper II 
 
Supplementary figure – directed acyclic graph 
 
 
Figure S1. Directed acyclic graph used in the development of regression models.  
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Sensitivity analyses 
As a sensitivity analysis, mortality after an MI was investigated comparing those who, for the 
purposes of this study, we presumed had asthma (those with a record of obstructive airway 
disease but no smoking history).  
 
Additional analysis in optimal and sub-optimal care groups 
We also compared mortality at 180 days for COPD patients and non-COPD patients within 
strata of optimal care, adjusted for age, sex, year, smoking status and co-morbidities. For 
STEMIs, patients were categorised as having optimal care if they had no delay in diagnosis, use 
of reperfusion and use of secondary prevention. For non-STEMIs, patients were categorised as 
having optimal care if they had no delay in diagnosis, use of angiography in-hospital, and use of 
secondary prevention. Sub-optimal care was defined as any factor missing from optimal care. 
We compared optimally treated COPD patients to optimally treated non-COPD patients; and 
non-optimally treated COPD patients to non-optimally treated non-COPD patients. We also 
compared mortality between those with optimal care and non-optimal care at 180 days among 
COPD patients. 
 
Results 
Difference in time to reperfusion between COPD patients and non-COPD patients among 
those without a delay in diagnosis 
The difference in time to reperfusion between COPD and non-COPD patients was not 
apparent among patients who did not have a delay in diagnosis (median time to reperfusion 35.0 
minutes (IQR, 21.8-63.4) for COPD patients, and 35.0 minutes (IQR, 21.8-61.2) for non-
COPD patients). Adjusted analysis also showed no difference in time to reperfusion for COPD 
patients compared to non-COPD patients among those who did not have a delay in diagnosis 
(ratio of geometric means 1.03, 95% CI 1.00 to 1.05). 
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Sensitivity analysis with asthmatic patients 
When in-hospital mortality after an MI was investigated for people who we presume to have 
asthma were compared to non-asthmatics, no difference in mortality was found in analysis 
adjusted for age, sex, smoking status, calendar year, co-morbidities and drugs on arrival (OR 
1.05, 95% CI 0.89-1.24 for STEMIs; OR 1.05, 95% CI 0.91-1.22 for non-STEMIs). 
 
Additional analysis in optimal and sub-optimal care groups 
After a STEMI, the effect of COPD on mortality at 180 days in the non-optimal care group 
(OR 1.39, 1.29-1.51; non-optimally treated COPD patients compared to non-optimally treated 
non-COPD patients) was comparable to that in the optimal care group (OR 1.44, 1.08-1.94; 
optimally treated COPD patients compared to optimally treated non-COPD patients).  After a 
non-STEMI, the effect of COPD on mortality at 180 days in the non-optimal care group (OR 
1.53, 1.45-1.61; non-optimally treated COPD patients compared to non-optimally treated non-
COPD patients) was lower than that in the optimal care group (OR 1.80, 1.36-2.37;  optimally 
treated COPD patients compared to optimally treated non-COPD patients). Among COPD 
patients, having optimal treatment was associated with lower risk of death at 180 days after both 
a STEMI (OR 0.31, 0.23-0.42; optimally treated COPD patients compared to non-optimally 
treated COPD patients) and a non-STEMI (OR 0.34, 0.26-.43; optimally treated COPD patients 
compared to non-optimally treated COPD patients). 
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Table S1 Predicted and observed mortality using normal GRACE model stratified by year of admission.  
 
 2006-2008   2009-2010   2012-2013   
GRACE 
predicted risk 
decile 
Average 
predicted 
mortality (%) 
Observed 
mortality - 
non-COPD 
(%) 
Observed 
mortality – 
COPD (%) 
Average 
predicted 
mortality (%) 
Observed 
mortality - 
non-COPD 
(%) 
Observed 
mortality – 
COPD (%) 
Average 
predicted 
mortality (%) 
Observed 
mortality - 
non-COPD 
(%) 
Observed 
mortality – 
COPD (%) 
1 
1.3 0.8 0.8 1.3 0.5 0.7 
1.3 0.6 1.1 
2 
2.5 1.6 3.2 2.5 1.3 2.4 
2.5 1.0 1.7 
3 
4.0 3.0 5.9 4.0 2.5 3.8 
4.0 1.7 4.5 
4 
5.0 3.9 7.6 5.0 3.2 6.0 
5.0 2.5 6.0 
5 
6.5 5.5 9.2 6.5 4.6 7.3 
6.4 3.3 6.2 
6 
8.9 8.6 13.3 8.9 7.2 12.6 
8.9 5.4 10.4 
7 
12.4 12.4 18.7 12.4 11.1 17.9 
12.4 8.4 13.7 
8 
17.2 18.8 24.8 17.2 16.8 22.0 
17.2 14.4 18.4 
9 
26.6 30.3 35.3 26.6 27.5 32.5 
26.6 23.0 27.8 
10 
48.5 46.6 50.8 48.3 44.5 48.0 
48.7 39.8 43.6 
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Table S2 Changes in level of risk for COPD patients after modifications after a STEMI  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Multiplying risk by 1.3 
GRACE score 
predicted 
risk of death Low risk (<3%) Moderate risk (3-6%) High risk (≥6%) 
Low risk 
(<3%) 791 (60.4%) 519 (39.6%) 0 (0.0%) 
Moderate 
risk (3-6%) 0 (0.0%) 499 (32.8%) 1,022 (67.2%) 
High risk 
(≥6%) 0 (0.0%) 0 (0.0%) 5,564 (100.0%) 
 Adding COPD into MINAP derived GRACE model 
GRACE score 
predicted 
risk of death Low risk (<3%) Moderate risk (3-6%) High risk (≥6%) 
Low risk 
(<3%) 1,171 (89.5%) 138 (10.5%) 7 (0.5%) 
Moderate 
risk (3-6%) 423 (27.8%) 909 (59.8%) 188 (12.4%) 
High risk 
(≥6%) 10 (0.2%) 587 (10.7%) 4,902 (89.1%) 
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Table S3 Changes in level of risk for COPD patients after modifications after a non-STEMI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Multiplying risk by 1.3 
GRACE score 
predicted 
risk of death Low risk (<3%) Moderate risk (3-6%) High risk (≥6%) 
Low risk 
(<3%) 1,742 (65.3%) 924 (34.7%) 0 (0.0%) 
Moderate 
risk (3-6%) 0 (0.0%) 912 (36.2%) 1,611 (63.9%) 
High risk 
(≥6%) 0 (0.0%) 0 (0.0%) 10,603 (100.0%) 
 Adding COPD into MINAP derived GRACE model 
GRACE score 
predicted 
risk of death Low risk (<3%) Moderate risk (3-6%) High risk (≥6%) 
Low risk 
(<3%) 1,909 (71.7%) 698 (26.2%) 55 (2.1%) 
Moderate 
risk (3-6%) 184 (7.3%) 1,227 (48.8%) 1,105 (43.9%) 
High risk 
(≥6%) 4 (0.0%) 289 (2.8%) 10,176 (97.2%) 
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Table S4 Changes in level of risk for COPD patients after modifications after unstable angina  
 
 
 
Multiple imputation and missing data 
There were significant levels of missing data for creatinine (40%), systolic blood pressure (11%), 
and heart rate (11%). Missingness was associated with year of event, and was greatly reduced in 
events after 2008 (<10% missingness for all three variables). 
As an additional analysis, we multiply imputed [1] values for serum creatinine, heart rate, and 
systolic blood pressure where these were missing. Predictor variables were all other GRACE 
score variables, COPD status and death at 6 months.  As the missing variables were all 
continuous, we performed multiple imputation using multivariate normal regression using the 
“mi impute mvn” command in Stata 14.1 MP. We imputed 30 additional datasets and used 
these to test our modifications to the GRACE score estimated probability of death. We did this 
using logistic regression to compare mortality at 6 months after admission  
The findings from the multiple imputation analysis indicated that GRACE scores underestimate 
the risk of death for people with COPD, that adding COPD to the GRACE score model would 
 Multiplying risk by 1.3 
GRACE score 
predicted 
risk of death Low risk (<3%) Moderate risk (3-6%) High risk (≥6%) 
Low risk 
(<3%) 1,569 (70.3%) 664 (29.7%) 0 (0.0%) 
Moderate 
risk (3-6%) 0 (0.0%) 589 (37.7%) 972 (62.3%) 
High risk 
(≥6%) 0 (0.0%) 0 (0.0%) 4, 623 (100.0%) 
 Adding COPD into MINAP derived GRACE model 
GRACE score 
predicted 
risk of death Low risk (<3%) Moderate risk (3-6%) High risk (≥6%) 
Low risk 
(<3%) 1,362 (61.1%) 746 (33.5%) 122 (5.5%) 
Moderate 
risk (3-6%) 74 (4.8%) 656 (42.2%) 824 (53.0%) 
High risk 
(≥6%) 1 (0.0%) 118 (2.6%) 4,449 (97.4%) 
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fix this problem, and that multiplying GRACE score predicted probability of death by 1.3 was a 
good approximation to adding COPD to the model.  
 
Table S5 Results of multiple imputation analysis  
GRACE model or modification OR (95% CI) 
Normal GRACE model 1.39 (1.36-1.43) 
Normal GRACE model x 1.3 for COPD 
patients 
0.95 (0.92-0.98) 
MINAP derived model 1.34 (1.30-1.39) 
MINAP derived model with smoking 1.42 (1.36-1.47) 
MINAP derived model with COPD 1.02 (0.99-1.06) 
 
References 
1. Carpenter JR, Kenward MG. Multiple imputation and its application. New York: Wiley, 
2013
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Appendix D– Additional material for Chapter 7 – Research paper V:  
 
Supplementary table 1 Comparison of responders and non-responders 
Characteristic 
 Responder 
N 
 Responder 
% 
non responder 
N 
Non responder 
% Chi2 p-value 
Age group     0.073 
≤55 212 
21.5 
111 
28.0 
 
55 to 64 359 
36.3 
133 
33.5 
 
65 to 74 301 
30.5 
107 
27.0 
 
≥ 75 116 
11.7 
46 
11.6 
 
Sex     0.850 
Male 481 
48.7 
191 
48.1 
 
Female 507 
51.3 
206 
51.9 
 
MRC breathlessness scale      0.170 
≥3 
449 47.3 195 51.5 
 
< 3 
501 52.7 184 48.6 
 
BMI     0.520 
< 19 
39 4.0 17 4.3 
 
19 - 25 
353 35.7 129 32.5 
 
≥25 
596 60.3 251 63.2 
 
Record of cardiovascular 
disease     0.090 
No 
731 74.0 311 78.3 
 
Yes 
257 26.0 86 21.7 
 
Record of asthma     0.380 
No 
482 48.8 204 51.4 
 
Yes 
506 51.2 193 48.6 
 
Record of GORD     0.260 
No 
729 73.8 281 70.8 
 
Yes 
259 26.2 116 29.2 
 
GOLD stage      0.330 
1 
76 12.8 39 16.7 
 
2 
285 48.1 113 48.5 
 
3 
185 31.3 61 26.2 
 
4 
46 7.8 20 8.6 
 
Smoking status     0.220 
Ex-smoker 
447 45.2 194 48.9 
 
Current smoker 
541 54.8 203 51.1 
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Index of multiple 
deprivation quintile      <0.001 
1 (least deprived) 
152 15.4 32 8.1 
 
2 
213 21.6 55 14.0 
 
3 
188 19.1 64 16.2 
 
4 
216 21.9 100 25.4 
 
5 (most deprived) 
216 21.9 143 36.3 
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Supplementary Table 2. PPV and sensitivity for algorithms not excluding annual review dates and dates on which rescue packs were prescribed 
 
Algorithm N events identified N events confirmed 
by reference 
standard 
PPV (95% CI) N events identified 
in last year 
N extra events 
identified by GPs 
in last year 
Sensitivity (95% CI) 
1.OCS prescription 
for 5-14 days 
1285 910 70.8 (68.3 - 73.3) 180 465 27.9 (24.5 - 31.5) 
2.Antibiotic 
prescription for 5-
14 days 
6283 3796 60.4 (59.2 - 61.6) 426 219 66.1 (62.3 - 69.7) 
3.OCS and 
antibiotic 
prescription for 5-
14 days 
919 705 76.7 (73.8 - 79.4) 142 503 22.0 (18.9 - 25.4) 
4. Symptom 
definition 
341 137 40.2 (34.9 - 45.6) 16 629 2.5 (1.4 - 4.0) 
5. Symptom 
definition and OCS 
prescription 
156 106 68.0 (60.0 - 75.2) 14 631 2.2 (1.2 - 3.6) 
6. Symptom 
definition and 
antibiotic 
prescription 
108 74 68.5 (58.9 - 77.1) 11 634 1.7 (0.9 - 3.0) 
7. Symptom 
definition and OCS 
& antibiotic 
prescription 
90 64 71.1 (60.6 - 80.2) 10 635 1.6 (0.8 - 2.8) 
8. LRTI code 1809 1435 79.3 (77.4 - 81.2) 132 513 20.5 (17.4 - 23.8) 
9. LRTI code and 
OCS prescription 
1617 1311 81.1 (79.1 – 83.0) 116 529 18.0 (15.1 - 21.2) 
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10. LRTI code and 
antibiotic 
prescription 
411 362 88.1 (84.6 - 91.1) 73 572 11.3 (9.0 - 14.0) 
11. LRTI code and 
OCS & antibiotic 
prescription 
388 342 88.1 (84.5 - 91.2) 70 575 10.9 (8.6 - 13.5) 
12. AECOPD code 966 905 93.7 (92.0 - 95.1) 147 498 22.8 (19.6 - 26.2) 
13. AECOPD code 
and OCS 
prescription 
698 667 95.6 (93.8 – 97.0) 105 540 16.3 (13.5 - 19.4) 
14. AECOPD code 
and antibiotic 
prescription 
466 443 95.1 (92.7 - 96.9) 98 547 15.2 (12.5 - 18.2) 
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Supplementary Table 3 PPVs for algorithms stratified by deprivation 
Algorithm 
N events 
identified 
N events 
confirmed by 
reference 
standard PPV (95% CI) 
N events 
identified 
N events 
confirmed by 
reference 
standard PPV (95% CI) 
 Less deprived More deprived 
1.OCS prescription 612 453 74.0 (70.4 - 77.5) 540 388 71.9 (67.9 - 75.6) 
2.Antibiotic prescription 3160 1955 61.9 (60.1 - 63.6) 2680 1604 59.9 (58.0 - 61.7) 
3.OCS and antibiotic 
prescription 
441 359 81.4 (77.5 - 84.9) 382 294 77.0 (72.4 - 81.1) 
4. Symptom definition 60 32 53.3 (40.0 - 66.3) 82 60 73.2 (62.2 - 82.4) 
5. Symptom definition and 
OCS prescription 
30 24 80.0 (61.4 - 92.3) 58 55 94.8 (85.6 - 98.9) 
6. Symptom definition and 
antibiotic prescription 
12 10 83.3 (51.6 - 97.9) 45 43 95.6 (84.9 - 99.5) 
7. Symptom definition and 
OCS & antibiotic 
prescription 9 8 88.9 (51.8 - 99.7) 39 39 
100.0 (91.0 - 
100.0) 
8. LRTI code 909 714 78.5 (75.7 - 81.2) 836 675 80.7 (77.9 - 83.4) 
9. LRTI code and OCS 
prescription 
804 649 80.7 (77.8 - 83.4) 754 619 82.1 (79.2 - 84.8) 
10. LRTI code and antibiotic 
prescription 
191 168 88.0 (82.5 - 92.2) 202 179 88.6 (83.4 - 92.6) 
11. LRTI code and OCS & 
antibiotic prescription 
177 155 87.6 (81.8 - 92.0) 194 172 88.7 (83.3 - 92.8) 
12. AECOPD code 502 476 94.8 (92.5 - 96.6) 383 374 97.7 (95.6 - 98.9) 
13. AECOPD code and OCS 
prescription 
365 350 95.9 (93.3 - 97.7) 273 268 98.2 (95.8 - 99.4) 
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14. AECOPD code and 
antibiotic prescription 
243 231 95.1 (91.5 - 97.4) 180 177 98.3 (95.2 - 99.7) 
15. AECOPD code and OCS 
& antibiotic prescription 
214 205 95.8 (92.2 - 98.1) 163 160 98.2 (94.7 - 99.6) 
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Supplementary Table 4 PPVs for algorithms stratified by GOLD stage 
Algorithm 
N events 
identified 
N events 
confirmed by 
reference 
standard PPV (95% CI) 
N events 
identified 
N events 
confirmed by 
reference 
standard PPV (95% CI) 
 GOLD 1-2 GOLD 3-4 
1.OCS prescription 839 621 74.0 (70.9 - 77.0) 313 220 70.3 (64.9 - 75.3) 
2.Antibiotic prescription 4484 2672 59.6 (58.1 - 61.0) 1356 887 65.4 (62.8 - 67.9) 
3.OCS and antibiotic 
prescription 
608 487 80.1 (76.7 - 83.2) 215 166 77.2 (71.0 - 82.6) 
4. Symptom definition 103 62 60.2 (50.1 - 69.7) 39 30 76.9 (60.7 - 88.9) 
5. Symptom definition and 
OCS prescription 
62 55 88.7 (78.1 - 95.3) 26 24 92.3 (74.9 - 99.1) 
6. Symptom definition and 
antibiotic prescription 
41 40 97.6 (87.1 - 99.9) 16 13 81.3 (54.4 - 96.0) 
7. Symptom definition and 
OCS & antibiotic prescription 
35 35 
100.0 (90.0 - 
100.0) 13 12 92.3 (64.0 - 99.8) 
8. LRTI code 1372 1075 78.4 (76.1 - 80.5) 373 314 84.2 (80.1 - 87.7) 
9. LRTI code and OCS 
prescription 
1229 986 80.2 (77.9 - 82.4) 329 282 85.7 (81.5 - 89.3) 
10. LRTI code and antibiotic 
prescription 
298 263 88.3 (84.0 - 91.7) 95 84 88.4 (80.2 - 94.1) 
11. LRTI code and OCS & 
antibiotic prescription 
285 251 88.1 (83.7 - 91.6) 86 76 88.4 (79.7 - 94.3) 
12. AECOPD code 617 594 96.3 (94.5 - 97.6) 268 256 95.5 (92.3 - 97.7) 
13. AECOPD code and OCS 
prescription 
445 432 97.1 (95.1 - 98.4) 193 186 96.4 (92.7 - 98.5) 
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14. AECOPD code and 
antibiotic prescription 
304 294 96.7 (94.0 - 98.4) 119 114 95.8 (90.5 - 98.6) 
15. AECOPD code and OCS & 
antibiotic prescription 
270 263 97.4 (94.7 - 99.0) 107 102 95.3 (89.4 - 98.5) 
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Supplementary Table 5 PPVs for algorithms stratified by record for asthma 
Algorithm 
N events 
identified 
N events 
confirmed by 
reference 
standard PPV (95% CI) 
N events 
identified 
N events 
confirmed by 
reference 
standard PPV (95% CI) 
 Asthma record No asthma record 
1.OCS prescription 639 468 73.2 (69.6 - 76.6) 513 373 72.7 (68.6 - 76.5) 
2.Antibiotic prescription 3085 1897 61.5 (59.7 - 63.2) 2755 1662 60.3 (58.5 - 62.2) 
3.OCS and antibiotic 
prescription 
444 359 80.9 (76.9 - 84.4) 379 294 77.6 (73.0 - 81.7) 
4. Symptom definition 80 56 70.0 (58.7 - 79.7) 62 36 58.1 (44.8 - 70.5) 
5. Symptom definition and 
OCS prescription 
51 47 92.2 (81.1 - 97.8) 37 32 86.5 (71.2 - 95.5) 
6. Symptom definition and 
antibiotic prescription 
36 34 94.4 (81.3 - 99.3) 21 19 90.5 (69.6 - 98.8) 
7. Symptom definition and 
OCS & antibiotic prescription 
30 29 96.7 (82.8 - 99.9) 
18 18 
100.0 (81.5 - 
100.0) 
8. LRTI code 925 751 81.2 (78.5 - 83.7) 820 638 77.8 (74.8 - 80.6) 
9. LRTI code and OCS 
prescription 
832 685 82.3 (79.6 - 84.9) 726 583 80.3 (77.2 - 83.1) 
10. LRTI code and antibiotic 
prescription 
233 208 89.3 (84.6 - 92.9) 160 139 86.9 (80.6 - 91.7) 
11. LRTI code and OCS & 
antibiotic prescription 
217 193 88.9 (84.0 - 92.8) 154 134 87.0 (80.7 - 91.9) 
12. AECOPD code 481 454 94.4 (91.9 - 96.3) 404 396 98.0 (96.1 - 99.1) 
13. AECOPD code and OCS 
prescription 
339 324 95.6 (92.8 - 97.5) 299 294 98.3 (96.1 - 99.5) 
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14. AECOPD code and 
antibiotic prescription 
224 211 94.2 (90.3 - 96.9) 199 197 99.0 (96.4 - 99.9) 
15. AECOPD code and OCS & 
antibiotic prescription 
192 182 94.8 (90.6 - 97.5) 185 183 98.9 (96.1 - 99.9) 
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Supplementary Table 6 PPVs for algorithms stratified by record for GORD 
Algorithm 
N events 
identified 
N events 
confirmed by 
reference 
standard PPV (95% CI) 
N events 
identified 
N events 
confirmed by 
reference 
standard PPV (95% CI) 
 GORD record No GORD record 
1.OCS prescription 
272 199 
73.2 (67.5 - 
78.3) 880 642 
73.0 (69.9 - 
75.9) 
2.Antibiotic prescription 
1623 941 
58.0 (55.5 - 
60.4) 4217 2618 
62.1 (60.6 - 
63.5) 
3.OCS and antibiotic prescription 
197 155 
78.7 (72.3 - 
84.2) 626 498 
79.6 (76.2 - 
82.6) 
4. Symptom definition 
37 22 
59.5 (42.1 - 
75.2) 105 70 
66.7 (56.8 - 
75.6) 
5. Symptom definition and OCS 
prescription 22 19 
86.4 (65.1 - 
97.1) 66 60 
90.9 (81.3 - 
96.6) 
6. Symptom definition and 
antibiotic prescription 13 11 
84.6 (54.6 - 
98.1) 44 42 
95.5 (84.5 - 
99.4) 
7. Symptom definition and OCS & 
antibiotic prescription 12 11 
91.7 (61.5 - 
99.8) 36 36 
100.0 (90.3 - 
100.0) 
8. LRTI code 
484 369 
76.2 (72.2 - 
80.0) 1261 1020 
80.9 (78.6 - 
83.0) 
9. LRTI code and OCS prescription 
424 337 
79.5 (75.3 - 
83.2) 1134 931 
82.1 (79.7 - 
84.3) 
10. LRTI code and antibiotic 
prescription 90 78 
86.7 (77.9 - 
92.9) 303 269 
88.8 (84.7 - 
92.1) 
11. LRTI code and OCS & 
antibiotic prescription 82 71 
86.6 (77.3 - 
93.1) 289 256 
88.6 (84.3 - 
92.0) 
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12. AECOPD code 
235 223 
94.9 (91.3 - 
97.3) 650 627 
96.5 (94.7 - 
97.7) 
13. AECOPD code and OCS 
prescription 161 155 
96.3 (92.1 - 
98.6) 477 463 
97.1 (95.1 - 
98.4) 
14. AECOPD code and antibiotic 
prescription 103 96 
93.2 (86.5 - 
97.2) 320 312 
97.5 (95.1 - 
98.9) 
15. AECOPD code and OCS & 
antibiotic prescription 91 86 
94.5 (87.6 - 
98.2) 286 279 
97.6 (95.0 - 
99.0) 
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Supplementary Table 7 PPVs for algorithms stratified by record for CVD 
Algorithm 
N events 
identified 
N events 
confirmed by 
reference 
standard PPV (95% CI) 
N events 
identified 
N events 
confirmed by 
reference 
standard PPV (95% CI) 
 CVD record No CVD record 
1.OCS prescription 296 198 66.9 (61.2 - 72.2) 856 643 75.1 (72.1 - 78.0) 
2.Antibiotic prescription 1536 924 60.2 (57.7 - 62.6) 4304 2635 61.2 (59.7 - 62.7) 
3.OCS and antibiotic 
prescription 
198 153 77.3 (70.8 - 82.9) 625 500 80.0 (76.6 - 83.1) 
4. Symptom definition 44 28 63.6 (47.8 - 77.6) 98 64 65.3 (55.0 - 74.6) 
5. Symptom definition and 
OCS prescription 
27 25 92.6 (75.7 - 99.1) 61 54 88.5 (77.8 - 95.3) 
6. Symptom definition and 
antibiotic prescription 
15 15 
100.0 (78.2 - 
100.0) 42 38 90.5 (77.4 - 97.3) 
7. Symptom definition and 
OCS & antibiotic 
prescription 15 15 
100.0 (78.2 - 
100.0) 33 32 97.0 (84.2 - 99.9) 
8. LRTI code 478 365 76.4 (72.3 - 80.1) 1267 1024 80.8 (78.5 - 83.0) 
9. LRTI code and OCS 
prescription 
415 325 78.3 (74.0 - 82.2) 1143 943 82.5 (80.2 - 84.7) 
10. LRTI code and antibiotic 
prescription 
106 92 86.8 (78.8 - 92.6) 287 255 88.9 (84.6 - 92.2) 
11. LRTI code and OCS & 
antibiotic prescription 
100 86 86.0 (77.6 - 92.1) 271 241 88.9 (84.6 - 92.4) 
12. AECOPD code 245 234 95.5 (92.1 - 97.7) 640 616 96.3 (94.5 - 97.6) 
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13. AECOPD code and OCS 
prescription 
159 152 95.6 (91.1 - 98.2) 479 466 97.3 (95.4 - 98.5) 
14. AECOPD code and 
antibiotic prescription 
107 103 96.3 (90.7 - 99.0) 316 305 96.5 (93.9 - 98.2) 
15. AECOPD code and OCS 
& antibiotic prescription 
95 91 95.8 (89.6 - 98.8) 282 274 97.2 (94.5 - 98.8) 
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Supplementary Table 8 PPVs for algorithms stratified by BMI 
Algorithm 
N events 
identified 
N events 
confirmed 
by 
reference 
standard PPV (95% CI) 
N events 
identified 
N events 
confirmed 
by 
reference 
standard PPV (95% CI) 
N events 
identified 
N events 
confirmed 
by 
reference 
standard PPV (95% CI) 
 BMI <19 BMI 19-25 BMI ≥25 
1.OCS prescription 54 40 74.1 (60.3 - 85.0) 445 344 77.3 (73.1 - 81.1) 653 457 70.0 (66.3 - 73.5) 
2.Antibiotic 
prescription 
252 169 67.1 (60.9 - 72.8) 2081 1330 63.9 (61.8 - 66.0) 3507 2060 58.7 (57.1 - 60.4) 
3.OCS and antibiotic 
prescription 
41 34 82.9 (67.9 - 92.8) 307 255 83.1 (78.4 - 87.1) 475 364 76.6 (72.6 - 80.4) 
4. Symptom definition 10 6 60.0 (26.2 - 87.8) 34 23 67.6 (49.5 - 82.6) 98 63 64.3 (54.0 - 73.7) 
5. Symptom definition 
and OCS prescription 
5 5 
100.0 (47.8 - 
100.0) 21 18 85.7 (63.7 - 97.0) 62 56 90.3 (80.1 - 96.4) 
6. Symptom definition 
and antibiotic 
prescription 
7 5 71.4 (29.0 - 96.3) 10 9 90.0 (55.5 - 99.7) 40 39 97.5 (86.8 - 99.9) 
7. Symptom definition 
and OCS & antibiotic 
prescription 4 4 
100.0 (39.8 - 
100.0) 9 8 88.9 (51.8 - 99.7) 35 35 
100.0 (90.0 - 
100.0) 
8. LRTI code 76 57 75.0 (63.7 - 84.2) 541 454 83.9 (80.5 - 86.9) 1128 878 77.8 (75.3 - 80.2) 
9. LRTI code and OCS 
prescription 
71 54 76.1 (64.5 - 85.4) 481 413 85.9 (82.4 - 88.9) 1006 801 79.6 (77.0 - 82.1) 
10. LRTI code and 
antibiotic prescription 
17 11 64.7 (38.3 - 85.8) 134 128 95.5 (90.5 - 98.3) 242 208 86.0 (80.9 - 90.1) 
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11. LRTI code and OCS 
& antibiotic 
prescription 
16 10 62.5 (35.4 - 84.8) 122 116 95.1 (89.6 - 98.2) 233 201 86.3 (81.2 - 90.4) 
12. AECOPD code 40 39 97.5 (86.8 - 99.9) 376 360 95.7 (93.2 - 97.5) 469 451 96.2 (94.0 - 97.7) 
13. AECOPD code and 
OCS prescription 
29 28 96.6 (82.2 - 99.9) 283 275 97.2 (94.5 - 98.8) 326 315 96.6 (94.0 - 98.3) 
14. AECOPD code and 
antibiotic prescription 
18 18 
100.0 (81.5 - 
100.0) 183 180 98.4 (95.3 - 99.7) 222 210 94.6 (90.7 - 97.2) 
15. AECOPD code and 
OCS & antibiotic 
prescription 16 16 
100.0 (79.4 - 
100.0) 167 164 98.2 (94.8 - 99.6) 194 185 95.4 (91.4 - 97.9) 
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Supplementary Table 9 PPVs for algorithms stratified by sex 
Algorithm 
N events 
identified 
N events 
confirmed by 
reference 
standard PPV (95% CI) 
N events 
identified 
N events 
confirmed by 
reference 
standard PPV (95% CI) 
 Female Male 
1.OCS prescription 609 469 77.0 (73.5 - 80.3) 536 367 68.5 (64.3 - 72.4) 
2.Antibiotic prescription 3015 1843 61.1 (59.4 - 62.9) 2777 1687 60.7 (58.9 - 62.6) 
3.OCS and antibiotic 
prescription 
433 352 81.3 (77.3 - 84.9) 385 296 76.9 (72.3 - 81.0) 
4. Symptom definition 66 41 62.1 (49.3 - 73.8) 75 51 68.0 (56.2 - 78.3) 
5. Symptom definition and 
OCS prescription 
40 34 85.0 (70.2 - 94.3) 48 45 93.8 (82.8 - 98.7) 
6. Symptom definition and 
antibiotic prescription 
28 25 89.3 (71.8 - 97.7) 29 28 96.6 (82.2 - 99.9) 
7. Symptom definition and 
OCS & antibiotic 
prescription 23 22 95.7 (78.1 - 99.9) 25 25 
100.0 (86.3 - 
100.0) 
8. LRTI code 913 732 80.2 (77.4 - 82.7) 818 646 79.0 (76.0 - 81.7) 
9. LRTI code and OCS 
prescription 
811 662 81.6 (78.8 - 84.2) 736 597 81.1 (78.1 - 83.9) 
10. LRTI code and antibiotic 
prescription 
217 193 88.9 (84.0 - 92.8) 175 153 87.4 (81.6 - 92.0) 
11. LRTI code and OCS & 
antibiotic prescription 
203 181 89.2 (84.1 - 93.1) 167 145 86.8 (80.7 - 91.6) 
12. AECOPD code 456 439 96.3 (94.1 - 97.8) 420 402 95.7 (93.3 - 97.4) 
13. AECOPD code and OCS 
prescription 
326 316 96.9 (94.4 - 98.5) 307 297 96.7 (94.1 - 98.4) 
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14. AECOPD code and 
antibiotic prescription 
224 218 97.3 (94.3 - 99.0) 196 187 95.4 (91.5 - 97.9) 
15. AECOPD code and OCS 
& antibiotic prescription 
195 190 97.4 (94.1 - 99.2) 179 172 96.1 (92.1 - 98.4) 
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Supplementary Table 10 PPVs for algorithms stratified by smoking status 
Algorithm 
N events 
identified 
N events 
confirmed by 
reference 
standard PPV (95% CI) 
N events 
identified 
N events 
confirmed by 
reference 
standard PPV (95% CI) 
 Ex-smoker Current smoker 
1.OCS prescription 490 344 70.2 (65.9 - 74.2) 662 497 75.1 (71.6 - 78.3) 
2.Antibiotic prescription 2621 1601 61.1 (59.2 - 63.0) 3219 1958 60.8 (59.1 - 62.5) 
3.OCS and antibiotic 
prescription 
345 271 78.6 (73.8 - 82.8) 478 382 79.9 (76.0 - 83.4) 
4. Symptom definition 58 45 77.6 (64.7 - 87.5) 84 47 56.0 (44.7 - 66.8) 
5. Symptom definition and 
OCS prescription 
39 37 94.9 (82.7 - 99.4) 49 42 85.7 (72.8 - 94.1) 
6. Symptom definition and 
antibiotic prescription 
27 24 88.9 (70.8 - 97.6) 30 29 96.7 (82.8 - 99.9) 
7. Symptom definition and 
OCS & antibiotic 
prescription 21 20 95.2 (76.2 - 99.9) 27 27 
100.0 (87.2 - 
100.0) 
8. LRTI code 805 663 82.4 (79.5 - 84.9) 940 726 77.2 (74.4 - 79.9) 
9. LRTI code and OCS 
prescription 
722 607 84.1 (81.2 - 86.7) 836 661 79.1 (76.1 - 81.8) 
10. LRTI code and 
antibiotic prescription 
166 143 86.1 (79.9 - 91.0) 227 204 89.9 (85.2 - 93.5) 
11. LRTI code and OCS & 
antibiotic prescription 
161 139 86.3 (80.0 - 91.2) 210 188 89.5 (84.6 - 93.3) 
12. AECOPD code 406 392 96.6 (94.3 - 98.1) 479 458 95.6 (93.4 - 97.3) 
13. AECOPD code and 
OCS prescription 
283 273 96.5 (93.6 - 98.3) 355 345 97.2 (94.9 - 98.6) 
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14. AECOPD code and 
antibiotic prescription 
171 164 95.9 (91.7 - 98.3) 252 244 96.8 (93.8 - 98.6) 
15. AECOPD code and 
OCS & antibiotic 
prescription 
147 140 95.2 (90.4 - 98.1) 230 225 97.8 (95.0 - 99.3) 
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Supplementary Table 11 PPVs for algorithms stratified by age group 
Algorithm N events 
identified 
N events 
confirmed 
by 
reference 
standard 
PPV 
(95% 
CI) 
N events 
identified 
N events 
confirmed 
by 
reference 
standard 
PPV 
(95% 
CI) 
N events 
identified 
N events 
confirmed 
by 
reference 
standard 
PPV 
(95% 
CI) 
N events 
identified 
N events 
confirmed 
by 
reference 
standard 
PPV 
(95% 
CI) 
 ≤55   55 to 64   65 to 74   ≥ 75   
1.OCS 
prescription 
288 205 71.2 
(65.6 - 
76.3) 
424 318 75.0 
(70.6 - 
79.1) 
340 245 72.1 
(67.0 - 
76.8) 
100 73 73.0 
(63.2 - 
81.4) 
2.Antibiotic 
prescription 
1234 691 56.0 
(53.2 - 
58.8) 
2127 1341 63.0 
(61.0 - 
65.1) 
1818 1130 62.2 
(59.9 - 
64.4) 
661 397 60.1 
(56.2 - 
63.8) 
3.OCS and 
antibiotic 
prescription 
210 168 80.0 
(73.9 - 
85.2) 
300 230 76.7 
(71.5 - 
81.3) 
247 200 81.0 
(75.5 - 
85.7) 
66 55 83.3 
(72.1 - 
91.4) 
4. Symptom 
definition 
24 15 62.5 
(40.6 - 
81.2) 
47 31 66.0 
(50.7 - 
79.1) 
45 26 57.8 
(42.2 - 
72.3) 
26 20 76.9 
(56.4 - 
91.0) 
5. Symptom 
definition 
and OCS 
prescription 
15 12 80.0 
(51.9 - 
95.7) 
28 26 92.9 
(76.5 - 
99.1) 
26 24 92.3 
(74.9 - 
99.1) 
19 17 89.5 
(66.9 - 
98.7) 
6. Symptom 
definition 
and 
antibiotic 
prescription 
8 8  100.0 
(63.1 - 
100.0) 
19 17 89.5 
(66.9 - 
98.7) 
17 15 88.2 
(63.6 - 
98.5) 
13 13 100.0 
(75.3 - 
100.0) 
7. Symptom 
definition 
and OCS & 
7 7 100.0 
(59.0 - 
100.0) 
15 15 100.0 
(78.2 - 
100.0) 
15 14 93.3 
(68.1 - 
99.8) 
11 11 100.0 
(71.5 - 
100.0) 
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antibiotic 
prescription 
8. LRTI 
code 
377 288 76.4 
(71.8 - 
80.6) 
645 501 77.7 
(74.3 - 
80.8) 
530 440 83.0 
(79.5 - 
86.1) 
193 160 82.9 
(76.8 - 
87.9) 
9. LRTI 
code and 
OCS 
prescription 
336 265 78.9 
(74.1 - 
83.1) 
580 463 79.8 
(76.3 - 
83.0) 
473 402 85.0 
(81.4 - 
88.1) 
169 138 81.7 
(75.0 - 
87.2) 
10. LRTI 
code and 
antibiotic 
prescription 
106 93 87.7 
(79.9 - 
93.3) 
129 115 89.1 
(82.5 - 
93.9) 
112 97 86.6 
(78.9 - 
92.3) 
46 42 91.3 
(79.2 - 
97.6) 
11. LRTI 
code and 
OCS & 
antibiotic 
prescription 
97 86 88.7 
(80.6 - 
94.2) 
121 107 88.4 
(81.3 - 
93.5) 
108 93 86.1 
(78.1 - 
92.0) 
45 41 91.1 
(78.8 - 
97.5) 
12. 
AECOPD 
code 
135 129 95.6 
(90.6 - 
98.4) 
385 372 96.6 
(94.3 - 
98.2) 
281 269 95.7 
(92.7 - 
97.8) 
84 80 95.2 
(88.3 - 
98.7) 
13. 
AECOPD 
code and 
OCS 
prescription 
95 92 96.8 
(91.0 - 
99.3) 
289 281 97.2 
(94.6 - 
98.8) 
200 193 96.5 
(92.9 - 
98.6) 
54 52 96.3 
(87.3 - 
99.5) 
14. 
AECOPD 
code and 
antibiotic 
prescription 
78 75 96.2 
(89.2 - 
99.2) 
196 190 96.9 
(93.5 - 
98.9) 
114 109 95.6 
(90.1 - 
98.6) 
35 34 97.1 
(85.1 - 
99.9) 
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15. 
AECOPD 
code and 
OCS & 
antibiotic 
prescription 
70 68 97.1 
(90.1 - 
99.7) 
176 170 96.6 
(92.7 - 
98.7) 
101 98 97.0 
(91.6 - 
99.4) 
30 29 96.7 
(82.8 - 
99.9) 
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Codes used to construct AECOPD algorithms 
 
Lower respiratory tract infection diagnostic codes 
Medical code Read term 
68 Chest infection 
312 Acute bronchitis 
556 Influenza 
1019 Acute bronchiolitis 
1382 Acute viral bronchitis unspecified 
2157 Flu like illness 
2476 Chest cold 
2581 Chest infection NOS 
3358 Lower resp tract infection 
5947 Influenza like illness 
5978 Acute wheezy bronchitis 
6124 Acute lower respiratory tract infection 
6181 Obliterating fibrous bronchiolitis 
8980 Influenza-like symptoms 
9043 Acute pneumococcal bronchitis 
11072 Acute purulent bronchitis 
14791 Influenza with gastrointestinal tract involvement 
15774 Influenza with laryngitis 
16388 Influenza NOS 
17185 Acute bronchiolitis with bronchospasm 
17359 Chest infection - unspecified bronchitis 
17917 Acute bronchiolitis NOS 
18451 Acute bronchiolitis due to respiratory syncytial virus 
20198 Acute bronchitis NOS 
21061 Chronic obstruct pulmonary dis with acute lower resp infectn 
21145 Acute croupous bronchitis 
21492 Acute haemophilus influenzae bronchitis 
23488 Influenza with respiratory manifestations NOS 
24316 Chest infection with infectious disease EC 
24800 Acute bacterial bronchitis unspecified 
26125 Bronchiolitis obliterans 
29273 Acute bronchitis due to parainfluenza virus 
29617 Influenza with pharyngitis 
29669 Acute bronchitis and bronchiolitis 
31363 Influenza with other manifestations NOS 
37447 Acute lower respiratory tract infection 
41137 Acute bronchitis or bronchiolitis NOS 
41589 Acute obliterating bronchiolitis 
43362 Acute streptococcal bronchitis 
43625 Influenza with other respiratory manifestation 
46157 Influenza with encephalopathy 
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47472 Influenza with other manifestations 
48593 Acute bronchitis due to respiratory syncytial virus 
49794 Acute neisseria catarrhalis bronchitis 
54533 Acute capillary bronchiolitis 
63697 Avian influenza virus nucleic acid detection 
64890 Acute bronchitis due to rhinovirus 
65916 Acute bronchitis due to echovirus 
66228 Acute bronchiolitis due to other specified organisms 
66397 [X]Other acute lower respiratory infections 
69192 Acute exudative bronchiolitis 
71370 Acute pseudomembranous bronchitis 
73100 [X]Acute bronchitis due to other specified organisms 
91123 Parainfluenza type 3 nucleic acid detection 
93153 Acute bronchitis due to coxsackievirus 
94130 Parainfluenza type 1 nucleic acid detection 
94858 Parainfluenza type 2 nucleic acid detection 
94930 Avian influenza 
96017 Influenza B virus detected 
96018 Influenza H3 virus detected 
96019 Influenza H1 virus detected 
96286 Human parainfluenza virus detected 
97062 Influenza A virus, other or untyped strain detected 
97279 [X]Influenza+other manifestations, virus not identified 
97605 [X]Influenza+oth respiratory manifestatns,virus not identifd 
97936 [X]Influenza+other manifestations,influenza virus identified 
98102 Influenza A (H1N1) swine flu 
98103 Possible influenza A virus H1N1 subtype 
98115 Suspected swine influenza 
98125 Suspected influenza A virus subtype H1N1 infection 
98129 Influenza due to Influenza A virus subtype H1N1 
98143 Influenza A virus H1N1 subtype detected 
98156 Influenza H5 virus detected 
98257 [X]Flu+oth respiratory manifestations,'flu virus identified 
99214 [X]Acute bronchiolitis due to other specified organisms 
101775 Acute membranous bronchitis 
102918 Influenza H2 virus detected 
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Acute exacerbation of COPD diagnostic codes 
Medical code  Read term 
1446 Acute exacerbation of chronic obstructive airways disease 
7884 Chron obstruct pulmonary dis wth acute exacerbation, unspec 
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Cough codes 
Medical code Read term 
92 Cough 
292 Chesty cough 
1025 Bronchial cough 
1160 [D]Cough 
1234 Productive cough NOS 
1273 C/O - cough 
3068 Night cough present 
3645 Coughing up phlegm 
4070 Morning cough 
4836 Nocturnal cough / wheeze 
4931 Dry cough 
7706 Productive cough -clear sputum 
7707 Cough symptom NOS 
7708 Productive cough-yellow sputum 
7773 Productive cough -green sputum 
8239 [D]Cough with haemorrhage 
18907 Cough with fever 
22318 Difficulty in coughing up sputum 
29318 Evening cough 
60903 Cough aggravates symptom 
100515 Cough swab 
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Breathlessness codes 
Medical code Read term 
735 [D]Breathlessness 
741 [D]Shortness of breath 
1429 Breathlessness 
2563 [D]Respiratory distress 
2575 Short of breath on exertion 
2737 Respiratory distress syndrome 
2931 Difficulty breathing 
3092 [D]Dyspnoea 
4822 Shortness of breath 
5175 Breathlessness symptom 
5349 Shortness of breath symptom 
5896 Dyspnoea - symptom 
6326 Breathless - moderate exertion 
6434 Paroxysmal nocturnal dyspnoea 
7000 O/E - dyspnoea 
7534 O/E - respiratory distress 
7683 Breathless - lying flat 
7932 Breathless - mild exertion 
9297 [D]Respiratory insufficiency 
18116 Nocturnal dyspnoea 
21801 Breathlessness NOS 
22094 Short of breath dressing/undressing 
24889 Breathless - strenuous exertion 
31143 Breathless - at rest 
40813 Unable to complete a sentence in one breath 
53771 Dyspnoea on exertion 
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Sputum codes 
Medical codes Read term 
292 Chesty cough 
1025 Bronchial cough 
1234 Productive cough NOS 
1251 [D]Abnormal sputum 
3645 Coughing up phlegm 
3727 Sputum sent for C/S 
7706 Productive cough -clear sputum 
7708 Productive cough-yellow sputum 
7773 Productive cough -green sputum 
8287 Sputum sample obtained 
8760 [D]Positive culture findings in sputum 
9807 Sputum - symptom 
11072 Acute purulent bronchitis 
14271 Sputum culture 
14272 Sputum microscopy 
14273 Sputum appearance 
14804 Sputum appears infected 
15430 [D]Sputum abnormal - colour 
16026 Sputum examination: abnormal 
18964 Sputum clearance 
20086 [D]Sputum abnormal - amount 
22318 Difficulty in coughing up sputum 
23252 Sputum microscopy NOS 
23582 [D]Abnormal sputum NOS 
24181 Sputum: mucopurulent 
30754 Yellow sputum 
30904 Sputum sent for examination 
36515 [D]Abnormal sputum - tenacious 
36880 Green sputum 
43270 Sputum evidence of infection 
44214 [D]Sputum abnormal - odour 
49144 Sputum: pus cells present 
49694 Sputum: organism on gram stain 
54177 Sputum: excessive - mucoid 
100484 Volume of sputum 
100524 Moderate sputum 
100629 White sputum 
100647 Copious sputum 
100931 Brown sputum 
101782 Profuse sputum 
103209 Grey sputum 
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COPD specific oral corticosteroid codes 
Product code Product name 
95 prednisolone 5mg tablets 
1063 prednesol 5mg tablet (sovereign medical ltd) 
2044 prednisone 2.5 mg tab 
2368 prednisolone 2.5mg tablet 
2390 prednisolone e/c 1 mg tab 
2799 prednisolone 10 mg tab 
2949 prednisone 5mg tablets 
3059 prednisolone 50 mg tab 
3345 sintisone tablet (pharmacia ltd) 
3557 prednisone 1mg tablets 
7584 prednisolone 4 mg tab 
7710 prednisolone 15 mg tab 
7934 prednisone 30 mg tab 
9727 prednisolone 50mg tablets 
13522 prednisolone 2 mg tab 
13615 prednisone 10 mg tab 
16724 prednisone 50 mg tab 
20095 precortisyl forte 25mg tablet (aventis pharma) 
20670 prednisolone e/c 
21833 decortisyl 5mg tablet (roussel laboratories ltd) 
23512 precortisyl 5mg tablet (hoechst marion roussel) 
24716 prednisolone e/c 
25272 precortisyl 1mg tablet (hoechst marion roussel) 
27889 prednisolone 
27959 prednisolone 
27962 deltastab 1mg tablet (waymade healthcare plc) 
28376 prednisolone 2.5mg gastro-resistant tablet (biorex laboratories ltd) 
28859 deltastab 5mg tablet (waymade healthcare plc) 
30390 deltastab 2 mg tab 
30971 decortisyl 25 mg tab 
31327 prednisolone steaglate 6.65mg tablet 
33691 prednisolone 5mg gastro-resistant tablet (biorex laboratories ltd) 
33988 prednisolone 5mg tablet (co-pharma ltd) 
33990 prednisolone 5mg tablet (ivax pharmaceuticals uk ltd) 
34109 prednisolone 5 mg gastro-resistant tablet 
34631 prednisolone 1mg tablet (co-pharma ltd) 
34914 prednisolone 1mg tablet (celltech pharma europe ltd) 
38407 prednisolone 20mg tablet 
43544 prednisone 5mg tablet (knoll ltd) 
44380 prednisone 1mg modified-release tablets 
44723 prednisone 5mg modified-release tablets 
44802 lodotra 5mg modified-release tablets (napp pharmaceuticals ltd) 
44803 lodotra 2mg modified-release tablets (napp pharmaceuticals ltd) 
45302 prednisolone 5mg tablet (biorex laboratories ltd) 
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46711 prednisone 2mg modified-release tablets 
47142 prednisolone 5mg soluble tablet (amdipharm plc) 
54432 lodotra 1mg modified-release tablets (napp pharmaceuticals ltd) 
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COPD specific antibiotic codes  
Product code Product name 
22029 amiclav 250mg/125mg tablets (ashbourne pharmaceuticals ltd) 
11634 amix 125 oral suspension (ashbourne pharmaceuticals ltd) 
11613 amix 250 capsules (ashbourne pharmaceuticals ltd) 
21844 amix 250 oral suspension (ashbourne pharmaceuticals ltd) 
18786 amix 500 capsules (ashbourne pharmaceuticals ltd) 
29697 amopen 125mg/5ml liquid (yorkshire pharmaceuticals ltd) 
30498 amopen 250mg capsule (yorkshire pharmaceuticals ltd) 
31423 amopen 250mg/5ml liquid (yorkshire pharmaceuticals ltd) 
17711 amopen 500mg capsule (yorkshire pharmaceuticals ltd) 
12378 amoram 125mg/5ml oral suspension (lpc medical (uk) ltd) 
9243 amoram 250mg capsules (lpc medical (uk) ltd) 
22438 amoram 250mg/5ml oral suspension (lpc medical (uk) ltd) 
22415 amoram 500mg capsules (lpc medical (uk) ltd) 
8906 amoxicillin 125mg / clavulanic acid 31mg/5ml oral suspension 
13285 amoxicillin 125mg / clavulanic acid 31mg/5ml oral suspension 
53942 amoxicillin 125mg / clavulanic acid 62.5mg/5ml oral suspension 
41835 amoxicillin 125mg powder (ivax pharmaceuticals uk ltd) 
3742 amoxicillin 125mg sugar free chewable tablets 
13848 amoxicillin 125mg sugar free powder 
485 amoxicillin 125mg/1.25ml oral suspension paediatric 
42822 amoxicillin 125mg/5ml mixture (celltech pharma europe ltd) 
28872 amoxicillin 125mg/5ml mixture (crosspharma ltd) 
41818 amoxicillin 125mg/5ml oral solution (berk pharmaceuticals ltd) 
42240 amoxicillin 125mg/5ml oral solution (co-pharma ltd) 
29337 amoxicillin 125mg/5ml oral solution (neo laboratories ltd) 
62 amoxicillin 125mg/5ml oral suspension 
33690 amoxicillin 125mg/5ml oral suspension (a a h pharmaceuticals ltd) 
34857 amoxicillin 125mg/5ml oral suspension (actavis uk ltd) 
42545 amoxicillin 125mg/5ml oral suspension (almus pharmaceuticals ltd) 
50002 amoxicillin 125mg/5ml oral suspension (bristol laboratories ltd) 
32622 amoxicillin 125mg/5ml oral suspension (generics (uk) ltd) 
23238 amoxicillin 125mg/5ml oral suspension (ivax pharmaceuticals uk ltd) 
48038 amoxicillin 125mg/5ml oral suspension (kent pharmaceuticals ltd) 
52685 
amoxicillin 125mg/5ml oral suspension (phoenix healthcare distribution 
ltd) 
28875 amoxicillin 125mg/5ml oral suspension (ranbaxy (uk) ltd) 
43229 amoxicillin 125mg/5ml oral suspension (sandoz ltd) 
55047 amoxicillin 125mg/5ml oral suspension (sandoz ltd) 
28870 amoxicillin 125mg/5ml oral suspension (teva uk ltd) 
56561 amoxicillin 125mg/5ml oral suspension (waymade healthcare plc) 
503 amoxicillin 125mg/5ml oral suspension sugar free 
33696 
amoxicillin 125mg/5ml oral suspension sugar free (a a h pharmaceuticals 
ltd) 
34679 amoxicillin 125mg/5ml oral suspension sugar free (actavis uk ltd) 
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53078 
amoxicillin 125mg/5ml oral suspension sugar free (alliance healthcare 
(distribution) ltd) 
36054 
amoxicillin 125mg/5ml oral suspension sugar free (almus pharmaceuticals 
ltd) 
52122 amoxicillin 125mg/5ml oral suspension sugar free (bristol laboratories ltd) 
31014 amoxicillin 125mg/5ml oral suspension sugar free (generics (uk) ltd) 
24150 
amoxicillin 125mg/5ml oral suspension sugar free (ivax pharmaceuticals 
uk ltd) 
34384 
amoxicillin 125mg/5ml oral suspension sugar free (kent pharmaceuticals 
ltd) 
52857 
amoxicillin 125mg/5ml oral suspension sugar free (phoenix healthcare 
distribution ltd) 
29858 amoxicillin 125mg/5ml oral suspension sugar free (sandoz ltd) 
34638 amoxicillin 125mg/5ml oral suspension sugar free (teva uk ltd) 
55626 
amoxicillin 125mg/5ml oral suspension sugar free (waymade healthcare 
plc) 
1391 amoxicillin 250mg / clavulanic acid 125mg tablets 
7636 amoxicillin 250mg / clavulanic acid 62mg/5ml oral suspension 
13262 amoxicillin 250mg / clavulanic acid 62mg/5ml oral suspension 
42809 amoxicillin 250mg capsule (c p pharmaceuticals ltd) 
31661 amoxicillin 250mg capsule (co-pharma ltd) 
28882 amoxicillin 250mg capsule (crosspharma ltd) 
34435 amoxicillin 250mg capsule (ddsa pharmaceuticals ltd) 
33222 amoxicillin 250mg capsule (lagap) 
32872 amoxicillin 250mg capsule (mepra-pharm) 
34714 amoxicillin 250mg capsule (neo laboratories ltd) 
45267 amoxicillin 250mg capsule (regent laboratories ltd) 
9 amoxicillin 250mg capsules 
25484 amoxicillin 250mg capsules (a a h pharmaceuticals ltd) 
33343 amoxicillin 250mg capsules (actavis uk ltd) 
54796 amoxicillin 250mg capsules (boston healthcare ltd) 
54491 amoxicillin 250mg capsules (bristol laboratories ltd) 
30745 amoxicillin 250mg capsules (generics (uk) ltd) 
34042 amoxicillin 250mg capsules (ivax pharmaceuticals uk ltd) 
30528 amoxicillin 250mg capsules (kent pharmaceuticals ltd) 
54271 amoxicillin 250mg capsules (mawdsley-brooks & company ltd) 
51536 amoxicillin 250mg capsules (milpharm ltd) 
30743 amoxicillin 250mg capsules (ranbaxy (uk) ltd) 
48006 amoxicillin 250mg capsules (sandoz ltd) 
23967 amoxicillin 250mg capsules (teva uk ltd) 
54185 amoxicillin 250mg capsules (wockhardt uk ltd) 
870 amoxicillin 250mg sugar free chewable tablets 
42815 amoxicillin 250mg/5ml mixture (celltech pharma europe ltd) 
33570 amoxicillin 250mg/5ml mixture (crosspharma ltd) 
40238 amoxicillin 250mg/5ml mixture (mepra-pharm) 
45317 amoxicillin 250mg/5ml oral solution (neo laboratories ltd) 
427 amoxicillin 250mg/5ml oral suspension 
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33165 amoxicillin 250mg/5ml oral suspension (a a h pharmaceuticals ltd) 
34760 amoxicillin 250mg/5ml oral suspension (actavis uk ltd) 
41090 amoxicillin 250mg/5ml oral suspension (almus pharmaceuticals ltd) 
55018 amoxicillin 250mg/5ml oral suspension (bristol laboratories ltd) 
33689 amoxicillin 250mg/5ml oral suspension (generics (uk) ltd) 
32640 amoxicillin 250mg/5ml oral suspension (ivax pharmaceuticals uk ltd) 
51382 
amoxicillin 250mg/5ml oral suspension (phoenix healthcare distribution 
ltd) 
55499 amoxicillin 250mg/5ml oral suspension (ranbaxy (uk) ltd) 
56223 amoxicillin 250mg/5ml oral suspension (sandoz ltd) 
37755 amoxicillin 250mg/5ml oral suspension (sandoz ltd) 
53924 amoxicillin 250mg/5ml oral suspension (sigma pharmaceuticals plc) 
27725 amoxicillin 250mg/5ml oral suspension (teva uk ltd) 
585 amoxicillin 250mg/5ml oral suspension sugar free 
34232 
amoxicillin 250mg/5ml oral suspension sugar free (a a h pharmaceuticals 
ltd) 
40243 amoxicillin 250mg/5ml oral suspension sugar free (actavis uk ltd) 
54222 
amoxicillin 250mg/5ml oral suspension sugar free (alliance healthcare 
(distribution) ltd) 
42732 
amoxicillin 250mg/5ml oral suspension sugar free (almus pharmaceuticals 
ltd) 
49065 amoxicillin 250mg/5ml oral suspension sugar free (bristol laboratories ltd) 
31535 amoxicillin 250mg/5ml oral suspension sugar free (generics (uk) ltd) 
33699 
amoxicillin 250mg/5ml oral suspension sugar free (ivax pharmaceuticals 
uk ltd) 
34855 
amoxicillin 250mg/5ml oral suspension sugar free (kent pharmaceuticals 
ltd) 
34775 amoxicillin 250mg/5ml oral suspension sugar free (teva uk ltd) 
17746 amoxicillin 375mg soluble tablets 
1140 amoxicillin 3g oral powder sachets sugar free 
33383 amoxicillin 3g oral powder sachets sugar free (a a h pharmaceuticals ltd) 
40168 amoxicillin 3g oral powder sachets sugar free (kent pharmaceuticals ltd) 
28130 amoxicillin 3g oral powder sachets sugar free (teva uk ltd) 
41734 amoxicillin 3g powder (actavis uk ltd) 
15192 amoxicillin 400mg / clavulanic acid 57mg/5ml sugar free oral suspension 
5662 amoxicillin 500mg / clarithromycin 500mg / lansoprazole 30mg triple pack 
13216 amoxicillin 500mg / clavulanic acid 125mg tablets 
38684 amoxicillin 500mg capsule (c p pharmaceuticals ltd) 
35570 amoxicillin 500mg capsule (crosspharma ltd) 
34885 amoxicillin 500mg capsule (ddsa pharmaceuticals ltd) 
44854 amoxicillin 500mg capsule (lagap) 
34912 amoxicillin 500mg capsule (neo laboratories ltd) 
48 amoxicillin 500mg capsules 
33692 amoxicillin 500mg capsules (a a h pharmaceuticals ltd) 
53627 amoxicillin 500mg capsules (accord healthcare ltd) 
26157 amoxicillin 500mg capsules (actavis uk ltd) 
52820 amoxicillin 500mg capsules (alliance healthcare (distribution) ltd) 
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47640 amoxicillin 500mg capsules (almus pharmaceuticals ltd) 
55527 amoxicillin 500mg capsules (boston healthcare ltd) 
52771 amoxicillin 500mg capsules (bristol laboratories ltd) 
23740 amoxicillin 500mg capsules (generics (uk) ltd) 
29463 amoxicillin 500mg capsules (ivax pharmaceuticals uk ltd) 
33706 amoxicillin 500mg capsules (kent pharmaceuticals ltd) 
52058 amoxicillin 500mg capsules (medreich plc) 
54725 amoxicillin 500mg capsules (milpharm ltd) 
34852 amoxicillin 500mg capsules (ranbaxy (uk) ltd) 
31801 amoxicillin 500mg capsules (sandoz ltd) 
34001 amoxicillin 500mg capsules (teva uk ltd) 
55394 amoxicillin 500mg capsules (wockhardt uk ltd) 
1722 amoxicillin 500mg dispersible tablets 
2281 amoxicillin 500mg sugar free chewable tablets 
4582 amoxicillin 750mg soluble tablets 
9343 amoxicillin 750mg sugar free powder 
439 amoxicillin with clavulanic acid dispersible tablets 
2171 amoxil 125mg/1.25ml paediatric oral suspension (glaxosmithkline uk ltd) 
2153 amoxil 125mg/5ml syrup sucrose free (glaxosmithkline uk ltd) 
133 amoxil 250mg capsules (glaxosmithkline uk ltd) 
1812 amoxil 250mg/5ml syrup sucrose free (glaxosmithkline uk ltd) 
2174 amoxil 3g oral powder sachets sucrose free (glaxosmithkline uk ltd) 
847 amoxil 500mg capsules (glaxosmithkline uk ltd) 
49590 amoxil 500mg capsules (lexon (uk) ltd) 
51436 amoxil 500mg capsules (mawdsley-brooks & company ltd) 
56700 amoxil 500mg capsules (necessity supplies ltd) 
15148 amoxil 500mg dispersible tablet (smithkline beecham plc) 
4010 amoxil 750mg sachets (glaxosmithkline uk ltd) 
4154 amoxil fiztab 125mg tablet (bencard) 
1637 amoxil fiztab 250mg tablet (bencard) 
7737 amoxil fiztab 500mg tablet (bencard) 
31571 amoxycillin 
32505 amoxycillin 
27897 amoxycillin 
7592 amoxycillin 125 mg cap 
22469 amoxycillin 125mg/31mg clavulanic acid 
25034 amoxycillin 125mg/62mg clavulanic acid 
7581 amoxycillin 125mg/62mg clavulanic acid syr 
27886 amoxycillin 250/clavulanic acid 125 disp 
19795 amoxycillin 250mg/clavulanic acid 125mg 
1570 amoxycillin 500 mg tab 
2902 amoxycillin fiztab 125 mg tab 
1393 amoxycillin fiztab 250 mg tab 
22293 amoxycillin trihydrate sachet 
21982 amoxycillin trihydrate sachet 
31286 amoxymed 125mg/5ml oral solution (medipharma ltd) 
333 
 
3669 amoxymed 250mg capsule (medipharma ltd) 
33109 amrit 125mg/5ml liquid (bhr pharmaceuticals ltd) 
27714 amrit 250mg capsule (bhr pharmaceuticals ltd) 
33110 amrit 250mg/5ml liquid (bhr pharmaceuticals ltd) 
33112 amrit 500mg capsule (bhr pharmaceuticals ltd) 
27495 arpimycin 125mg/5ml liquid (rosemont pharmaceuticals ltd) 
36544 arpimycin 125mg/5ml oral suspension (rosemont pharmaceuticals ltd) 
24220 arpimycin 250mg/5ml liquid (rosemont pharmaceuticals ltd) 
36514 arpimycin 250mg/5ml oral suspension (rosemont pharmaceuticals ltd) 
37022 arpimycin 500mg/5ml liquid (rosemont pharmaceuticals ltd) 
415 augmentin 125/31 sf oral suspension (glaxosmithkline uk ltd) 
50595 augmentin 125/31 sf oral suspension (mawdsley-brooks & company ltd) 
51164 augmentin 125/31 sf oral suspension (waymade healthcare plc) 
569 augmentin 250/62 sf oral suspension (glaxosmithkline uk ltd) 
52666 augmentin 250/62 sf oral suspension (sigma pharmaceuticals plc) 
2507 augmentin 375mg dispersible tablets (glaxosmithkline uk ltd) 
49063 augmentin 375mg tablets (doncaster pharmaceuticals ltd) 
399 augmentin 375mg tablets (glaxosmithkline uk ltd) 
48683 augmentin 375mg tablets (lexon (uk) ltd) 
49374 augmentin 375mg tablets (mawdsley-brooks & company ltd) 
49048 augmentin 375mg tablets (waymade healthcare plc) 
50279 augmentin 625mg tablets (doncaster pharmaceuticals ltd) 
509 augmentin 625mg tablets (glaxosmithkline uk ltd) 
49656 augmentin 625mg tablets (lexon (uk) ltd) 
52207 augmentin 625mg tablets (mawdsley-brooks & company ltd) 
49321 augmentin 625mg tablets (sigma pharmaceuticals plc) 
49683 augmentin 625mg tablets (waymade healthcare plc) 
5341 augmentin-duo 400/57 oral suspension (glaxosmithkline uk ltd) 
56591 augmentin-duo 400/57 oral suspension (lexon (uk) ltd) 
51194 augmentin-duo 400/57 oral suspension (sigma pharmaceuticals plc) 
31007 aureomycin powder (wyeth pharmaceuticals) 
25127 avelox 400mg tablets (bayer plc) 
26289 bacticlor mr 375mg tablets (ranbaxy (uk) ltd) 
4895 benzoyl peroxide 5% / erythromycin 3% gel 
21802 berkmycen 250mg tablet (berk pharmaceuticals ltd) 
17093 bisolvomycin capsule (boehringer ingelheim ltd) 
13910 cefaclor 125mg/5ml liquid (generics (uk) ltd) 
14607 cefaclor 125mg/5ml liquid (lagap) 
1038 cefaclor 125mg/5ml oral suspension 
39703 cefaclor 125mg/5ml oral suspension (a a h pharmaceuticals ltd) 
34913 cefaclor 125mg/5ml oral suspension (genus pharmaceuticals ltd) 
32235 cefaclor 125mg/5ml oral suspension (ranbaxy (uk) ltd) 
7526 cefaclor 125mg/5ml oral suspension sugar free 
56610 
cefaclor 125mg/5ml oral suspension sugar free (phoenix healthcare 
distribution ltd) 
9520 cefaclor 250mg capsule (lagap) 
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366 cefaclor 250mg capsules 
30772 cefaclor 250mg capsules (ranbaxy (uk) ltd) 
20420 cefaclor 250mg/5ml liquid (generics (uk) ltd) 
20409 cefaclor 250mg/5ml liquid (lagap) 
3737 cefaclor 250mg/5ml oral suspension 
46973 cefaclor 250mg/5ml oral suspension (genus pharmaceuticals ltd) 
48025 cefaclor 250mg/5ml oral suspension (ranbaxy (uk) ltd) 
9293 cefaclor 250mg/5ml oral suspension sugar free 
3180 cefaclor 375mg modified-release tablets 
34838 cefaclor 375mg modified-release tablets (a a h pharmaceuticals ltd) 
20881 cefaclor 375mg modified-release tablets (ranbaxy (uk) ltd) 
4689 cefaclor 500mg capsule (lagap) 
2976 cefaclor 500mg capsules 
43425 cefaclor 500mg capsules (a a h pharmaceuticals ltd) 
55211 cefaclor 500mg capsules (kent pharmaceuticals ltd) 
30771 cefaclor 500mg capsules (ranbaxy (uk) ltd) 
8051 cefaclor 500mg modified-release tablets 
12248 cefalexin 125mg/1.25ml paediatric drops 
1693 cefalexin 125mg/5ml oral suspension 
29748 cefalexin 125mg/5ml oral suspension (a a h pharmaceuticals ltd) 
32181 cefalexin 125mg/5ml oral suspension (actavis uk ltd) 
53945 
cefalexin 125mg/5ml oral suspension (alliance healthcare (distribution) 
ltd) 
39417 cefalexin 125mg/5ml oral suspension (generics (uk) ltd) 
32642 cefalexin 125mg/5ml oral suspension (kent pharmaceuticals ltd) 
36578 cefalexin 125mg/5ml oral suspension (ranbaxy (uk) ltd) 
33329 cefalexin 125mg/5ml oral suspension (teva uk ltd) 
6651 cefalexin 125mg/5ml oral suspension sugar free 
19144 cefalexin 125mg/5ml oral suspension sugar free (teva uk ltd) 
1384 cefalexin 125mg/5ml suspension 
18451 cefalexin 1g tablets 
33802 cefalexin 250mg capsule (berk pharmaceuticals ltd) 
155 cefalexin 250mg capsules 
34253 cefalexin 250mg capsules (a a h pharmaceuticals ltd) 
19152 cefalexin 250mg capsules (actavis uk ltd) 
54864 cefalexin 250mg capsules (alliance healthcare (distribution) ltd) 
52283 cefalexin 250mg capsules (arrow generics ltd) 
19160 cefalexin 250mg capsules (generics (uk) ltd) 
19133 cefalexin 250mg capsules (ivax pharmaceuticals uk ltd) 
41736 cefalexin 250mg capsules (kent pharmaceuticals ltd) 
52282 cefalexin 250mg capsules (milpharm ltd) 
24090 cefalexin 250mg capsules (pliva pharma ltd) 
36599 cefalexin 250mg capsules (ranbaxy (uk) ltd) 
9690 cefalexin 250mg capsules (teva uk ltd) 
40747 cefalexin 250mg chewable tablets 
1146 cefalexin 250mg tablets 
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33334 cefalexin 250mg tablets (a a h pharmaceuticals ltd) 
36330 cefalexin 250mg tablets (actavis uk ltd) 
47163 cefalexin 250mg tablets (arrow generics ltd) 
36701 cefalexin 250mg tablets (generics (uk) ltd) 
31825 cefalexin 250mg tablets (ivax pharmaceuticals uk ltd) 
9698 cefalexin 250mg tablets (teva uk ltd) 
41825 cefalexin 250mg/5ml oral solution (c p pharmaceuticals ltd) 
1860 cefalexin 250mg/5ml oral suspension 
42008 cefalexin 250mg/5ml oral suspension (a a h pharmaceuticals ltd) 
45221 cefalexin 250mg/5ml oral suspension (actavis uk ltd) 
29464 cefalexin 250mg/5ml oral suspension (generics (uk) ltd) 
41192 cefalexin 250mg/5ml oral suspension (ranbaxy (uk) ltd) 
41968 cefalexin 250mg/5ml oral suspension (teva uk ltd) 
6671 cefalexin 250mg/5ml oral suspension sugar free 
34133 cefalexin 250mg/5ml oral suspension sugar free (teva uk ltd) 
1713 cefalexin 250mg/5ml suspension 
44755 cefalexin 500mg capsule (berk pharmaceuticals ltd) 
400 cefalexin 500mg capsules 
32643 cefalexin 500mg capsules (a a h pharmaceuticals ltd) 
19138 cefalexin 500mg capsules (actavis uk ltd) 
52851 cefalexin 500mg capsules (alliance healthcare (distribution) ltd) 
19184 cefalexin 500mg capsules (generics (uk) ltd) 
9664 cefalexin 500mg capsules (ivax pharmaceuticals uk ltd) 
36569 cefalexin 500mg capsules (kent pharmaceuticals ltd) 
54955 cefalexin 500mg capsules (milpharm ltd) 
19161 cefalexin 500mg capsules (ranbaxy (uk) ltd) 
29281 cefalexin 500mg capsules (teva uk ltd) 
865 cefalexin 500mg tablets 
29202 cefalexin 500mg tablets (a a h pharmaceuticals ltd) 
22321 cefalexin 500mg tablets (generics (uk) ltd) 
31827 cefalexin 500mg tablets (ivax pharmaceuticals uk ltd) 
9689 cefalexin 500mg tablets (teva uk ltd) 
2227 cefalexin 500mg/5ml oral suspension 
17150 ceporex 125mg/1.25ml drops (glaxo laboratories ltd) 
7560 ceporex 125mg/5ml liquid (galen ltd) 
3609 ceporex 125mg/5ml oral solution (galen ltd) 
41106 ceporex 125mg/5ml syrup (co-pharma ltd) 
12235 ceporex 1g tablet (galen ltd) 
192 ceporex 250mg capsule (galen ltd) 
40884 ceporex 250mg capsules (co-pharma ltd) 
8019 ceporex 250mg tablet (galen ltd) 
41049 ceporex 250mg tablets (co-pharma ltd) 
8625 ceporex 250mg/5ml liquid (galen ltd) 
8008 ceporex 250mg/5ml oral solution (galen ltd) 
40945 ceporex 250mg/5ml syrup (co-pharma ltd) 
2661 ceporex 500mg capsule (galen ltd) 
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40915 ceporex 500mg capsules (co-pharma ltd) 
8085 ceporex 500mg tablet (galen ltd) 
40914 ceporex 500mg tablets (co-pharma ltd) 
5859 ceporex 500mg/5ml oral solution (galen ltd) 
41230 ceporex 500mg/5ml syrup (co-pharma ltd) 
7881 chlortetracycline 250mg capsules 
36689 chlortetracycline hcl syr 
12016 chymocyclar capsule (rorer pharmaceuticals ltd) 
27016 ciprofloxacin 
498 ciprofloxacin 100mg tablets 
42507 ciprofloxacin 100mg tablets (a a h pharmaceuticals ltd) 
48031 ciprofloxacin 100mg tablets (almus pharmaceuticals ltd) 
54555 ciprofloxacin 100mg tablets (doncaster pharmaceuticals ltd) 
54674 ciprofloxacin 100mg tablets (phoenix healthcare distribution ltd) 
39913 ciprofloxacin 100mg tablets (sandoz ltd) 
52309 ciprofloxacin 100mg tablets (sigma pharmaceuticals plc) 
52945 ciprofloxacin 200mg/100ml solution for infusion vials 
56439 
ciprofloxacin 200mg/100ml solution for infusion vials (a a h 
pharmaceuticals ltd) 
34647 ciprofloxacin 250mg tablet (neo laboratories ltd) 
281 ciprofloxacin 250mg tablets 
29343 ciprofloxacin 250mg tablets (a a h pharmaceuticals ltd) 
50601 ciprofloxacin 250mg tablets (accord healthcare ltd) 
34308 ciprofloxacin 250mg tablets (actavis uk ltd) 
51537 ciprofloxacin 250mg tablets (alliance healthcare (distribution) ltd) 
54393 ciprofloxacin 250mg tablets (arrow generics ltd) 
54701 ciprofloxacin 250mg tablets (bristol laboratories ltd) 
56381 ciprofloxacin 250mg tablets (co-pharma ltd) 
43814 ciprofloxacin 250mg tablets (dr reddy's laboratories (uk) ltd) 
33989 ciprofloxacin 250mg tablets (generics (uk) ltd) 
41561 ciprofloxacin 250mg tablets (ivax pharmaceuticals uk ltd) 
54302 ciprofloxacin 250mg tablets (medreich plc) 
34448 ciprofloxacin 250mg tablets (niche generics ltd) 
34694 ciprofloxacin 250mg tablets (pliva pharma ltd) 
34559 ciprofloxacin 250mg tablets (sandoz ltd) 
34478 ciprofloxacin 250mg tablets (teva uk ltd) 
34655 ciprofloxacin 250mg tablets (wockhardt uk ltd) 
4091 ciprofloxacin 250mg/5ml oral suspension 
10304 ciprofloxacin 2mg/ml infusion 
45341 ciprofloxacin 500mg tablet (neo laboratories ltd) 
34322 ciprofloxacin 500mg tablet (niche generics ltd) 
583 ciprofloxacin 500mg tablets 
29458 ciprofloxacin 500mg tablets (a a h pharmaceuticals ltd) 
52501 ciprofloxacin 500mg tablets (accord healthcare ltd) 
34605 ciprofloxacin 500mg tablets (actavis uk ltd) 
49445 ciprofloxacin 500mg tablets (almus pharmaceuticals ltd) 
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56789 
ciprofloxacin 500mg tablets (apc pharmaceuticals & chemicals (europe) 
ltd) 
52616 ciprofloxacin 500mg tablets (arrow generics ltd) 
53641 ciprofloxacin 500mg tablets (co-pharma ltd) 
50055 ciprofloxacin 500mg tablets (doncaster pharmaceuticals ltd) 
53088 ciprofloxacin 500mg tablets (dr reddy's laboratories (uk) ltd) 
30707 ciprofloxacin 500mg tablets (generics (uk) ltd) 
42174 ciprofloxacin 500mg tablets (ivax pharmaceuticals uk ltd) 
55917 ciprofloxacin 500mg tablets (medreich plc) 
43557 ciprofloxacin 500mg tablets (pliva pharma ltd) 
53878 ciprofloxacin 500mg tablets (ranbaxy (uk) ltd) 
43797 ciprofloxacin 500mg tablets (sandoz ltd) 
45285 ciprofloxacin 500mg tablets (teva uk ltd) 
34494 ciprofloxacin 500mg tablets (wockhardt uk ltd) 
34973 ciprofloxacin 750mg tablet (niche generics ltd) 
1837 ciprofloxacin 750mg tablets 
29472 ciprofloxacin 750mg tablets (a a h pharmaceuticals ltd) 
43517 ciprofloxacin 750mg tablets (actavis uk ltd) 
52099 ciprofloxacin 750mg tablets (bristol laboratories ltd) 
56856 ciprofloxacin 750mg tablets (ranbaxy (uk) ltd) 
28544 ciprofloxaxin 400mg/200ml in glucose 5% infusion 
9154 ciproxin 100mg tablets (bayer plc) 
1202 ciproxin 250mg tablets (bayer plc) 
52353 ciproxin 250mg tablets (doncaster pharmaceuticals ltd) 
53519 ciproxin 250mg tablets (lexon (uk) ltd) 
163 ciproxin 250mg/5ml oral suspension (bayer plc) 
728 ciproxin 500mg tablets (bayer plc) 
52807 ciproxin 500mg tablets (mawdsley-brooks & company ltd) 
52177 ciproxin 500mg tablets (sigma pharmaceuticals plc) 
49839 ciproxin 500mg tablets (waymade healthcare plc) 
7752 ciproxin 750mg tablets (bayer plc) 
45591 clarie xl 500mg tablets (teva uk ltd) 
10326 clarithromycin 125mg granules straws 
331 clarithromycin 125mg/5ml oral suspension 
45795 clarithromycin 125mg/5ml oral suspension (a a h pharmaceuticals ltd) 
54903 
clarithromycin 125mg/5ml oral suspension (alliance healthcare 
(distribution) ltd) 
51831 
clarithromycin 125mg/5ml oral suspension (phoenix healthcare 
distribution ltd) 
41453 clarithromycin 125mg/5ml oral suspension (ranbaxy (uk) ltd) 
53168 clarithromycin 125mg/5ml oral suspension (sandoz ltd) 
26059 clarithromycin 187.5mg granules straws 
765 clarithromycin 250mg granules sachets 
17645 clarithromycin 250mg granules straws 
537 clarithromycin 250mg tablets 
34650 clarithromycin 250mg tablets (a a h pharmaceuticals ltd) 
54472 clarithromycin 250mg tablets (accord healthcare ltd) 
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48163 clarithromycin 250mg tablets (actavis uk ltd) 
52158 clarithromycin 250mg tablets (alliance healthcare (distribution) ltd) 
54882 clarithromycin 250mg tablets (almus pharmaceuticals ltd) 
52719 clarithromycin 250mg tablets (apotex uk ltd) 
53086 clarithromycin 250mg tablets (doncaster pharmaceuticals ltd) 
34394 clarithromycin 250mg tablets (generics (uk) ltd) 
51154 clarithromycin 250mg tablets (kent pharmaceuticals ltd) 
53153 clarithromycin 250mg tablets (phoenix healthcare distribution ltd) 
53688 clarithromycin 250mg tablets (ranbaxy (uk) ltd) 
47582 clarithromycin 250mg tablets (sandoz ltd) 
50946 clarithromycin 250mg tablets (sigma pharmaceuticals plc) 
54269 clarithromycin 250mg tablets (somex pharma) 
34533 clarithromycin 250mg tablets (teva uk ltd) 
54897 clarithromycin 250mg tablets (tillomed laboratories ltd) 
53144 clarithromycin 250mg tablets (wockhardt uk ltd) 
5357 clarithromycin 250mg/5ml oral suspension 
54241 clarithromycin 250mg/5ml oral suspension (a a h pharmaceuticals ltd) 
55148 
clarithromycin 250mg/5ml oral suspension (alliance healthcare 
(distribution) ltd) 
34811 clarithromycin 250mg/5ml oral suspension (ranbaxy (uk) ltd) 
53179 clarithromycin 250mg/5ml oral suspension (sandoz ltd) 
54208 clarithromycin 250mg/5ml oral suspension (sigma pharmaceuticals plc) 
55428 clarithromycin 250mg/5ml oral suspension (waymade healthcare plc) 
54529 
clarithromycin 500mg modified-release tablet (hillcross pharmaceuticals 
ltd) 
6803 clarithromycin 500mg modified-release tablets 
681 clarithromycin 500mg tablets 
38163 clarithromycin 500mg tablets (a a h pharmaceuticals ltd) 
51426 clarithromycin 500mg tablets (accord healthcare ltd) 
48023 clarithromycin 500mg tablets (actavis uk ltd) 
49939 clarithromycin 500mg tablets (alliance healthcare (distribution) ltd) 
53715 clarithromycin 500mg tablets (almus pharmaceuticals ltd) 
53776 clarithromycin 500mg tablets (doncaster pharmaceuticals ltd) 
34608 clarithromycin 500mg tablets (generics (uk) ltd) 
53703 clarithromycin 500mg tablets (kent pharmaceuticals ltd) 
46488 clarithromycin 500mg tablets (ranbaxy (uk) ltd) 
40784 clarithromycin 500mg tablets (sandoz ltd) 
53109 clarithromycin 500mg tablets (somex pharma) 
34974 clarithromycin 500mg tablets (teva uk ltd) 
53875 clarithromycin 500mg tablets (tillomed laboratories ltd) 
11433 
clarithromycin 500mg with lansoprazole 30mg and amoxicillin 500mg 
triple pack 
6497 
clarithromycin 500mg with metronidazole 400mg with lansoprazole 30mg 
triple pack 
28349 clarosip 125mg granules for oral suspension straws (grunenthal ltd) 
31689 clarosip 187.5mg granules for oral suspension straws (grunenthal ltd) 
31690 clarosip 250mg granules for oral suspension straws (grunenthal ltd) 
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9925 clavulanic acid 125mg with amoxicillin 250mg tablets 
13239 clavulanic acid 125mg with amoxicillin 500mg tablets 
24006 clavulanic acid 31mg with amoxcillin 125mg/5ml oral suspension 
21775 
clavulanic acid 31mg with amoxicillin 125mg/5ml sugar free oral 
suspension 
20432 clavulanic acid 57mg with amoxicillin 400mg/5ml sugar free suspension 
42485 clavulanic acid 62mg with amoxicillin 250mg/5ml oral suspension 
16612 clavulanic acid 62mg with amoxicillin 250mg/5ml sugar free suspension 
24093 clavulanic acid with amoxicillin dispersible tablets 
12504 clomocycline 170mg capsules 
10200 co-amoxiclav 125mg/31mg/5ml oral suspension 
54052 
co-amoxiclav 125mg/31mg/5ml oral suspension (a a h pharmaceuticals 
ltd) 
54732 co-amoxiclav 125mg/31mg/5ml oral suspension (generics (uk) ltd) 
1638 co-amoxiclav 125mg/31mg/5ml oral suspension sugar free 
43548 
co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (a a h 
pharmaceuticals ltd) 
54324 co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (actavis uk ltd) 
54452 
co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (alliance 
healthcare (distribution) ltd) 
54808 
co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (almus 
pharmaceuticals ltd) 
28874 
co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (ivax 
pharmaceuticals uk ltd) 
56884 
co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (phoenix 
healthcare distribution ltd) 
34680 
co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (ranbaxy (uk) 
ltd) 
34972 co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (sandoz ltd) 
829 co-amoxiclav 250mg/125mg dispersible tablets sugar free 
545 co-amoxiclav 250mg/125mg tablets 
30786 co-amoxiclav 250mg/125mg tablets (a a h pharmaceuticals ltd) 
19209 co-amoxiclav 250mg/125mg tablets (actavis uk ltd) 
51623 co-amoxiclav 250mg/125mg tablets (alliance healthcare (distribution) ltd) 
48147 co-amoxiclav 250mg/125mg tablets (almus pharmaceuticals ltd) 
34297 co-amoxiclav 250mg/125mg tablets (generics (uk) ltd) 
28871 co-amoxiclav 250mg/125mg tablets (ivax pharmaceuticals uk ltd) 
33693 co-amoxiclav 250mg/125mg tablets (kent pharmaceuticals ltd) 
50446 co-amoxiclav 250mg/125mg tablets (phoenix healthcare distribution ltd) 
30783 co-amoxiclav 250mg/125mg tablets (ranbaxy (uk) ltd) 
19414 co-amoxiclav 250mg/125mg tablets (sandoz ltd) 
34734 co-amoxiclav 250mg/125mg tablets (teva uk ltd) 
55312 co-amoxiclav 250mg/125mg tablets (waymade healthcare plc) 
46915 co-amoxiclav 250mg/125mg tablets (zentiva) 
7364 co-amoxiclav 250mg/62mg/5ml oral suspension 
54708 
co-amoxiclav 250mg/62mg/5ml oral suspension (a a h pharmaceuticals 
ltd) 
54780 co-amoxiclav 250mg/62mg/5ml oral suspension (generics (uk) ltd) 
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524 co-amoxiclav 250mg/62mg/5ml oral suspension sugar free 
42227 
co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (a a h 
pharmaceuticals ltd) 
51678 
co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (almus 
pharmaceuticals ltd) 
37304 
co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (ivax 
pharmaceuticals uk ltd) 
40320 
co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (ranbaxy (uk) 
ltd) 
46918 co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (sandoz ltd) 
34234 co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (teva uk ltd) 
56578 
co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (waymade 
healthcare plc) 
6687 co-amoxiclav 400mg/57mg/5ml oral suspension sugar free 
51637 
co-amoxiclav 400mg/57mg/5ml oral suspension sugar free (a a h 
pharmaceuticals ltd) 
641 co-amoxiclav 500mg/125mg tablets 
33701 co-amoxiclav 500mg/125mg tablets (a a h pharmaceuticals ltd) 
50742 co-amoxiclav 500mg/125mg tablets (actavis uk ltd) 
50341 co-amoxiclav 500mg/125mg tablets (alliance healthcare (distribution) ltd) 
53609 
co-amoxiclav 500mg/125mg tablets (apc pharmaceuticals & chemicals 
(europe) ltd) 
53996 co-amoxiclav 500mg/125mg tablets (aurobindo pharma ltd) 
30705 co-amoxiclav 500mg/125mg tablets (generics (uk) ltd) 
29356 co-amoxiclav 500mg/125mg tablets (ivax pharmaceuticals uk ltd) 
40148 co-amoxiclav 500mg/125mg tablets (kent pharmaceuticals ltd) 
49610 co-amoxiclav 500mg/125mg tablets (medreich plc) 
54591 co-amoxiclav 500mg/125mg tablets (phoenix healthcare distribution ltd) 
34493 co-amoxiclav 500mg/125mg tablets (ranbaxy (uk) ltd) 
32910 co-amoxiclav 500mg/125mg tablets (sandoz ltd) 
29353 co-amoxiclav 500mg/125mg tablets (teva uk ltd) 
44154 co-amoxiclav 500mg/125mg tablets (zentiva) 
21860 cyclodox 100mg capsule (berk pharmaceuticals ltd) 
21878 demix 100 capsules (ashbourne pharmaceuticals ltd) 
21828 demix 50 capsules (ashbourne pharmaceuticals ltd) 
2428 distaclor 125mg/5ml liquid (dista products ltd) 
25384 distaclor 125mg/5ml oral suspension (flynn pharma ltd) 
4576 distaclor 250mg capsule (dista products ltd) 
9219 distaclor 250mg/5ml liquid (dista products ltd) 
22042 distaclor 250mg/5ml oral suspension (flynn pharma ltd) 
7889 distaclor 375mg modified-release tablet (dista products ltd) 
319 distaclor 500mg capsule (dista products ltd) 
18243 distaclor 500mg capsules (flynn pharma ltd) 
3523 distaclor 500mg modified-release tablet (dista products ltd) 
20992 distaclor mr 375mg tablets (flynn pharma ltd) 
21038 doxatet 100mg tablet (manufacturer unknown) 
2884 doxycycline (as hyclate) 100mg dispersible tablets 
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970 doxycycline (as hyclate) 100mg tablets 
12987 doxycycline (as hyclate) 50mg capsules with microgranules 
23819 doxycycline (as hyclate) 50mg capsules with microgranules 
8724 doxycycline (as hyclate) 50mg/5ml oral solution 
41560 doxycycline 100mg capsule (ivax pharmaceuticals uk ltd) 
34594 doxycycline 100mg capsule (neo laboratories ltd) 
34423 doxycycline 100mg capsule (pliva pharma ltd) 
41605 doxycycline 100mg capsule (sandoz ltd) 
1046 doxycycline 100mg capsules 
24149 doxycycline 100mg capsules (a a h pharmaceuticals ltd) 
34300 doxycycline 100mg capsules (actavis uk ltd) 
49737 doxycycline 100mg capsules (alliance healthcare (distribution) ltd) 
46807 doxycycline 100mg capsules (almus pharmaceuticals ltd) 
32066 doxycycline 100mg capsules (generics (uk) ltd) 
24126 doxycycline 100mg capsules (ivax pharmaceuticals uk ltd) 
33671 doxycycline 100mg capsules (kent pharmaceuticals ltd) 
53310 doxycycline 100mg capsules (sigma pharmaceuticals plc) 
30739 doxycycline 100mg capsules (teva uk ltd) 
55519 doxycycline 100mg capsules (waymade healthcare plc) 
6396 doxycycline 100mg dispersible tablets sugar free 
26747 doxycycline 100mg tablet (neo laboratories ltd) 
40796 doxycycline 40mg modified-release capsules 
264 doxycycline 50mg capsules 
34175 doxycycline 50mg capsules (a a h pharmaceuticals ltd) 
48095 doxycycline 50mg capsules (actavis uk ltd) 
53973 doxycycline 50mg capsules (alliance healthcare (distribution) ltd) 
34765 doxycycline 50mg capsules (generics (uk) ltd) 
40391 doxycycline 50mg capsules (ivax pharmaceuticals uk ltd) 
32419 doxycycline 50mg capsules (teva uk ltd) 
23405 doxylar 100mg capsules (sandoz ltd) 
23432 doxylar 50mg capsules (sandoz ltd) 
17226 economycin 250mg capsule (ddsa pharmaceuticals ltd) 
26111 economycin 250mg tablet (ddsa pharmaceuticals ltd) 
40980 efracea 40mg modified-release capsules (galderma (uk) ltd) 
4489 erycen 250mg tablet (berk pharmaceuticals ltd) 
23017 erycen 500mg tablet (berk pharmaceuticals ltd) 
318 erymax 250mg capsule (elan pharma) 
10190 erymax 250mg gastro-resistant capsules (teva uk ltd) 
14511 erymax sprinkle 125mg capsule (elan pharma) 
9434 erymin 250mg/5ml oral suspension (elan pharma) 
48017 erythoden 125mg/5ml liquid (stevenden healthcare) 
41389 erythoden 250mg/5ml liquid (stevenden healthcare) 
39616 erythrocin 250 tablets (amdipharm plc) 
480 erythrocin 250mg tablet (abbott laboratories ltd) 
1072 erythrocin 500 500mg tablet (abbott laboratories ltd) 
39613 erythrocin 500 tablets (amdipharm plc) 
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53449 erythrocin 500 tablets (lexon (uk) ltd) 
51984 erythrocin 500 tablets (mawdsley-brooks & company ltd) 
53004 erythrocin 500 tablets (necessity supplies ltd) 
50693 erythrocin 500 tablets (sigma pharmaceuticals plc) 
50223 erythrocin 500 tablets (stephar (u.k.) ltd) 
27768 erythrolar 250mg tablet (lagap) 
50205 erythrolar 250mg tablets (ennogen pharma ltd) 
4153 erythrolar 250mg/5ml liquid (lagap) 
23954 erythrolar 500mg tablet (lagap) 
49301 erythrolar 500mg tablets (ennogen pharma ltd) 
3209 erythromid 250mg tablet (abbott laboratories ltd) 
9148 erythromid ds 500mg tablet (abbott laboratories ltd) 
1376 erythromycin 100 mg syr 
7792 erythromycin 12 mg syr 
14429 erythromycin 125mg sprinkle capsules 
34231 erythromycin 125mg/5ml liquid (berk pharmaceuticals ltd) 
33248 erythromycin 125mg/5ml liquid (ivax pharmaceuticals uk ltd) 
397 erythromycin 125mg/5ml oral suspension 
9656 erythromycin 2% gel 
1969 erythromycin 250 mg mix 
29154 erythromycin 250mg capsule (actavis uk ltd) 
103 erythromycin 250mg gastro-resistant capsules 
33686 erythromycin 250mg gastro-resistant capsules (a a h pharmaceuticals ltd) 
50580 erythromycin 250mg gastro-resistant capsules (actavis uk ltd) 
50694 
erythromycin 250mg gastro-resistant capsules (alliance healthcare 
(distribution) ltd) 
55133 erythromycin 250mg gastro-resistant capsules (kent pharmaceuticals ltd) 
49952 
erythromycin 250mg gastro-resistant capsules (phoenix healthcare 
distribution ltd) 
34512 erythromycin 250mg gastro-resistant capsules (teva uk ltd) 
55397 erythromycin 250mg gastro-resistant capsules (waymade healthcare plc) 
34837 erythromycin 250mg gastro-resistant tablet (co-pharma ltd) 
63 erythromycin 250mg gastro-resistant tablets 
24127 erythromycin 250mg gastro-resistant tablets (a a h pharmaceuticals ltd) 
33703 erythromycin 250mg gastro-resistant tablets (abbott laboratories ltd) 
29344 erythromycin 250mg gastro-resistant tablets (actavis uk ltd) 
52906 
erythromycin 250mg gastro-resistant tablets (alliance healthcare 
(distribution) ltd) 
42661 erythromycin 250mg gastro-resistant tablets (almus pharmaceuticals ltd) 
52952 erythromycin 250mg gastro-resistant tablets (co-pharma ltd) 
42296 
erythromycin 250mg gastro-resistant tablets (dr reddy's laboratories (uk) 
ltd) 
34334 erythromycin 250mg gastro-resistant tablets (generics (uk) ltd) 
24129 erythromycin 250mg gastro-resistant tablets (ivax pharmaceuticals uk ltd) 
53986 erythromycin 250mg gastro-resistant tablets (medreich plc) 
55483 erythromycin 250mg gastro-resistant tablets (milpharm ltd) 
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52428 
erythromycin 250mg gastro-resistant tablets (phoenix healthcare 
distribution ltd) 
31530 erythromycin 250mg gastro-resistant tablets (ranbaxy (uk) ltd) 
34479 erythromycin 250mg gastro-resistant tablets (sovereign medical ltd) 
33685 erythromycin 250mg gastro-resistant tablets (teva uk ltd) 
34873 erythromycin 250mg tablet (berk pharmaceuticals ltd) 
34189 erythromycin 250mg tablet (c p pharmaceuticals ltd) 
553 erythromycin 250mg.5ml oral suspension 
47242 erythromycin 250mg/5ml liquid (c p pharmaceuticals ltd) 
41584 erythromycin 250mg/5ml liquid (ivax pharmaceuticals uk ltd) 
3408 erythromycin 500 mg cap 
401 erythromycin 500mg ec gastro-resistant tablets 
34869 erythromycin 500mg tablet (c p pharmaceuticals ltd) 
41604 erythromycin 500mg tablet (hillcross pharmaceuticals ltd) 
26365 erythromycin 500mg tablet (ivax pharmaceuticals uk ltd) 
55300 erythromycin 500mg tablet (teva uk ltd) 
47676 erythromycin 500mg/5ml liquid (c p pharmaceuticals ltd) 
2326 erythromycin 500mg/5ml oral suspension 
37796 erythromycin estolate 125mg/5ml suspension 
9903 erythromycin estolate 250mg capsules 
40073 erythromycin estolate 250mg/5ml suspension 
37694 erythromycin estolate 500mg tablets 
2429 erythromycin ethyl succinate 125mg/5ml oral suspension 
13167 
erythromycin ethyl succinate 125mg/5ml oral suspension (a a h 
pharmaceuticals ltd) 
49978 
erythromycin ethyl succinate 125mg/5ml oral suspension (focus 
pharmaceuticals ltd) 
50948 
erythromycin ethyl succinate 125mg/5ml oral suspension (phoenix 
healthcare distribution ltd) 
47126 
erythromycin ethyl succinate 125mg/5ml oral suspension (pinewood 
healthcare) 
34779 erythromycin ethyl succinate 125mg/5ml oral suspension (sandoz ltd) 
4672 erythromycin ethyl succinate 125mg/5ml oral suspension sugar free 
33697 
erythromycin ethyl succinate 125mg/5ml oral suspension sugar free (a a h 
pharmaceuticals ltd) 
42659 
erythromycin ethyl succinate 125mg/5ml oral suspension sugar free 
(abbott laboratories ltd) 
55589 
erythromycin ethyl succinate 125mg/5ml oral suspension sugar free 
(alliance healthcare (distribution) ltd) 
48101 
erythromycin ethyl succinate 125mg/5ml oral suspension sugar free 
(focus pharmaceuticals ltd) 
33695 
erythromycin ethyl succinate 125mg/5ml oral suspension sugar free 
(generics (uk) ltd) 
34795 
erythromycin ethyl succinate 125mg/5ml oral suspension sugar free (ivax 
pharmaceuticals uk ltd) 
45870 
erythromycin ethyl succinate 125mg/5ml oral suspension sugar free 
(pinewood healthcare) 
33705 
erythromycin ethyl succinate 125mg/5ml oral suspension sugar free (teva 
uk ltd) 
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2376 erythromycin ethyl succinate 250mg/5ml oral suspension 
13120 
erythromycin ethyl succinate 250mg/5ml oral suspension (a a h 
pharmaceuticals ltd) 
32902 
erythromycin ethyl succinate 250mg/5ml oral suspension (kent 
pharmaceuticals ltd) 
46696 erythromycin ethyl succinate 250mg/5ml oral suspension (sandoz ltd) 
2225 erythromycin ethyl succinate 250mg/5ml oral suspension sugar free 
32898 
erythromycin ethyl succinate 250mg/5ml oral suspension sugar free (a a h 
pharmaceuticals ltd) 
46154 
erythromycin ethyl succinate 250mg/5ml oral suspension sugar free 
(abbott laboratories ltd) 
52860 
erythromycin ethyl succinate 250mg/5ml oral suspension sugar free 
(alliance healthcare (distribution) ltd) 
33694 
erythromycin ethyl succinate 250mg/5ml oral suspension sugar free 
(generics (uk) ltd) 
30177 
erythromycin ethyl succinate 250mg/5ml oral suspension sugar free (ivax 
pharmaceuticals uk ltd) 
34853 
erythromycin ethyl succinate 250mg/5ml oral suspension sugar free (teva 
uk ltd) 
733 erythromycin ethyl succinate 500mg tablets 
2226 erythromycin ethyl succinate 500mg/5ml oral suspension 
30980 
erythromycin ethyl succinate 500mg/5ml oral suspension (kent 
pharmaceuticals ltd) 
14171 erythromycin ethyl succinate 500mg/5ml oral suspension sugar free 
31514 
erythromycin ethyl succinate 500mg/5ml oral suspension sugar free 
(abbott laboratories ltd) 
25595 
erythromycin ethyl succinate 500mg/5ml oral suspension sugar free (ivax 
pharmaceuticals uk ltd) 
27203 
erythromycin ethyl succinate 500mg/5ml oral suspension sugar free (teva 
uk ltd) 
25751 
erythromycin ethylsuccinate (coated) 250mg/5ml oral suspension sugar 
free 
30234 erythromycin ethylsuccinate 125mg sachets 
12330 erythromycin ethylsuccinate 1g sachets 
13635 erythromycin ethylsuccinate 250mg sachets 
15713 erythromycin ethylsuccinate 500mg sachets 
1037 erythromycin ethylsuccinate sf 125 mg/5ml sus 
3907 erythromycin sf sach 250 mg 
438 erythromycin stearate 250mg tablets 
2350 erythromycin stearate 500mg tablets 
3572 erythroped 250mg powder (abbott laboratories ltd) 
16747 erythroped 250mg sachets (abbott laboratories ltd) 
105 erythroped 250mg/5ml liquid (abbott laboratories ltd) 
532 erythroped 250mg/5ml oral suspension (abbott laboratories ltd) 
4596 erythroped a 1g sachets (abbott laboratories ltd) 
327 erythroped a 500mg tablet (abbott laboratories ltd) 
39632 erythroped a 500mg tablets (amdipharm plc) 
54098 erythroped a 500mg tablets (lexon (uk) ltd) 
56203 erythroped a 500mg tablets (sigma pharmaceuticals plc) 
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4372 erythroped forte 500mg sachets (abbott laboratories ltd) 
993 erythroped forte 500mg/5ml liquid (abbott laboratories ltd) 
4610 erythroped forte 500mg/5ml oral suspension (abbott laboratories ltd) 
39642 erythroped forte sf 500mg/5ml oral suspension (amdipharm plc) 
3042 erythroped pi 125mg sachets (abbott laboratories ltd) 
997 erythroped pi 125mg/5ml liquid (abbott laboratories ltd) 
825 erythroped pi 125mg/5ml oral suspension (abbott laboratories ltd) 
39623 erythroped pi sf 125mg/5ml oral suspension (amdipharm plc) 
39669 erythroped sf 250mg/5ml oral suspension (amdipharm plc) 
18930 flemoxin 375mg soluble tablet (paines & byrne ltd) 
24396 flemoxin 750mg soluble tablet (paines & byrne ltd) 
14386 galenamox 125mg/5ml oral suspension (galen ltd) 
14371 galenamox 250mg capsules (galen ltd) 
14407 galenamox 250mg/5ml oral suspension (galen ltd) 
14396 galenamox 500mg capsules (galen ltd) 
18682 ilosone 125mg/5ml liquid (dista products ltd) 
17207 ilosone 250mg capsule (dista products ltd) 
19330 ilosone 250mg/5ml liquid (dista products ltd) 
18643 ilosone 500mg tablet (dista products ltd) 
23244 ilotycin 250mg tablet (eli lilly and company ltd) 
12541 imperacin 250mg tablet (astrazeneca uk ltd) 
7485 keflex 125mg/5ml liquid (eli lilly and company ltd) 
27072 keflex 125mg/5ml oral suspension (flynn pharma ltd) 
7430 keflex 250mg capsule (eli lilly and company ltd) 
11989 keflex 250mg capsules (flynn pharma ltd) 
9157 keflex 250mg tablet (eli lilly and company ltd) 
830 keflex 250mg tablets (flynn pharma ltd) 
10455 keflex 250mg/5ml liquid (eli lilly and company ltd) 
28722 keflex 250mg/5ml oral suspension (flynn pharma ltd) 
12276 keflex 500mg capsule (eli lilly and company ltd) 
24618 keflex 500mg capsules (flynn pharma ltd) 
9603 keflex 500mg tablet (eli lilly and company ltd) 
31110 keflex 500mg tablets (flynn pharma ltd) 
26233 keftid 125mg/5ml oral suspension (co-pharma ltd) 
26207 keftid 250mg capsules (co-pharma ltd) 
41853 keftid 250mg/5ml oral suspension (co-pharma ltd) 
26236 keftid 500mg capsules (co-pharma ltd) 
33304 kerymax 250mg gastro-resistant capsules (kent pharmaceuticals ltd) 
26989 kiflone 125mg/5ml oral solution (berk pharmaceuticals ltd) 
21835 kiflone 250mg capsule (berk pharmaceuticals ltd) 
21979 kiflone 250mg/5ml oral solution (berk pharmaceuticals ltd) 
27017 kiflone 500mg capsule (berk pharmaceuticals ltd) 
26992 kiflone 500mg tablet (berk pharmaceuticals ltd) 
3736 klaricid 125mg/5ml oral suspension (abbott laboratories ltd) 
2719 klaricid 250mg tablets (abbott laboratories ltd) 
52411 klaricid 250mg tablets (necessity supplies ltd) 
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9583 klaricid 250mg/5ml oral suspension (abbott laboratories ltd) 
6623 klaricid 500 tablets (abbott laboratories ltd) 
14816 klaricid adult 250mg granules sachets (abbott laboratories ltd) 
38997 klaricid paediatric 125mg/5ml oral suspension (abbott laboratories ltd) 
39010 klaricid paediatric 250mg/5ml oral suspension (abbott laboratories ltd) 
6121 klaricid xl 500mg tablets (abbott laboratories ltd) 
15290 
lansoprazole with amoxicillin and clarithromycin 30mg + 500mg + 500mg 
triple pack 
7439 ledermycin 150mg capsule (wyeth pharmaceuticals) 
16613 ledermycin 150mg capsules (mercury pharma group ltd) 
22076 ledermycin 300mg tablet (wyeth pharmaceuticals) 
6295 levofloxacin 250mg tablets 
55708 levofloxacin 250mg tablets (actavis uk ltd) 
56012 levofloxacin 250mg tablets (dr reddy's laboratories (uk) ltd) 
5238 levofloxacin 500mg tablets 
53673 levofloxacin 500mg/100ml infusion bags 
19001 megaclor 170mg capsule (pharmax ltd) 
6306 moxifloxacin 400mg tablets 
17222 mysteclin oral solution (bristol-myers squibb pharmaceuticals ltd) 
15071 nordox 100mg capsule (sankyo pharma uk ltd) 
8393 novobiocin/tetracycline 125 mg cap 
25752 nystatin with tetracycline hc capsule 
9361 oxymycin 250mg tablets (dr reddy's laboratories (uk) ltd) 
2458 oxytetracycline 100 mg tab 
9034 oxytetracycline 125mg/5ml syrup 
8285 oxytetracycline 250 mg syr 
132 oxytetracycline 250mg capsules 
34888 oxytetracycline 250mg tablet (c p pharmaceuticals ltd) 
77 oxytetracycline 250mg tablets 
34044 oxytetracycline 250mg tablets (a a h pharmaceuticals ltd) 
34040 oxytetracycline 250mg tablets (actavis uk ltd) 
34336 oxytetracycline 250mg tablets (ivax pharmaceuticals uk ltd) 
40483 oxytetracycline 250mg tablets (sandoz ltd) 
34141 oxytetracycline 250mg tablets (teva uk ltd) 
28291 oxytetracycline 3%/hydrocortisone 1% 
10542 oxytetracycline hcl/hydrocortisone .5 % ear 
17703 oxytetramix 250 tablets (ashbourne pharmaceuticals ltd) 
30520 primacine 125mg/5ml liquid (pinewood healthcare) 
39118 primacine 250mg/5ml liquid (pinewood healthcare) 
27504 primacine 500mg/5ml liquid (pinewood healthcare) 
27681 ranclav 125mg/31mg/5ml sf oral suspension (ranbaxy (uk) ltd) 
25370 ranclav 375mg tablets (ranbaxy (uk) ltd) 
22017 respillin 125mg/5ml oral solution (opd pharm) 
22015 respillin 125mg/5ml oral solution (opd pharm) 
24203 respillin 250mg capsule (opd pharm) 
24200 respillin 500mg capsule (opd pharm) 
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31428 retcin 250mg tablet (ddsa pharmaceuticals ltd) 
21808 
rommix 125mg/5ml oral suspension sugar free (ashbourne 
pharmaceuticals ltd) 
11611 rommix 250 ec tablets (ashbourne pharmaceuticals ltd) 
25278 rommix 500mg tablet (ashbourne pharmaceuticals ltd) 
24097 rondomycin 150mg capsule (pfizer ltd) 
18109 sebomin mr 100mg capsules (actavis uk ltd) 
37440 sebren mr 100mg capsules (teva uk ltd) 
19693 sustamycin 250mg capsule (boehringer mannheim uk ltd) 
17693 tavanic 250mg tablets (sanofi) 
6206 tavanic 500mg tablets (sanofi) 
27254 tenkorex 500mg capsule (opd pharm) 
7455 terramycin 250mg capsule (pfizer ltd) 
17467 terramycin 250mg tablets (pfizer ltd) 
9014 tetrabid-organon 250mg capsule (organon laboratories ltd) 
8219 tetrachel 250mg capsule (berk pharmaceuticals ltd) 
3816 tetrachel 250mg tablet (berk pharmaceuticals ltd) 
25017 tetracycline 
56044 tetracycline 125mg/5ml oral solution 
8284 tetracycline 125mg/5ml syrup 
21804 tetracycline 125mg/5ml syrup 
41547 tetracycline 250mg capsule (berk pharmaceuticals ltd) 
121 tetracycline 250mg capsules 
34011 tetracycline 250mg capsules 
56181 tetracycline 250mg tablet (celltech pharma europe ltd) 
45271 tetracycline 250mg tablet (numark management ltd) 
386 tetracycline 250mg tablets 
43538 tetracycline 250mg tablets (a a h pharmaceuticals ltd) 
41636 tetracycline 250mg tablets (actavis uk ltd) 
54214 tetracycline 250mg tablets (alliance healthcare (distribution) ltd) 
53117 tetracycline 250mg tablets (almus pharmaceuticals ltd) 
48100 tetracycline 250mg tablets (teva uk ltd) 
2922 tetracycline 250mg with nystatin 250000units tablets 
2636 tetracycline 500 mg cap 
3528 tetracycline 500 mg tab 
21654 tetracycline ear/eye 
21629 tetracycline eye 
31425 tetracycline hcl/pancreatic concentrate cap 
28736 tetracycline hydrochloride/amphotericin syr 
15355 tetracycline with chlortetracycline & demeclocycline tablets 
25071 tetracycline with nystatin capsules 
4951 tetralysal 300 capsules (galderma (uk) ltd) 
20054 tetralysal 408mg capsule (pharmacia ltd) 
25280 tiloryth 250mg gastro-resistant capsules (tillomed laboratories ltd) 
268 vibramycin 100mg capsules (pfizer ltd) 
3152 vibramycin 100mg dispersible tablet (pfizer ltd) 
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10454 vibramycin 50mg/5ml oral solution (pfizer ltd) 
9267 vibramycin acne pack 50mg capsules (pfizer ltd) 
56198 vibramycin-d 100mg dispersible tablets (mawdsley-brooks & company ltd) 
14904 vibramycin-d 100mg dispersible tablets (pfizer ltd) 
52967 vibramycin-d 100mg dispersible tablets (stephar (u.k.) ltd) 
53135 vibramycin-d 100mg dispersible tablets (waymade healthcare plc) 
26392 vibrox 100mg capsules (kent pharmaceuticals ltd) 
21829 zoxycil 250mg capsule (trinity pharmaceuticals ltd) 
26262 zoxycil 500mg capsule (trinity pharmaceuticals ltd) 
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Codes used to identify annual reviews and rescue pack prescriptions 
 
Annual review and rescue pack prescription codes 
Medical code Read term 
9520 Chronic obstructive pulmonary disease monitoring 
10043 Asthma annual review 
11287 Chronic obstructive pulmonary disease annual review 
25997 Deferred antibiotic therapy 
28743 Number of COPD exacerbations in past year 
100459 Advance supply of steroid medication 
101042 Issue of chronic obstructive pulmonary disease rescue pack 
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Appendix E– Additional material for Chapter 8 – Research paper VI 
 
Table S1. PPV and sensitivity of CPRD strategies to identify hospitalisations for AECOPD 
using different HES definitions as reference standard using day of admission in HES only 
HES AECOPD 
definition 
CPRD strategy PPV (95% CI) Sensitivity (95% 
CI) 
AECOPD 
hospitalisation or 
LRTI code in any 
position or COPD in 
first position in any 
FCE 
AECOPD identified 
by algorithm  
0.7% (0.7-0.7%) 7.2% (6.9-7.6%) 
Non-specific 
hospitalisation code 
10.3% (10.1-10.6%) 27.1% (26.5-27.7%) 
Either specific 
AECOPD code in 
any position or 
COPD code in 1st 
position 
AECOPD identified 
by algorithm  
0.6% (0.6-0.6%) 7.2% (6.9-7.6%) 
Non-specific 
hospitalisation code 
9.1% (8.9-9.3%) 27.6% (27.0-28.2%) 
Either specific 
AECOPD code in 
first position in any 
finished consultant 
episode 
AECOPD identified 
by algorithm  
0.6% (0.6-0.6%) 7.4% (7.1-7.9%) 
Non-specific 
hospitalisation code 
8.7% (8.5-8.9%) 28.1% (27.4-28.7%) 
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Table S2. PPV and sensitivity of CPRD strategies to identify hospitalisations for AECOPD 
using different HES definitions as reference standard using day of admission in HES only 
HES AECOPD 
definition 
CPRD strategy PPV (95% CI) Sensitivity (95% 
CI) 
AECOPD 
hospitalisation or 
LRTI code in any 
position or COPD in 
first position in any 
FCE 
AECOPD 
hospitalisation code 
47.6% (44.3-50.8%) 1.9% (1.7-2.0%) 
AECOPD identified 
using validated 
algorithm & 
hospitalisation code 
41.9% (39.8-44.0%) 3.7% (3.5-4.0%) 
Either specific 
AECOPD code in 
any position or 
COPD code in 1st 
position 
AECOPD 
hospitalisation code 
43.6% (40.5-46.9%) 2.1% (1.9-2.3%) 
AECOPD identified 
using validated 
algorithm & 
hospitalisation code 
36.8% (34.7-38.9%) 3.7% (3.5-4.0%) 
Either specific 
AECOPD code in 
first position in any 
finished consultant 
episode 
AECOPD 
hospitalisation code 
46.5% (44.9-48.2%) 2.1% (1.9-2.3%) 
AECOPD identified 
using validated 
algorithm & 
hospitalisation code 
35.3% (33.2-37.4%) 3.8% (3.5-4.1%) 
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Table S3. PPV and sensitivity of record of AECOPD or non-specific hospitalisation code to 
identify hospitalisations for AECOPD using different HES definitions as reference standard 
allowing 30 days after HES record of hospitalisation for AECOPD 
HES AECOPD 
definition 
CPRD strategy PPV (95% CI) Sensitivity (95% 
CI) 
AECOPD 
hospitalisation or 
LRTI code in any 
position or COPD in 
first position in any 
FCE 
AECOPD identified 
by algorithm  
1.8% (1.7-1.8%) 34.2% (33.7-34.6%) 
Non-specific 
hospitalisation code 
14.5% (14.3-14.6%) 53.5% (53.0-54.0%) 
Either specific 
AECOPD code in 
any position or 
COPD code in 1st 
position 
AECOPD identified 
by algorithm  
1.5% (1.5-1.6%) 34.6% (34.1-35.1%) 
Non-specific 
hospitalisation code 
12.6% (12.5-12.8%) 54.1% (53.6-54.6%) 
Either specific 
AECOPD code in 
first position in any 
finished consultant 
episode 
AECOPD identified 
by algorithm  
1.5% (1.4-1.5%) 35.1% (34.6-35.6%) 
Non-specific 
hospitalisation code 
12.0% (11.9-12.2%) 54.8% (54.3-55.3%) 
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Table S4. PPV and sensitivity of CPRD strategies to identify hospitalisations for AECOPD 
using different HES definitions as reference standard allowing 60 days after HES record of 
hospitalisation for AECOPD 
HES AECOPD 
definition 
CPRD strategy PPV (95% CI) Sensitivity (95% 
CI) 
AECOPD 
hospitalisation or 
LRTI code in any 
position or COPD in 
first position in any 
FCE 
AECOPD 
hospitalisation code 
50.7% (49.1-52.3%) 4.4% (4.3-4.6%) 
AECOPD identified 
using validated 
algorithm & 
hospitalisation code 
46.1% (44.3-47.8%) 6.1% (5.8-6.4%) 
Either specific 
AECOPD code in 
any position or 
COPD code in 1st 
position 
AECOPD 
hospitalisation code 
49.5% (48.0-51.1%) 5.0% (4.8-5.3%) 
AECOPD identified 
using validated 
algorithm & 
hospitalisation code 
41.2% (39.5-42.9%) 6.2% (5.9-6.6%) 
Either specific 
AECOPD code in 
first position in any 
finished consultant 
episode 
AECOPD 
hospitalisation code 
46.6% (45.0-48.2%) 5.0% (4.8-5.3%) 
AECOPD identified 
using validated 
algorithm & 
hospitalisation code 
39.5% (37.8-41.2%) 6.4% (6.1-6.8%) 
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Table S5. PPV and sensitivity of record of AECOPD or non-specific hospitalisation code to 
identify hospitalisations for AECOPD using different HES definitions as reference standard 
allowing 60 days after HES record of hospitalisation for AECOPD 
HES AECOPD 
definition 
CPRD strategy PPV (95% CI) Sensitivity (95% 
CI) 
AECOPD 
hospitalisation or 
LRTI code in any 
position or COPD in 
first position in any 
FCE 
AECOPD identified 
by algorithm  
2.3% (2.3-2.3%) 46.3% (45.8-46.7%) 
Non-specific 
hospitalisation code 
14.5% (14.4-14.7%) 55.9% (55.4-56.4%) 
Either specific 
AECOPD code in 
any position or 
COPD code in 1st 
position 
AECOPD identified 
by algorithm  
2.0% (2.0-2.1%) 46.8% (46.3-47.3%) 
Non-specific 
hospitalisation code 
12.7% (12.5-12.9%) 56.5% (56.0-57.0%) 
Either specific 
AECOPD code in 
first position in any 
finished consultant 
episode 
AECOPD identified 
by algorithm  
1.9% (1.9-1.9%) 47.3% (46.8-47.8%) 
Non-specific 
hospitalisation code 
12.1% (11.9-12.2%) 57.2% (56.6-57.7%) 
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Table S6. Generic hospitalisation Read codes.  
Read term medcode 
Admit to respiratory ITU 67786 
In-patient stay 9 days 62577 
In-patient stay 7 days 62578 
Listed for admission to hosp. 9744 
Discharge from adult intensive care service 53495 
In-patient stay NOS 21153 
Listed for hosp admission NOS 25524 
In-patient stay 10 days 62574 
In-patient stay > 12 hours 62572 
Died in hospital 1868 
Discharge by ITU specialist 37697 
In-patient stay 12 days 62579 
Intensive care monitoring 45334 
Emergency hospital admission 314 
Hospital admission note 43828 
Under care of casualty doctor 59130 
Under care of ITU specialist 42924 
Duration of in-patient stay 56256 
Discharge to tertiary referring hospital 43900 
In-patient stay 8 days 62570 
Night hospital care 46759 
In-patient stay 11 days 36131 
Patient in hospital 61893 
Inpatient care 35252 
Discharged from hospital 480 
Admit geriatric emergency 30002 
Admit to intensive care unit 11413 
Discharge by adult ITU specialist 46901 
Seen in hospital ward 6527 
Self-referral to hospital 21264 
Death in hospital 9059 
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Discharge from hospital 10866 
Under care of adult ITU specialist 43881 
In-patient stay 1 day 43149 
Admit to intensive c.u. NOS 22374 
Discharged from inpatient care 4774 
Refer to hospital 3975 
Under care of intensive care specialist 18522 
Hospital inpatient 10533 
In-patient stay 6 days 62575 
Hospital inpatient report 63999 
Patient died in community hospital 30357 
Seen by adult ITU specialist 53501 
Hospital death disch. NOS 28927 
Other hospital admission NOS 1047 
In-patient stay 14 days 60689 
Discharge by adult intensive care specialist 68130 
Discharge by intensive care specialist 47108 
Self-referral to hospital NOS 38567 
Seen by adult intensive care specialist 40768 
Discharge from intensive care service 42177 
Discharge from casualty service 48490 
Referral to ITU specialist 69617 
In-patient stay 4 days 62576 
Admit medical emergency unsp. 18512 
Hospital death discharge notif 28879 
In-patient stay 13 days 62569 
Admission to hospital 9821 
Transferred from hospital 8091 
Admit hospital emergency NOS 6885 
Seen by ITU specialist 53496 
In-patient stay 3 days 62573 
In-patient stay 5 days 57174 
Discharge to hospital 41976 
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Discharge from adult ITU service 47585 
In-patient stay 2 days 62571 
Under care of adult intensive care 
specialist 12839 
Death notif. from hospital 28801 
Patient died in hospital 6897 
Hospital patient 23536 
Inpatient care 51466 
Admit to I.T.U. 8265 
Referral to intensive care specialist 42668 
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Appendix F– Additional material for Chapter 9 – Research paper VII 
 
Table S1: Incidence rate ratios of first myocardial infarction in risk periods after an acute 
exacerbation of COPD (AECOPD) relative to stable periods sensitivity analysisexcluding 
periods before first AECOPD. 
 
 
Table S2: Incidence rate ratios of first myocardial infarction in risk periods after an acute 
exacerbation of COPD (AECOPD) relative to stable periods sensitivity analysis censoring 
within six months of MI 
 
 
 
 
Table S3: Incidence rate ratios of first myocardial infarction in risk periods after an acute 
exacerbation of COPD (AECOPD) relative to stable periods sensitivity analysis censoring 
within 12 months of MI 
 
 
Risk period N  outcome events (MI) IRR (95% CI) 
Total risk period (91 
days) 
898 1.73 (1.57-1.91) 
1-3 days 92  3.07 (2.47-3.82) 
4-7 days 99  2.59 (2.10-3.20) 
8-14 days 161  2.53 (2.13-3.01) 
15-28 days 217  2.03 (1.74-2.37) 
29-91 days 329  1.23 (1.08-1.39) 
Risk period N  outcome events (MI) IRR (95% CI) 
Total risk period (91 
days) 
695 1.53 (1.38-1.68) 
1-3 days 73  2.68 (2.11-3.41) 
4-7 days 66  1.91 (1.48-2.45) 
8-14 days 121  2.11 (1.74-2.56) 
15-28 days 172  1.80 (1.52-2.12) 
29-91 days 263  1.12 (0.97-1.29) 
Risk period N  outcome events (MI) IRR (95% CI) 
Total risk period (91 
days) 
586 1.49 (1.34-1.67) 
1-3 days 59  2.48 (1.90-3.25) 
4-7 days 56  1.85 (1.41-2.44) 
8-14 days 104  2.08 (1.69-2.56) 
15-28 days 138  1.67 (1.39-2.01) 
29-91 days 229  1.14 (0.98-1.32) 
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Table S4. Read codes for MI. 
Read term medcode 
acute myocardial infarction 241 
heart attack 1204 
mi - acute myocardial infarction 1677 
inferior myocardial infarction nos 1678 
other specified anterior myocardial infarction 5387 
acute non-st segment elevation myocardial 
infarction  
10562 
acute st segment elevation myocardial 
infarction 
12229 
acute myocardial infarction nos 14658 
anterior myocardial infarction nos 14897 
lateral myocardial infarction nos 14898 
posterior myocardial infarction nos 23892 
acute transmural myocardial infarction of 
unspecif site 
29758 
acute posterolateral myocardial infarction 32854 
other acute myocardial infarction 34803 
other acute myocardial infarction nos 46017 
true posterior myocardial infarction 63467 
[x]acute transmural myocardial infarction of 
unspecif site 
96838 
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Table S5. Angina Read codes. 
Read term medcode 
angina on effort 1414 
angina pectoris 1430 
unstable angina 1431 
crescendo angina 4656 
h/o: angina pectoris 6336 
unstable angina 7347 
post infarct angina 9555 
variant angina pectoris 11048 
acute coronary syndrome 11983 
stable angina 12804 
prinzmetal's angina 12986 
angina control 13185 
angina control - improving 14782 
angina control nos 15349 
angina control - poor 15373 
angina at rest 17307 
worsening angina 18118 
nocturnal angina 18125 
angina control - good 19542 
angina at rest 19655 
angina decubitus 20095 
angina pectoris nos 25842 
new onset angina 26863 
angina pectoris nos 28554 
angina control - worsening 29300 
angina decubitus nos 29902 
ischaemic chest pain 32450 
refractory angina 34328 
[x]other forms of angina pectoris 39546 
antianginal therapy 45960 
h/o: angina in last year 57062 
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Table S6. Read codes for stroke. 
Read term medcode 
intracerebral haemorrhage nos 3535 
intracerebral haemorrhage 5051 
cva - cerebrovascular accid due to 
intracerebral haemorrhage 
6960 
pontine haemorrhage 7912 
cerebellar haemorrhage 13564 
stroke due to intracerebral haemorrhage 18604 
right sided intracerebral haemorrhage, 
unspecified 
19201 
left sided intracerebral haemorrhage, 
unspecified 
28314 
external capsule haemorrhage 30045 
intracerebral haemorrhage, intraventricular 30202 
intracerebral haemorrhage in hemisphere, 
unspecified 
31060 
cortical haemorrhage 31595 
internal capsule haemorrhage 40338 
basal nucleus haemorrhage 46316 
[x]other intracerebral haemorrhage 53810 
intracerebral haemorrhage, multiple localized 57315 
bulbar haemorrhage 62342 
[x]intracerebral haemorrhage in hemisphere, 
unspecified 
96630 
lobar cerebral haemorrhage 107440 
infarction - cerebral 569 
cerebral infarction nos 3149 
cva - cerebral artery occlusion 5363 
cerebellar infarction 5602 
stroke due to cerebral arterial occlusion 6155 
left sided cerebral infarction 9985 
right sided cerebral infarction 10504 
cerebral embolism 15019 
brainstem infarction nos 15252 
cerebral thrombosis 16517 
cerebral infarct due to thrombosis of 
precerebral arteries 
23671 
cerebral infarction due to embolism of 
precerebral arteries 
24446 
brainstem infarction 25615 
infarction of basal ganglia 26424 
cerebral infarction due to embolism of 
cerebral arteries 
27975 
cerebrl infarctn due/unspcf occlusn or 
sten/cerebrl artrs 
33543 
cerebral embolus 34758 
cerebral infarction due to thrombosis of 
cerebral arteries 
36717 
cereb infarct due unsp occlus/stenos 
precerebr arteries 
40758 
[x]other cerebral infarction 53745 
[x]occlusion and stenosis of other precerebral 
arteries 
90572 
[x]cerebrl infarctn due/unspcf occlusn or 
sten/cerebrl artrs 
91627 
362 
 
[x]occlusion and stenosis of other cerebral 
arteries 
92036 
[x]cereb infarct due unsp occlus/stenos 
precerebr arteries 
94482 
subarachnoid haemorrhage 1786 
subarachnoid haemorrhage from posterior 
communicating artery 
9696 
subarachnoid haemorrh from intracranial 
artery, unspecif 
17326 
subarachnoid haemorrhage from middle 
cerebral artery 
19412 
subarachnoid haemorrhage nos 23580 
subarachnoid haemorrhage following injury 28807 
ruptured berry aneurysm 29939 
subarachnoid haemorrhage from basilar 
artery 
41910 
subarachnoid haemorrhage from anterior 
communicating artery 
42331 
subarachnoid haemorrhage from carotid 
siphon and bifurcation 
56007 
subarachnoid haemorrhage from vertebral 
artery 
60692 
[x]subarachnoid haemorrh from intracranial 
artery, unspecif 
108630 
[x]subarachnoid haemorrhage from other 
intracranial arteries 
108668 
cva unspecified 1298 
stroke and cerebrovascular accident 
unspecified 
1469 
cva - cerebrovascular accident unspecified 6116 
stroke unspecified 6253 
left sided cva 7780 
brain stem stroke syndrome 8443 
right sided cva 12833 
cerebellar stroke syndrome 17322 
middle cerebral artery syndrome 18689 
posterior cerebral artery syndrome 19260 
anterior cerebral artery syndrome 19280 
pure motor lacunar syndrome 33499 
pure sensory lacunar syndrome 51767 
subdural haemorrhage - nontraumatic 4273 
subdural haematoma - nontraumatic 17734 
subdural haemorrhage nos 18912 
intracranial haemorrhage nos 20284 
haemorrhagic stroke monitoring 28914 
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Figure S7. Heart failure Read codes.  
Read term medcode 
h/o: heart failure 15058 
h/o: heart failure in last year 46912 
heart failure confirmed 9913 
heart failure self-management plan agreed 106198 
congestive heart failure monitoring 12366 
heart failure annual review 30779 
heart failure 6 month review 83502 
education about deteriorating heart failure 105002 
heart failure care plan discussed with patient 32945 
has heart failure management plan 103732 
heart failure clinical pathway 106008 
preferred place of care for next exacerbation 
heart failure 
105542 
admit heart failure emergency 32898 
heart failure follow-up 17851 
referral to heart failure exercise programme 70619 
seen in heart failure clinic 12627 
seen by community heart failure nurse 19002 
referred by heart failure nurse specialist 69062 
malignant hypertensive heart disease with ccf 72668 
benign hypertensive heart disease with ccf 52127 
hypertensive heart disease nos with ccf 62718 
hypertensive heart&renal dis wth (congestive) 
heart failure 
21837 
heart failure 2062 
cardiac failure 1223 
congestive heart failure 398 
congestive cardiac failure 2906 
right heart failure 10079 
right ventricular failure 10154 
biventricular failure 9524 
acute congestive heart failure 23707 
chronic congestive heart failure 32671 
decompensated cardiac failure 27884 
compensated cardiac failure 11424 
congestive heart failure due to valvular 
disease 
94870 
left ventricular failure 884 
impaired left ventricular function 5942 
acute left ventricular failure 5255 
acute heart failure 27964 
heart failure with normal ejection fraction 101138 
hfnef - heart failure with normal ejection 
fraction 
101137 
heart failure with preserved ejection fraction 106897 
right ventricular failure 104275 
heart failure nos 4024 
cardiac failure nos 17278 
post cardiac operation heart failure nos 96799 
heart failure as a complication of care 66306 
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Table S8. Aspirin product codes 
Product name prodcode 
anhydrous citric acid /aspirin /calcium 8 mg 
tab 24427 
asasantin retard capsules (boehringer 
ingelheim ltd) 4679 
aspav dispersible tablets (actavis uk ltd) 685 
aspirin 23495 
aspirin & caffeine disp 300 mg tab 12605 
aspirin & codeine 500 mg tab 13598 
aspirin & codeine 75 mg tab 22450 
aspirin & codeine paed 75 mg tab 19724 
aspirin & dover's pwdr tab 30432 
aspirin & papaverutum 10 mg tab 4557 
aspirin & paracetamol tab 15352 
aspirin / caffeine cit./ codeine phos./ 200 mg 
tab 31498 
aspirin /caffeine /quinine sulphate 325 mg 
tab 40191 
aspirin /ethoheptazine citrate /meprobam 
250 mg tab 23250 
aspirin 100 mg sup 15517 
aspirin 100mg effervescent tablets 36543 
aspirin 100mg modified-release tablets 9301 
aspirin 120 mg sup 30695 
aspirin 125 mg sup 26792 
aspirin 150 mg tab 2924 
aspirin 150mg / isosorbide mononitrate 60mg 
modified-release tablets 21382 
aspirin 162.5mg modified-release capsules 39738 
aspirin 175 mg sup 26099 
aspirin 200 mg sup 26424 
aspirin 250 mg sup 24857 
aspirin 25mg with dipyridamole 200mg 
modified-release capsules 10031 
aspirin 300mg/lysine 245mg 300 mg tab 28238 
aspirin 324mg modified-release tablets 22138 
aspirin 325 mg cap 7462 
aspirin 325 mg tab 8843 
aspirin 325mg / caffeine 22mg tablets 24622 
aspirin 37.5 mg tab 7486 
aspirin 40 mg cap 111 
aspirin 40 mg tab 7417 
aspirin 50 mg cap 4523 
aspirin 50 mg sup 20206 
aspirin 500 mg sup 23491 
aspirin 500mg / papaveretum 7.71mg 
dispersible tablets sugar free 6226 
aspirin 60 mg tab 383 
aspirin 600mg / caffeine 50mg oral powder 
sachets sugar free 12964 
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aspirin 600mg/glycine 300mg 600 mg tab 33075 
aspirin 65 mg sup 42061 
aspirin 70 mg tab 216 
aspirin 75 mg sup 1486 
aspirin 75mg / isosorbide mononitrate 60mg 
modified-release tablets 21380 
aspirin 75mg dispersible tablet (a a h 
pharmaceuticals ltd) 31211 
aspirin 75mg dispersible tablet (nucare plc) 34942 
aspirin 75mg dispersible tablet (sovereign 
medical ltd) 33320 
aspirin 75mg dispersible tablets 3 
aspirin 75mg dispersible tablets (a a h 
pharmaceuticals ltd) 33656 
aspirin 75mg dispersible tablets (actavis uk 
ltd) 32036 
aspirin 75mg dispersible tablets (alliance 
healthcare (distribution) ltd) 49060 
aspirin 75mg dispersible tablets (bristol 
laboratories ltd) 52618 
aspirin 75mg dispersible tablets (ivax 
pharmaceuticals uk ltd) 31953 
aspirin 75mg dispersible tablets (kent 
pharmaceuticals ltd) 33676 
aspirin 75mg dispersible tablets (sigma 
pharmaceuticals plc) 49685 
aspirin 75mg dispersible tablets (teva uk ltd) 31954 
aspirin 75mg dispersible tablets (the boots 
company plc) 50926 
aspirin 75mg dispersible tablets (thornton & 
ross ltd) 34434 
aspirin 75mg dispersible tablets (wockhardt 
uk ltd) 47937 
aspirin 75mg gastro-resistant tablet (galen 
ltd) 34796 
aspirin 75mg gastro-resistant tablets 34 
aspirin 75mg gastro-resistant tablets (a a h 
pharmaceuticals ltd) 47992 
aspirin 75mg gastro-resistant tablets (actavis 
uk ltd) 34797 
aspirin 75mg gastro-resistant tablets (almus 
pharmaceuticals ltd) 43709 
aspirin 75mg gastro-resistant tablets (c p 
pharmaceuticals ltd) 34611 
aspirin 75mg gastro-resistant tablets 
(generics (uk) ltd) 32992 
aspirin 75mg gastro-resistant tablets (ivax 
pharmaceuticals uk ltd) 34485 
aspirin 75mg gastro-resistant tablets (kent 
pharmaceuticals ltd) 31956 
aspirin 75mg gastro-resistant tablets (sandoz 
ltd) 31938 
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aspirin 75mg gastro-resistant tablets (sterwin 
medicines) 33293 
aspirin 75mg gastro-resistant tablets (teva uk 
ltd) 41512 
aspirin 75mg gastro-resistant tablets 
(wockhardt uk ltd) 53178 
aspirin 75mg gastro-resistant tablets (zanza 
laboratories ltd) 51561 
aspirin 75mg soluble tablet (c p 
pharmaceuticals ltd) 40381 
aspirin 75mg soluble tablet (celltech pharma 
europe ltd) 45643 
aspirin 75mg soluble tablet (co-operative) 34385 
aspirin 75mg tablet (hillcross pharmaceuticals 
ltd) 48021 
aspirin 75mg tablets 16 
aspirin 75mg tablets (a a h pharmaceuticals 
ltd) 50949 
aspirin 75mg tablets (phoenix healthcare 
distribution ltd) 48974 
aspirin disp 150 mg tab 9027 
aspirin disp 200 mg tab 22107 
aspirin disp 37.5 mg tab 8734 
aspirin disp 500 mg tab 15044 
aspirin disp 600 mg tab 22824 
aspirin dispersible 19674 
aspirin m/f 324 mg tab 28707 
aspirin paed 100 mg sup 26582 
aspirin paed 150 mg sup 22253 
aspirin paed 81 mg tab 8424 
aspirin paed mix 22864 
aspirin s/r 500 mg tab 22863 
aspirin sachets 30 mg 11941 
aspirin soluble 19813 
aspirin soluble 100 mg tab 12102 
aspirin soluble 150 mg tab 2754 
aspirin soluble 200 mg tab 4271 
aspirin soluble 40 mg cap 7944 
aspirin soluble 400 mg tab 27467 
aspirin soluble 50 mg tab 15397 
aspirin soluble 500 mg tab 8920 
aspirin soluble 600 mg tab 15447 
aspirin sr 100 mg tab 7915 
aspirin sr 300 mg tab 7665 
aspirin/caffeine/codeine phosphate 300 mg 
tab 28606 
aspirin/caffeine/dextropropoxyphene naps 
pul 25959 
aspirin/codeine phosphate/paracetamol 250 
mg tab 7770 
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aspirin/codeine phosphate/paracetamol 300 
mg tab 24498 
aspirin/paracetamol tab 7769 
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Table S9. Beta-blocker product codes.  
Product name prodcode 
atenolol 50mg tablets 5 
atenolol 100mg tablets 24 
atenolol 25mg tablets 26 
propranolol 5mg/5ml oral solution 220 
propranolol 10mg tablets 297 
bisoprolol 5mg tablets 472 
atenolol 50mg with chlortalidone 12.5mg 
tablets 581 
bisoprolol 2.5mg tablets 594 
bisoprolol 1.25mg tablets 599 
propranolol 40mg tablets 707 
metoprolol 50mg tablets 739 
nebivolol 5mg tablets 751 
metoprolol 100mg tablets 753 
propranolol 80mg modified-release 
capsules 769 
sotalol 40mg tablets 786 
carvedilol 3.125mg tablets 817 
bisoprolol 1.5mg/5ml oral suspension 822 
propranolol 80mg tablets 940 
half inderal la 80mg capsules (astrazeneca 
uk ltd) 1006 
inderal 80mg tablets (astrazeneca uk ltd) 1048 
inderal 40mg tablets (astrazeneca uk ltd) 1050 
tenoretic 100mg/25mg tablets (astrazeneca 
uk ltd) 1124 
tenoret 50mg/12.5mg tablets (astrazeneca 
uk ltd) 1288 
bisoprolol 10mg tablets 1290 
labetalol 400mg tablets 1295 
oxprenolol 40mg tablets 1333 
oxprenolol 160mg modified-release tablets 1334 
propranolol 160mg modified-release 
capsules 1448 
sotalol 80mg tablets 1572 
labetalol 100mg tablets 1597 
beta-adalat modified-release capsules 
(bayer plc) 1684 
atenolol 100mg with chlortalidone 25mg 
tablets 1788 
trasicor 80mg tablet (novartis 
pharmaceuticals uk ltd) 2361 
inderal 10mg tablets (astrazeneca uk ltd) 2414 
tenormin ls 50mg tablets (astrazeneca uk 
ltd) 2432 
nadolol 80mg tablets 2499 
tenormin 100mg tablets (astrazeneca uk 
ltd) 2587 
tenormin 25mg tablets (astrazeneca uk ltd) 2590 
carvedilol 12.5mg tablets 2629 
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labetalol 200mg tablets 2775 
oxprenolol 80mg tablets 2780 
inderal la 160mg capsules (astrazeneca uk 
ltd) 3005 
propranolol 40mg/5ml oral solution sugar 
free 3087 
propranolol 160mg tablets 3167 
betaloc 100mg tablets (astrazeneca uk ltd) 3344 
betaloc-sa 200mg tablets (astrazeneca uk 
ltd) 3474 
oxprenolol 20mg tablets 3516 
amiloride with atenolol with 
hydrochlorothiazide capsules 3526 
monocor 5mg tablets (wyeth 
pharmaceuticals) 3588 
sotalol 160mg with hydrochlorothiazide 
25mg tablet 3691 
oxprenolol 160mg tablet 3748 
propanix 40mg tablet (ashbourne 
pharmaceuticals ltd) 3827 
sotacor 80mg tablets (bristol-myers squibb 
pharmaceuticals ltd) 4004 
slow-trasicor 160mg tablets (amdipharm 
plc) 4025 
celectol 200mg tablet (pantheon healthcare 
ltd) 4265 
carvedilol 6.25mg tablets 4410 
trasidrex modified-release tablets (mercury 
pharma group ltd) 4429 
atenolol 50mg / nifedipine 20mg modified-
release capsules 4542 
visken 5mg tablet (sovereign medical ltd) 4588 
moducren tablets (merck sharp & dohme 
ltd) 4605 
labetalol 50mg tablets 4725 
emcor ls 5mg tablets (merck serono ltd) 4771 
inderetic 80mg/2.5mg capsules 
(astrazeneca uk ltd) 4796 
atenolol with amiloride and 
hydrochlorothiazide capsules 4983 
pindolol 5mg tablets 5284 
corgaretic 40mg tablets (sanofi-synthelabo 
ltd) 5330 
propranolol 10mg/5ml oral solution sugar 
free 5478 
bisoprolol 7.5mg tablets 5713 
co-tenidone 100mg/25mg tablets 5721 
beta-cardone 40mg tablets (focus 
pharmaceuticals ltd) 5858 
monocor 10mg tablets (wyeth 
pharmaceuticals) 5968 
atenolol 25mg/5ml oral solution sugar free 6066 
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beta-cardone 80mg tablets (focus 
pharmaceuticals ltd) 6751 
carvedilol 25mg tablets 7049 
metoprolol 100mg / hydrochlorothiazide 
12.5mg tablets 7066 
bisoprolol 3.75mg tablets 7091 
trasicor 20mg tablet (novartis 
pharmaceuticals uk ltd) 7474 
nebilet 5mg tablets (a menarini pharma uk 
s.r.l.) 7528 
kalten capsules (m & a pharmachem ltd) 7543 
bisoprolol 5mg/5ml oral suspension 7553 
acebutolol 400mg tablets 7620 
blocadren 10mg tablet (merck sharp & 
dohme ltd) 7852 
timolol 10mg tablets 7853 
celiprolol 400mg tablets 7974 
sectral 400mg tablets (sanofi) 8023 
sotalol 80mg with hydrochlorothiazide 
12.5mg tablet 8061 
metoprolol 200mg modified-release tablets 8068 
betaloc 50mg tablets (astrazeneca uk ltd) 8071 
acebutolol 200mg capsules 8113 
lopresoretic tablet (novartis 
pharmaceuticals uk ltd) 8147 
acebutolol 100mg capsules 8172 
secadrex 200mg/12.5mg tablets (sanofi) 8189 
celiprolol 200mg tablets 8262 
trasicor 40mg tablet (novartis 
pharmaceuticals uk ltd) 8290 
inderal 160mg tablet (astrazeneca uk ltd) 8331 
inderex 160mg/5mg modified-release 
capsules (astrazeneca uk ltd) 8369 
sectral 200mg capsules (sanofi) 8555 
prestim tablet (icn pharmaceuticals france 
s.a.) 8623 
tenif 50mg/20mg modified-release capsules 
(astrazeneca uk ltd) 8642 
oxprenolol with cyclopenthiazide 
160mg+0.25mg modified-release tablet 8673 
trandate 200mg tablets (focus 
pharmaceuticals ltd) 8707 
trandate 400mg tablets (focus 
pharmaceuticals ltd) 8807 
nadolol 40mg tablets 8935 
propanix 160mg modified-release capsule 
(ashbourne pharmaceuticals ltd) 8978 
propranolol 160mg modified-release / 
bendroflumethiazide 5mg capsules 8987 
trandate 100mg tablets (focus 
pharmaceuticals ltd) 9016 
viskaldix tablets (amdipharm plc) 9143 
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atenolol 25mg / bendroflumethiazide 
1.25mg capsules 9178 
propranolol 80mg/5ml oral solution 9185 
trandate 50mg tablets (focus 
pharmaceuticals ltd) 9273 
sotalol 160mg tablets 9292 
co-tenidone 50mg/12.5mg tablets 9783 
atenix 50 tablets (ashbourne 
pharmaceuticals ltd) 10191 
lopresor 50mg tablet (novartis 
pharmaceuticals uk ltd) 10429 
co-betaloc tablets (pfizer ltd) 10627 
corgard 80mg tablets (sanofi) 10716 
trasicor 160mg tablet (novartis 
pharmaceuticals uk ltd) 10777 
emcor 10mg tablets (merck serono ltd) 10892 
bendroflumethiazide 5mg with nadolol 
40mg tablets 11338 
sotacor 160mg tablets (bristol-myers squibb 
pharmaceuticals ltd) 11380 
propranolol 50mg/5ml oral solution 11711 
metoprolol 50mg/5ml oral suspension 11793 
betim 10mg tablet (icn pharmaceuticals 
france s.a.) 12037 
propranolol 80mg / bendroflumethiazide 
2.5mg capsules 12054 
sectral 100mg capsules (sanofi) 12296 
sotazide tablet (bristol-myers squibb 
pharmaceuticals ltd) 12456 
berkolol 10mg tablet (berk pharmaceuticals 
ltd) 12495 
timolol maleate with bendroflumethiazide 
20mg + 5mg tablet 12517 
timolol 10mg / bendroflumethiazide 2.5mg 
tablets 12651 
sotalol 200mg tablets 13051 
tenormin 25mg/5ml syrup (astrazeneca uk 
ltd) 13394 
corgard 40mg tablets (sanofi-synthelabo 
ltd) 13415 
beta-cardone 200mg tablets (focus 
pharmaceuticals ltd) 13487 
lopresor 100mg tablet (novartis 
pharmaceuticals uk ltd) 13499 
atenix co 100 tablets (ashbourne 
pharmaceuticals ltd) 13526 
co-prenozide 160mg/0.25mg modified-
release tablets 13871 
cardicor 2.5mg tablets (merck serono ltd) 14030 
pindolol 10mg / clopamide 5mg tablets 14057 
cardicor 1.25mg tablets (merck serono ltd) 14058 
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eucardic 3.125mg tablets (roche products 
ltd) 14117 
acebutolol 200mg / hydrochlorothiazide 
12.5mg tablets 14126 
eucardic 6.25mg tablets (roche products 
ltd) 14146 
corgaretic 80mg tablets (sanofi-synthelabo 
ltd) 14438 
propanix 10mg tablet (ashbourne 
pharmaceuticals ltd) 14552 
pindolol 15mg tablets 14673 
bedranol sr 80mg capsules (sandoz ltd) 14808 
tolerzide tablet (bristol-myers squibb 
pharmaceuticals ltd) 15042 
nifedipine with atenolol 20mg + 50mg 
capsule 15117 
totamol 50mg tablet (c p pharmaceuticals 
ltd) 15176 
metoprolol tartrate with chlortalidone 
tablet 15488 
half-betadur cr 80mg capsule (monmouth 
pharmaceuticals ltd) 15619 
totamol 100mg tablet (c p pharmaceuticals 
ltd) 15730 
labrocol 400mg tablet (lagap) 16645 
celectol 400mg tablet (pantheon healthcare 
ltd) 16776 
chlortalidone 25mg with atenolol 100mg 
tablets 16786 
syprol 5mg/5ml oral solution (rosemont 
pharmaceuticals ltd) 17082 
monozide 10 tablets (wyeth 
pharmaceuticals) 17149 
atenix 25 tablets (ashbourne 
pharmaceuticals ltd) 17322 
bisoprolol 10mg / hydrochlorothiazide 
6.25mg tablets 17462 
cardicor 5mg tablets (merck serono ltd) 17615 
spiroprop tablet (pharmacia ltd) 17783 
cardicor 7.5mg tablets (merck serono ltd) 18185 
co-betaloc sa tablets (pfizer ltd) 18287 
eucardic 12.5mg tablets (roche products 
ltd) 18414 
tenben 25mg/1.25mg capsules (galen ltd) 18743 
totamol 25mg tablet (c p pharmaceuticals 
ltd) 18950 
chlortalidone 12.5mg with atenolol 50mg 
tablets 19055 
bendroflumethiazide 2.5mg with timolol 
maleate 10mg tablets 19142 
atenolol 25mg tablets (ivax pharmaceuticals 
uk ltd) 19172 
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bisoprolol 10mg tablets (ranbaxy (uk) ltd) 19178 
atenolol 50mg tablets (ivax pharmaceuticals 
uk ltd) 19182 
atenolol 100mg tablets (teva uk ltd) 19191 
bisoprolol 5mg tablets (ivax 
pharmaceuticals uk ltd) 19200 
carvedilol 6.25mg tablets (teva uk ltd) 19202 
eucardic 25mg tablets (roche products ltd) 19437 
cardicor 3.75mg tablets (merck serono ltd) 19853 
cardicor 10mg tablets (merck serono ltd) 19858 
visken 15mg tablet (sovereign medical ltd) 20012 
lopresor sr 200mg tablets (recordati 
pharmaceuticals ltd) 20082 
metoprolol 200mg modified-release / 
hydrochlorothiazide 25mg tablets 20093 
half beta-prograne 80mg modified-release 
capsules (tillomed laboratories ltd) 20468 
atenix 100 tablets (ashbourne 
pharmaceuticals ltd) 20502 
atenamin 25mg tablet (opd pharm) 20728 
prestim forte tablet (leo pharma) 21025 
atenamin 50mg tablet (opd pharm) 21133 
hydrochlorothiazide with timolol and 
amiloride 25mg with 10mg with 2.5mg 
tablet 21182 
propanix 80mg tablet (ashbourne 
pharmaceuticals ltd) 21838 
berkolol 80mg tablet (berk pharmaceuticals 
ltd) 21839 
berkolol 40mg tablet (berk pharmaceuticals 
ltd) 21866 
atenix co 50 tablets (ashbourne 
pharmaceuticals ltd) 21873 
oxyprenix sr 160mg tablets 21885 
bipranix 10mg tablets (ashbourne 
pharmaceuticals ltd) 21905 
bipranix 5mg tablets (ashbourne 
pharmaceuticals ltd) 21966 
half propanix la 80mg modified-release 
capsule (ashbourne pharmaceuticals ltd) 22208 
labrocol 200mg tablet (lagap) 22793 
bendroflumethiazide 2.5mg with 
propanolol 80mg capsules 22912 
bendroflumethiazide 5mg with propanolol 
160mg modified-release capsules 23131 
nadolol 40mg / bendroflumethiazide 5mg 
tablets 23134 
betadur cr 160mg modified-release capsule 
(monmouth pharmaceuticals ltd) 23326 
sloprolol 160mg capsule (c p 
pharmaceuticals ltd) 23587 
bisoprolol 5mg tablets (teva uk ltd) 24083 
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trasicor 40mg tablets (amdipharm plc) 24094 
antipressan 50mg tablets (teva uk ltd) 24191 
antipressan 100mg tablets (teva uk ltd) 24195 
berkolol 160mg tablet (berk 
pharmaceuticals ltd) 24218 
totaretic 100mg+25mg tablet (c p 
pharmaceuticals ltd) 24280 
rapranol sr 160mg capsules (ranbaxy (uk) 
ltd) 25359 
prestim tablets (meda pharmaceuticals ltd) 25363 
rapranol sr 80mg capsules (ranbaxy (uk) ltd) 25367 
clopamide 5mg with pindolol 10mg tablets 25462 
apsolox 80mg tablet (approved prescription 
services ltd) 25644 
timolol maleate with amiloride and 
hydrochlorothiazide tablet 25730 
antipressan 25mg tablets (teva uk ltd) 26211 
propanix la 160mg modified-release capsule 
(ashbourne pharmaceuticals ltd) 26228 
beta-prograne 160mg modified-release 
capsules (tillomed laboratories ltd) 26229 
tenchlor 100mg/25mg tablets (teva uk ltd) 26248 
lopranol la 160mg capsule (opus 
pharmaceuticals ltd) 26255 
totaretic 50mg+12.5mg tablet (c p 
pharmaceuticals ltd) 26741 
syprol 10mg/5ml oral solution (rosemont 
pharmaceuticals ltd) 26895 
oxprenolol 40mg tablet (actavis uk ltd) 27357 
propranolol 40mg tablets (actavis uk ltd) 27700 
metoros ls 95mg tablet (geigy 
pharmaceuticals) 27719 
nadolol 80mg / bendroflumethiazide 5mg 
tablets 27946 
apsolol 40mg tablet (approved prescription 
services ltd) 27964 
angilol 10mg tablet (ddsa pharmaceuticals 
ltd) 28048 
propranolol 80mg modified-release capsule 
(actavis uk ltd) 28128 
hydrochlorothiazide with atenolol and 
amiloride capsule 28177 
half propatard la 80mg modified-release 
capsule (galen ltd) 28788 
bedranol sr 160mg capsules (sandoz ltd) 28996 
trasicor 80mg tablets (amdipharm plc) 29180 
slow-pren 160mg tablet (ivax 
pharmaceuticals uk ltd) 29230 
atenolol 25mg tablets (teva uk ltd) 29368 
atenamin 100mg tablet (opd pharm) 29398 
hydrochlorothiazide with metoprolol 
tartrate 12.5mg with 100mg tablet 29427 
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betim 10mg tablets (meda pharmaceuticals 
ltd) 29610 
mepranix 50mg tablet (ashbourne 
pharmaceuticals ltd) 29762 
propanix 160mg tablet (ashbourne 
pharmaceuticals ltd) 29763 
metoros 190mg tablet (novartis 
pharmaceuticals uk ltd) 29998 
mepranix 100mg tablet (ashbourne 
pharmaceuticals ltd) 30400 
amiloride with timolol with 
hydrochlorothiazide tablets 30519 
vasaten 50mg tablet (shire pharmaceuticals 
ltd) 30636 
labetalol 200mg tablets (a a h 
pharmaceuticals ltd) 30770 
propranolol 80mg tablets (generics (uk) ltd) 31214 
tenchlor 50mg/12.5mg tablets (teva uk ltd) 31470 
atenolol 25mg tablets (kent 
pharmaceuticals ltd) 31536 
co-tenidone 50mg/12.5mg tablets (actavis 
uk ltd) 31708 
propranolol 40mg tablets (generics (uk) ltd) 31776 
angilol 80mg tablet (ddsa pharmaceuticals 
ltd) 31833 
atenolol 100mg tablets (ivax 
pharmaceuticals uk ltd) 31934 
co-tenidone 50mg/12.5mg tablets (a a h 
pharmaceuticals ltd) 32094 
bisoprolol 5mg tablets (generics (uk) ltd) 32114 
propranolol 80mg modified-release capsule 
(lagap) 32162 
congescor 2.5mg tablets (tillomed 
laboratories ltd) 32552 
vivacor 10mg tablets (lexon (uk) ltd) 32630 
visken 15mg tablets (amdipharm plc) 32787 
metoprolol 50mg tablets (generics (uk) ltd) 32836 
atenolol 100mg tablets (generics (uk) ltd) 33079 
atenolol 100mg tablets (a a h 
pharmaceuticals ltd) 33085 
atenolol 50mg tablets (a a h 
pharmaceuticals ltd) 33092 
atenolol 100mg tablets (wockhardt uk ltd) 33184 
carvedilol 12.5mg tablets (genus 
pharmaceuticals ltd) 33374 
probeta la 160mg capsule (trinity 
pharmaceuticals ltd) 33376 
oxprenolol sr 160mg modified-release 
tablet (hillcross pharmaceuticals ltd) 33569 
slo-pro 160mg capsules (generics (uk) ltd) 33602 
propranolol 80mg tablets (a a h 
pharmaceuticals ltd) 33644 
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atenolol 50mg tablets (generics (uk) ltd) 33650 
atenolol 25mg tablets (a a h 
pharmaceuticals ltd) 33657 
hydrochlorothiazide with metoprolol 
tartrate 25mg with 200mg modified-release 
tablet 33659 
apsolol 160mg tablet (approved 
prescription services ltd) 33836 
bisoprolol 10mg tablets (actavis uk ltd) 33839 
atenolol 50mg tablets (actavis uk ltd) 33850 
congescor 1.25mg tablets (tillomed 
laboratories ltd) 33909 
co-tenidone 100mg/25mg tablets (ivax 
pharmaceuticals uk ltd) 34012 
co-tenidone 50mg/12.5mg tablets (ivax 
pharmaceuticals uk ltd) 34034 
metoprolol 100mg tablets (teva uk ltd) 34092 
metoprolol 50mg tablets (a a h 
pharmaceuticals ltd) 34094 
metoprolol 100mg tablets (a a h 
pharmaceuticals ltd) 34125 
labetalol 100mg tablet (c p pharmaceuticals 
ltd) 34171 
labetalol 100mg tablets (a a h 
pharmaceuticals ltd) 34177 
propranolol la 80mg modified-release 
capsule (approved prescription services ltd) 34185 
labetalol 200mg tablet (celltech pharma 
europe ltd) 34188 
propranolol sr 160mg modified-release 
capsule (c p pharmaceuticals ltd) 34208 
propranolol 160mg tablets (actavis uk ltd) 34214 
atenolol 50mg tablets (sandoz ltd) 34265 
atenolol 50mg tablets (teva uk ltd) 34365 
sotalol 40mg tablets (a a h pharmaceuticals 
ltd) 34371 
propranolol 10mg tablets (a a h 
pharmaceuticals ltd) 34378 
metoprolol 50mg tablets (teva uk ltd) 34407 
metoprolol 50mg tablets (actavis uk ltd) 34430 
atenolol 50mg tablets (wockhardt uk ltd) 34443 
co-tenidone 50mg/12.5mg tablets (generics 
(uk) ltd) 34449 
atenolol 25mg tablets (generics (uk) ltd) 34492 
carvedilol 12.5mg tablets (actavis uk ltd) 34501 
metoprolol 100mg tablets (generics (uk) ltd) 34509 
sotalol 80mg tablets (generics (uk) ltd) 34520 
atenolol 25mg tablets (wockhardt uk ltd) 34575 
metoprolol 50mg tablets (ivax 
pharmaceuticals uk ltd) 34584 
atenolol 25mg tablets (sandoz ltd) 34585 
sotalol 40mg tablets (teva uk ltd) 34600 
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sotalol 40mg tablet (tillomed laboratories 
ltd) 34640 
sotalol 80mg tablets (sandoz ltd) 34690 
atenolol 50mg tablets (kent 
pharmaceuticals ltd) 34695 
carvedilol 6.25mg tablets (actavis uk ltd) 34740 
carvedilol 3.125mg tablets (ivax 
pharmaceuticals uk ltd) 34741 
atenolol 100mg tablets (sandoz ltd) 34754 
propranolol 10mg tablets (actavis uk ltd) 34783 
propranolol 10mg tablets (teva uk ltd) 34804 
bisoprolol 10mg tablets (generics (uk) ltd) 34821 
co-tenidone 50mg/12.5mg tablets (teva uk 
ltd) 34825 
metoprolol 100mg tablets (actavis uk ltd) 34854 
propranolol 80mg capsule (ivax 
pharmaceuticals uk ltd) 34867 
propranolol 40mg tablets (teva uk ltd) 34868 
atenolol 50mg tablet (berk pharmaceuticals 
ltd) 34882 
propranolol 160mg modified-release 
capsule (sandoz ltd) 34884 
metoprolol 50mg tablet (berk 
pharmaceuticals ltd) 34890 
co-tenidone 100mg/25mg tablets (a a h 
pharmaceuticals ltd) 34899 
metoprolol 50mg tablets (sandoz ltd) 34925 
propranolol 160mg modified-release 
capsule (lagap) 34945 
propranolol 160mg modified-release 
capsule (actavis uk ltd) 34949 
bisoprolol 5mg tablets (actavis uk ltd) 34963 
atenolol 25mg tablets (tillomed laboratories 
ltd) 34976 
celectol 200mg tablets (zentiva) 35054 
trasicor 20mg tablets (amdipharm plc) 35062 
visken 5mg tablets (amdipharm plc) 35695 
sotalol 25mg/5ml oral suspension 35710 
labrocol 100mg tablet (lagap) 35778 
propranolol 80mg modified-release 
capsules (a a h pharmaceuticals ltd) 35938 
celectol 400mg tablets (zentiva) 35940 
atenolol 50mg tablets (tillomed laboratories 
ltd) 36261 
propranolol 10mg tablets (generics (uk) ltd) 36576 
propranolol sr 160mg modified-release 
capsule (hillcross pharmaceuticals ltd) 36603 
bisoprolol 2.5mg tablets (a a h 
pharmaceuticals ltd) 37118 
co-tenidone 100mg/25mg tablets (generics 
(uk) ltd) 37725 
bisoprolol 2.5mg tablet (teva uk ltd) 37837 
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propranolol 50mg/5ml oral solution 
(rosemont pharmaceuticals ltd) 38433 
bisoprolol 7.5mg tablets (a a h 
pharmaceuticals ltd) 38991 
propranolol 80mg modified-release 
capsules (teva uk ltd) 39233 
sotalol 80mg tablets (a a h pharmaceuticals 
ltd) 39423 
bisoprolol 0.625mg/5ml oral solution 39646 
vivacor 5mg tablets (lexon (uk) ltd) 39846 
metoprolol 100mg tablets (ivax 
pharmaceuticals uk ltd) 40167 
labetalol 400mg tablets (a a h 
pharmaceuticals ltd) 40240 
propranolol la 160mg capsule (approved 
prescription services ltd) 40241 
nebivolol 2.5mg tablets 40761 
propranolol 40mg tablets (a a h 
pharmaceuticals ltd) 41555 
co-tenidone 100mg/25mg tablets (teva uk 
ltd) 41572 
bisoprolol 10mg tablets (teva uk ltd) 41591 
celiprolol 200mg tablets (teva uk ltd) 41740 
labetalol 100mg tablets (generics (uk) ltd) 41827 
syprol 50mg/5ml oral solution (rosemont 
pharmaceuticals ltd) 42152 
celiprolol 200mg tablets (generics (uk) ltd) 42795 
bisoprolol 1.25mg tablets (generics (uk) ltd) 43251 
propranolol 10mg tablets (ivax 
pharmaceuticals uk ltd) 43525 
sotalol 40mg tablets (ivax pharmaceuticals 
uk ltd) 43549 
bisoprolol 5mg tablet (pliva pharma ltd) 43564 
bisoprolol 2.5mg/5ml oral suspension 44000 
labetalol 200mg tablets (actavis uk ltd) 44083 
nebivolol 2.5mg tablets (a a h 
pharmaceuticals ltd) 44808 
atenolol 25mg tablets (actavis uk ltd) 44858 
labetalol 400mg tablets (sandoz ltd) 45250 
metoprolol tartrate oral solution 45289 
propranolol 40mg tablets (ivax 
pharmaceuticals uk ltd) 45297 
acebutolol 400mg tablets (a a h 
pharmaceuticals ltd) 45309 
propranolol sr 80mg modified-release 
capsule (c p pharmaceuticals ltd) 45343 
propranolol 10mg tablets (almus 
pharmaceuticals ltd) 45494 
syprol 40mg/5ml oral solution (rosemont 
pharmaceuticals ltd) 45765 
beta-prograne 160mg modified-release 
capsules (teva uk ltd) 45877 
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half beta-prograne 80mg modified-release 
capsules (teva uk ltd) 46363 
lopresor 50mg tablets (recordati 
pharmaceuticals ltd) 46614 
lopresor 100mg tablets (recordati 
pharmaceuticals ltd) 46740 
atenolol 100mg tablets (kent 
pharmaceuticals ltd) 46908 
atenolol 100mg tablets (actavis uk ltd) 46931 
carvedilol 3.125mg tablets (actavis uk ltd) 46935 
carvedilol 3.125mg tablets (a a h 
pharmaceuticals ltd) 46936 
co-tenidone 100mg/25mg tablets (actavis 
uk ltd) 46952 
bisoprolol 2.5mg tablets (generics (uk) ltd) 47041 
carvedilol 5mg/5ml oral suspension 47107 
nebivolol 2.5mg tablets (glenmark generics 
(europe) ltd) 47300 
metoprolol tartrate 12.5mg/5ml oral 
suspension 47536 
half beta-prograne 80mg modified-release 
capsules (actavis uk ltd) 47543 
labetalol 400mg tablet (approved 
prescription services ltd) 47673 
labetalol 200mg tablet (c p pharmaceuticals 
ltd) 47674 
bedranol sr 80mg capsules (almus 
pharmaceuticals ltd) 47833 
atenolol 25mg tablets (almus 
pharmaceuticals ltd) 47870 
bedranol sr 160mg capsules (almus 
pharmaceuticals ltd) 47907 
propranolol 50mg/5ml oral solution sugar 
free 48682 
carvedilol 3.125mg/5ml oral suspension 49142 
propranolol 5mg/5ml oral solution sugar 
free 49863 
atenolol 25mg tablets (bristol laboratories 
ltd) 49953 
congescor 2.5mg tablets (teva uk ltd) 50224 
congescor 1.25mg tablets (teva uk ltd) 50300 
bisoprolol 1.25mg tablet (teva uk ltd) 50403 
bisoprolol 2.5mg tablets (chanelle medical 
uk ltd) 50514 
atenolol 25mg tablets (alliance healthcare 
(distribution) ltd) 50702 
metoprolol 12.5mg/5ml oral suspension 51447 
sotalol 25mg/5ml oral solution 51492 
bisoprolol 1.25mg tablets (actavis uk ltd) 51528 
atenolol 25mg/5ml oral solution sugar free 
(alliance healthcare (distribution) ltd) 51643 
atenolol 25mg tablets (co-pharma ltd) 51998 
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bedranol sr 160mg capsule (lagap) 52136 
atenolol 25mg tablets (crescent pharma ltd) 52310 
atenolol 50mg tablets (almus 
pharmaceuticals ltd) 52500 
bisoprolol 1.25mg tablets (almus 
pharmaceuticals ltd) 52548 
inderal la 160mg capsules (sigma 
pharmaceuticals plc) 52609 
bisoprolol 5mg tablets (alliance healthcare 
(distribution) ltd) 52635 
bisoprolol 2.5mg/5ml oral solution 52686 
beta-adalat modified-release capsules 
(lexon (uk) ltd) 52728 
propranolol 40mg tablets (kent 
pharmaceuticals ltd) 52777 
atenolol 50mg tablets (alliance healthcare 
(distribution) ltd) 53204 
atenolol 50mg tablets (bristol laboratories 
ltd) 53215 
bisoprolol 10mg tablets (a a h 
pharmaceuticals ltd) 53334 
atenolol 50mg tablets (accord healthcare 
ltd) 53414 
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Table S10. Statin product codes 
Product name prodcode 
simvastatin 20mg tablets 25 
atorvastatin 10mg tablets 28 
simvastatin 10mg tablets 42 
simvastatin 40mg tablets 51 
atorvastatin 20mg tablets 75 
fluvastatin 20mg capsules 379 
pravastatin 10mg tablets 490 
rosuvastatin 10mg tablets 713 
pravastatin 20mg tablets 730 
atorvastatin 40mg tablets 745 
simvador 40mg tablets (discovery 
pharmaceuticals ltd) 802 
simvastatin 20mg/5ml oral solution sugar 
free 818 
pravastatin 40mg tablets 1219 
lipostat 10mg tablets (bristol-myers squibb 
pharmaceuticals ltd) 1221 
lipostat 40mg tablets (bristol-myers squibb 
pharmaceuticals ltd) 1223 
fluvastatin 40mg capsules 2137 
zocor 10mg tablets (merck sharp & dohme 
ltd) 2718 
lipitor 40mg tablets (pfizer ltd) 2955 
lipitor 10mg tablets (pfizer ltd) 3411 
lipostat 20mg tablets (bristol-myers squibb 
pharmaceuticals ltd) 3690 
simvastatin 80mg tablets 5148 
atorvastatin 80mg tablets 5775 
lescol xl 80mg tablets (novartis 
pharmaceuticals uk ltd) 5985 
zocor 40mg tablets (merck sharp & dohme 
ltd) 6168 
rosuvastatin 20mg tablets 6213 
zocor 20mg tablets (merck sharp & dohme 
ltd) 7196 
crestor 10mg tablets (astrazeneca uk ltd) 7347 
lipitor 20mg tablets (pfizer ltd) 7374 
rosuvastatin 5mg tablets 7554 
lescol 20mg capsules (novartis 
pharmaceuticals uk ltd) 8380 
lescol 40mg capsules (novartis 
pharmaceuticals uk ltd) 9153 
rosuvastatin 40mg tablets 9897 
simvador 20mg tablets (discovery 
pharmaceuticals ltd) 9920 
crestor 40mg tablets (astrazeneca uk ltd) 9930 
fluvastatin 80mg modified-release tablets 11627 
simvador 10mg tablets (discovery 
pharmaceuticals ltd) 13041 
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crestor 20mg tablets (astrazeneca uk ltd) 15252 
lipitor 80mg tablets (pfizer ltd) 17683 
crestor 5mg tablets (astrazeneca uk ltd) 17688 
zocor 80mg tablets (merck sharp & dohme 
ltd) 22579 
zocor heart-pro 10mg tablet (mcneil 
products ltd) 31930 
simvastatin 80mg tablets (a a h 
pharmaceuticals ltd) 32909 
pravastatin 10mg tablet (dr reddy's 
laboratories (uk) ltd) 32921 
simvastatin 20mg tablets (a a h 
pharmaceuticals ltd) 33082 
simvastatin 20mg tablets (generics (uk) ltd) 34312 
simvastatin 20mg tablets (teva uk ltd) 34316 
simvastatin 40mg tablets (generics (uk) ltd) 34353 
simvastatin 20mg tablets (ivax 
pharmaceuticals uk ltd) 34366 
simvastatin 40mg tablets (teva uk ltd) 34376 
simvastatin 40mg tablets (ivax 
pharmaceuticals uk ltd) 34381 
simvastatin 20mg tablet (ratiopharm uk ltd) 34476 
simvastatin 10mg tablets (ivax 
pharmaceuticals uk ltd) 34481 
simvastatin 40mg tablets (a a h 
pharmaceuticals ltd) 34502 
simvastatin 10mg tablets (generics (uk) ltd) 34535 
simvastatin 40mg tablet (ratiopharm uk ltd) 34545 
simvastatin 10mg tablet (ratiopharm uk ltd) 34560 
simvastatin 20mg tablet (niche generics ltd) 34746 
simvastatin 20mg tablets (wockhardt uk 
ltd) 34814 
pravastatin 40mg tablets (a a h 
pharmaceuticals ltd) 34820 
simvastatin 40mg tablet (niche generics ltd) 34879 
simvastatin 20mg tablets (kent 
pharmaceuticals ltd) 34891 
simvastatin 40mg tablets (wockhardt uk 
ltd) 34907 
simvastatin 10mg tablets (a a h 
pharmaceuticals ltd) 34955 
simvastatin 40mg tablets (actavis uk ltd) 34969 
pravastatin 20mg tablets (teva uk ltd) 36377 
simvastatin 40mg tablets (sandoz ltd) 37434 
simvastatin 20mg tablets (dexcel-pharma 
ltd) 39060 
simvastatin 40mg/5ml oral solution sugar 
free 39652 
simvastatin 20mg/5ml oral suspension 
(martindale pharmaceuticals ltd) 39675 
simvador 80mg tablets (discovery 
pharmaceuticals ltd) 39870 
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simvastatin 10mg tablets (teva uk ltd) 40340 
pravastatin 20mg tablets (a a h 
pharmaceuticals ltd) 40382 
simvastatin 20mg tablets (ranbaxy (uk) ltd) 40601 
simvastatin 80mg tablets (teva uk ltd) 41657 
pravastatin 10mg tablets (teva uk ltd) 43218 
simvastatin 20mg/5ml oral suspension 
sugar free (rosemont pharmaceuticals ltd) 44528 
simvastatin 40mg tablets (dexcel-pharma 
ltd) 44650 
ranzolont 10mg tablets (ranbaxy (uk) ltd) 44878 
simvastatin 40mg tablets (kent 
pharmaceuticals ltd) 45219 
simvastatin 20mg tablets (sandoz ltd) 45235 
simvastatin 20mg tablets (actavis uk ltd) 45245 
simvastatin 40mg tablets (arrow generics 
ltd) 45346 
simvastatin 40mg tablets (almus 
pharmaceuticals ltd) 46878 
simvastatin 80mg tablets (arrow generics 
ltd) 46956 
atorvastatin 20mg chewable tablets sugar 
free 47065 
atorvastatin 10mg chewable tablets sugar 
free 47090 
lipitor 20mg chewable tablets (pfizer ltd) 47630 
lipitor 10mg chewable tablets (pfizer ltd) 47721 
simvastatin 10mg tablets (arrow generics 
ltd) 47774 
simvastatin 10mg tablets (tillomed 
laboratories ltd) 47948 
pravastatin 40mg tablets (generics (uk) ltd) 47988 
simvastatin 20mg tablets (arrow generics 
ltd) 48018 
simvastatin 10mg tablets (kent 
pharmaceuticals ltd) 48051 
simvastatin 10mg tablets (ranbaxy (uk) ltd) 48058 
simvastatin 10mg tablets (actavis uk ltd) 48078 
pravastatin 40mg tablets (teva uk ltd) 48097 
simvastatin 20mg/5ml oral suspension 
sugar free 48221 
atorvastatin 60mg tablets 48346 
simvastatin 40mg/5ml oral suspension 
sugar free 48431 
atorvastatin 10mg/5ml oral solution 48518 
simvastatin 40mg tablets (alliance 
healthcare (distribution) ltd) 48867 
atorvastatin 30mg tablets 48973 
simvastatin 40mg tablets (bristol 
laboratories ltd) 49061 
simvastatin 20mg tablets (alliance 
healthcare (distribution) ltd) 49062 
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atorvastatin 20mg tablets (a a h 
pharmaceuticals ltd) 49558 
simvastatin 80mg tablets (almus 
pharmaceuticals ltd) 49587 
atorvastatin 40mg tablets (alliance 
healthcare (distribution) ltd) 49751 
atorvastatin 10mg tablets (zentiva) 50236 
atorvastatin 40mg tablets (pfizer ltd) 50272 
simvastatin 40mg tablets (relonchem ltd) 50483 
simvastatin 20mg tablets (relonchem ltd) 50564 
simvastatin 40mg tablets (aurobindo 
pharma ltd) 50670 
simvastatin 40mg tablets (accord 
healthcare ltd) 50703 
simvastatin 20mg tablets (medreich plc) 50754 
atorvastatin 20mg tablets (pfizer ltd) 50788 
atorvastatin 20mg tablets (dexcel-pharma 
ltd) 50790 
simvastatin 40mg tablets (somex pharma) 50882 
pravastatin 10mg tablets (sigma 
pharmaceuticals plc) 50925 
atorvastatin 40mg tablets (teva uk ltd) 50963 
simvastatin 10mg tablets (medreich plc) 51085 
atorvastatin 10mg tablets (a a h 
pharmaceuticals ltd) 51134 
simvastatin 40mg tablets (medreich plc) 51166 
atorvastatin 40mg tablets (arrow generics 
ltd) 51200 
simvastatin 10mg tablets (alliance 
healthcare (distribution) ltd) 51233 
atorvastatin 20mg tablets (arrow generics 
ltd) 51359 
simvastatin 20mg tablets (aurobindo 
pharma ltd) 51483 
atorvastatin 20mg tablets (consilient health 
ltd) 51622 
pravastatin 40mg tablets (medreich plc) 51676 
simvastatin 10mg tablets (sigma 
pharmaceuticals plc) 51715 
atorvastatin 40mg tablets (consilient health 
ltd) 51876 
pravastatin 20mg tablets (medreich plc) 51890 
atorvastatin 40mg tablets (wockhardt uk 
ltd) 52097 
simvastatin 40mg tablets (ranbaxy (uk) ltd) 52098 
atorvastatin 20mg tablets (aspire pharma 
ltd) 52168 
atorvastatin 20mg tablets (actavis uk ltd) 52211 
simvastatin 20mg tablets (accord 
healthcare ltd) 52257 
atorvastatin 40mg tablets (dr reddy's 
laboratories (uk) ltd) 52397 
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atorvastatin 40mg tablets (a a h 
pharmaceuticals ltd) 52398 
atorvastatin 80mg tablets (actavis uk ltd) 52459 
atorvastatin 40mg tablets (aspire pharma 
ltd) 52460 
simvastatin 10mg tablets (wockhardt uk 
ltd) 52625 
simvastatin 10mg/5ml oral suspension 52676 
pravastatin 20mg tablets (alliance 
healthcare (distribution) ltd) 52755 
simvastatin 20mg tablets (sigma 
pharmaceuticals plc) 52812 
atorvastatin 80mg tablets (dr reddy's 
laboratories (uk) ltd) 52821 
simvastatin 20mg tablets (bristol 
laboratories ltd) 52953 
simvastatin 80mg tablets (medreich plc) 52962 
simvastatin 20mg tablets (somex pharma) 53087 
zocor 40mg tablets (lexon (uk) ltd) 53340 
simvastatin 10mg tablets (aurobindo 
pharma ltd) 53415 
crestor 10mg tablets (doncaster 
pharmaceuticals ltd) 53460 
lipitor 80mg tablets (mawdsley-brooks & 
company ltd) 53594 
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